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Approximately 17,000 patients a year receive radiotherapy for the pelvic cancers. 
Acute radiation-induced damage to normal non-cancerous tissues (toxicity) is 
characterised by an inflammatory response which has many pathophysiological 
similarities to inflammatory bowel disease (IBD). Preventing or reducing the severity of 
treatment-induced toxicity is of increasing importance as the number of survivors of 
cancer treatment increases. Dietary fibre may be an attractive option through the anti-
inflammatory action of its fermentation metabolites short chain fatty acids (SCFA) and 
its beneficial effect on stool frequency and form.  
Methods 
A systematic review of the efficacy of dietary fibre in the management of IBD was 
undertaken. The aims were firstly to identify evidence for the manipulation of dietary 
fibre in this inflammatory condition of the bowel as it was anticipated that little 
evidence would be available in patients receiving pelvic radiotherapy and secondly to 
gain insight as to the nutritional interventional approaches employed. A further 
systematic review was undertaken to identify evidence for the efficacy of dietary fibre 
manipulation in patients receiving pelvic radiotherapy. A 3-arm randomised controlled 
trial (RCT) manipulating dietary fibre intake in pelvic radiotherapy patients was 
subsequently carried out, powered on the difference in the change in Inflammatory 
Bowel Disease Questionnaire - Bowel subset (IBDQ-B) score between study groups 
consuming a high fibre, low fibre or habitual dietary fibre intake measured as non-
starch polysaccharide (NSP) in g/day. Other measurements included concentration of 
faecal SCFA at start and end of radiotherapy, daily patient-reported bowel habit using 
the Bristol Stool Form scale and quality of life assessed using the IBDQ tool. 
Results 
A total of 4232 original citations were identified in the systematic review of fibre in 
IBD, of which 23 articles (1296 patients) were included.  Evidence for the efficacy of 
increased dietary fibre on disease outcomes was found in 4/23 RCTs, 3/10 in ulcerative 
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colitis and 1/1 in pouchitis. Meta-analysis was not possible due to widely differing 
study designs. The systematic review of fibre during pelvic radiotherapy identified 
4188 original citations of which 4 articles (264 patients) were included. Meta-analysis 
(2 studies) showed increased or modified dietary fibre to be of benefit as a 
prophylactic against new-onset diarrhoea with a risk ratio of 0.75 (95% CI: 0.56 – 1.01). 
However, this result was not statistically significant (p=0.06). A total of 166 patients 
were randomised to the ‘Fibre Study’ RCT with 159 providing evaluable data of the 
required 156 patients. A significant difference in the change in IBDQ-B score between 
baseline and end of radiotherapy was identified between the high fibre and no 
intervention (control) group of 7.7 points in favour or the high fibre group (p=0.007).  A 
difference in the change in IBDQ-B score of 3.4 points was also found between the low 
fibre and control group in favour of the low fibre group although this difference was 
not significant (p=0.535). No significant differences between groups were found in the 
incidence of loose stool (Bristol Stool type 6/7) or stool frequency although there was a 
marked increase in the use of anti-diarrhoeal medication by the high fibre group 
during week 5 of radiotherapy treatment.  Mean (sd) NSP consumption of the control, 
low and high fibre groups at the start of radiotherapy was 13.6 (5.3), 10.2 (3.4) and 
17.1 (4.8) g / day and at the end of radiotherapy was 12.2 (5.2), 8.9 (2.9) and 15.7 (5.1) 
g / day. No significant difference between groups in the concentration of faecal SCFA 
was found (n=41 paired samples) between start and end of radiotherapy. There was a 
significant difference in the change in IBDQ quality of life scores between the high fibre 
and control groups between start and end of radiotherapy in favour of the high fibre 
group (p=0.010)   
Conclusion 
Dietary advice to increase fibre during pelvic radiotherapy may protect against bowel 
symptoms compared to no dietary advice. However, advice to reduce fibre intake may 
also be of benefit compared to no dietary advice. High and low fibre intakes may have 
differing, independent benefits in comparison to ad-libitum intake. High fibre intake 
did not adversely affect stool frequency or type although use of anti-diarrhoeal 
medication may have masked these effects. The possible placebo effect of specific 
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CIN  Carcinoma in Situ 
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COMA Committee on Medical Aspects of Food 
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CRP   C-reactive protein 
CT   Chemotherapy 
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CTCAE Common Terminology Criteria for Adverse Events 
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DRV   Dietary Reference Value 
DVH   Dose Volume Histogram 
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ESPEN  European Society for Nutrition and Metabolic Medicine 
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GCP   Good Clinical Practice 
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g/d  grams per day 
GP  General Practitioner 
GvHD  Graft versus Host Disease 
Gy   Gray (Radiotherapy) 
HDR  High Dose Rate (Brachytherapy) 
HMGB1 High Mobility Group Box 1 proteins 
HMG Co-A Hydroxymethyglutaryl Coenzyme-A 
HPV     Human Papilloma Virus 
HSP  Heat Shock Protein 
IBD   Inflammatory Bowel Disease 
IBDQ   Inflammatory Bowel Disease Questionnaire 
IBDQ-B  Inflammatory Bowel Disease Questionnaire – Bowel Subset 
IBS  Irritable Bowel Syndrome 
ICAM  Intracellular Adhesion Molecule 
IFN-ɣ  Interferon gamma 
Ig  Immunoglobulin 
IGD  Institute of Grocery Distribution 
IGRT  Image-Guided Radiotherapy 
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IL  Interleukin 
IMRT   Intensity Modulated Radiotherapy 
ISI   Web of Science (formerly International Science Citation Index) 
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LPS  Lipopolysaccharide 
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MCT  Medium Chain Triglycerides 
MFI  Multidimensional Fatigue Index 
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MHC  Major Histocompatibility Complex 
MMP-2, 9  Matrix Metalloproteinases 
MPO  Myeloperoxidase 
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NCI  National Cancer Institute 
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NOD  Nucleotide Oligomerisation Domain 
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PDGF  Platelet Derived Growth Factor 
PICOS  Population, Intervention, Comparisons, Outcomes, Study Design 
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QoL   Quality of Life 
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RhoK  Rho Kinase (‘ROCK’) 
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ROS  Reactive Oxygen Species 
RR  Relative Risk or Risk Ratio 
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RSCH  Royal Surrey County Hospital 
RT   Radiotherapy 
RTOG  Radiation Therapy Oncology Group 
SCFA   Short-Chain Fatty Acids 
sd  Standard Deviation 
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SI   International System of Units 
SIBO  Small Intestinal Bacterial Overgrowth 
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TAH  Total Abdominal Hysterectomy 
TGF-beta  Transforming Growth Factor-beta 
Th  Helper T cell (immunology) 
Tis  Tumour-in-situ 
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TM  Thrombomodulin 
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TNM   Tumour Node Metastases (cancer staging) 
Treg  Regulatory T cell (immunology) 
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UK  United Kingdom 
UKRO  UK Radiation Oncology group  
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1.1 Background to clinical setting  
Cancer is a vast medical problem and a major cause of mortality both in the UK and the 
rest of the Western world1. Current estimates suggest that worldwide, the number of 
cancer cases is rising by about 1.5% per annum1. In the UK, this figure is likely to 
increase as the percentage of the population aged over 65 years rises from 16% in 
2004 to an estimated 23% by 2030.  
 
The term pelvic cancer refers to cancers that arise from anatomical sites within the 
pelvis, defined as the region extending from lumbar vertebra L4 to the anal verge2. 
Pelvic cancer includes tumours of a gynaecological, urological or lower gastrointestinal 
origin. In the UK in 2011 of the 331,487 new cancer diagnoses 35% (116,294) were of 
pelvic origin (Table 1.1)3.  
 
Table 1.1 New Pelvic Cancer Diagnoses in the United Kingdom: 2011 
Cancer site Incidence 
Urological Total: 52,135 
Bladder 10,399 
Prostate 41,736 






Lower Gastrointestinal Total: 44,045 
Colon 






TOTAL (All pelvic diagnoses): 116,294 
 
Radiotherapy remains the most important non-surgical treatment in the management 
of cancer4 and is widely employed in the treatment of pelvic cancers. A recent report 
 25 
from the UK Royal College of Radiographers assessing the contribution of different 
modalities to cancer cure rates, estimated that ‘of those cured, 49% are cured by 
surgery, 40% by radiotherapy and 11% by chemotherapy’5. 
 
Estimating the number of patients treated with curative, long-course (radical) 
radiotherapy in the UK is complicated by the fragmentation of UK cancer registries and 
the lack of uniformity in data reported. The most recent quantitatively-based estimate 
reported that 12,000 patients received long-course pelvic radiotherapy annually6. 
However, this figure, derived in 2003 is likely to have risen in the last decade.  
 
The proportion of patients with new pelvic cancer diagnoses in whom radiotherapy (of 
palliative or curative intent) is clinically indicated is 45%7. Assuming that 30 to 40% of 
these patients will require long-course treatment with curative (rather than short 
course palliative) intent, with reference to Table 1.1, the number of patients receiving 
long-course pelvic radiotherapy in 2011 in the UK is estimated to be between 15,699 
and 20,929. One recent publication estimates the figure to be 17,000 patients per 
annum8.  
 
However, despite major advances in the planning and delivery of radiotherapy, the 
tolerance of normal tissues within the radiotherapy treatment field remains dose-
limiting. For pelvic tumours, treatment-induced gastrointestinal toxicity as an 
unwanted side-effect of treatment causes acute and chronic morbidity of varying 
severity.  
 
As the number of long term survivors of pelvic cancer continues to grow, estimated to 
be in excess of 3 million in the US in 2013, strategies to limit its damaging side-effects 
are acknowledged as becoming increasingly important9. It is in this clinical setting and 






1.2 Therapeutic pelvic radiotherapy 
1.2.1 Radiotherapy: an introduction 
The delivery of therapeutic, high voltage, ionising radiation with the explicit intention 
of destroying cancerous cells (radiotherapy) remains a critical component of cancer 
treatment. Over 50% of patients will receive this form of treatment at some time 
during the management of their malignant disease4 either alone or in combination 
with surgery and/or chemotherapy. The most common treatment modality is external 
beam radiotherapy (EBRT) which is delivered in the form of very high energy, 
collimated and flattened x-ray beams of 4-25 Mega electron volts (MeV) generated by 
a linear accelerator or ‘Linac’.  
 
Designed to be skin-sparing, these mega-voltage beams penetrate the human body to 
predetermined depths to destroy cancerous cells through the process of ionisation (i.e. 
the displacement of an electron from its orbital path and the creation of an unstable or 
‘ionised’ atom and free electron) with ensuing particle chain reactions and free radical 
mediated damage. The nuclear DNA of cancer cells is the primary target of this 
planned radiobiological destruction. The effects may be immediate cellular ablation or, 
often quantitatively more significant, latent but permanent damage which is expressed 
when the cells attempt to divide.  
 
Total prescribed radiotherapy dose is defined in Gray (Gy) the SI unit of absorbed 
radiation dose. The prescribed radiation dose, which for long-course treatments is 
typically 45 to 54 Gray, is divided into a series of equal daily fractions. Fractionation is 
intended to exploit the differential in the cytotoxic effect of ionising radiation on 
cancerous versus normal tissue, reparative processes being generally greater in normal 
tissues through which the radiation beams inevitably pass to reach their target. 
 
For any given tumour, the greater the reparative powers of normal cells compared to 
tumour, the wider the therapeutic window and thus the increased certainty of tumour 
control with minimised damage to normal cells.  
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Dose per fraction for treatments relevant to the thesis is generally 1.8 Gray per 
fraction and thus a prescription dose of 45 Gray delivered at a rate of 1.8 Gray / 
fraction would require the patient to attend for 25 treatments over an elapsed time of 
at least five weeks, assuming a Monday to Friday treatment schedule.   
 
During pelvic radiotherapy the normal tissues or organs that may lie within the (pelvic) 
radiotherapy field are at risk of radiation-induced damage. They include the distal 
portion of the small bowel, the terminal ileum, the caecum, the large bowel including 
the ascending, mid-transverse, sigmoid colon and rectum. In wide pelvic fields, which 
may encompass pelvic lymph nodes, it is not uncommon for loops of the small bowel 
or transverse colon to dip down into the field thus also receiving radiation dose. 
Treatment margins which allow for systematic and random treatment errors in patient 
set-up or positioning add to the overall treatment volume.  
 
Organ motion, which is technically difficult to control may further contribute to the 
dose received by normal tissues and may vary both intra- and inter-fractionally (i.e. 
during the delivery of individual fractions and between fractions). Daily treatment is 
usually based on the acquisition of a single computed tomography planning scan in 
which transverse slices through the pelvis are acquired at 5 or 7 mm intervals and 
upon which both tumour volume and organs at risk are delineated. Typically, but not in 
all instances, a dose volume histogram is produced which constitutes a composite 2-
dimensional graphical representation of the total dose to be delivered to the tumour 
and the dose that will be received by all adjacent structures.  
 
Brachytherapy describes the use of small, sealed radioactive sources placed close to 
the tumour delivering a high dose to a small target volume10. Brachytherapy limits the 
dose to normal tissue as dose falls quickly with increasing distance from the 
radioactive source. The use of High Dose Rate (HDR) systems is now widespread in the 
UK and uses radioisotopes of very high specific activity such as cobalt (60-Co) and 
Iridium (192-Ir) which have important practical advantages over Low Dose Rate 
systems10. After loading delivery techniques allow remote handling and accurate 
placement and verification of applicators. Treatment takes place in a shielded room. 
 28 
HDR intracavity brachytherapy is commonly used as adjuvant treatment in cervical and 
endometrial cancers11. Cervical applicators are usually placed under anaesthetic as 
dilation of the cervical canal is required and treatment delivery takes place over 
several days with the patient remaining in hospital. In endometrial tumours, a plastic 
tube is inserted into the vagina to carry the afterloading catheter and treatments 
delivered over two to three daily sessions, typically each delivering 4.0 Gy at a distance 
of 5 mm from the applicator surface10.   
 
1.2.2 Treatment induced gastrointestinal toxicity 
In recent years, the increasing use of computer technology and the involvement of 
highly skilled medical physicists have enabled the radiotherapy planning process to 
become increasingly sophisticated. Further, the introduction of advanced radiotherapy 
delivery techniques including intensity modulated radiotherapy (IMRT), image-guided 
radiotherapy (IGRT) and Cyberknife techniques has enabled radiographers to deliver 
daily treatment fractions with millimetre precision.  
 
Despite these advances, normal tissue tolerance remains the limiting factor in 
escalating tumour dose. Organ motion continues to challenge the ability of 
radiotherapists (without daily image guidance) to replicate initial CT planning 
geometry at each treatment fraction. To date, patient-centric approaches to 
standardise organ motion have so far met with only limited success12. Unlike ‘adverse 
events’ which can be defined quite specifically in the context of new medical 
treatments or procedures, treatment-induced radiation toxicity was, until recently an 
ill-defined concept.  
 
The term toxicity refers to unwanted radiation-induced damage or injury to normal 
tissues as distinct from planned destruction of malignant cells. In 2010 a new unified 
definition of pelvic radiation disease was proposed as ‘transient or longer term 
problems ranging from mild to very severe, arising in non-cancerous tissues resulting 
from radiotherapy treatment to a tumour of pelvic origin’13. Comprehensive guidelines 
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for the diagnosis and management of symptoms resulting from cancer treatment (i.e. 
radiotherapy and/or chemotherapy and/or surgery) were published soon afterwards14.  
 
The definition of pelvic radiation disease and associated guidelines will legitimise 
radiation induced toxicity although recent evidence suggests that the provision of 
clinical services for patients may remain sub-optimal for some time. A survey of 314 
clinical oncologists in 2011 reported that although 76% screened for gastrointestinal 
problems following pelvic radiotherapy, less than 10% referred patients to a 
gastroenterologist or gastrointestinal surgeon8.  
 
Failure or reluctance to refer patients to specialist services probably reflects the fact 
that very few specialist centres exist to treat these patients. The low response rate of 
gastroenterologists (20%) to a more recent survey in which they were asked to give 
their opinion on the provision of such services indicates that few even regard it as a 
significant problem15.   
 
1.2.2.1 Scope and nature of toxicity 
Radiation-induced toxicity in normal tissues was initially described in terms of the 
target-cell hypothesis16. Under this model the effect of ionising radiation on non-
cancerous (normal) tissues and organs was thought to be a direct consequence of cell 
killing, resulting in the depopulation of crucial cell lines and subsequent functional 
deficiency17. This radiobiological model prevailed until the mid-1990s when a more 
holistic view of damage was proposed to take account of the fact that quantitative 
damage to specific cellular lineages alone could not explain the range of late (or 
chronic) effects emerging months to years after treatment16.  
 
Radiation-induced toxicity has since been described as a radio-therapeutic injury in 
which tissues within the irradiated volume are responding to insult through normal 
wound healing mechanisms whilst at the same time undergoing a series of transient or 
permanent alterations to cellular and extracellular components18. Reparative 
processes are unable to resolve due to repeated fractionated insults with resulting 
ongoing damage to organised tissues.  
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In 2001, a new classification of radiation toxicity into cytocidal, indirect and functional 
effects was proposed. Acute toxicity was recognised as being characterised by a 
mucosal inflammatory processes, whilst in the chronic or late toxicity, submucosal, 
ischaemic and fibrotic mechanisms predominate (Figure 1.1)16. 
 
Figure 1.1 Proposed categorisation of normal tissue radiation injury 
 
Source: Figure derived by author based on information in Denham16  
 
Many studies in the last decade have augmented our understanding of the molecular 
mechanisms and mediators of damage depicted in the above model (Section 1.3.3).  
Further, emerging data on the role of the gut microbiota and immune systems point to 
the critical role they play in orchestrating inflammatory mechanisms.  
 
Mechanistic, cellular damage in the gastrointestinal tract leads to organ dysfunction. 
Disruption to normal secretory and absorptive functions includes malabsorption of 
disaccharides, bile acid malabsorption and small intestinal bacterial overgrowth due to 
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disruption of normal gastrointestinal motility and normally benign gastrointestinal 
secretions (e.g. bile acids and pancreatic enzymes) potentiate damage to an already 
inflamed mucosa. 
 
1.2.2.2 Definition and prevalence of acute and late toxicity 
Radiation-induced toxicity has historically been divided into acute and late reactions or 
‘effects’19. Acute reactions are defined as those occurring during treatment or in the 
three months immediately following treatment and may lead to symptoms. Research 
investigating time patterns of endoscopic and histological change in the acute setting 
has shown that symptoms tend to start during the second week of treatment (when 
histological damage is at a maximum) and peak towards the end of treatment (week 4 
to 5) when histological changes are stabilising or improving,20 21.  
 
These acute changes may resolve 9 - 10 weeks post treatment20 22 23. However 
objective, prospective, histological data on toxicity is rare. Assessment of acute toxicity 
is addressed in more detail below but generally relies on the measurement of 
symptoms. However, robust prospective data on the nature and severity of 
gastrointestinal symptoms and impact on quality of life in large cohorts are lacking.  
 
Attempts to correlate changes in symptom scores with histological findings or 
biomarkers have failed to yield definitive evidence of an association22 24. Accurate 
assessment of the prevalence of acute toxicity, where prevalence is defined as ‘the 
proportion of individuals in a population who have the disease at a specific instant25’ is 
also limited by the blunt or varied nature of scoring tools in current use.  
 
Table 1.2 shows the prevalence of gastrointestinal symptoms in a recent cohort of 107 
patients receiving pelvic radiotherapy, comprising 36% urological, 28% colorectal and 
36% gynaecological patients6. The reported prevalence of the impact of acute 




Table 1.2 Prevalence of acute gastrointestinal symptoms during pelvic radiotherapy 
Symptoms Prevalence (%) 
Gastrointestinal symptoms: 
Change in bowel habit 94 




Faecal incontinence 37 
Use of anti-diarrhoeal medication 40 
 
Source: Khalid6  
 
Table 1.3 Prevalence of social / lifestyle effects during pelvic radiotherapy  
Impact of symptoms on lifestyle Prevalence (%) 
Lifestyle activities 
‘Unable to do what you want because of your bowels’ 40 
‘Cancelled an engagement because of your bowels’ 20 
‘Not done leisure or sport because of your bowels’ 27 
‘Not gone somewhere because there is no lavatory nearby’ 30 
‘Felt limited in sexual activity because of your bowels’ 14 
 
Source: Khalid6  
 
Frequently patients report more than one symptom26 and frequently one symptom 
may result from multiple changes or damage to different parts of the gastrointestinal 
tract. Diarrhoea, for example, can result from one of thirteen different physiological 
mechanisms21. Small intestinal bacterial overgrowth with symptoms of bloating and 
abdominal discomfort occurs in 26% of patients during pelvic radiotherapy27. Bile acid 
malabsorption and new-onset lactose intolerance, both of which result in diarrhoea, is 
reported to occur in up to 50% of patients during treatment21.   
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Late reactions may occur months or years after treatment ranging in severity from 
mild and treatable to irreversible, severe or fatal. Serious and life-threatening changes 
including transfusion-dependent bleeding, fistula formation and bowel obstruction 
have been reported in 4 – 10% of patients five to ten years after treatment28 29 and in 
15 – 20% of patients twenty years or more after pelvic radiotherapy30.  
 
Table 1.4 summarises the range and frequencies of patient-reported gastrointestinal 
symptoms at least three months after pelvic radiotherapy for gynaecological and 
colorectal or anal cancer21. Much of this data is derived from retrospective cohorts.  
 
Table 1.4 Frequency of reported gastrointestinal symptoms after pelvic radiotherapy 
Symptoms 
Gynaecological cancer 
Reported frequency (%) 
Rectal or anal cancer 
Reported frequency (%) 
Rectal bleeding 23 – 26% 23 – 25% 
Bloating 32 - 45% 13 – 32% 
Change in bowel habit 75 – 89% 38 – 93% 
Constipation 21% No data available 
Diarrhoea (loose or soft stool) 52% 5 – 60% 
Faecal incontinence 25 – 47% 7 – 60% 
Increased frequency (of defaecation) 56% 14 – 59% 
Excessive flatulence 23 – 50% 38 – 55% 
Pain (abdominal, rectal, perineal) 34 – 52% 13 – 27% 
Tenesmus  14 – 31% 13 – 36% 
Urgency (of defaecation) 48 – 53% 14 – 78% 
 
Source: Adapted from Andreyev21 
The lack of prospective, long-term, post-treatment, outcome data and use of blunt 
symptom scoring tools insensitive to the range of late reactions that can occur may 
bias the outcomes reported21 and complicates the synthesis of data. Further, there is 
no consensus regarding time since treatment for onset of late effects. A recent survey 
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of clinical oncologists (190 responders) reported that at least 24% of patients could be 
expected to present with gastrointestinal symptoms one year after treatment8. Table 
1.5 illustrates the range of different definitions used by different authors.  
 
Table 1.5 Time-points for assessing late GI toxicity after pelvic radiotherapy 
Author (year) Time points / definitions for defining onset of late effects 
Schultheiss (1997)31 A median of 13.7 months found as the latency period for the 
emergence of late Grade 2 gastrointestinal morbidity. 
Wang (1998)32 18 months post treatment found to be the time of peak prevalence 
of radiation proctitis.   
47% of patients experiencing severe diarrhoea during treatment 
were found to be symptomatic after 12 months. 
Denham (1999)33 The ‘vast majority’ of symptoms associated with the chronic 
proctitic syndrome found to develop in the first 24 months 
following treatment. 
Weiss (1999)34 Half of all complications are diagnosed within approximately the 
first year after treatment 
Jereczek-Fossa (2002)35 Late reactions defined as those occurring after 90 days from 
completion of radiotherapy. 
Late bowel reactions occur a median of 11 months after the 
completion of radiotherapy. 
O’Brien (2002)36 Patients followed-up every 3 and then 6 months for 63 months. 
 Peters (2005)37  Late toxicity scored from 120 days after start of radiotherapy 
treatment. 
Vargas (2005)38  Grade 2 gastrointestinal toxicity found to be present in 10.3% of 
patients at 1.1 years. 
Heemsbergen (2006)39 Patients followed-up every 3 months for the first year after 
treatment and then every 6 months. 
Zelefsky (2008)40  Median time to development of late gastrointestinal toxicity found 
to be 17 months (range: 4 – 102 months) 
 





1.2.3 Consequential late effects (CQLE) 
The term ‘consequential late effects’ (CQLE) has been used to describe 
pathophysiological mechanisms that occur secondary to acute radiation injury and 
contribute to injury that manifests itself sometime after apparent healing of the early 
injury16. However, it is now recognised that cytocidal, indirect and functional effects 
(Figure 1.1) all contribute to late, chronic or ‘delayed’ radiation injury and that it is 
somewhat artificial to attempt to separate toxicity into acute and late effects16.  
 
It is now recognised that models such as Normal Tissue Complications Probability 
modelling and outcome predictions based on alpha/beta ratios, which attempt to 
classify organs as ‘early’ or ‘late’ responding in terms of their cytotoxic cellular 
response to fractionated radiotherapy, fall far short of describing the long-term 
response of complex multi-cellular tissues to radiation16 39 41 42. 
 
It is appreciated that increasing radiotherapy dose leads to accumulating tissue dose 
and thus incremental damage or toxicity. Toxicity in the acute setting is characterised 
by an inflammatory response in the gastrointestinal mucosa, which leads to 
microvasculature damage and resulting ischaemia and fibrosis in the late setting. 
These tissue responses to radiation cause symptoms because they compromise normal 
gastrointestinal tract physiology. However, the relationship between accumulating 
dose and resulting toxicity is not straightforward.  
 
Long-term outcomes in patients receiving the same radiotherapy dose, with similar 
volumes of normal organs at risk, can be very different. The point is well illustrated by 
a recent retrospective analysis of 388 patients receiving radical radiotherapy for 
prostate cancer43. Stringent rectal constraints (i.e. the maximum volume of rectum to 
receive a specified radiotherapy dose) were applied to planning data to reveal the 
number of patients who met or did not meet the specified dose constraints and 
compared to the same patients’ self-reported toxicity data.  
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In theory, patients who failed no dose constraints could be expected to experience 
minimal rectal toxicity. However, the analysis showed that even in patients who failed 
no constraints, 35% still experienced grade 2 (moderate/severe) rectal toxicity 
including rectal bleeding and urgency43.       
 
Further, a number of authors have shown that the severity of toxicity experienced 
acutely predicts for the severity of late effects 31-36 38-40 44 45 and several have 
highlighted that this association is independent of dose received32 39. However, one 
complication in predicting those patients at most risk of late toxicity, on the basis of 
the severity of the acute reaction, is the lack of consistency in the measurement of 
acute symptoms as a surrogate for toxicity. Analyses using approaches such as Area 
under the Curve (AUC) and Integrated Longitudinal Toxicity have shown that moderate 
but sustained toxicity, rather than a single severe peak in symptoms, may predict more 
strongly for late toxicity46 47.   
 
The importance of the contribution of the as yet incompletely defined (non-treatment 
related) factors that influence both acute and late outcomes is that they provide an 
opportunity for manipulation for patient benefit9. Simple and cost-effective 
interventions such as anti-inflammatory nutritional strategies may help to limit the 
extent of acute and thus late damage. Low Body Mass Index (BMI) and cessation of 
smoking, both of which can be addressed and treated, also predict for greater 
toxicity46.  
 
Other factors which may influence outcomes include genetics, gastrointestinal co-
morbidities (e.g. history of Inflammatory Bowel Disease) and the nature of the host’s 
gut bacteria or microbiota48 49. Our group has also recently shown that the use of 
certain medications including statins (HMG Co-A Reductase inhibitors) and Angiotensin 





1.2.4 Toxicity assessment and measurement 
1.2.4.1 Toxicity versus symptoms 
The objective assessment and measurement of treatment-induced toxicity is 
problematic. Symptom scoring is a poor surrogate of toxicity giving only limited or no 
insight as to underlying pathophysiological mechanisms. Reliable biomarkers of 
gastrointestinal damage would be a significant advantage in the radiotherapy setting 
but none of a number of the possible candidate markers has yet proved sufficiently 
reliable to be recommended for routine clinical use.  
 
At least ten small studies have been conducted investigating the potential efficacy of 
different blood and faecal markers in the pelvic radiotherapy setting but the available 
data is sparse and lacking in large homogeneous cohorts. Meta-analysis is hampered 
by the diversity of approach and differing outcomes employed.   
 
In the absence of a gold standard biomarker of toxicity there remains a reliance on 
scoring tools to assess treatment-induced toxicity. Some of these tools focus 
exclusively on patient reported symptoms which in terms of importance or severity 
may differ markedly from the views and interpretation of the responsible clinician51.  
 
Also, as our research group and others have shown, the correlation between 
symptoms and objective assessment of treatment-induced toxicity, at least with the 
biomarkers evaluated to date, remains poor22-24. Truly objective data regarding the 
measurement of treatment-induced gastrointestinal damage (e.g. histological scoring 
based on acquisition of data from biopsied gut) is rarely available and requires invasive 
procedures to acquire. Histological damage of the gastrointestinal mucosa in both IBD 
and radiation-induced gastrointestinal toxicity is in any case, poorly associated with 
symptoms20 22 23.  
 
Ideally, the term toxicity should be reserved to describe the unintended effects of 
treatment (in the case of this thesis, radiation-induced damage to non-cancerous 
gastrointestinal tissue) and must be assessed (or quantified) in an objective manner to 
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give insight as to possible future risk related to scope and severity of damage. Clearly, 
whilst symptoms may reflect underlying damage and loss of function they do not 
equate to toxicity.  
 
A recent communication to the author from a clinical gastroenterologist dealing with 
both acute and late effects of pelvic radiotherapy illustrates the point: “….diarrhoea on 
day 20 (of treatment) could be due to an entero-enteric fistula (terrible toxicity), new 
onset, transient, lactose intolerance due to brush border enzyme dysfunction (maybe 
less important with limited long-term sequelae), new onset bile acid malabsorption (of 
unpredictable long-term importance) OR a community acquired infection, suspect food 
item on day 19 (of treatment), ….. etc, etc.” 52.  
 
The evolution of different scoring tools for the assessment of pelvic radiation-induced 
gastrointestinal toxicity is described in more detail below (Section 1.3.5). Whilst a 
number of important improvements have been made to these tools over the years, the 
choice of instrument is limited. 
 
Many studies employ a range of tools and although the collection of data to complete 
multiple scales may appear excessive and possibly unwarranted, it enables useful 
comparison and should facilitate their future refinement51.  
 
1.2.4.2 Biomarkers of toxicity 
A biomarker is a biological molecule found in blood, other body fluids, or tissues that is 
a sign of a normal or abnormal process, or of a condition or disease53. No one ‘gold 
standard’ marker for gastrointestinal damage resulting from therapeutic pelvic 
irradiation exists.  
 
Since 2011, ten studies have investigated the use of various plasma or faecal 









Citrulline ECP CRP Calprotectin Lactoferrin 
Author  year  
Onal 201154 √     
Jakobsson 201055 √  √   
Hille 200956    √ √ 
Wedlake 200824 √ √ √ √  
Larsen 200723    √ √ 
Bowen 200557  √    
Lutgens 200458 √     
Larsen 200459    √ √ 
Koc 200360   √   
Cengiz 200161   √   
TOTAL STUDIES: 4 2 4 4 3 
 
KEY: ECP: eosinophyllic cationic protein, CRP: C-Reactive Protein 
 
Two narrative reviews have also been published53 62 but no systematic reviews or 
meta-analyses. The need for an objective measure of damage is recognised and will 
enable a better examination of the relationship between toxicity and symptoms42 53. 
 
1.2.4.3 Plasma Biomarkers  
The amino acid citrulline is the end-product of glutamine metabolism in small 
intestinal enterocytes. These cells lack the cytosolic enzymes required to convert 
citrulline to arginine and this, coupled with the fact that citrulline is not metabolised by 
the liver, means that plasma citrulline reflects small bowel enterocyte mass and thus 
functional capability63.  
 
In coeliac disease, citrulline concentrations of ≤ 10 µmol/l (equating to 25% of the 
mean normal value) are indicative of severe and extensive villous atrophy and values ≤ 
20 µmol/l indicative of severe atrophy64 Four prospective cohort studies have explored 
the citrulline as a possible biomarker of toxicity during pelvic radiotherapy24 54 55 58. In 
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all four studies levels fell significantly compared to baseline after 3 and 5 weeks of 
radiotherapy However, in no studies did concentrations reach levels associated with 
severe villous atrophy (Table 1.7)64. 
 
Table 1.7 Citrulline levels in prospective cohorts of pelvic radiotherapy patients 
Author n Baseline (µmol/l) 
Mean (sd) or  
Average (range) 
3 weeks (µmol/l) 
Mean (sd) 
5 weeks (µmol/l) 
Mean (sd) 
Wedlake24 50    28.1 (7.6)     25.9 (9.2)* 
Lutgens58 23    30.9 (19.1 – 52.9)    23.6 (2.4)*  
Jakobsson55 29    41.0 (11.0)    28.0 (9.6)*    26.0 (9.8)* 
Onal54 53    38.0 (10.1)    27.4 (5.9)*  
 
KEY: * significant difference (p<0.005) compared to baseline (start of radiotherapy)  
 
In the earliest study, which assessed citrulline concentrations weekly during treatment, 
lowest mean citrulline concentrations were observed at 3 weeks of treatment, co-
incident with a peak in the number of patients with maximum toxicity (RTOG=2) 
assessed using the Radiation Therapy Oncology Group scoring tool and fewest number 
of patients with absence of symptoms (‘% zero score’).  
 
However, a significant correlation between toxicity, measured using the RTOG tool, 
and citrulline levels was found only at week 4 (p=0.007) and week 6 (p=0.027)58. Whilst 
the total time during treatment with absence of symptoms (% zero score) correlated 
with the overall change in citrulline concentration (p=0.002), no relationship was 
observed between maximum toxicity (RTOG 2) and citrulline concentration58.  
 
Further, citrulline concentrations fell in 17/23 patients (mean decrease: 43%) during 
treatment but rose in 5/23 (mean increase: 38%) and remained unchanged in one 
patient. Despite this, a significant decrease in citrulline concentration was observed as 
a function of increasing radiation dose and of increasing volume of small bowel 
treated. The authors noted the lack of correlation between maximal toxicity and 
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citrulline concentration and remarked that several pathophysiological mechanisms, in 
addition to loss of small intestinal mucosal mass, contribute to clinical symptoms. They 
also acknowledged the difficulties of correlating subjective measures of toxicity (e.g. 
RTOG score) with objective endpoints of toxicity58.  
 
Our research group, using a potentially more sensitive tool for the identification of 
gastrointestinal symptoms, the Inflammatory Bowel Disease Questionnaire-Bowel 
subset (IBDQ-B), found no correlation between fall in citrulline concentration and 
IBDQ-B score after 5 weeks of treatment24.   
 
Two further studies have been conducted. One, recruited women with uterine or anal 
cancers and explored the link between fatigue, measured using the Multidimensional 
Fatigue Inventory (MFI)-20 general fatigue subscale (range of scores attainable: 4 – 20 
with higher scores indicating worse fatigue) and epithelial atrophy as evidenced by 
change in citrulline concentration55. The association between the intensity and 
frequency of radiotherapy-induced diarrhea, assessed using the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ-C30) and the Common Terminology Criteria for Adverse Events (CTCAE) 
v.3 respectively, and plasma citrulline concentration was also examined55.  
 
A significant correlation between MFI-20 and citrulline concentration was observed at 
three but not five weeks (p<0.05) although only five patients had values of <20 µmol/l 
at the three week time-point and the majority of patients displaying values of between 
20 – 30 µmol/l (13/27 patients) and >30 µmol/l (10/27 patients) with MFI-20 scores of 
>12 or <12 evenly split (i.e. showing no association) between these two 
concentrations. No correlation between the severity or frequency of treatment-
induced diarrhoea and citrulline was found at 3 or 5 weeks55.  
 
The most recent study evaluated the feasibility of plasma citrulline levels in predicting 
toxicity in 53 patients receiving radiotherapy for prostate or endometrial cancer54. 
Mean citrulline concentration was significantly reduced at week three and at the end 
of treatment (Table 1.12) compared to baseline values (p<0.0001 for comparison of 
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both time-points with baseline). In line with previous findings58, citrulline 
concentrations fell during treatment in 43/53 patients but rose in 9/53 and were 
unchanged in one patient. Increased toxicity, measured weekly using the RTOG tool, 
was significantly correlated with reduced citrulline concentration (p<0.0001) at week 3 
and at the end of treatment. However, a 7% change (fall) in citrulline concentration 
was also noted at week 3 despite patients reporting absence of toxicity (RTOG=0)54.   
 
Citrulline is a marker of enterocyte mass rather than inflammation. This, coupled with 
the heterogeneous cohorts used in these four studies, with differing volume of small 
bowel in receipt of radiation dose may have contributed to these equivocal results. 
 
C-reactive protein (CRP) is an acute phase protein with systemic as opposed to 
gastrointestinal-specific response. Modest (<10mg/l) but significant rises (p<0.001) in 
CRP between start and end of radiotherapy in mixed pelvic cohorts have been 
reported of 1.4 (0.21-9.8) to 2.7g/l (0.12-32.2)61, 0.70 (±0.12) to 2.74g/l (±0.61)60, and 
3.0 (±8.1) to 14.0 g/l (±25)55.  However, two of these studies reported no correlation 
between change in CRP levels and toxicity assessed using the RTOG and EORTC QLQ-
C3055 61.  
 
A third study did not investigate toxicity and only 9 of the 52 recruited patients had 
pelvic malignancy60. Our group reported no significant increase in CRP in 59 patients 
between start and following 4/5 weeks of radiotherapy24. CRP reflects a systemic 
reponse and is not specific for intestinal injury and change in levels which do rise 
above 10 g/l are of questionable clinical significance62.  
 
Eosinophilic cationic protein (ECP) which is released from activated eosinophils has 
been investigated in two cohorts receiving pelvic irradiation. Although one 
observational pilot study in 15 patients reported a significant rise in ECP (p=0.02) after 
4 weeks of pelvic radiotherapy there was no correlation between the rise in ECP and 
toxicity assessed using the Common Toxicity Criteria (CTC) v.257. In a later study, our 
group showed no significant increase in ECP in a mixed pelvic malignancy cohort of 59 
patients between start and following 4/5 weeks of radiotherapy24. 
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1.2.4.4 Faecal biomarkers 
Calprotectin is a 36-kDa calcium binding protein and member of the S100 protein 
family. It accounts for approximately 60% of the total soluble proteins found in human 
neutrophils and is released when neutrophils become activated as a direct 
consequence of underlying organ pathology with increased levels in plasma, urine or 
faeces53. Calprotectin is acknowledged as a biomarker of inflammation in inflammatory 
bowel disease (IBD) and has been used to differentiate patients with Crohn’s disease 
from those with Irritable Bowel Syndrome (IBS) or non-diseased individuals65. Levels of 
>50 µg/g are considered borderline abnormal and those >100 µg/g strongly positive65 
(Table 1.8).  
 
Four studies have examined the potential value of faecal calprotectin as a biomarker of 
gastrointestinal inflammation during pelvic radiotherapy23 24 56 59. However one of 
these studies aimed to correlate acute and late toxicity and refers to acute data which 
is only available in a non-English publication (author not contacted) and thus is not 
discussed further56. The results of the remaining studies are equivocal and comparison 
is hampered by the use of different measurement units. Table 1.8 compares the 
results of a study by our group with data from other patient groups24.  
 
Table 1.8 Calprotectin in pelvic radiotherapy patients and other patient groups 
Author n Baseline (µg/g) 
Mean (sd)  
 





Wedlake24 59 35.7 (103)     62.9 (121)* 
Costa65  
   Comparator groups: 
 
Median value and (95% confidence interval) 
Gastrointestinal cancers 26 105 µg/g  (0 – 272 µg/g) 
Crohn’s Disease 49 231 µg/g  (110 – 353 µg/g) 
Ulcerative Colitis 82 167 µg/g  (59 – 276 µg/g) 
Healthy subjects 34 11 µg/g  (3 – 18 µg/g) 
 
KEY: * significant difference (p<0.01) compared to baseline (start of radiotherapy)  
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The results of our group are in line with expectations, including a rise in levels of f. 
calprotectin after 5 weeks of pelvic radiotherapy with values beyond the threshold 
considered normal for healthy subjects. However, no correlation was seen between 
the change in f. calprotectin and clinical symptoms assessed using the IBDQ-B tool 
(p=0.304)24.  
 
In a further two studies23 59, although a significant difference in faecal calprotectin 
levels between baseline and end-of-radiotherapy (receipt of 60 Gy) was reported 
(p=0.0005) in one study, in a later study, by the same group, no difference in faecal 
calprotectin levels between baseline and 6 weeks of radiotherapy treatment was 
found. Both studies were small, recruiting fifteen59 and twenty23 patients with prostate 
cancer. The possible association between change in faecal calprotectin and toxicity 
was not explored in the earlier of these studies59 and in the later one, lack of a 
significant difference in faecal calprotectin levels precluded correlational analysis23.  
 
It is possible that neutropenia induced by chemotherapy agents given simultaneously 
with radiotherapy, may contribute to low levels of granulocytic neutrophils in the 
bowel resulting in low levels of this biomarker in faeces53. 
 
The use of an alternative faecal marker, faecal lactoferrin has been examined in two 
studies23 59. Rising lactoferrin concentrations are indicative of disease flares or relapse 
in IBD53. Both studies, reported that concentrations of faecal lactoferrin (mg/kg) rose 
significantly during radiotherapy, although in the earlier study, the possible association 
between a rise in the concentration of faecal lactoferrin and clinical symptoms was not 
explored59. In the later study, there was no significant correlation between lactoferrin 
in stool and symptom scores measured using a bespoke Total Symptom Score index 
assessing stool characteristics, pain, flatulence, bloating and nausea23. 
 
In summary, no one reliable biomarker of damage to the gastrointestinal tract during 
pelvic radiotherapy has been found and it is possible that a combination of markers, 
measured at specific time-points will yield more promising results. The lack of 
correlation between change in biomarker and change in symptom score is frustrating 
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and hampered by the number of different toxicity scoring tools in use of widely varying 
sensitivity. Some progress has been made with respect to the identification of markers 
of fibrotic change in the acute setting which may have relevance to chronic change 
although none of these are in routine clinical use.66 It seems that the convenience and 
non-invasive nature of symptom scoring tools means that they will continue to be used 
routinely in clinical practice to indicate individual patient’s tolerance to treatment for 
some time to come.  
 
1.2.5 Symptom scoring tools: acute radiotherapy setting 
1.2.5.1 The development of radiation toxicity scoring tools 
The Radiation Therapy Oncology Group was formed in 1971 and their well-established 
scoring tool, the Radiation Therapy Oncology Group / European Organisation for 
Research and Treatment Cancer (RTOG/EORTC) tool, is a formerly extensively used, 
validated tool for assessing acute toxicity resulting from therapeutic radiotherapy67.  
 
The original RTOG tool was developed in the early 1980s and was designed as a simple 
scoring scale aimed at giving a quick and objective assessment of a patient’s degree of 
toxicity to radiotherapy. Radiation effects were graded on a categorical 0 – 5 scale, 
with score of ‘0’ representing absence of symptoms and a score of ‘5’ death. The RTOG 
tool is somewhat blunt in its assessment with large differences in severity of effect 
between grades. Further, it does not allow for the recording of emotional distress or 
social effects or impact of toxicity burden on quality of life. However, it has important 
historical context and has been widely used in clinical trials for the rapid assessment 
and capture of acute radiation-induced toxicity data.  
 
In 1982 the RTOG tool was extended in collaboration with the EORTC to produce the 
joint RTOG/EORTC criteria for late toxicities in recognition of the need for a more 
standardised approach to reporting treatment-related toxicity, thus resulting in two 
scoring tools, the RTOG acute scale and RTOG/EORTC late toxicity scale68. A 90 day rule 
was created with a recommendation to use the acute RTOG tool for toxicities 
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emerging within 90 days of the start of radiotherapy and the RTOG/EORTC late tool to 
capture toxicities emerging more than 90 days from the start of treatment.  
 
In 1998 The National Cancer Institute (NCI) developed version 2 of their Common 
Toxicity Criteria (CTC) in collaboration with the RTOG. This version of the tool which 
replaced the original (1983) version was extended from its original focus on 
chemotherapy-related toxicity, to include acute radiation-induced toxicities. As such 
CTC v2.0 quickly replaced the RTOG acute scale in many studies although the 
RTOG/EORTC late toxicity scale continued in use until late 2003 when the CTC v3.0 was 
developed. The new version of the CTC relabelled ‘CTCAE v3.0’ (Common Terminology 
Criteria for Adverse Events) encompassed both acute and late toxicities relating to 
chemotherapy and radiotherapy and resulted in the dropping of the old 90 day rule 
which was recognised as a somewhat arbitrary cut-off for the definition of acute 
versus late effects.  
 
The CTCAE v3.0 was regarded as the first comprehensive multimodality grading system 
for reporting both acute and late effects in oncology and is the required toxicity 
scoring tool for all NCI-funded trails. In 2009, the fourth edition of the CTCAE was 
published and revised in 2010 and is available online. The 78-page revised document in 
essence constitutes a comprehensive standardised terminology, with accompanying 
categorical 0 – 5 grading system for reporting the scope and severity of treatment-
induced events or toxicities covering 26 major organ systems. A total of 117 
gastrointestinal ‘adverse events’ are listed covering the upper and lower 
gastrointestinal organs.  
 
However, despite progress in achieving standardisation of toxicity nomenclature and 
reporting, a major criticism of the CTCAE is that in practice, there is no clear consensus 
as to how to score multiple signs and symptoms. Often, they are combined into a 
single (averaged) grade which, not least in studies where toxicity is a primary endpoint, 
is associated with a loss of specificity42.  
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Whilst the focus of this thesis is the acute radiotherapy setting, one instrument 
designed for use in the late setting should be mentioned. The Subjective, Objective, 
Management, Analytic /Late Effects Normal Tissue (SOMA/LENT) system69 70 was first 
published in 1995 by an expert working group within the EORTC/RTOG. As suggested 
by its acronym the characteristic feature of the system is that each toxicity item is 
classified by its subjective symptoms, objective signs and management-related or 
analytical measures71. Scoring is performed by healthcare professionals, based upon an 
interview and clinical examination.  
 
Whilst this system embodies patient and clinician rated signs and symptoms of toxicity 
the problem of how to derive an aggregate score from a series of scores obtained for 
each individual aspect of toxicity is (as with the CTCAE) debated and there is obvious 
loss of fidelity in the aggregation process. Never-the-less the ‘LENT-SOMA’ system was 
the first attempt to produce a single comprehensive scoring tool incorporating both 
clinician and patient (subjective) scoring of toxicity51. LENT-SOMA items (including 
subjective elements) were incorporated within CTCAE v3.0, published in 200351. 
 
1.2.5.2 An alternative tool for scoring symptoms from gastroenterology 
One validated gastrointestinal scoring tool that has been used quite extensively in the 
UK72 and has performed well in validation studies against the RTOG /EORTC lower GI 
including pelvis toxicity morbidity scoring criteria in both the acute6 and late73 
radiotherapy setting is the Inflammatory Bowel Disease Questionnaire (IBDQ) and 
integral Bowel sub-set of questions (IBDQ-B).  
 
The IBDQ was originally developed as a disease-specific measure of quality of life for 
patients with inflammatory bowel disease. It consists of four sub-scales of which bowel 
symptoms (IBDQ-B) form a subset of ten questions. A maximum score of 7 (absence of 
symptoms) and a minimum score of 1 (symptoms worse than ever before) is given for 
responses to each question thus allowing a maximum attainable score of 70 and a 
minimum score of 10 for the IBDQ-B subset. A fall in score between measurement 
time-points is indicative of worsening symptoms. The entire IBDQ (all sub-scales) 
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comprises 32 questions, following the same scoring system as the IBDQ-B with a 
maximum 224 points (Quality of Life best score) and a minimum 32 points (worst 
score). A fall in score between time-points is indicative of worsening quality of life.  
 
The IBDQ questionnaire has been used to assess treatment-induced toxicity in six 
previous cohorts of patients with mixed pelvic malignancy receiving radiotherapy6 24 46 
74-76. In these previous studies, the change in IBDQ-B score has ranged from a fall of 7.2 
to 10.8 points from the start to the end of radiotherapy (Table 1.9). This equates to a 
12 to 18% change in score out of a total possible 60 point change in score between the 
maximum (70 points) to minimum (10 points) scores attainable. 
 
Table 1.9 Change in IBDQ-B Scores in previous pelvic cancer cohorts 
Study, Reference 
Measurement 
IBDQ-B Scores Cohort description (n) 
U: Urological; Gi: 
Gastrointestinal 
Gy: Gynaecological 




(44 - 70) 
61 
(33 - 70) 
- 8 107 




(54 - 70) 
59 
(35 - 69) 
- 9 50 







- 9.7 59 







- 9.6 193 







- 10.8 21 







- 7.2 117 
U: 56; Gi: 38; Gy: 23 
 
This description of toxicity scoring tools concludes a summary of the clinical setting 
within which the research described in this thesis takes place. The following sections of 
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this chapter explore the extent to which radiation-induced gastrointestinal toxicity and 
another inflammatory condition of the gastrointestinal tract, Inflammatory Bowel 
Disease (IBD) are similar and thus may benefit from similar management strategies.  
 
The rationale for specific nutritional interventions in patients receiving pelvic 
radiotherapy with the aim of damping the inflammatory response, thus reducing 
clinical symptoms associated with acute treatment-induced toxicity, is examined.  
 
1.3   Radiotherapy-induced gastrointestinal toxicity and 
Inflammatory Bowel Disease: Comparable diseases? 
1.3.1 Introduction 
It could be argued that acute radiation-induced gastrointestinal toxicity and IBD are 
comparable diseases in as much as gastrointestinal inflammation is the hallmark of 
both. If parallels can be drawn between the inflammatory mechanisms in these two 
diseases, it follows that strategies designed to prevent or reduce gastrointestinal 
inflammation in IBD may be applicable and transferrable to acute radiation-induced 
gastrointestinal toxicity, from this point referred to as ‘radiation-induced GI toxicity’.  
 
IBD is perhaps a ‘gold standard’ model of inflammation. It is certainly the most 
researched model of gastrointestinal inflammation and a condition in which nutritional 
strategies for the prevention of inflammation have been widely explored. 
Approximately 1.4 million Americans are affected by IBD77 a figure remarkably similar 
to recent estimates of the prevalence of chronic bowel dysfunction following 
therapeutic pelvic irradiation in the US of 1.5-2 million78.  
 
IBD is a multi-factorial disorder which has been extensively studied. In contrast, pelvic 
radiation disease13 has only recently begun to receive the degree of attention in 
keeping with its prevalence. This is despite the fact that radiation-induced 
gastrointestinal toxicity was first described over 100 years ago by Walsh in 1897 as 
‘inflammation of the gastrointestinal mucous membranes’ soon after Roentgen’s 
description of X-rays79.  
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This section explores the similarities between radiation-induced GI toxicity and IBD 
with the aim of providing a rationale to argue that these diseases display many 
similarities and that knowledge regarding the nutritional management of IBD can be 
usefully extrapolated to radiation-induced GI toxicity. 
 
1.3.2 Aetiology, histology and clinical presentation of IBD and radiation- 
           induced GI toxicity 
1.3.2.1 Inflammatory Bowel Disease 
The idiopathic inflammatory bowel diseases (IBD) comprise two major forms of chronic 
intestinal inflammatory disorders, Crohn’s disease (CD) and ulcerative colitis (UC). A 
third condition, pouchitis, is a complication of ileal pouch-anal anastomosis following 
colectomy in UC patients.  
 
The incidence of Crohn’s disease at 5-6 per 100,000 is rising slightly and varies country 
to country (Male: Female ratio of 1 : 1.2) whilst that of ulcerative colitis at 6-15 per 
100,000 (Male: Female ratio of 1.2 : 1) is currently stable80.  
 
It has long been appreciated that the aetiology of IBD has a genetic component80. It is 
now acknowledged that IBD results from an inappropriate inflammatory response to 
intestinal microbiota in genetically susceptible individuals77. 
 
In addition to genetic susceptibility, the development and course of IBD is affected by 
gut microbiota, immune dysregulation and environmental factors80. There is 
substantial overlap in susceptibility gene loci for CD and UC. Some loci are unique to 








Figure 1.2 Factors affecting the course and development of IBD.  
 
 
Source: Kaser80. Key: Factors common to CD and UC in black font, CD-specific polymorphisms 
in magenta, UC-specific polymorphisms in blue font, for abbreviations see glossary.  
 
Heritable risk for IBD shows greater phenotypic concordance in monozygotic than 
dizygotic twins for both CD and UC with considerably higher concordance for CD (50-
75%) compared to UC (10-20%) suggesting a greater role for environmental factors in 
UC 80 81. In familial studies, 10-20% of individuals with IBD report one or more relatives 
also having the disease82. The relative risk of familial occurrence in European 
populations (i.e. prevalence of IBD among first degree relatives divided by the 
population prevalence) is approximately 15-fold83. 
 
Peak onset of CD is between 20 - 30 years of age with a second minor peak at 50 - 60 
years. Peak onset of UC is between 20 - 40 years with a later minor peak at 60+ years. 
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Smokers are at increased risk of CD and former and non-smokers are at greater risk of 
UC. IBD carries increased risk of primary sclerosing cholangitis, ankylosing spondylitis 
and psoriasis77. A recent review suggested that patients with IBD have a 29 - 46% 
increased risk of severe acute toxicity or chronic complications following therapeutic 
radiotherapy84. 
 
Disease site in CD is most frequently the ileum and colon although any part of the 
intestine may be affected. In UC, site of disease is almost always the rectum (95% of 
patients) with varying degrees of proximal extension83. The inflammatory pattern in CD 
is typically patchy and transmural with lesions from the mucosa into the underlying 
serosa. Small superficial (aphthoid) ulcerations over Peyer’s patches may be seen with 
deep focal inflammation sometimes accompanied by non-caseating granulomas83. 
Fistula formation and strictures are chronic complications.  
 
The inflammatory pattern in UC is continuous and generally confined to the mucosa 
with ulceration, oedema and haemorrhage of varying severity. There is increased 
intestinal permeability as a result defective regulation and sealing of tight junctions. 
Defective Paneth and goblet cell function further compromises barrier integrity77. In 
ileal CD, Paneth cell secretion of anti-microbial α-defensins is reduced, whilst in colonic 
CD, expression of β-defensins is inadequate85. In UC, production of mucus is reduced 
due to insufficient differentiation of stem cells to goblet cells85.  
 
Clinical symptoms of IBD vary but can have a profound impact on patients’ quality of 
life86. In CD symptoms reflect the location, extent and severity of disease and include 
diarrhoea, bile salt malabsorption (following terminal ileum resection) small bowel 
malabsorption of nutrients and vitamins, weight loss, anorexia and abdominal pain83.  
 
In contrast, bloody diarrhoea or passage of blood and mucus are cardinal symptoms of 
UC and present in over 90% of patients at presentation. Other symptoms of UC include 
urgency, tenesmus (sensation of needing to pass stool when no stool is present) and 
nocturnal diarrhoea. Cramping or abdominal pain may be mild or absent and unlike 
CD, weight loss is not usually a feature at presentation.       
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1.3.2.2 Radiation-induced GI toxicity 
The aetiology of acute clinical radiation-induced GI toxicity is multifactorial22. 
Susceptibility genes for increased risk of severe toxicity have not been definitively 
identified. A recent validation study (n=1613) of 92 single nucleotide polymorphisms 
(SNPs) in 46 previously identified ‘DNA damage and repair’ genes concluded that, on 
reanalysis, none were significantly associated with late radiation toxicity87. Rare 
syndromes (Nijmegen breakage syndrome, Fanconianaemia, and ataxia telangiectasia) 
predispose to increased radio-sensitivity17. The role of patient and lifestyle factors is 
poorly defined with no high quality prospective studies. Smoking, low Body Mass Index 
(BMI), connective tissue disorders, auto-immune pathologies, vascular disorders and 
diabetes may also affect toxicity outcomes46 78. 
 
Ionising radiation provokes an acute inflammatory response in irradiated cells via 
reactive oxygen species (ROS) from the interaction of electrons and cellular water. 
ROS-mediated damage includes single and double strand DNA breaks and structural 
disruption of proteins, lipids and carbohydrates18 88. Down-stream cellular effects 
include cellular apoptosis, necrosis, mitotic catastrophe and phenotypic modification89.  
 
Unlike IBD, onset of radiation-induced damage can be precisely determined. In 
preclinical studies, mitotic inhibition (G2 block) of stem cell differentiation has been 
reported within 30 minutes of radiation exposure with consequent changes in cell 
kinetics90 and severely depleted crypt mitotic counts91. Apoptotic cells appear within 2 
- 3 hours of irradiation90 and are seen in crypts of the small and large intestine at one 
week91. In clinical fractionated delivery, repeated exposure leads to accumulating 
damage against a backdrop of incomplete repair18. The result is that normal tissue that 
is irradiated at the start of radiotherapy is qualitatively very different to the ‘normal’ 
tissue that is irradiated towards the end18.  
 
Preclinical studies investigating the effects of radiation on small intestinal morphology 
in rodent models have shown reduced crypt circumference, mucosal atrophy, grossly 
abnormal epithelial cells, decreased villus height and surface area, abnormalities in 
microvilli structure and goblet cell disorganisation and degeneration90 91. Similar 
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morphological features are observed in IBD. Derangement of tight junction protein 
occludin has also been reported with increased paracellular permeability. In vitro 
studies using marker molecules have confirmed increased intestinal permeability in 
irradiated human rectal tissue92.  
 
Sequential investigations20 22 23 of rectal morphology in patients receiving pelvic 
radiotherapy for prostate cancer with biopsies taken at baseline (prior to start of 
radiotherapy) and after two and six weeks of fractionated radiotherapy have elegantly 
revealed the extent of change that occurs after just two weeks of fractionated 
radiotherapy treatment (Figures 1.3a, 1.3b).  
 
















In the Hovdenak study, maximum histological damage was evident at two weeks in 
contrast to symptoms, the prevalence and number of which rose throughout 
treatment20. Invasion of epithelial, glandular and stromal rectal tissue with neutrophils 
and eosinophilic granulocytes was seen with macrophages in the deeper lamina 
propria20.  
 
Congestion of the lamina propria with innate and adaptive immune cells and 
eosinophilic and neutrophilic abscesses has also been observed in-vitro in irradiated 
human rectal tissue93.  
 
Depletion of glands, defective barrier function and atrophy of surface epithelium all 
result in disruption to secretary and absorptive functions, effects on gastrointestinal 





1.3.3 Molecular mechanisms of inflammation and immune-mediated      
 effects in IBD and radiation-induced GI toxicity 
1.3.3.1 Introductory comments 
A number of molecular mediators of inflammation are common to radiation-induced 
toxicity and IBD. They include cytokines, growth factors, integrins, cellular receptors 
and signalling pathway proteins. Their role in IBD has been extensively studied.  
 
However, it was not until more recently that their role in radiation-induced GI toxicity 
was more fully understood to the extent that it is now described as an immuno-
inflammatory response in a particularly radiosensitive body compartment, in which the 
gut microbiota plays a key role89. 
 
1.3.3.2 Inflammatory mediators: Inflammatory Bowel Disease 
The stimulus for onset of IBD is not known but the concept that resident microbiota 
are largely tolerated whilst pathogenic species are targeted for destruction is not 
entirely correct94. In health, the intestinal lamina propria contains a mixed population 
of innate and adaptive immune system cells. Continual microbial sensing of resident 
and emergent microbiota is important in regulating the intestinal immune response94.  
 
To this end, epithelial cells, dendritic cells and macrophages (as components of the 
innate immune system) display pattern recognition receptors (PRRs) that recognise 
general microbial patters77. This contrasts with antigen-specific recognition in which 
IgA antibodies secreted by B plasma cells of the adaptive immune system contribute to 
host protection without provoking inflammation94.  
 
Toll-like receptors (TLRs) of which at least 12 have been described and intra-cellular 
nucleotide oligomerisation domains (NODs) recognise conserved microbial structures 
or pathogen-associated molecular patterns (PAMPs) and can respond to both 
pathogenic and harmless resident microbes with constitutive antimicrobial 
mechanisms94. Activation of TLRs induces various pathways that mediate microbial 
killing and activate adaptive cells. Activation of the NOD2 protein by bacterial 
peptidoglycan activates nuclear factor кB (NF-кB) and the mitogen-activated protein 
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kinase (MAPK) signalling pathway which in turn leads to production of tumour necrosis 
factor (TNF), interleukin-1β and anti-microbial peptides.  
 
Most importantly, perturbation of the homeostatic balance between defence and 
tolerance is thought to be the critical factor predisposing to IBD94. In active IBD, 
inadequate resolution of inflammation and continued epithelial injury facilitates 
increased microbiota exposure which perpetuates the disease process77.  
 
In health, the innate and adaptive immune systems work together to regulate the 
immune response and prevent over-activation of defensive or inflammatory strategies. 
Dendritic cells present antigens to naïve CD4+T cells in gastrointestinal lymphoid tissue 
(GALT) where their phenotype and local cytokine environment moderates 
differentiation into T cell subgroups of helper (Th1, Th2 and Th17) and regulatory 
(Treg) cells. Activated T helper cells then circulate to the lamina propria, secrete their 
own compliment of inflammatory cytokines and carry out effector functions. 
Regulation of these T cell sub-groups must be continually fine-tuned to maintain 
intestinal homeostasis.  
 
In active IBD, there is pronounced infiltration of the lamina propria with innate 
immune cells (neutrophils, macrophages, dendritic cells and natural killer T cells) and 
adaptive immune (B and T) cells77 83. This phenomena is similar to that observed (and 
described earlier) by Hovdenak20. Increased activation of these cells elevate local levels 
of pro-inflammatory tumour necrosis factor α (TNF-α), interleukin (IL) 1β, interferon-γ 
and cytokines of the interleukin-23-Th17 pathway94. The resulting imbalance between 
these and anti-inflammatory cytokines, transforming growth factor β (TGF-β), cytokine 
interleukin-10 (IL-10) and regulatory Treg cells (differentiation of which is regulated by 
TGF-β, IL-10 and retinoic acid) predisposes to a pro-inflammatory environment94.  
 
Up-regulation of adhesion molecules on vascular endothelial cells by elevated TNF-α 
and IL-1β causes increased leucocyte attraction and adherence with consequent 
abnormalities in intestinal microvasculature including ischemia, local tissue hypoxia, 
ongoing mucosal inflammation and impaired mucosal healing77 94. 
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1.3.3.3 Inflammatory mediators: radiation-induced GI toxicity 
As in IBD, recent evidence suggests that normal tissue inflammatory responses to 
irradiation are, as in IBD, inextricably linked to innate and adaptive immunity95. 
Damaged self-molecules or damage-associated molecular patterns (DAMPs), in a 
similar manner to PAMPs, are recognised and dealt with by the same immune 
pathways that orchestrate the host response to microbial and other threats.  
 
In contrast to IBD where the initial inflammatory stimulus is not known, ionising 
radiation is a pro-inflammatory signal, the initiation of which can be precisely 
documented. In a similar manner to IBD, radiation-induced GI toxicity is now thought 
to involve the full repertoire of innate and adaptive immune responses (Figure 1.4)89.  
 





TLRs present on epithelial cells respond to DAMPs including high-mobility-group box 1 
(HMGB1) proteins, heat shock proteins and proteins damaged by reactive oxygen 
species (ROS)95. DAMP-activation of TLRs results in translocation of transcription factor 
NF-кB, which in the inactive state is sequestered in the cytoplasm, and activator 
protein-1 (AP-1). Translocation results in transcription of pro-inflammatory cytokines 
similar to those observed in IBD including IL-1β, IL-6, IL-8 and TNF-α96. In pre-clinical 
models, radiation exposure has been demonstrated to increase TLR expression and 
enhanced expression of interleukin-12 (IL-12) and interleukin-18 (IL-18)97.  
 
 Mast cells are resident immune cells in the gut, capable of mounting a particularly 
rapid response to various physiological and pathological stimuli with vigorous secretion 
of pro-inflammatory, vasoactive and mitogenic mediators89. Rapid proliferation of 
mast cells has been observed in mucosa and submucosa following radiotherapy for 
rectal carcinoma89.  
 
As in IBD, endothelial dysfunction has been reported in the pathogenesis of early and 
late radiation damage98. Endothelial cells form the inner lining of blood vessels 
representing a total surface area of 4000-7000m2 and under normal conditions 
maintain an antithrombotic and anticoagulant balance by exerting molecular control 
over platelet aggregation, coagulation and fibrinolysis98.  
 
Marked loss of thromboresistance occurs following exposure to ionising radiation as 
radiation causes a deficiency in thrombomodulin (TM) which results in insufficient 
activation of protein C, a plasma protein with anti-coagulant, anti-inflammatory, and 
cytoprotective properties thus potentiating a pro-inflammatory vascular 
environment98.  
 
Other work has shown the importance of leukocyte recruitment in exacerbating 
damage mediated by vascular adhesion molecules (ICAM-1 and VCAM-1) and 
leukocyte adhesion receptors, selectins ‘L’, ‘P’ and ‘E’99-101. Increased expression of 
ICAM-1 in response to ionising radiation has also been reported in IBD patients101 and 
up-regulation of adhesion molecules has similarly been reported in IBD. 
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Pre-clinical intravital microscopy studies have reported involvement of the p38 MAPK 
and rho kinase (ROCK) signalling pathways in radiotherapy-induced vascular 
inflammation with increased platelet recruitment, leucocyte rolling, adhesion and 
increased myeloperoxidase ‘MPO’ and CXC chemokines102 103.  
 
Increased colonic permeability has also been reported suggesting more wide-spread 
effects of MAPK and ROCK signalling. Increased activation of p38 MAPK signalling 
pathways in response to ionising radiation104 has also been observed in patients with 
inflammatory bowel disease105.  
 
As with IBD, perturbation of the balance between pro-and anti-inflammatory cytokines 
in radiation-induced GI toxicity may be particularly important in perpetuating the pro-
inflammatory response. In a pre-clinical model using rat ileal muscularis tissue, 
radiation exposure caused rapid translocation of NF-кB sub-units p65 and p50 to the 
nucleus with increased transcription of proinflammatory IL-1β, TNF-α, IL-6 and 
cytokine-induced neutrophil chemoattractant (CINC) resulting in an imbalance in 
interleukin 1 receptor antagonist (IL-1ra) and IL-1096. An imbalance between IL-1β and 
IL-1ra has been reported to be an important factor in the pathogenesis of IBD96.  
 
Much of the early work in radiation-induced toxicity focussed on the role of specific 
inflammatory mediators. However, more recent research in this area, in common with 
IBD, has focussed on the elucidation of immuno-inflammatory processes89 95. In 
radiation-induced toxicity eicosanoids were initially identified as mediators of vascular 
damage with significant increases in the levels leukotriene B4, (LTB4), thromboxane B2 
(TXB2) and prostaglandin E2 (PGE2) found in rectal dialysate following pelvic 
radiotherapy106. However, these findings have not been repeated23.  
 
Other studies have observed increased expression of cyclooxygenase-1 and 2 (Cox-1, 
Cox-2) and NF-кB91 93, in pre-clinical 91 and ex-vivo irradiated colorectal tissue93; 
significantly upregulated mRNA levels of IL-1β, Il-6 and TNF-α in irradiated rat colon 
and jejenum107; significantly increased IFN-ɣ and IL-6 in proteonomic profiling of 
peripheral blood from patients undergoing IMRT for prostate cancer108; significantly 
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elevated IL-6 in prostate cancer patients on day 15 of radiotherapy109 and positive 
correlations between IL-6, matrix metalloproteinase 9 (MMP-9), platelet derived 
growth factor (PDGF) and symptom scores assessed using the IBDQ-B tool in patients 
receiving pelvic radiotherapy66.  
 
1.3.4 Microbiota and gastrointestinal inflammation in IBD and radiation- 
    induced GI toxicity 
1.3.4.1 Introductory comments 
Culture-independent techniques and computational taxonomy has enabled dramatic 
improvements in our understanding of the bacteria (microbiota) that inhabit the gut 
and the crucial role they play in gastrointestinal inflammatory processes. The human 
gastrointestinal tract has a mucosal surface area of 300 – 400 m2 (similar in size to a 
tennis court)110. In absolute terms it harbours more than 1014 microorganisms the 
majority of which (1011 cells/g) inhabit the colon.  
 
In total, the microbiota comprises over 1000 prevalent bacterial species with a biomass 
of over 1kg and at least 160 species per individual111. In health it seems an individual’s 
microbiota, especially mucosa-associated communities are relatively stable over 
time110.  
 
Microbiota composition is influenced by birth (caesarean section versus vaginal 
delivery) breastfeeding, diet and therapeutic intervention. By 2.5 years of age, an 
infant’s microbial community resembles that of an adult112. The mix of microbiota 
species influences metabolic capability (metabolomics) which includes vitamin 
synthesis, bile salt metabolism, xenobiotic degradation and carbohydrate fermentation 
and resulting production of SCFA111.  
 
In health, anaerobes are several orders of magnitude more abundant than aerobes 









1.3.4.2 Inflammatory Bowel Disease 
Dysbiosis (perturbation in the microbiota) is associated with the pathogenesis of IBD 
although it is unclear whether this is a cause or effect of disease. Evidence indicates 
that the presence of gut bacteria is a necessary pre-requisite for an immune-
inflammatory response110. In CD, diversion of the faecal stream induces remission 
whilst reinfusion of intestinal contents reactivates disease, in UC, broad-spectrum 
antibiotics can reduce metabolic activity of microbiota and mucosal inflammation110.  
 
However, whilst microbiota can drive inflammation, the opposite is also true. Pre-
clinical studies show that microbiota metabolites, SCFA can moderate immune 
responses by suppression of transcription activator NF-кB or promotion of the 
expansion of the anti-inflammatory Treg cell populations.   
 
Dysbiosisis in IBD is characterised by a reduction in overall microbiota diversity and 
over- or under-expression of individual species (Figures 1.6a and 1.6b).  
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Figure 1.6a Dysbiosis in UC patients   
 
 




Reduced numbers of Bacteroides in UC and pouchitis patients, Firmicutes and 
Roseburia in CD and UC patients and Faecalibacterium prausnitzii in CD, UC and 
pouchitis patients has been observed110 114.  
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In contrast, increases in Proteobacteria in UC and pouchitis patients, Enterobacteria in 
UC and CD patients, Actinobacteria in UC patients110 and Ruminococcus, 
Bifidobacterium and Lactobacillus in CD patients have been reported110 115. A new 
pathogenic strain of E. coli, ‘adherent-invasive E. coli’ (AIEC) has been found in CD 
patients and in UC increased gram-negative, crypt-associated, anaerobic sulphate-
reducing bacteria have been observed110.  
 
In CD and UC there is decreased stability in the mix of species. Sequential faecal 
sampling in UC patients has shown that only one third of dominant taxa are 
consistently detected over time110. Change in composition is associated with striking 
changes in metabolic pathways and products. A recent analysis in 231 IBD patients 
reported that even small (2%) changes in genera resulted in a 12% change in metabolic 
pathways including reduced SCFA production116.  
 
1.3.4.3 Radiation-induced GI toxicity  
Few studies have examined the direct effects of radiation on the intestinal microbiota. 
One pre-clinical study (available in abstract only) reported ‘postradiation 
dysbacteriosis’ with decreased Lactobacilli and Bifidobacteria and a concomitant 
increase in Escherichia, Proteus and Clostridium in guinea pigs subjected to 
irradiation117. 
 
A notable recent pilot study comprising 10 patients undergoing fractionated 
radiotherapy for pelvic malignancies used cluster analysis to investigate the similarity 
in bacterial profiles of patients who developed new-onset diarrhoea48 versus those 
who remained diarrhoea-free. The six patients reporting new-onset diarrhoea (graded 
using Common Toxicity Criteria for reporting Adverse Events ‘CTCAE’ v.2) showed a 
significantly modified bacterial profile (p<0.05) and clustered separately from those 
who remained diarrhoea-free. Sub-group analysis further revealed increased 
Actinobacteria and Bacilli in the two patients reporting worst diarrhoea48.  
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Another pilot study from our group in collaboration with Coventry University used 
electronic nose (e-nose) technology and Field Asymmetric Ion Mobility Spectrometry 
(FAIMS) in 23 patients undergoing pelvic radiotherapy. Patients who reported the 
worst on-treatment symptoms (scored using the IBDQ-B) clustered separately on the 
basis of their fermentone profile (volatiles emitted from faecal samples) from those 
who reported least toxicity before and after treatment, suggesting predictive benefits 
of the e-nose technology49.  
 
It has been reported that this technology may be equally relevant for diagnostic or 
predictive purposes in other inflammatory conditions such as IBD118. Evidence of the 
adverse impact of irradiation on gut motility and consequent outcomes such as small 
intestinal bacterial overgrowth (SIBO) has long been recognised particularly in late 
(post-radiation) ’enteropathy’119. In the acute setting, our group used glucose 
hydrogen breath testing to test for SIBO in 39 patients receiving pelvic radiotherapy 
and reported that 26% developed new-onset glucose intolerance, indicative of SIBO27.  
 
Preclinical studies provide evidence of a dynamic interaction between the host 
microbiota and the innate immune system in modulating the intestinal response to 
radiation120. Germ-free mice show increased radiation resistance with fewer apoptotic 
endothelial cells and lymphocytes in small intestinal villi cores than conventionally 
raised animals121. Paradoxically, though, lipopolysaccharide (LPS) a component of the 
external membrane of gram-negative bacteria and a ligand for TLR4 is radio-protective, 
reducing crypt cell apoptosis and improving intestinal crypt cell survival through a 
prostaglandin-mediated mechanism122-124.  
 
Flagellin, a component of flagellated bacteria and a ligand for TLR5 is also radio-
protective against sub-lethal doses of whole body irradiation in mice and primates89 
120. Lactobacillus rhamnosus GG administered prophylactically improved crypt survival 
and reduced epithelial apoptosis in wild-type but not TLR2 / MyD88 / COX-2 knock-out 
animals, suggesting a TLR2/MyD88 mediated mechanism that involved a repositioning 
of constitutive COX-2 expressing mesenchymal stem cells to the crypt base122.   
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1.3.5  Summary: similarities between IBD and radiation-induced 
gastrointestinal inflammation 
This section has compared the mechanism and mediators of gastrointestinal 
inflammation in IBD with those known to occur in radiation-induced GI toxicity and 
found many similarities between these two inflammatory conditions.  
 
Whilst the aetiologies of IBD and radiation-induced GI toxicity are quite distinct, there 
are specific aspects of IBD that closely resemble radiation-induced GI toxicity. 
Therefore, it is concluded that sufficient similarities exist in histology, clinical 
presentation and molecular mediators of inflammation to indicate that management 
strategies, appropriate to IBD may also be applicable to radiation-induced GI toxicity. 
Since nutritional strategies have been widely explored in IBD, it follows that they might 
also be helpful in radiation-induced GI toxicity. 
 
The next step in this introduction is to explore nutritional strategies, with particular 
emphasis on their potential impact on inflammatory mechanisms that may be 
potentially beneficial. Since the clinical interest of this thesis is directed towards 
patients receiving pelvic radiotherapy, the emphasis will be on strategies which may 
show promise in this setting. 
 
1.4    Novel nutritional strategies for the prevention of 
gastrointestinal inflammation  
1.4.1 Introduction 
No pharmacological preparations have been approved for prevention or treatment of 
gastrointestinal inflammation during pelvic radiotherapy125. Nutritional intervention is 
popular with patients who have amply demonstrated that they are capable of 
following dietary prescriptions for extended periods in this setting75 126. In the last 
decade, two systematic reviews127 128 including a recent review by our group127 and 
one meta-analysis129 have been conducted exploring the efficacy of nutritional 
interventions in patients receiving pelvic radiotherapy.  
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Interventions have included elemental formulas (pre-hydrolysed enteral formulas), low 
or modified fat diets, lactose-restricted diets, probiotics and prebiotics and low residue 
or modified fibre diets. Whilst all of these interventions have a sound scientific 
rationale for use127 and some have been trialled (with limited success) for the 
prevention or treatment of radiation-induced GI toxicity, there remains a lack of high 
grade evidence to recommend any one of these strategies over another during pelvic 
radiotherapy. Highly variable study quality, potential for bias, difficulties with 
compliance and palatability and lack of validated endpoints are acknowledged as 
problematic by all authors127-129.  
 
The sole meta-analysis of nutritional interventions, using a fixed effect model, based 
on 4 studies (n=413) returned a positive result for dietary intervention for the 
prevention of radiotherapy-induced diarrhoea, risk ratio of 0.66 (95% CI: 0.51 - 
0.87)129. However all but one of the four studies used a combined intervention (e.g. a 
low fat plus low lactose diet) making it difficult to draw firm conclusions about the 
nature of the effective intervention129. Further, it could be argued that given the 
widely differing design of the interventions included in the analysis, a random effects 
model might have been more appropriate. One study included in the review was 
classified as therapeutic130 although our group, on contact with the author has learned 
that this study was actually preventative in design and aim. The Cochrane meta-
analysis did not include probiotic interventions. However, the two previous systematic 
reviews alluded to their possible benefits127 128.  
 
1.4.2 Importance and relevance of probiotic interventions 
Probiotic interventions are relevant to radiation-induced GI toxicity via their ability to 
directly influence the host immune response, and thus inflammatory processes, 
through promotion of beneficial microbiota species. Recent guidelines from the 
Mucositis Study Group of the Multinational Association of Supportive Care in cancer / 
International Society of Oral Oncology (MASCC/ISOO) suggested that Lactobacillus-
containing probiotic preparations might be helpful for the prevention of radiotherapy-
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induced diarrhoea but declined to recommend specific doses or regimens125. This 
suggestion was based on evidence from five studies.  
 
Two meta-analyses131 132 have also examined the evidence for probiotic intervention in 
cancer patients receiving pelvic radiotherapy. The earlier analysis, based on four 
studies (n=632), using a random effects model, reported an odds ratio of 0.47 (95% CI: 
0.13 – 1.67) in favour of probiotic intervention for the prevention of radiotherapy-
induced diarrhoea but hesitated to draw firm conclusions or make specific 
recommendations due to clinical and statistical heterogeneity131.  
 
The more recent meta-analysis, based on ten studies (n=1449) of which six were 
included in the meta-analysis, reported an odds ratio for incidence of diarrhoea of 0.44 
(95% CI: 0.21 – 0.92) in favour of probiotic supplementation and concluded a probable 
benefit132. Probiotic supplements vary widely in composition and strength and may be 
expected to have differing effects given the wide inter-individual variation in 
microbiota composition.  
 
Although the safety profile of probiotic interventions appears to be good, rigorous 
safety testing employing high dose agents has not been conducted in the oncology 
setting and risk of translocation remains.   
 
1.4.3 Dietary fibre 
1.4.3.1 Introduction 
Dietary fibre may mitigate inflammation during pelvic radiotherapy. Short chain fatty 
acids, the fermentation products of non-digested dietary fibre have direct anti-
inflammatory effects, stimulate colonic water and sodium absorption, preserve tight 
junction integrity and provide a fuel source to colonic mucosa133.  
 
Despite this, patients receiving pelvic radiotherapy are often advised to reduce their 
dietary fibre consumption, which is also the case in some IBD centres. This practice is 
not evidence-based and may be counter-productive.  This section defines what is 
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meant by the term ‘dietary fibre’ and discusses its potential importance for patients 
undergoing pelvic radiotherapy with respect to its impact on gut microbiota and 
production of fermentation metabolites, SCFA.  
 
1.4.3.2 Definition, composition and recommended intakes 
In 1972, dietary fibre was defined as ‘the skeletal remains of plant cells that are 
resistant to digestion by enzymes of man’134. Whilst this concept still broadly meets 
the public perception of dietary fibre, the situation today is confusing because 
different definitions of dietary fibre are in use. This situation exists because historically 
two different methods for the analysis and definition of dietary fibre have been used: 
the enzymatic-gravimetric and the enzymatic-chemical methods.  
 
The enzymatic-gravimetric method estimates total dietary fibre in foods by a series of 
steps including: enzymatic hydrolysis of proteins, sugars and starches; precipitation of 
soluble fibre components by aqueous ethanol; isolation and weighing of the dietary 
fibre residue and final correction for protein and ash in the residue135. The method has 
been adopted, simplified and modified by the Association of Official Analytical 
Chemists (AOAC) and is used in the US as the basis of food composition tables136. It is 
in widespread use, with minor modifications, in many countries.   
 
The enzymatic-chemical or Englyst method also starts with the enzymatic removal of 
starch but goes on to measure non-starch (i.e. non-α-glucan) polysaccharides (NSP) as 
the sum of the constituent individual monosaccharides (hexoses, pentoses, uronic 
acids) released by acid hydrolysis and measured using gas liquid chromatography or 
colorimetry135. Differences between the enzymatic-gravimetric and Englyst methods 
have important implications for public health recommendations and food labelling. 
The enzymatic-gravimetric method measures both lignin (a minor component of the 
diet but chemically not a carbohydrate) and resistant starch, neither of which is 
measured by the Englyst method.  
 
Table 1.10 outlines some of the definitions of dietary fibre in use today by different 
organisations, illustrating the differing derivations of dietary fibre. 
 70 




Method of analysis Definition 
 
Codex Committee on 
Nutrition and Foods 














Based on AOAC 





Dietary fibre means carbohydrate polymers with ten or more 
monomeric units, which are not hydrolysed by the endogenous 
enzymes in the small intestine of humans and belong to the 
following categories:  
Edible carbohydrate polymers naturally occurring in the food 
as consumed, Carbohydrate polymers, which have been 
obtained from food raw material by physical, enzymatic or 
chemical means and which have been shown to have a 
physiological effect of benefit to health as demonstrated by 
generally accepted scientific evidence to competent 
authorities, Synthetic carbohydrate polymers which have been 
shown to a have a physiological effect of benefit to health as  
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For the purposes of this directive ‘fibre’ means carbohydrate 
polymers with three or more monomeric units, which are 
neither digested nor absorbed in the human small intestine and 
belong to the following categories: Edible carbohydrate 
polymers naturally occurring in the food as consumed, 
Carbohydrate polymers, which have been obtained from food 
raw material by physical, enzymatic or chemical  means and 
which have a beneficial physiological effect  demonstrated by 
generally accepted scientific evidence, Edible synthetic 
carbohydrate polymers which have a beneficial physiological 
effect demonstrated by generally accepted scientific evidence 
 
 
Dietary Fiber consists of non-digestible carbohydrates and 
lignin that are intrinsic and intact in plants  
Added Fiber consists of isolated, nondigestible carbohydrates 
that have beneficial physiological effects in humans 
Total Fiber is the sum of Dietary Fiber and Added Fiber 
 
Dietary fibre is the material isolated by AOAC methods 985.29 









Of key importance is the fact that the enzymatic-gravimetric method results in a higher 
value for the fibre content of a food than the Englyst method. One gram of NSP is 
estimated to be equivalent to 1.6g of dietary fibre140. In addition, the enzymatic-
gravimetric method recognises and includes synthetic and extracted substrates that 
behave like fibre provided they have proven physiological benefits thus increasing the 
discrepancy between fibre and NSP.   
 
An important distinction exists between the CODEX137 and European Commission 
definitions of dietary fibre138 with respect to the degree of polymerisation (DP) of 
carbohydrate polymers (i.e. linear or branched chains of monomeric carbohydrate 
units) to qualify as dietary fibre. Whilst a carbohydrate polymer must be ≥ 10 
monomeric units to classify as ‘fibre’ according to the CODEX definition, it need only 
have a DP of ≥3 monomeric units according to the European Commission, provided 
physiological benefit has been demonstrated (Table 1.10).  
 
This means that the inulin-type fructans (e.g. oligofructose, fructooligosaccharides 
(FOS)) with DP 3-8 qualify as a fibre substrate according to the European Commission 
definition. Fructans are naturally occurring plant storage carbohydrates (wheat and 
onions constitute major dietary sources) which escape digestion in the small intestine 
which lacks the enzymes required to digest its β-(2-1) fructosyl-fructose glycosidic 
bonds141. 
 
Fructans are fermentable substrates and importantly has demonstrable prebiotic 
capability through its ability to selectively stimulate the growth of microbial genera or 
species of potential health benefit to the host142. Commercial fructans (i.e. FOS) can be 
synthetically manufactured from sucrose or chicory root and are added to pre-
prepared foods for their textual and sensory properties. FOS, as a prebiotic substrate 
has also attracted attention for use in clinical research and in this respect constitutes a 
fibre supplement either in its own right or more commonly, mixed with inulin.           
 
Non-starch polysaccharides in the human diet include cellulose and hemicellulose 
(plant cell walls), xylans (cereals), galactomannans (legumes), β-glucans (cereals), 
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inulin (onions, root vegetables and artichokes), pectins, gums and mucilages140. Each of 
these fractions of fibre has differing solubility. Cellulose and hemi-cellulose are 
insoluble in water, xylans and galactomannans partially soluble and inulin, pectin, 
gums and mucilages are all water soluble140. Most foods contain a mix of soluble and 
insoluble fractions. Insoluble fibre is poorly fermentable and has been described as 
chemically inert. However it increases faecal bulk and reduces bowel transit time thus 
contributing to bowel heath. Soluble fibre (capable of forming viscous gels) has a 
number of health benefits but importantly is readily fermentable by saccharolytic 
bacteria producing beneficial metabolites, SCFA.   
 
The UK Dietary Reference Value (DRV) for fibre is based on NSP content and set at a 
level which aims to optimise bowel function and stool output at about 100 g / day 139. 
In contrast, Guideline Daily Amounts (GDAs) in the UK used for nutritional labelling (to 
be superseded in 2014 by Reference Intakes in line with EU Regulation 1169/2011) are 
based on the fibre content of foods derived using the AOAC methods and result in 
higher values. Recommended intake of ‘fiber’ in the US (from government and 
professional organisations) is based on AOAC methods but given in terms of total 
energy intake as shown in Table 1.11143 144.   
 
Table 1.11 Recommended fibre intakes: UK and US 
Organisation / Date 
 
Recommended Intake 
Committee on Medical 




Dietary Reference Value (men and women): 18 g NSP / day  
Institute of Grocery 
Distribution (IGD) UK, 1998
145 
Guideline Daily Amount (men and women):  24 g fibre / day 
 




Dietary Reference Intake (men and women):  14 g / 1000 kcal / day 
 
Institute of Medicine (IOM)  
Guidelines in: 
US Departments of 




Dietary guideline recommendations: 14 g / 1000 kcal / day 
Men: 34 g / day (19 – 30 yrs), 31 g / day (31 – 50 yrs),  
28 g / d (51+ years) 
Women: 28 g / day (19 – 30 yrs), 25 g / day (31 – 50 yrs),  
22 g / d (51+ years) 
 
 73 
1.4.3.3 Fibre, diet and microbiota 
The major saccharolytic bacteria (i.e. capable of degrading fibre) are listed in Table 
1.12 together with their known substrate preferences113.  
 
Table 1.12 Fibre fractions and major bacterial utilisers 
Substrate  Major bacterial utilisers 
Cellulose  Ruminococcus, Bacteroides 
Hemicelluloses Roseburia, Bacteroides, Prevotella 
Pectin Bacteroides, Faecalibacterium,  
Fructans, including: inulin and  
fructo-oligosaccharides ‘FOS’) 
Bacteroides, Roseburia, Faecalibacterium, 
Bifidobacterium 
Resistant starch Ruminococcus, Bacteroides 
 
Source: Based on Chassard113 
 
Overall, microbiota composition reflects habitual diet but can change in response to 
dietary manipulation146. As such it represents an important target for therapeutic 
intervention147. Recently a unique locus encoding enzymes for degradation of 
xyloglucan (a plant polysaccharide widely occurring in salad and cereal crops) was 
discovered in Bacteroides ovatus underlining the importance of niche species in 
dietary fibre metabolism148. 
 
A cross sectional study in 98 individuals using both recent (recall) and long term (food 
frequency questionnaire) dietary assessments and 16SrDNA sequencing to 
characterise faecal bacteria, reported a clustering of faecal communities into two 
distinct groups: a Bacteroides-rich cluster associated with a high-fat / low-fibre intake 
and a Prevotella-rich cluster associated with low-fat / high fibre intakes149. Firmicutes 
and Bacteroidetes phyla were positively associated with fibre and negatively 
associated with fat intake.  
 
However, a 10-day feeding trial in 10 subjects failed to demonstrate similar trends 
suggesting that longer-term changes were necessary to influence bacterial community 
structure149. In contrast, a recent 5-day dietary intervention reported that gut 
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microbial communities can change in a rapid, diet-specific manner150. A cross-over 
design was used to compare alterations in microbiota resulting from adherence to two 
diets characterised as either plant-based, with a fibre intake of 25.6 ± 1.1 g / 1000 kcal 
or animal-based, with fibre intake amounting to a trace only. Although marked 
changes in composition were observed only with the animal-based diet, including 
increased abundance of bile-tolerant organisms and decreased level of Firmicutes, a 
significant positive correlation was reported between subjects’ fibre intake over the 
previous 12 months and baseline levels of Prevotella suggesting that habitual high-
fibre diets induce saccharolytic species150.  
 
In another large study, using classical culture-based methods, faecal samples obtained 
from 144 vegetarians and 105 vegans were compared with samples from an equal 
number of age / gender matched controls consuming an omnivorous diet151. The total 
microbial count did not differ between groups. However, stool pH of subjects having 
vegan or vegetarian diets was significantly lower (p=0.0001) than those on the 
omnivorous diet and total counts of Bacteriodes, Bifidbacterium, Escherichia coli and 
Enterobacteria were all significantly lower in vegans compared to control subjects151.  
 
Another recent analysis of 178 elderly subjects found microbiota groupings were 
defined by residence (community dwelling versus residential care) and that these 
groupings were sustained when diet was used as the basis for grouping. The authors 
concluded that their data supported a relationship between diet, microbiota and 
health status pointing to the importance of diet-driven alterations in age-associated 
declining health status including what they termed ‘immuno-senescence’152. 
 
1.4.4 Focus on short-chain fatty acids and therapeutic potential 
1.4.4.1 Introduction 
Short-chain fatty acids are the end products of the bacterial digestion of carbohydrates 
and peptides that reach the colon, with carbohydrates by far the most abundant 
substrate153. They have multiple effects on colonic health and physiology including 
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electrolyte and water absorption, regulation of inflammation, contribution to colonic 
pH and energy provision to colonocytes.  
 
In healthy individuals, substrate type and availability, microbiota composition and 
intestinal transit time determine the character of SCFA produced. For example, 
bacteria of the Bacteroidetes phylum produce high levels of acetate and propionate 
whilst those of the Firmicutes phylum produce high amounts of butyrate153. Degree of 
fermentation varies with substrate solubility and ranges from 0 to 5% for lignin, 20% 
for cellulose, 70% for bran, 90 – 95% for pectin and psyllium and up to 100% for 
mono= and oligosaccharides133.  
 
The principal SCFAs resulting from carbohydrate degradation are straight chain fatty 
acids, comprising 2, 3 and 4 carbon (‘C’) chains. They are acetate (C2), propionate (C3) 
and butyrate (C4) in the relative proportion of 6:3:1 (141)133. SCFA concentration is 
highest in proximal colon, due to greater carbohydrate availability, ranging from 70 - 
100 mM. Daily production of SCFA in healthy adults is estimated to be 100 – 200 mM, 
the majority of which is absorbed and used by colonocytes which have a preference for 
butyrate which is 70 – 90% metabolised. Concentrations in peripheral blood are much 
lower and in micromolar amounts154.  
 
Intake of dietary fibre has recently been directly associated with faecal SCFA 
concentrations155. Total, soluble and insoluble fibre intakes, assessed using a validated 
Food Frequency Questionnaire (FFQ) and faecal SCFA concentrations were measured 
in 32 institutionalised elderly subjects who consumed a mean 11.6 g of fibre / day of 
which 82% comprised insoluble fibre. Significant positive associations were reported 
between consumption of insoluble fibre (g/d) and faecal butyrate concentration 
(mg/g) (p=0.049) and between total fibre (g/d) and acetate and propionate (p=0.003 
and p=0.004 respectively). The authors acknowledged the wide inter-subject variation 
in basal faecal butyrate levels that have been previously reported156 but pointed out 
that subjects with low levels may constitute a particularly responsive group to 
intervention155. In healthy subjects, formula diets (comprising 100% of energy intake 
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for 14 days) supplemented with fructo-oligosaccharides and fibre maintained faecal 
SCFA concentrations157 possibly mediated through Faecalibacterium prausnitzii158.    
  
1.4.4.2 Therapeutic potential of SCFA in gastrointestinal inflammation 
Surprisingly, despite the acknowledged association between dietary fibre and the 
production of SCFA and the potentially crucial importance of SCFA in reducing the 
inflammatory response and promoting colonic fluid absorption, no studies have 
assessed the effect of dietary fibre on SCFA production and bowel-related toxicity 
during pelvic radiotherapy.  
 
Five studies have investigated the efficacy of SCFA and butyrate enemas in the 
treatment of radiation-induced ‘proctitis’. However, whilst the findings of these 
studies contribute to the body of research regarding the therapeutic potential of SCFA 
after pelvic radiation, the use of the term ‘chronic proctitis’ is considered 
inappropriate159. The suffix ‘itis’, in medical terminology specifically describes an 
inflammatory process. Unlike IBD where inflammatory mechanisms in the gut mucosa 
predominate throughout the course of the disease, in the chronic post-radiotherapy 
setting, three months or more after treatment, sub-mucosal pathology, noteably 
fibrosis rather than mucosal inflammation is the predominant finding. Thus the term 
‘chronic proctopathy’ is preferred and is used in this brief overview of relevant studies.  
 
Three randomised, double-blind, placebo controlled trials (Table 1.13) have been 
conducted160-162. The most recent trial used a cross-over design and reported a 
significant improvement in post radiation proctopathy, assessed clinically and 
endoscopically for the butyrate enema arm compared to placebo162. However, an 
earlier randomised controlled trial (RCT) using a similar design in patients with 
persistent proctopathy one year after radiotherapy found no significant improvement 
in the treatment group versus placebo160.  
 
A third RCT using a combined SCFA enema for the treatment of chronic proctopathy 
reported significant improvements in the treatment group following five weeks of 
twice daily enemas versus placebo although these differences were not sustained at 6 
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months after cessation of daily SCFA irrigation161. This latter study was conducted in 
patients with persistent rectal bleeding of >12 months duration after radiotherapy and 
it is argued that bleeding was not a result of mucosal inflammation at this stage post-
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In the most recent prospective open label study, patients on radiotherapy treatment 
reported reduced severity of proctopathy with butyrate enema treatment, however, 
there was no correlation between severity or incidence of acute toxicity and 
protection in the late setting164. A small pilot study reported non-significant 
improvements with use of a combined SCFA enema for 4 weeks although this report 
was available in abstract only and thus data are lacking163. 
 
The efficacy of SCFA enemas has also been explored in IBD.  Four open label 
prospective cohort studies in patients with distal UC165-168 have reported positive 
effects of SCFA enemas165 168 butyrate enemas166 and butyrate enemas in combination 
with 5-ASA167. Further, in five double-blind, randomised, placebo-controlled trials, two 
reported a significant improvement in clinical symptoms compared to placebo169 170, 
one failed to find any significant differences171 the largest (in 91 patients) reported 
only non-significant improvements over placebo172 and one recent study found only 
minor beneficial effects on inflammatory markers following 20 days of butyrate 
treatment173.  
 
1.4.4.3 Mechanisms of action 
SCFA-mediated regulation of inflammation has been extensively reviewed174. Butyrate 
has an inhibitory effect on NF-ĸB which plays a central role in immune and 
inflammatory responses175-177. In colonic biopsy specimens obtained from CD patients, 
butyrate inhibited LPS-induced activation of NF-ĸB through stabilisation of its inhibitor 
protein kappa B (I-ĸB) ensuring its continued sequestration in the cytoplasm and 
preventing translocation and transcription of pro-inflammatory cytokines TNF, IL-1 and 
IL-6176. In the same study, butyrate significantly reduced TNF levels in a dose-
dependent manner in both inflamed (p=0.0001) and non-inflamed (p=0.0153) 
biopsies176.  
 
Another pre-clinical study reported that acetate, propionate and butyrate inhibited 
TNFα-stimulated activation of NF-ĸB in colo320DM cells in a dose-dependent manner 
and decreased LPS-stimulated TNFα release from human neutrophils177. Butyrate, 
propionate and acetate also suppressed LPS-induced production of Nitric Oxide (NO) 
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and cytokines TNF-α, IL-1β and IL-6 in RAW264.7 cells with enhanced production of 
anti-inflammatory IL-10175. Butyrate also potentiates the generation of anti-
inflammatory Treg cells178 179 and protects against the accumulation of high 
intracellular levels of reactive oxygen species (ROS) thus inhibiting NF-ĸB translocation 
and suppressing pro-inflammatory cytokine production180.  
 
The G-protein coupled receptor GPR43 expressed on leukocytes, neutrophils and 
endothelial cells may provide a link between diet, gastrointestinal microbiota and 
immune and inflammatory responses181. Binding of SCFA to GPR43 results in activation 
of the MAPK signalling pathway and inhibition of histone deacetylase (HDAC) with anti-
inflammatory downstream effects on gene transcription174. GPR43 deficient mice show 
exacerbated and unresolved inflammation as do germ-free mice which express little or 
no SCFA181.  
 
In addition to these anti-inflammatory actions, SCFA regulate colonic fluid balance by 
stimulating Na-dependent fluid absorption via a cyclic AMP-independent process 
involving apical membrane exchanges: Na-H, SCFA-HCO3 and Cl–SCFA182 183. SCFA can 
also affect secretory function via inhibition of cAMP-mediated chloride secretion133. 
Animal models have shown that SCFA ion exchange mechanisms are severely 
perturbed during chronic ileal inflammation due to reduced transporter protein 
numbers184.  
 
The potential anti-diarrhoeal properties of SCFA have recently received attention. SCFA 
reduce water and electrolyte loss in cholera toxin-induced colonic secretion185. Oral 
rehydration solutions (ORS) enriched with high amylase resistant starch promote 
colonic SCFA production and improve ORS effectiveness by stimulating water and 
sodium absorption in acute diarrhoea in children 182.   
 
The beneficial effect of butyrate in particular on colonic mucosal functions has been 
recently reviewed186. Butyrate preserves the colonic mucosal barrier through 
facilitation of the assembly of tight junctions and preservation of the protective 
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epithelial mucin layer187 an effect that may be mediated by promotion of the 
expression of tight junction proteins caludin-2, and occludin188.  
 
The impact of butyrate on epithelial barrier function was recently explored in 
artificially stressed human colon-derived T84 epithelial cells. Cell monolayers were 
exposed to dinitrophenol which uncouples oxidative phosphorylation, and to non-
pathogenic E.coli189. Bacterial translocation was significantly reduced by butyrate 
which was associated with inhibition of I-ĸB phosphorylation and NF-ĸB activation189.  
 
1.4.5 Summary: dietary fibre for the prevention of gastrointestinal 
inflammation and toxicity in patients undergoing pelvic 
radiotherapy for cancer 
This section has explored dietary strategies that could be beneficial in patients being 
treated with pelvic radiotherapy with the aim of preventing or reducing radiation-
induced GI toxicity. Despite a robust rationale it appears that there is a lack of data in 
support of increased fibre intake and its possible benefits mediated through SCFA.  
 
Current practice in many radiotherapy departments continues to be to advise patients 
to reduce dietary fibre during treatment with the aim of reducing bowel frequency and 
optimising stool form. Local experience of the author suggests that many oncologists 
and dietitians are reluctant to challenge this advice in the absence of definitive data.  
However, patients have demonstrated that they are willing and able to follow specific 
dietary advice in this highly technical setting and thus do not present a barrier to fibre 
manipulation.  
 
It is concluded that a sound rationale for dietary fibre manipulation during pelvic 
radiotherapy exists. However, evidence of the efficacy of dietary fibre in this setting 
appears to be lacking. Since IBD provides a model of gastrointestinal inflammation 
with many mechanisms and mediators that resemble those in radiation-induced GI 
toxicity and it is well known that nutritional strategies have been widely explored in 
IBD, the next step in this thesis is to gather evidence for the efficacy of dietary fibre 
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manipulation in IBD. If this shows anti-inflammatory benefit in IBD then it can logically 
be assumed that these benefits may be transferrable to radiation-induced GI toxicity.  
 
Further, if on closer examination, it is found that there is a lack of robust data 
regarding the efficacy of dietary fibre manipulation in radiation-induced GI toxicity, 
this thesis proposes to undertake new research (a randomised controlled nutritional 
intervention study) to test the efficacy of dietary fibre manipulation in patients 
receiving radiotherapy for pelvic cancers.     
 
1.5   Reflection and remit of this thesis 
1.5.1 Reflection 
Treatment-induced toxicity resulting from cancer therapy is an increasingly important 
issue in the current era of improved cancer survivorship. Strategies that can be 
employed to prevent acute severe toxicity and thus consequential late effects should 
continue to be explored. Nutritional strategies may be helpful. In particular, dietary 
fibre may offer benefit to stool type through the bulking properties of insoluble fibre 
and the multiple beneficial effects of SCFA, the fermentation products of soluble fibre.  
 
IBD provides a model of gastrointestinal inflammation in which previously conducted 
research may provide helpful pointers for the feasibility, practicality and efficacy of a 
fibre nutritional intervention in patients receiving pelvic radiotherapy. A thorough 
evaluation of previous literature on this subject would be helpful.  
 
The measurement of treatment-induced toxicity associated with pelvic irradiation 
remains complex; symptoms are a poor surrogate of underlying pathology and no gold 
standard markers of gastrointestinal damage have been recommended for routine use 
in the clinical or research setting.  
 
The conclusion of this introduction is that evidence for the potential efficacy of dietary 
fibre in the management of IBD should be evaluated and that the nature of 
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interventional strategies employed and the results obtained should inform future 
research for evaluating the efficacy of similar interventions during pelvic radiotherapy.  
 
A review of the evidence for the efficacy of fibre manipulation in patients receiving 
pelvic radiotherapy is essential. If, as suspected, a lack of robust evidence exists, this, 
coupled with positive evidence for the efficacy of fibre manipulation in the 
management of IBD patients, would justify the conducting of an adequately powered 
RCT in pelvic radiotherapy patients, powered to an appropriate symptom endpoint. 
     
1.5.2 Research questions identified 
The following research questions have been identified and merit further exploration: 
 
 Has manipulation of dietary fibre been shown to be a useful intervention in the 
treatment and management of gastrointestinal inflammation in diseases such 
as IBD or in the prevention of radiation-induced gastrointestinal toxicity? 
 
 Can a high fibre diet reduce or prevent the severity of acute radiation-induced 
gastrointestinal toxicity and symptoms during pelvic radiotherapy? 
 
 How does dietary fibre manipulation affect the concentration or proportions of 
faecal SCFA during pelvic radiotherapy treatment? 
 
 How does dietary fibre manipulation affect stool frequency, stool form, number 
of days with loose stool or use of anti-diarrhoeal medication during pelvic 
radiotherapy treatment? 
 
 Can patients comply with high or low fibre dietary interventional advice for the 
duration of pelvic radiotherapy and does adherence affect body weight, body 




1.5.3 Research hypothesis 
The research hypothesis to be addressed is this thesis is as follows:  
 
‘Dietary fibre can prevent or reduce gastrointestinal inflammation in diseases 
such as inflammatory bowel disease and may be a simple cost-effective 
nutritional intervention to reduce or prevent acute symptoms during pelvic 
radiotherapy. Its mechanism of action is via production of anti-inflammatory 
fermentation products short chain fatty acids and through beneficial effects of 
dietary fibre on stool frequency and form’.       
 
1.5.4 Aim and scope of thesis chapters 
The scope of research encompassed within this thesis addresses the hypothesis 
identified above, which will be answered in the following chapters:   
 
Chapter 2: Aims  
 To conduct a systematic review of the efficacy of oral (dietary) fibre 
interventions for the treatment or prevention of gastrointestinal inflammation 
in patients with IBD which represents one of the most studied and best models 
of gastrointestinal inflammation available and has been widely researched with 
respect to the efficacy of nutritional interventions. 
 
 In the event that fibre is seen to have a positive effect in IBD, to conduct a 
second systematic review to establish whether any studies have been 
conducted assessing the efficacy of oral (dietary) fibre interventions for the 
treatment or prevention of radiation-induced gastrointestinal toxicity or 
symptoms in patients receiving radiotherapy for pelvic cancers.  
 
 In the event that studies are identified of dietary fibre interventions in patients 
receiving pelvic radiotherapy, to assess whether the evidence emerging from 
these studies is sufficient to answer the research hypothesis outlined above 
(Section 1.5.3) and to decide if additional investigation is warranted.  
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Chapter 3: Aims 
 If appropriate and further investigation is warranted to design an adequately 
powered, randomised controlled trial to investigate the efficacy of an oral 
dietary fibre intervention for the prevention of gastrointestinal symptoms in 
patients receiving radiotherapy for pelvic cancers.  
 
 In the event that a new trial is warranted, to use the information gleaned from 
the two systematic reviews to inform the design of the trial, including the 
primary endpoint, secondary endpoints and interventional materials.  
 
Chapters 4 and 5: Aims 
 In the event that a new randomised controlled trial is conducted, to present the 
clinical (Chapter 4) and nutritional (Chapter 5) results of the trial with reference 
to the research issues identified above (Section 1.5.2) and to provide a critical 
discussion of the results, highlighting any limitations of the research conducted. 
 
Chapter 6: Aims 
 In the event that a new randomised controlled trial is conducted, to state 
whether the research hypothesis outlined above (Section 1.5.3) can be 
accepted or rejected and to highlight the most important findings of the trial 
and discuss their implications for ongoing clinical practice. 
 
 In the event that a new randomised controlled trial is conducted, to identify 
fruitful areas for follow-on or additional future research. 
 
 To reflect generally on what has been learnt in the research process and how 
these insights might affect ongoing clinical research in this area to ensure 














2.1 Introduction  
The Introduction to this thesis has explored the inflammatory mechanisms in 
radiation-induced GI toxicity and IBD and found many similarities including mediators 
of inflammation, immunological responses, histopathology, effects on the gut 
microbiota and clinical symptoms. Patients with IBD and those undergoing pelvic 
radiation share an interest in dietary approaches to managing symptoms. Reduced 
incidence or severity of symptoms may occur in response to the reduction or 
prevention of inflammation to the gut mucosa.  
 
Dietary fibre may be an attractive option. IBD provides an excellent model of 
gastrointestinal inflammation and is a disease in which the efficacy of nutritional 
intervention has been widely explored. Therefore, the next step in this thesis was to 
conduct a systematic review to gather and evaluate the evidence for the efficacy of 
dietary fibre manipulation in patients with IBD since it was expected that few data 
were available on this topic in patients receiving pelvic radiotherapy. If this review 
yielded promising results, a second systematic review would be indicated.  
 
The second systematic review would aim to evaluate whether any robust evidence 
existed regarding dietary fibre manipulation in patients receiving pelvic radiotherapy 
and if so, whether the evidence enabled acceptance or rejection of the research 
hypothesis posed in this thesis (Section 1.5.3). If insufficient data was available, then 
the logical next step in the thesis would be to design a randomised controlled trial to 
test this hypothesis.  
 
2.2 Aims   
The aims of the research described in this chapter were to initially undertake a 
systematic review of the evidence for the efficacy of dietary fibre manipulation in the 
management of patients with IBD. Importantly, it was hoped that this would also 
inform the feasibility and nature of fibre interventional strategies that might be 
successfully employed in a future RCT in patients receiving pelvic radiotherapy.   
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Based on the results of the first review, a further systematic review would be 
undertaken to evaluate whether robust evidence existed for the efficacy of dietary 
fibre manipulation in the management of radiation-induced toxicity in patients 
receiving pelvic radiotherapy. If the evidence proved to be equivocal, lacking or trial 
designs not robust, a randomised controlled nutritional intervention trial would be 
recommended to test the efficacy of dietary fibre manipulation in patients receiving 
pelvic radiotherapy.  
 
2.3 Methods employed in conducting systematic reviews  
The methods to be employed in conducting the systematic review of the efficacy of 
dietary fibre in patients with IBD were agreed in advance and documented in a review 
protocol. In the event that a second review of the efficacy of fibre in patients receiving 
pelvic radiotherapy was appropriate it was agreed that the methodology employed 
would as far as possible be similar to ensure continuity of approach.   
 
Both reviews would be undertaken in line with the guidelines within the Cochrane 
Handbook for Systematic Reviews of Interventions190 and in accordance with the 
relevant criteria of the PRISMA statement (Preferred Reporting Items for Systematic 
reviews and Meta-Analyses)191 and with particular reference to guidelines for the 
reporting of nutritional reviews192.  
 
2.3.1 Search strategy  
Relevant studies would be identified through electronic database interrogation and 
hand-searching for conference abstracts. Reference lists of key publications would be 
screened and experts contacted for additional articles.  
 
The electronic search strategy would be developed by the author with expert advice 
from a Senior Information Specialist at King’s College London and in conjunction with a 
second researcher undertaking an MSc, also at King’s College London. For electronic 
searching, it was agreed that limits would not be applied to ensure as wide as possible 
capture of all potentially relevant citations.  
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2.3.2 Inclusion and exclusion criteria  
It was agreed that inclusion and exclusion criteria would be developed using a PICOS 
structure (Patient, Intervention, Comparators, Outcome, Study design) with the 
inclusion criteria being original randomised controlled trials reporting the effect of an 
oral fibre intervention (either increasing or decreasing intake) on clinical outcomes 
(e.g. disease, toxicity or symptom indices, disease activity or histology indices) or 
physiological outcomes (e.g. inflammatory markers) in adult patients (≥ 18 years).  
 
Dietary fibre interventions eligible for inclusion would include pharmacological fibre 
supplements; food supplements (e.g. added cereal); or dietary advice (e.g. high fibre 
dietary advice) with stated focus of the intervention being dietary fibre modification.  
 
The definition of fibre would embrace either plant cell-wall non-starch polysaccharide 
(NSP), which specifically excludes lignin and resistant starch139, or the recent CODEX or 
European Community definitions137 138. Studies employing fibre-containing or fibre-free 
enteral formulas would not be eligible as their efficacy could relate to reasons other 
than the presence or absence of fibre.  
 
Study designs would be limited to RCTs with appropriate intervention and comparator 
arm(s). Quality scoring would be undertaken using the JADAD scale193. 
 
2.3.3 Management and mediation 
References would be imported into a bibliographic database (EndNote, version x5) to 
enable de-duplication. As far as possible, independent review (e.g. by a co-author) of 
the title and abstract of each reference would be undertaken prior to a final decision 
on eligibility. Full papers would be obtained for all potentially eligible articles and the 
inclusion criteria applied to each. Where papers contained insufficient information, the 
corresponding author would be contacted for further information. Non-English 
titles/abstracts would be screened by a native speaker where possible. Disagreements 
regarding eligibility and data extraction were to be mediated by Professor Kevin 
Whelan.  
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2.3.4 Suitability of data for meta-analysis 
Suitability of data for meta-analysis would be based on degree of similarity in 
intervention, outcomes and patient group. Choice of the most appropriate summary 
statistic and model (e.g. fixed or random effect models) would depend on degree of 
heterogeneity of study design and the number of studies to be included within the 
meta-analysis. If considered appropriate, meta-analysis would be performed using 
Review Manager v.5 and statistical significance set at p≤0.05 where ‘p’ is the 
probability of the result being obtained under the null hypothesis.   
 
2.4 Methods for systematic review: efficacy of fibre in IBD  
2.4.1 Selection of sources and search terms  
Seven electronic databases were selected and searched for relevant publications 
(Table 2.1).  
 
Table 2.1 Electronic databases interrogated for systematic review: fibre & IBD  
Online database Years searched Limits applied 
Inflammatory Bowel Disease Adults        Study design      Humans 
MEDLINE 1956 - October 2012 No No No 
EMBASE 1947 - December 2012  No No No 
CINAHL (Nursing database) 1983 - 2012 No No No 
Cochrane CENTRAL library All years available No No No 
CAB Direct (Nutrition) All years available No No No 
Web of Science 1900 - December 2012 No No No 
Scopus 1996 – December 2012 No No No 
 
Search terms and syntax differed for each database (Table 2.2).  
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Table 2.2 Search terms for electronic databases: fibre & IBD 
Medline and Embase 
1. (((Dietary adj1 Fibre) or Dietary) adj1 Fib*).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
2. Dietary Fibre/ 
3. (Non-starch polysaccharide or NSP).mp [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
4. Cellulose.mp. or Cellulose/ 
5. Methylcellolose.mp. or Methylcellulose/ 
6. Cereals/ or Cereal*.mp. 
7. (Residue adj1 Diet).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
8>.Roughage.mp. 
9.(Bran or (Oat and Diet)).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
10. Psyllium.mp. or Psyllium/ 
11. Plantago/ or Plantago*.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
12. (Ispaghula* or ispaghulahusk).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
13. Pectin.mp. or pectins/ 
14. Guar gum.mp. 
15.Prebiotics.mp. or prebiotics/ 
16. (Prebiotoc* or Synbioitc).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
17. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 
18. exp Inflammatory Bowel Diseases/ or Inflammatory bowel disease*.mp. 
19. IBD.mp. 
20. Intestinal inflammation.mp. 
21. Crohn Disease/ or Crohn* disease.mp. 
22. (Ulcerative colitis or UC).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
23. Pouchitis.mp. or pouchitis/ 
24. 18 or 20 or 21 or 22 or 23 












CENTRAL (Cochrane Database) 
 
#1(Dietary Fibre OR Dietary Fibre OR Non starch polysaccharide OR NSP OR cellulose OR methylcellulose 
OR cereal* OR “Residue Diet” OR Roughage OR Bran OR Oat AND Diet OR Psyllium OR Plantago* OR 
ispaghula* OR Pectin OR Guar gum OR Prebiotic OR Synbiotic) and (Inflammatory Bowel Disease OR IBD 
OR “Intestinal Inflammation” OR “Crohn* Disease” OR Ulcerative Colitis OR UC OR Pouchitis) 
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Table 2.2 Search Terms for electronic databases: fibre & IBD 
CAB Direct: Fibre & IBD 
 
(Dietary Fibre OR Non Starch Polysaccharide OR NSP) OR (Cellulose OR Methylcellulose OR Cereal OR 
Residue Diet OR Roughage OR Bran OR Oat OR Psyllium OR Plantago OR Ispaghula OR Pectin OR Guar 
gum OR Prebiotic OR Synbiotic) AND (Inflammatory Bowel Disease OR IBD OR Intestinal Inflammation 
OR Crohn’s Disease OR Ulcerative Colitis OR UC OR Pouchitis) 
 
Web of Science: Fibre & IBD 
  
#1: TS=(“Dietary Fibre” OR 2Dietary Fibre” OR “Dietary Fib*”OR Non starch polysachharide OR NSP OR 
Cellulose OR Methylcelluloe OR Cereal* OR “Residue Diet” OR Roughage OR Bran OR Oat AND Diet OR 
Psyllium OR Plantago* OR Ispaghula OR Pectin OR Guar gum OR Prebiotic OR Synbiotic) #2: 
TS=(Inflammatory Bowel Disease OR IBD OR “Intestinal Inflammation” OR “Crohn* Disease” OR 
Ulcerative Colitis OR UC OR Pouchitis) #3: #1 AND #2 
 
SCOPUS: Fibre & IBD 
 
 (((“Dietary Fibre” OR “Dietary Fibre” OR “Dietary Fib*”OR Non starch polysaccharide OR NSP OR 
cellulose OR methylcellulose OR cereal* OR “Residue Diet” OR Roughage OR Bran OR Oat AND Diet OR 
Psyllium OR Plantago* OR ispaghula* OR Pectin OR Guar gum OR Prebiotic OR Synbiotic) AND 
((Inflammatory Bowel Disease OR IBD OR “Intestinal Inflammation” OR “Crohn* Disease” OR Ulcerative 





Hand searching to identify non-electronically indexed items spanned the period 2001-
2013 (Table 2.3). 
 
 
Table 2.3 Hand searching sources: fibre & IBD  
  
Organisation / Event Relevant publication(s)  
Digestive Diseases Week Gastroenterology 
British Society of Gastroenterology Gut 
American Society for Parental and Enteral Nutrition Journal of Parenteral and Enteral Nutrition 
European Society for Clinical Nutrition & Metabolism Clinical Nutrition, Clinical Nutrition Supp, e-SPEN 
British Dietetic Association Journal of Human  Nutrition and Dietetics 
British Association for Parenteral & Enteral Nutrition Proceedings of the Nutrition Society 
 
 
2.4.2 Inclusion and exclusion criteria 
 
Inclusion and exclusion criteria were defined according to the PICOS structure and are 
detailed in Table 2.4 
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Table 2.4 Inclusion and exclusion criteria: fibre & IBD        
 PICOS Inclusion and exclusion criteria Data extracted 
Patient Adult (in- or out-patients) over 18 y with 
Crohn’s disease, UC or pouchitis in remission 
or relapse. Original cohorts only (i.e. excluding 
previous reports and abstracts of the same 
patients) to avoid duplication of patient 
numbers.  
 
Location, clinical setting, age, gender, number 
of patients recruited, number of patients 
evaluated (i.e. those with evaluable data at 




Intervention Oral pharmacological fibre supplement, food 
supplement or dietary advice to increase or 
decrease fibre intake were eligible. Fibre 
interventions were required to meet the 
acknowledged definitions of fibre (15-17), and 
therefore included prebiotic fibres.  Synbiotic 
preparations containing a named prebiotic 
fibre complying with the cited fibre definitions 
were also eligible irrespective of probiotic 
species and strain(s) used. 
 
Fibre source, dose, presentation and period of 
administration. Presence of co-administered 
‘standard’ medication(s) or supplemental 
nutritional substances. Compliance with 
interventional dose (if reported) and method of 
computing compliance. Genus/species/strain 
of probiotic if administered in conjunction with 
synbiotic preparation.  
 
Comparators Reports including a comparator group of either 
a placebo, no dietary intervention, an 
alternative dietary intervention or a 
pharmacological intervention were included. 
Reports comparing doses of fibre without any 
other comparator group were excluded. 
 
Patient numbers in the intervention and 
comparator groups and nature of intervention. 
Group names standardised to avoid confusion 
Outcomes  Clinical outcomes or endpoints including 
remission, relapse, mortality, morbidity, 
medication use, symptoms, Quality of Life. 
Physiological outcomes or endpoints related to 
gastrointestinal inflammation including 
histology, inflammatory and immunological 
markers, microbiota and metabolic substrates. 
Presence or absence of adverse events related 
to interventional substrate. 
Values, scores or counts for remission rates, 
remission duration, response rates, disease 
activity (measured using standardised indices), 
mortality, morbidity, medication use, 
symptoms, Quality of Life. Otherwise all other 
relevant clinical or physiological outcomes or 
endpoints at relevant time-points including 
statistical significance if reported.  
Comparisons of endpoint data between groups 
were extracted where possible, but within 
group comparisons between baseline and 
follow-up were extracted where of interest. 
 
 
Study design Randomised controlled trials (RCT).  Open 
label, wholly or partially blinded or placebo-
controlled nutritional interventional studies 
were eligible. Single or multi-centre. English 
or foreign language. Non-RCTs and 
uncontrolled trials were excluded. 
 
Type of study design, nature of blinding, active 
interventional period and duration of follow-
up. Authors and publication details. Abstract or 
full report. Language of publication. 
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2.5 Results of systematic review: efficacy of fibre in IBD  
2.5.1 Results of the search process 
A total of 4232 non-duplicated papers were identified. Titles and abstracts of each 
were reviewed and 123 papers were potentially eligible. Following full review, 23 
papers (detailing 23 eligible studies) fulfilled the inclusion criteria (Figure 2.1).   
 
 
 4227 non-duplicated citations identified during electronic database searching 
4 citations identified from hand searching reference lists and abstracts (not previously identified) 
1 citation from key opinion leaders (not previously identified) 
 4109 citations rejected based on review of title/abstract 
 123 citations potentially eligible 
on review of title/abstract 
reporting 127 original trials 
 104/127 trials rejected following review of full paper due to (numbers not mutually exclusive): 
 
  Non-adult population (n=5) 
  Non-IBD population (n=8) 
  Not concerning IBD treatment or remission (n=18) 
  Not an original cohort (n=34) 
  Not oral fibre intervention (n=59) 
  No appropriate comparator group/measurement (n=58) 
  Non-relevant outcome (n=26) 
  Not an RCT (n=68) 
 
23 citations of 23 trials of fibre  
interventions in IBD (1296 patients) 
   Ulcerative colitis (n=10) Crohn’s disease (n=12)     Pouchitis (n=1) 
Figure 2.1 Fibre & IBD: Summary of review process and results 
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Ten studies were in patients with UC194-203 of which one was published as an abstract 
only196; 12 were in CD204-215, of which two were non-English language210 215, two were 
abstracts205 212 and one a letter213; and one was in pouchitis216. Of the 17 experts 
contacted, 71% responded and one additional study was identified. 
 
2.5.2 Patients, interventions and comparators 
The 23 studies comprised 1296 recruited patients of which 35% were male (where 
reported).  This included 447 patients with UC (46% in remission; 26% with active 
disease; 28% with ‘mixed’ disease activity), 829 with CD (56% remission; 23% active; 
21% ‘mixed’) and 20 with pouchitis, all in remission. The methods used to classify 
patients as in remission or not varied between and within diseases. Where employed 
(16/23 studies) nine different named disease indices were used (5 different indices in 
UC; 4 in CD; one in pouchitis) and one study (in UC) used a bespoke symptom 
questionnaire. Use of concomitant medications was reported in 20/23 studies and 
included 5-ASA, 6MP, steroids, anti-TNF-α antibody or none.    
    
Fibre supplements were used in seventeen194-205 208 210 213 216 studies and dietary 
interventions were used in six206 207 211 212 214 215. Most investigated the efficacy of 
increased fibre intake, except for one dietary intervention that investigated a low fibre 
diet211. Double blinding occurred in ten studies196 198-200 204 205 208 209 213 216 and blinding 
of some or all researchers in an additional seven studies201 203 206 207 211 214 215. Most 
studies compared fibre to no intervention or placebo.  
 
The majority (10/17) of fibre supplement studies were compared with placebo195 198-200 
204 205 208 209 213 216, whereas most high fibre dietary interventions were compared with 
other dietary interventions (e.g. low fibre) and none were compared with a ‘sham 
diet’. In the fibre supplement studies, intervention periods ranged from 2-w to 24-m. 
All supplements were soluble fibres (e.g. germinated barley, inulin, 
oligosaccharide/inulin mix, psyllium) in doses ranging from 5-30 g/d. Seven studies also 
used probiotics alongside the fibre supplement198 199 202-205 208. In the supplement 
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studies, some reported compliance, commonly based on counts of unused sachets, 
however, none quantified fibre intake from background diet. 
  
Of the dietary interventions, the duration ranged from 28-d to 24-m resulting in 
intakes of between 13-46 g/d of fibre (where reported), although none reported the 
relative contributions of insoluble and soluble fibres. Monitoring of dietary compliance 
varied and included monthly, quarterly, 6-monthly and ad-hoc reviews using a variety 
of methods to estimate fibre intake (e.g. food diary, 24-hour recalls). 
 
2.5.3 Study quality and adverse events  
Serious adverse events were inconsistently reported and where reported were 
unrelated to intervention. No studies were terminated on safety grounds. Most studies 
clearly reported patient withdrawals (19/23). Few studies were of high quality, with 
only 17% (4/23) scoring the maximum 5 points, 26% (6/23) 4 points, 22% (5/23) 3 
points, 17% (4/23) 2 points and 17% (4/23) 1 point on the JADAD score (Tables 2.5, 
2.6, 2.7). 
 
2.5.4 Clinical and physiological outcomes  
2.5.4.1 Fibre and Ulcerative colitis (remission) 
Four studies in UC patients in remission recruited 213 patients. In a large 3-arm open 
label RCT, comparing psyllium fibre versus mesalamine versus mesalamine and 
psyllium fibre194, continued remission at 12-m was similar across all groups, implying 
equivalence between fibre and medication (although it was not powered for an 
equivalence endpoint) and lower relapse rates in the mesalamine and psyllium fibre 
group194. A further small RCT (n=31) showed lower treatment failure rates due to 
relapse at 12-m for psyllium fibre and mesalamine versus mesalamine alone196.  
 
In a double-blind cross-over RCT, although disease activity (remission, relapse) were 
not measured, patients consuming psyllium fibre reported lower global symptom 
scores and total number of symptoms at 2-m compared with placebo195.  In a recent 
open label study, disease outcomes were not reported with no difference in blood 
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markers Tumour Necrosis Factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8) 
between supplemented and non-supplemented groups at 2-m197.  
 
2.5.4.2 Fibre and Ulcerative Colitis (active disease or mixed active/remission) 
Five studies in UC patients with active disease198-202 recruited 114 patients, although 
four of these studies198-201 each recruited ≤20. In one double-blind RCT, there were no 
differences in the numbers achieving remission after two weeks between patients 
receiving prebiotic fibres (oligofructose/inulin) or placebo200. Those receiving prebiotic 
fibres had significantly lower fecal calprotectin compared to placebo on day 7 but not 
on day 14, and lower values on day 7 and 14 compared to baseline200. However, there 
were no differences between groups in the change in inflammatory markers such as IL-
6 and prostaglandin-2 (PGE-2)200.  
 
The same prebiotic fibre was used in a double-blind RCT in combination with a 
probiotic (synbiotic)199. The synbiotic did not result in significantly lower disease 
activity and sigmoidoscopy scores compared with placebo, although there was lower 
TNFα and IL-1α expression. Compared to baseline values, the synbiotic increased 
luminal bifidobacteria-specific total rRNA and a reduction in epithelial immunological 
markers (e.g. human β-defensins) compared to baseline values, indicating a reduced 
inflammatory profile199. 
 
A small open-label RCT using 20-30 g/d of germinated barley fibre resulted in lower 
disease activity compared with no intervention at one month but no change in 
physiological markers of disease activity201. A double-blind RCT of prebiotic fibre 
(oligosaccharides/inulin) with added glutamine found no differences in clinical 
variables (e.g. rectal bleeding, bowel frequency) compared with placebo or baseline, 
but at 2-m there was reduced expression of pro-inflammatory IL-6 and IL-8 compared 
to baseline, but not to placebo198. The largest (n=41) and most recent open label study 
reported no clinical benefit of a synbiotic supplement comprising 5 g/d galacto-
oligosaccharide plus probiotic at 1-y. However, significantly reduced expression of 




One open-label RCT (n=120) in a mixed UC cohort (remission and mildly active) 
comparing psyllium fibre versus probiotic versus psyllium fibre/probiotic did not find 
differences in endpoints between the groups, although an increase in total IBDQ score 
(improvement in symptoms) and reduction in C-reactive protein occurred at one 
month in the psyllium fibre/probiotic group203.  
 
2.5.4.3 Fibre and Crohn’s disease (remission) 
Four studies in CD patients in remission have recruited 465 patients. Two studies 
investigated a combined high fibre, low sugar diet206 207. In one, twenty patients with 
parenteral- or enteral-induced remission had their standard medication ceased. 
Patients randomised to the high fibre diet experienced significantly higher treatment 
failure and shorter time to relapse (1.4 versus 2.8 m) compared with patients on a low 
fibre exclusion diet206. The other study, recruited 352 patients with inactive disease 
and found no differences in the number of patients with deteriorating disease at 24 m 
between the high fibre (mean intake 27 g/d) and low fibre (mean intake 15 g/d) groups 
although any effect of concomitant low sugar consumption in the high fibre group was 
not adjusted for207.  
 
Two RCTs investigated the efficacy of a fibre and prebiotic supplement in combination 
with probiotics compared with placebo to maintain remission204 205. One aimed to 
prevent post-operative disease recurrence204 and the other aimed to prolong the time 
between ‘rescue’ anti-TNF-α infusions205. There were no differences between 
intervention and placebo groups in clinical, endoscopic or physiological outcomes at 
24-m204 or median time to next infusion at 6-m205.     
 
2.5.4.4 Fibre and Crohn’s disease (active disease or mixed active/remission)  
Five studies in CD patients with active disease recruited 193 patients, two of which 
used a dietary intervention211 212. One study compared a high fibre diet (mean intake 
46 g/d), rich in organic foods, with a low fibre (16 g/d), non-organic diet and reported a 
similar proportion of patients achieving remission211. Although those in the high fibre 
group had improved endoscopic appearance and bowel sonography scores after 6-w, 
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numbers were small and no other differences in physiological or clinical outcomes 
were observed. A further open label study (n=7) reported significantly improved IBDQ 
scores following a 28-d high fibre low refined carbohydrate diet compared to those in 
the non-intervention group, but disease activity was not measured per se 212.   
 
Of the three studies using fibre supplements, one open-label RCT did not record the 
impact on disease activity specifically, although it did report that patients taking 
psyllium fibre for 3-m had significantly improved stool consistency and slower gut 
transit times compared with controls210. Two recent double-blind RCTs using 12-15 g/d 
of prebiotic fibre (oligofructose/inulin), one in combination with probiotic208, have 
returned mixed results208 209. 
 
In the smaller, long term study, only 24 patients were available for follow-up at 6-m, at 
which point there were no statistically significant differences in remission rates 
between groups208. Patients in the fibre group had reductions in histological and 
disease activity scores at 6-m and increases in bifidobacteria, however, these effects 
were in comparison with baseline values rather than with the placebo group. In the 
larger RCT there was no difference between groups in clinical endpoints (disease 
activity, numbers achieving response or remission), fecal calprotectin or selected 
microbiota at one month209, indeed, significantly more patients withdrew in the 
prebiotic fibre group due to increased gastrointestinal symptoms including flatulence, 
borborygmi and abdominal pain. However, there were indications of a shift to greater 
mucosal immunoregulation in the prebiotic fibre group including significantly higher IL-
10 and lower IL-6 positive dendritic cells209.  
 
Three RCTs in mixed patient cohorts (i.e. active disease/remission) recruited 171 
patients. One used a high fibre diet compared with an exclusion diet and found no 
difference between groups in clinical or physiological outcomes at one year215. One 
study investigated a fibre-restricted diet (mean intake 3 g/d) and found no difference 
in clinical outcomes at 29-m compared with patients consuming their habitual diet 
(mean intake 13 g/d)214. A recent study reported that prebiotic fibre (oligofructose/ 
inulin) resulted in no difference in disease activity compared to placebo at 4-w, 
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although there were improvements compared with baseline values213, alongside 
significant increases in Bifidobacteria longum in the prebiotic fibre group.  
 
2.5.4.5 Fibre and Pouchitis 
A single cross-over RCT of 20 patients with pouchitis in remission investigated an oral 
nutritional supplement (consumed in conjunction with normal diet) with or without an 
additional prebiotic fibre (inulin) supplement for 3-w216. Favourable outcomes were 
reported during fibre supplementation including significantly lower disease activity and 
higher butyrate concentration compared to placebo. There were no differences in 
bifidobacteria and lactobacilli, however, there was a reduction in Bacteroides fragilis, 
some strains of which are enterotoxigenic and induce colitis217.   
 
In summary, fibre supplementation had a positive effect on disease outcomes in 3/10 
studies in UC194 196 201 and in the sole pouchitis study216. In contrast, none of the 12 
studies in CD showed a benefit with 5/12 studies reporting no effect on disease 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   















































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































        Table 2.8 Fibre and IBD: Summary of fibre effects on disease activity compared with     





Stage   
Study aim Effect on disease activity between groups  
(score, remission, relapse rates)  
Summary  




194 Remission  Maintenance Equivalent relapse rates to drug treatment Positive 
196 Remission  Maintenance Reduced relapse rate versus no fibre Positive 
201 Active Treatment Reduced disease activity versus no intervention Positive 
199 Active Treatment No effect on disease activity versus placebo No effect 
200 Active Treatment No effect on disease activity versus placebo No effect 
202 Active Treatment No effect on disease activity versus no intervention No effect 
195 Remission Physiological Disease activity not reported Not reported 
197 Remission Physiological Disease activity not reported Not reported 
198 Active  Physiological Disease activity not reported Not reported 
203 Mixed  Physiological Disease activity not reported Not reported 
Crohn’s disease 
207 Remission Maintenance Equivalent relapse rates versus low fibre Equivalence 
211 Active Treatment Equivalent remission rates versus low fibre Equivalence 
215 Mixed Treatment Equivalent disease activity versus exclusion diet  Equivalence 
204 Remission Maintenance No effect on relapse rates versus placebo No effect 
205 Remission Maintenance No effect on relapse times versus placebo No effect 
208 Active  Treatment No effect on remission rates versus placebo No effect 
209 Active Treatment No effect on remission rates versus placebo No effect 
213 Mixed Treatment No effect on disease activity versus placebo No effect 
214 Mixed  Maintenance No effect on disease activity of low fibre versus normal diet No effect 
206 Remission Maintenance Reduced relapse times in high fibre  versus low fibre Negative 
210 Active Physiological Disease activity not reported Not reported 
212 Active Physiological Disease activity not reported Not reported 
Pouchitis 
216 Remission Treatment Reduced disease activity versus placebo Positive 
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2.6 Discussion: efficacy of fibre in IBD 
In this systematic review of fibre in IBD, three studies in UC and the sole study in 
pouchitis reported a positive effect of fibre supplementation on disease activity 
outcomes (Table 2.8). These effects included equivalence of psyllium to 
mesalamine194, additional benefit when the two are used concomitantly194 196, 
extended maintenance of remission of UC194, and reduced disease activity scores with 
the use of germinated barley fibre in active UC201. The sole study in pouchitis reported 
that inulin lowered disease activity scores during disease remission216.  
 
In CD, no studies showed fibre to have a significant impact on disease activity when 
comparing between groups, although one very small dietary intervention study did 
show improvement in quality of life in patients with active CD on a wheat-bran 
enriched high fibre diet212. Meanwhile, three studies showed equivalent effects of a 
high fibre diet compared with low207 211 or fibre-excluded215 diets in active211, 
inactive207 or mixed215 CD. One further study reported that a low fibre diet had no 
impact on disease activity score compared with habitual diet214 and another early 
study (conducted in 1985) reported a negative effect (greater relapse rates) of a high 
fibre compared with low fibre diet206. 
 
Despite the small number of studies (4/23) showing a between-group benefit for the 
efficacy of fibre supplementation on disease activity, a number of studies reported 
within-group benefits in the increased fibre group on alternative clinical or 
physiological outcomes. These included increased f. butyrate194 216, reduced number or 
severity of gastrointestinal symptoms195 196 199 210, reduced inflammatory markers200 208, 
positive effects on inflammatory or immunological mediators197 199 203 206 209, positive 
effects on microbiota199 208 213 and improved histology199 208 211 216 (Tables 2.5, 2.6, 2.7).  
 
Whilst the positive effects were mostly evident in UC patients in studies employing 
supplement interventions it does not necessarily follow that increased fibre intake is 
not effective in CD or that dietary intervention is inappropriate. Of the three studies in 
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CD that returned equivalent results (Table 2.9) all used dietary interventions rather 
than supplements.  
 
However, the systematic review of fibre in IBD showed that in general, UC was more 
amenable to therapeutic fibre interventions than CD. The superior efficacy of fibre in 
UC patients may be linked to the formation of its fermentation products, SCFA and in 
particular butyrate, in the colon at the site of the disease. Approximately 26% of 
patients with CD have inflammation regionalized only to the small intestine, with 
another 43% having both small and large intestinal inflammation218. Therefore, in the 
majority of patients with CD, inflammation occurs at least in part, proximal to the site 
of fibre fermentation. Two studies have reported increased faecal or colonic 
butyrate194 216 in the high fibre group, one in UC194 and one in pouchitis216. Restriction 
of dietary fibre in patients with IBD, on the basis of the results from this systematic 
review seems inappropriate219. 
 
2.7  Weight of evidence in support of conducting a second  
systematic review 
The data emerging from the systematic review of fibre in IBD suggests that there is 
evidence for the potential efficacy of increased dietary fibre in IBD. In addition to those 
studies which returned positive between group effects of increased fibre intake on 
disease activity outcomes, a number of studies demonstrated positive within-group 
effects of increased fibre intake on inflammatory mediators or indicators of 
inflammation.  
 
It is concluded that there is sufficient weight of evidence to conduct a second 
systematic review to evaluate whether any evidence exists regarding the efficacy of 
dietary fibre in preventing gastrointestinal inflammation, symptoms (or toxicity) in 
patients receiving pelvic radiotherapy and if data does exist, to assess whether it is 
sufficiently robust to accept or reject the hypothesis posed in this thesis.  
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As an aside to the thesis and with reference to patients with IBD, the evidence from 
the review of fibre and IBD suggests that in those patients without overt risk of bowel 
obstruction, restriction of dietary fibre is unnecessary but that all patients should be 
appropriately monitored regarding tolerance to fibre intake. 
 
2.8  Methods for systematic review: efficacy of fibre during 
pelvic radiotherapy 
2.8.1 Selection of sources and search terms 
Seven electronic databases were selected for searching (Table 2.9).  
 
Table 2.9 Electronic databases interrogated for systematic review: fibre & RT  
Online database Years searched Limits applied 
Radiation-induced GI toxicity     Adults         Study design      Humans 
MEDLINE 1956 - October 2013 No No No 
EMBASE 1947 - December 2013  No No No 
CINAHL (Nursing database) 1983 - 2013 No No No 
Cochrane CENTRAL Library All years available No No No 
CAB Direct (Nutrition)  All years available No No No 
Web of Science 1900 - December 2013 No No No 
Scopus 1996 – December 2013 No No No 
 
Terms and syntax differed for each database and varied from the previous systematic 
review due a less established literature on the topic of nutritional intervention during 
irradiation (Table 2.10). 
 
Table 2.10 Search terms electronic database searching: fibre & RT 
 
Medline and Embase 
 
1. (((Dietary adj1 Fibre) or Dietary) adj1 Fib*).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
2. Dietary Fibre/ 
3. (Non-starch polysaccharide or NSP).mp [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
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Table 2.10 Search terms electronic database searching: fibre & RT 
4. Cellulose.mp. or Cellulose/ 
5. Methylcellolose.mp. or Methylcellulose/ 
6. Cereals/ or Cereal*.mp. 
7. (Residue adj1 Diet).mp. [mp=title, original title, abstract, name of substance word, subject heading 
word, unique identifier] 
8. Roughage.mp. 
9.  (Bran or (Oat and Diet)).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
10. Psyllium.mp. or Psyllium/ 
11. Plantago/ or Plantago*.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
12. (Ispaghula* or ispaghulahusk).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
13. (Metamucil or Fybogel or Isogel or Reguval or Normocol).mp. [mp=title, original title, abstract, name 
of substance word, subject heading word, unique identifier] 
14. Sterculia.mp. or Sterculia/ 
15. Senna Extract/ or Senna*.mp. 
16. Benefiber.mp 
17. Pectin.mp. or pectins/ 
18. Guar gum.mp. 
19.Prebiotics.mp. or prebiotics/ 
20. (Prebiotic* or Synbiotic).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
21. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 
22. (Diet* or Nutritional intervention or Formula* or Supplement*).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier] 
23. 21 or 22 
24. (Radiotherapy or Therapeutic Irradiation).mp [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
25. (Radiation and (Enteritis or Enteropathy or Toxicity or Injury or Side Effects or Proctitis or 
Mucositis)).mp. [mp=title, original title, abstract, name of substance word, subject heading word, unique 
identifier] 
26. 24 or 25 




















Table 2.10 Search terms electronic database searching: fibre & RT 
CENTRAL (Cochrane Database) 
 
#1(Radiation) and (Enteritis OR Enteropathy OR Toxicity OR Injury OR Side Effects OR Proctitis OR 
Mucositis)#2(Radiotherapy or Therapeutic Irradiation) #3(Dietary Fibre OR Dietary Fibre OR Non starch 
polysaccharide OR NSP OR cellulose OR methylcellulose OR cereal* OR “Residue Diet” OR Roughage OR 
Bran OR Oat AND Diet OR Psyllium OR Plantago* OR ispaghula* OR Metamucil OR Fybogel OR Isogel OR 
Reguval OR Normocol OR Sterculia OR Senna OR Benefiber OR Pectin OR Guar gum OR Prebiotic OR 





(Dietary Fibre OR Non Starch Polysaccharide OR NSP) OR (Cellulose OR Methylcellulose OR Cereal OR 
Residue Diet OR Roughage OR Bran OR Oat OR Psyllium OR Plantago OR Ispaghula OR Metamucil OR 
Fybogel OR Isogel OR Reguval OR Normocol OR Sterculia OR Senna OR Benefiber OR Pectin OR Guar 
gum OR Prebiotic OR Synbiotic) OR (Diet* OR Nutritional Intervention OR Formula* OR Supplement*) 
AND (Radiotherapy OR Therapeutic irradiation OR Radiation Enteritis)  
 
Web of Science 
 
#1:TS=(“Dietary Fibre” OR 2Dietary Fibre” OR “Dietary Fib*”OR Non starch polysachharide OR NSP OR 
Cellulose OR Methylcelluloe OR Cereal* OR “Residue Diet” OR Roughage OR Bran OR Oat AND Diet OR 
Psyllium OR Plantago* OR Ispaghula OR Metamucil OR Fybogel OR Isogel OR Reguval OR Normocol OR 
Sterculia OR Senna OR Benefiber OR Pectin OR Guar gum OR Prebiotic OR Synbiotic) #2: TS=(Diet* OR 
Nutritional Intervention OR Formula* OR Supplement*) #3:#2 OR #1, #4: TS=(Radiation), #5: 
TS=(Enteritis OR Enteropathy OR Toxicity OR Injury OR side effects OR Proctitis OR Mucositis) #6: #4 





((((“Dietary Fibre” OR “Dietary Fibre” OR “Dietary Fib*”OR non starch polysaccharide OR nsp OR 
cellulose OR methylcellulose OR cereal* OR “Residue Diet” OR roughage OR bran OR oat AND diet OR 
psyllium OR plantago* OR ispaghula* OR metamucil OR fybogel OR isogel OR reguval OR normocol OR 
sterculia OR senna OR benefiber OR pectin OR guar gum OR prebiotic OR synbiotic) AND ((diet* OR 
nutritional intervention OR formula* OR supplement)))) AND ((((radiotherapy OR therapeutic 
irradiation)) OR ((radiation)) AND (enteritis OR enteropathy OR toxicity OR injury OR side effect* OR 




Hand searching spanned the period 2001 – 2013 (Table 2.11). 
 
Table 2.11 Hand searching sources: fibre & RT  
  
Organisation / Event Relevant publication(s)  
ASTRO (American Society for Radiation Oncology) Int. J. of Radiation Oncology Biology & Physics 
UKRO (UK Society for Radiation Oncology) Clinical Oncology, J Royal College of Radiologists 
ESTRO (European Society for Radiation Oncology) Radiotherapy and Oncology 
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2.8.2 Inclusion and exclusion criteria 
Inclusion and exclusion criteria were defined according to the PICOS structure and are 
detailed in Table 2.12 
 
Table 2.12 Inclusion and exclusion criteria: fibre & RT        
PICOS Inclusion and exclusion criteria Data extracted 
Patient Adult (in- or out-patients) over 18 y  
receiving radical radiotherapy for pelvic 
malignancies (acute setting only).  
 
Original cohorts only (i.e. excluding previous 
reports and abstracts of the same patients) to 
avoid duplication of patient numbers.  
 
Location, clinical setting, age, gender, number 
of patients recruited, number of patients 
evaluated (i.e. those with evaluable data at 
study end). 
Cancer location, pelvic site, radiotherapy dose, 
duration of treatment, concomitant 
chemotherapy.  
Intervention Oral pharmacological fibre supplement, food 
supplement or dietary advice to increase or 
decrease fibre intake were eligible. Fibre 
interventions were required to meet the 
acknowledged definitions of fibre (15-17), and 
therefore included prebiotic fibres.  Synbiotic 
preparations containing a named prebiotic 
fibre complying with the cited fibre definitions 
were also eligible irrespective of probiotic 
species and strain(s) used. 
 
Fibre source, dose, presentation and period of 
administration. Presence of co-administered 
‘standard’ medication(s) or supplemental 
nutritional substances. Compliance with 
interventional dose (if reported) and method of 
computing compliance. Genus/species/strain 
of probiotic if administered in conjunction with 
synbiotic preparation.  
 
Comparators Reports including a comparator group of either 
a placebo, no dietary intervention, an 
alternative dietary intervention or a 
pharmacological intervention were included. 
Reports comparing doses of fibre without any 
other comparator group were excluded. 
 
Patient numbers in the intervention and 
comparator groups and nature of intervention. 















Clinical outcomes or endpoints including: 
bowel habit and treatment-related toxicity,  
medication use, symptoms, quality of life, 
histology.  
Physiological outcomes or endpoints related to 
gastrointestinal inflammation including 
histology, inflammatory and immunological 
markers, microbiota and metabolic substrates. 
Presence or absence of adverse events related 
to interventional substrate. 
 
Randomised controlled trials (RCT). Open 
label, wholly or partially blinded or placebo-
controlled nutritional interventional studies. 
Single or multi-centre. English or foreign 
language. Non-RCTs and uncontrolled trails 
excluded. 
 
Specific toxicity questionnaire scores or 
histology scores. Otherwise all other relevant 
clinical or physiological outcomes or endpoints 
at relevant time-points including statistical 
significance if reported.  
Comparisons of endpoint data between groups 
were extracted where possible, but within 
group comparisons between baseline and 
follow-up were extracted where of interest. 
 
 
Type of study design, nature of blinding, active 
interventional period and duration of follow-
up. Authors and publication details. Abstract or 




2.9 Results of the systematic review: efficacy of fibre during 
pelvic radiotherapy 
2.9.1 Results of the search process 
A total of 4192 non-duplicated papers were identified. Titles and abstracts of each 
were reviewed and 16 papers were potentially eligible. Following full review, only 4 
papers (detailing 4 eligible studies) fulfilled the inclusion criteria and were included in 




 4188 non-duplicated citations identified during electronic database searching 
1 citation identified from hand searching reference lists and abstracts (not previously identified) 
3 citations from experts in the field (not previously identified) 
 4176 citations rejected based on review of title/abstract 
 16 citations potentially eligible 
on review of title/abstract 
reporting 16 original trials 
 12/16 trials rejected following review of full paper due to 
(numbers not mutually exclusive): 
 
  Non-pelvic radiotherapy population (n=1) 
  Not an acute intervention during radiotherapy (n=4) 
  Not an original cohort (n=3) 
  Not an oral fibre intervention (n=7) 
  No appropriate comparator group/measurement (n=4) 
  Non-relevant outcome (n=1) 
  Not an RCT (n=5) 
4 citations reporting 4 trials of fibre 
interventions in patients receiving 
pelvic radiotherapy (264 patients) 
 
Figure 2.2 Fibre and radiation-induced GI toxicity: summary of review process and 
results 
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All studies were reported in full (i.e. none as abstracts) and published in English 
language130 220-223. Study locations included United Kingdom, Canada, Sweden and 
Spain. Of the six experts contacted, all responded and three articles were identified 
that had not previously been identified through electronic searching (Figure 2.2)130 220 
223. 
 
2.9.2 Patients, interventions and comparators 
The four studies recruited 264 patients, comprising 19% of patients with mixed 
gynaecological cancers, 68% with prostate cancer and for the remaining 13% the pelvic 
site at recruitment was not reported. All patients were treated with 45 Gy or above to 
the pelvis in 1.8 – 2.0 Gy fractions with radiotherapy treatment periods of between 5 
and 7 weeks.  
 
The use or not of concomitant chemotherapy was not reported in one study220 and not 
administered in one study as it included only prostate cancer patients222. In the 
remaining study223, it is reported that patients who received previous or adjuvant 
chemotherapy were not eligible for inclusion in the study223. 
 
One study220 was therapeutic in aim, designed to evaluate the efficacy of the fibre 
supplement Fybogel versus codeine phosphate for the treatment of new onset 
radiation-induced diarrhoea220. Two studies130 222 were preventative in design, with the 
aim of examining dietary fibre manipulation in the prevention of radiation-induced GI 
toxicity. One used a fibre supplement in combination with a reduced insoluble dietary 
fibre intake130 and the other a soluble fibre rich diet222. Both aimed to examine the 
effect of the intervention on incidence and severity of new-onset of diarrhoea. 
 
For one of these studies, the first author was contacted to clarify that the nature of the 
study was therapeutic in aim as this was not clear from the published article 130. The 
remaining study was physiological in aim and designed to examine the effect of a 
prebiotic supplement on microbiota dynamics although surrogate inflammatory 
markers were also measured223. All four studies employed a two-way group 
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comparison of which three used an open label design130 220 222, one of which employed 
a cross-over design220 and one a double blind placebo controlled design223.  One study 
used a dietary intervention based on dietary advice and patient coaching222 whilst 
three used soluble fibre supplements130 220 223. All employed multiple interventions, 
using additional single or multiple dietary restrictions in combination with fibre 
supplements (Table 2.13). 
 
Table 2.13 Fibre and radiation-induced GI toxicity: summary of study interventions 
Reference Primary Intervention 







Lodge220 Soluble fibre 
supplement 
√   
Murphy130 Soluble fibre 
supplement 
√  √ 
Pettersson222 Soluble fibre rich diet √ √  
Garcia-Peres223 Prebiotic supplement √ √  
 
Intervention periods spanned active radiation treatment periods. In two studies, the 
intervention continued for 21223 and 28130 days after the last fraction of radiotherapy. 
One study is currently ongoing with patients being asked to continue the intervention 
up to 24m after cessation of radiotherapy222. Fibre doses were reported in 2/4 studies 
and varied from 12 g/d inulin/FOS223 to ‘1 to 2 teaspoons’, equivalent to 8 to 12 g/d, of 
a psyllium-based supplement130.   
 
The sole dietary intervention study was unable to report absolute insoluble or soluble 
fibre intake, or change in intake, as it employed a Food Frequency Questionnaire (FFQ) 
with no information on portion sizes222. Compliance was reported in two studies130 222. 
One of these studies asked patients to record dose consumed (teaspoons) in symptom 
dairies but did not report the results or quantify fibre intake from dietary sources130. 
The other used an FFQ based scoring system to reflect compliance although was 
unable to report quantitative information222.  
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2.9.3 Study quality and adverse events 
Quality scores (Jadad scale) reflected the fact that only one study employed a placebo 
controlled design. Three studies scored three points (of a maximum 5) and one study 
scored one point. No studies reported serious or adverse events resulting from the 
intervention. However, one was terminated early on safety grounds due the lack of 
efficacy of the fibre supplement intervention versus standard medication as a 
treatment for radiation-induced diarrhoea220.   
 
2.9.4 Clinical and physiological outcomes 
2.9.4.1 Fibre for the prevention of radiation induced GI toxicity 
Two studies examined the benefit of manipulating fibre intake for the prevention of 
radiation-induced GI toxicity during pelvic radiotherapy130 222. Each used a different 
intervention comprising a low fibre + low fat diet combined with soluble fibre 
supplement130 and a high soluble fibre + low insoluble fibre diet combined with low 
lactose222.  
 
In the earlier of these studies, Murphy et al., recruited 84 patients and randomised 
them to receive either a daily dose of psyllium (Metamucil) in combination with 
standard dietary advice (i.e. low fibre + low fat diet) or dietary advice alone130. A 
bespoke diarrhoea scale termed the Murphy Diarrhea Scale was devised to calculate 
severity of on-treatment diarrhoea (Table 2.14). Patients were instructed to record the 
number of days during radiotherapy on which they experienced a ‘diarrhoea day’ 
defined as follows:  
 
 4 to 6 bowel movements > normal 
 1 or more watery bowel movements 
 2 to 3 loose or poorly formed bowel movements > normal 
 Use of anti-diarrhoea medication 
 
The number of diarrhoea days per patient was then summed to give a mean Murphy 
Diarrhea Scale severity score for each group (Table 2.14). However, 25% of patients 
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were excluded from the analysis, due to failure to return symptom diaries leaving 60 
patients with evaluable data. 
 
Table 2.14 Murphy Diarrhoea Scale severity rating and ‘MDS’ Score  
Diarrhoea severity MDS Score 
Mild diarrhoea: <11% days with diarrhoea 1 
Moderate diarrhoea:  11 - 20% days with diarrhoea 2 
Severe diarrhoea: >20% days with diarrhoea 3 
 
A significant difference (p=0.030) was reported in the mean diarrhoea severity score 
between groups in favour of the Metamucil group with mean Murphy Diarrhea Scale 
score of 1.8 ± 0.96 points versus the no intervention group with a mean severity score 
of 2.33 ± 0.84 points130. Incidence of diarrhoea was also reported to be significantly 
reduced (p=0.049) in the Metamucil group at 60% (18/30 patients) compared with 83% 
(25/30 patients) in the no intervention group130. Mean time to onset of diarrhoea, 
duration of diarrhoea and percentage of days on which anti-diarrhoeal medications 
were taken was not significantly different between groups.  
 
Whilst this study showed a benefit for Metamucil supplementation the difference in 
the Murphy Diarrhea Scale severity score whilst significant was modest and included 
wide standard deviations compared to the mean difference obtained130. The authors 
acknowledged this was a pilot study and that accrual to the study was limited by 
resource constraints but argued that the number of patients recruited were sufficient 
for statistical analysis. However the study was not statistically powered for a specific 
endpoint. Further the MDS, although based on previously published scoring systems, is 
not a validated tool and it would have been useful if a more commonly used tool 
(CTCAE or RTOG) had been used for comparison purposes.  
 
Nevertheless the Murphy Diarrhea Scale represents an interesting attempt to define a 
diarrhoea day in different ways of relevance to patients and importantly recognises 
that subsequent ranking of patient-reported outcomes into a composite ‘severity’ 
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score facilitates analysis. However individual patients’ interpretation of watery or 
poorly formed bowel movements is subjective and whilst this could be improved with 
the use of visual materials or individual coaching these methods are rarely employed 
and labour-intensive to develop and test. Unfortunately this open label study failed to 
measure and/or report on dietary fibre or fat intake and did not comment on possible 
cross-talk between patients in different study groups both of which may have 
influenced results. Recruitment took place at two sites and advice given to patients 
was standardised with the use of a locally-produced hospital booklet130.       
 
In the second, eligible open label study, Pettersson et al, recruited 130 men receiving 
radiotherapy for localised prostate cancer (i.e. without lymph node involvement) and 
randomised them to receive standard care (i.e. to continue with their habitual diet) or 
a dietary intervention in which they were advised to avoid foods high in insoluble fibre 
and lactose in favour of foods high in soluble fibre and low in lactose222.  A bespoke 
Food Frequency Questionnaire (FFQ) comprising 14 food groups with 6 groups low, 
and 8 groups high in insoluble fibre and lactose was designed to guide patients’ food 
choices and monitor adherence to dietary instructions. The FFQ was used in both 
standard care and intervention groups. Patients were interviewed immediately before 
the start of radiotherapy and at 4 weeks and 8 weeks from the start of treatment, and 
two months following radiotherapy treatment.  
 
Radiotherapy-induced toxicity was assessed using the prostate-specific QLQ-PR25 and 
EORTC QLQ-C30 together with a non-validated study-specific Gastrointestinal Side 
Effects Questionnaire (GISEQ) which assessed ‘bother’ associated with diarrhoea, 
blood in stool, mucous discharge, intestinal cramps, intestinal pain, intestinal gas and 
flatulence222.  At two-months from treatment commencement there was an attrition 
rate of 12% (58/66 patients) in the standard care group and 14% (55/64 patients) in 
the intervention group. Analysis of compliance reported an interaction effect (p<0.001) 
between randomisation and time in the FFQ scores at the 8 week follow-up point 
indicating that both groups adhered to dietary instructions222.  
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However, despite a trend towards reduced incidence of symptoms (using selected 
variables taken from the QLQ-PR25) no significant differences between groups in any 
gastrointestinal toxicity or quality of life measures were found. Incidence of self-
reported diarrhoea at 8 weeks or end of radiotherapy was slightly less in the 
interventional group 30% (14/51 patients) versus the standard care arm 33% (19/60 
patients) but not significant222.  
 
There are a number of reasons why this study may have failed to detect a significant 
difference between groups. The authors acknowledge that the study may have been 
underpowered. Much lower rates of on-treatment toxicity were observed than 
expected. Thirty percent of patients reported presence of bowel symptoms at 
randomisation whilst just 50% reported presence of gastrointestinal symptoms during 
treatment. Thus larger numbers would have been required to detect such small 
differences in toxicity. The low toxicity rates experienced may have reflected the size 
of the radiotherapy treatment field. Conformal prostate radiotherapy includes a small 
portion of the rectal wall immediately adjacent to the prostate gland but generally 
does not include other portions of the large or small intestine, both of which cannot be 
avoided when irradiating the prostate gland and pelvic nodes.  
 
Thus, if the study had included patients with nodal involvement, higher rates of toxicity 
may have been observed. It is also possible that the dietary adjustments made by 
patients were ineffective. However, quantitative values for differences between 
groups in fibre or lactose intake could not be extrapolated from the FFQ which 
contained no details on portion size. Many of these points are acknowledged by the 
authors222. Study outcomes are summarised in Table 2.15. 
 
In contrast to the IBS systematic review, for the radiation-induced GI toxicity 
systematic review, meta-analysis was considered appropriate to assess whether the 
dietary fibre intervention had an effect on the endpoint, incidence of new-onset 
diarrhoea during radiotherapy, as reported in the above two studies130 222. A random 
effects model was chosen due to the differing experimental design of the two studies 
and in consultation with Ms Eirini Dimidi, King’s College London who advised and 
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assisted with this analysis. The risk ratio (RR)190 or relative risk was used to compare 
the efficacy of a dietary fibre intervention (experimental group) versus no intervention 
(control group) where: 
 
   RR =   Risk of the event in the experimental group  
                 Risk of the event in the control group 
 
In the analysis depicted below in the form of a forest plot, the Risk Ratio (CI) of 0.75 
(0.56, 1.01) indicates that the probability of new onset diarrhoea in the treatment 
groups is 25% less than that in the control (or standard care) groups, therefore 
favouring a fibre intervention. However, the test for the overall effect is not 
statistically significant, falling just short of the accepted level of statistical significance 
(p=0.06).  
 
Figure 2.3 Forest plot comparing fibre interventions and incidence of diarrhoea 
 
 
2.9.4.2 Fibre for the treatment of radiation-induced GI toxicity 
One study in female patients receiving radiotherapy for gynaecological cancer (Table 
2.15) examined the efficacy of a soluble fibre supplement, ispaghula husk (Fybogel) for 
the control of radiation induced diarrhoea220. Using an open label cross-over design 
patients were randomly assigned to receive Fybogel or standard medication, codeine 
phosphate, at new onset of treatment-related diarrhoea, defined as ‘excessively 
frequent and loose bowel movements’. In addition, all patients were advised to follow 
a low residue diet (not defined) whilst on radiotherapy treatment. The trial was closed 
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after ten patients had been randomised to the study (five per arm) due to a reported 
lack of bowel control in the Fybogel group. All patients in this group were crossed-over 
to standard medication.  
 
Although 2/5 patients in the Fybogel group reported improvements in stool 
consistency they found the supplement unpalatable and difficult to swallow and did 
not wish to continue taking it. In contrast all patients randomised to receive codeine 
phosphate regained what was termed normal bowel control. The authors reported 
that ispaghula husk was not totally ineffective at controlling diarrhoea but 
nevertheless concluded that it was a less effective and less palatable preparation than 
codeine phosphate220.  
 
2.9.4.3 Physiological effects of fibre during pelvic radiation 
One study has explored the efficacy of a fibre-based prebiotic supplement for the 
promotion of beneficial bacterial species, Lactobacillus and Bifidobacterium during 
pelvic radiotherapy223. In a randomised, double-blind placebo controlled design, 40 
patients with gynaecological cancer receiving post-operative radiotherapy (of whom 
31 provided evaluable data) were randomised to receive either 6g of an inulin / fructo-
oligosaccharide (FOS) mixture in a 50:50 ratio twice daily or placebo (Table 2.15). The 
intervention commenced one week prior to start of radiotherapy and continued for 
three weeks after the last fraction of treatment. All patients were additionally advised 
to avoid foods high in insoluble fibre and lactose.  
 
Faecal samples were obtained at four time-points and analysed using cell culture and 
fluorescent in-situ hybridisation (FISH) methods. Inflammatory marker faecal 
calprotectin and faecal DNA as a marker of epithelial desquamation were also 
analysed. Results indicated that during radiotherapy, counts of both Lactobacillus and 
Bifidobacterium were significantly reduced in both groups. However three weeks after 
treatment there was a significant increase in the number of both Lactobacillus and 
Bifidobacteria in the prebiotic group (p=0.04 and p=0.03 respectively) compared to 
placebo which led the authors to conclude that the inulin/FOS mix improved recovery 
of both genera after radiotherapy.  
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No significant difference between groups was found in inflammatory marker faecal 
calprotectin or faecal DNA and unfortunately the published article did not include any 
data in respect of either of these inflammatory or mucosal damage-related markers. 
Further, although no adverse effects were reported resulting from the intervention, 
the study failed to assess clinical endpoints223. No information was provided regarding 
the recommended on-treatment diet nor of patients’ compliance with this during 
radiotherapy. The authors state that a study using a similar intervention in a similar 
patient group is currently underway and that this study will include clinical variables 
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2.10  Discussion: efficacy of fibre during pelvic radiotherapy 
In the systematic review of fibre in patients undergoing pelvic radiation the data in 
support of fibre intervention is equivocal. Only four RCTs exploring the manipulation of 
dietary fibre in this treatment setting were identified. One study reported a benefit for 
psyllium supplementation, in combination with reduced dietary fibre and fat intake, 
for the prevention of new-onset treatment-induced diarrhoea130. However, 
methodological criticisms of this study can be made regarding the lack of statistical 
powering and the use of non-validated outcome tools.  
 
A further initially adequately powered study failed to demonstrate the efficacy of an 
insoluble fibre rich + low lactose diet for the prevention of new onset gastrointestinal 
symptoms, including diarrhoea, due to unexpectedly low rates of toxicity in the study 
cohort222. The two studies combined in meta-analysis showed a 25% reduction in the 
relative risk of developing new-onset treatment induced diarrhoea in the 
interventional groups but lacked significance (p=0.06). However, these studies were 
heterogeneous in nature employing different measurement tools, using differing 
interventions and recruiting cancer patients with differing pelvic malignancies.  
 
One small therapeutic study found no benefit of psyllium versus standard medication 
for the control (i.e. treatment) of new-onset diarrhoea and was terminated early220. A 
final study using an inulin/FOS prebiotic intervention reported positive effects on 
beneficial microbiota species recovery following radiotherapy but did not measure 
clinical endpoints223.  
 
Unfortunately, in contrast to studies in IBD, 3/4 of the studies included in the 
systematic review of fibre during pelvic radiotherapy did not employ physiological 
endpoints to provide added insight as to fibre’s possible mechanism of action130 220 222. 
The only study which investigated physiological mechanisms, the effect of a prebiotic 
on selected microbiota genera / species, failed to include clinical endpoints223.  
 
Methodological difficulties were apparent in the majority of studies. Use of multiple 
interventions, lack of robust data on fibre intake or compliance, use of non-validated 
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endpoints and recruitment of patients with heterogeneous treatment fields may have 
served to confound the true efficacy of fibre in this setting. 
 
2.11  Weight of evidence in support of conducting a randomised 
controlled trial  
Dietary fibre has physiological properties that may impact on gastrointestinal 
inflammation and therefore may be beneficial in the management of radiation-induced 
inflammation and toxicity. However, the data available from the four studies included 
in the systematic review of the efficacy of fibre in patients receiving pelvic 
radiotherapy is not sufficiently robust to answer the research hypothesis posed in this 
thesis.  
 
The next step is to design an adequately powered, randomised controlled trial to 
assess the efficacy of manipulating dietary fibre intake in patients receiving pelvic 
radiotherapy.  
 
2.12  Learning from the systematic reviews  
The reviews have raised some interesting and important issues with respect to the 
choice of intervention for a new randomised controlled trial. The majority of studies 
identified in the two reviews used fibre supplements rather than dietary interventions 
and it is clear, that if a dietary-based interventional design is to be used for the 
randomised controlled trial it will be more time-consuming to administer than a 
supplement intervention and that double-blinding is virtually impossible.  
 
Further, it is recognised that dietary interventions require the provision of definitive 
and meaningful guidelines to patients to ensure achievement of desired aims 
combined with rigorous monitoring and meticulous analysis if they are to provide 
meaningful data. This implies the use of validated tools for assessing dietary intake at 
appropriate time-points. Despite these drawbacks, dietary interventions are of course 
more physiological, and in contrast to fibre supplements, will comprise foods with 
differing but naturally occurring quantities of both soluble and insoluble fractions with 
mixed fermentative properties. Gut microbiota have evolved in response to host diet 
 129 
and may respond differently to supplement as opposed to dietary intervention. 
Further, dietary interventions can be designed to be empowering rather than 
prescriptive and if appropriately designed, should be readily adaptable for the 
treatment (non-research) setting. 
 
Another important message emerging from the two systematic reviews is that 
compliance with dietary intervention is a complex process and is not well defined or 
measured. In the first instance, compliance with a dietary intervention requires 
patients to understand the information being delivered to them (influenced by the 
skills of the health professional or researcher), to value it (influenced by their health 
psychology) and then have the ability to adopt it (influenced by their food access, food 
knowledge).  
 
Unfortunately compliance was not robustly measured in many of the dietary 
intervention trials included in the two reviews undertaken in this thesis. Therefore, the 
extent to which the variable success of the dietary intervention studies was due to 
poorer study design, failure to achieve the dietary fibre target or a true lack of impact 
of fibre from dietary sources to manage gastrointestinal inflammation, is unclear.  An 
intervention of advice to manipulate dietary fibre intake (increasing or decreasing 
intake) must therefore include some measure of compliance and if necessary take 
account of any confounding factors. Equally, and in a similar manner to the well-known 
placebo effect in clinical research, dietary intervention, simply through contact with 
the relevant health professional may positively affect outcomes. Minimising the 
potential role of bias with respect to the intervention is thus seen as another 
important aspect of any nutritional interventional randomised controlled trial.  
 
Finally, although some studies in IBD did employ clinical and physiological endpoints, 
none in the radiotherapy setting adopted this approach. This is felt to be vital 
requirement since in the event of significantly differing outcomes associated with 
intervention, physiological endpoints may provide valuable insight as to the biological 
mechanism underlying any effect. Since dietary fibre is the nutritional intervention of 
choice, the inclusion of measurement of faecal short chain fatty acids would be a 






CHAPTER 3: Methods 




3.1 Introduction to methods 
There is a lack of robust evidence to support or refute the efficacy of increased dietary 
fibre in the management of gastrointestinal symptoms arising during pelvic 
radiotherapy. This chapter describes the methods used in the design and conduct of an 
adequately powered randomised controlled trial to investigate the role of fibre during 
pelvic radiotherapy.  
 
The trial and all nutritional intervention material was designed by the author and drew 
on knowledge gained from the conducting of the two systematic reviews previously 
described. The trial was entitled ‘a randomised controlled trial to investigate the role 
of low or high fibre diets in patients undergoing pelvic radiotherapy’, abbreviated to 
‘The Fibre Study’.  
 
The trial rationale and design are described first, followed by a description of trial 
procedures. Methods used for collection of trial measurements follows and finally, 
statistical methods.  
 
3.2 Clinical trial: design  
3.2.1 Rationale  
An estimated half of all newly diagnosed cancer patients will receive radiotherapy at 
some point in the course of their disease4. As the number of long-term post-
radiotherapy cancer survivors continues to grow, preventing or reducing the side 
effects of irradiation treatment is becoming an increasing priority224.  
 
During radical pelvic radiotherapy treatment, more than 90% of patients develop 
gastrointestinal symptoms with 40% of patients requiring anti-diarrhoeal medication. 
At the author’s institution, healthcare professionals frequently advise patients to 
reduce dietary fibre during pelvic radiotherapy to control these symptoms despite the 
lack of robust evidence in this respect.  
 
As the systematic review of the efficacy of fibre in IBD has shown, there is evidence 
that fibre has a potentially beneficial effect on disease outcomes and may reduce 
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inflammatory processes219. Further, as the systematic review of fibre in patients 
receiving pelvic radiotherapy has shown, no adequately powered, single intervention, 
high quality, randomised controlled trials have examined the potentially beneficial 
effects of dietary fibre on gastrointestinal symptoms and inflammatory processes 
during pelvic radiotherapy.  
 
The design of the fibre study was conceived by the author with input from associated 
professionals including the Trust’s statistician, a consultant dietitian, research 
radiographer, gastroenterologist and nutritional / fibre expert. The study design was 
influenced by lessons learned from the two systematic reviews and as a result, 
particular emphasis was placed on the following requirements: 
 
 The need for a robust, achievable, meaningful and measurable dietary 
intervention, including the provision of appropriate guidance to patients which 
they could readily assimilate and adopt with minimal additional burden. 
 
 The need for the accurate capture and analysis of dietary intake, including fibre 
intake data using as far as possible gold standard methods of data capture and 
analysis via appropriate dietary software (i.e. analysis) tools. 
 
 The need for an appropriate measure of compliance to ascertain whether 
patients were able to adopt and comply with the advice given and thus allow 
study investigators to ascertain whether an appropriate differential in fibre 
intake was maintained between study groups. 
 
 The need for the inclusion of an appropriate physiological endpoint (SCFA) to 
provide insight regarding the mechanism of efficacy (or not) of the dietary fibre 
intervention. 
 
 The need to employ objective measures of stool-related toxicity to allow for the 
analysis of the effects of radiotherapy and fibre intake on stool parameters in 
the absence of a clear and agreed definition of treatment-induced diarrhoea.  
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3.2.2 Aims and hypothesis 
The primary aim of the study was to examine the effect of a low or high fibre diet, 
compared with a normal diet (i.e. a patient’s habitual fibre intake) on gastrointestinal 
symptoms in adult patients receiving radical radiotherapy for pelvic malignancies. In 
view of the important relationship between the severity of toxicity experienced in the 
acute setting (i.e. during radiotherapy) and the risk of late effects, a single measure of 
gastrointestinal symptom burden was included one year after radiotherapy31 32 34-36 38-
40 46. The data from this longer-term outcome of the study are currently maturing and 
will be reported separately. 
 
The secondary aims were to assess the effect of low or high fibre diets on:  
 
 Quality of life during and one year after radiotherapy 
 Faecal SCFA concentration at start and end of radiotherapy 
 Stool characteristics at start and end of radiotherapy 
 Compliance with dietary intervention 
 Nutritional parameters at start and end of radiotherapy, including weight, 
height, BMI, macro- and micronutrient intake 
 
The research hypothesis (H1) for the study was:  
 
‘A high fibre diet (defined as 18 - 22 g/d of non-starch polysaccharide) will reduce or 
prevent gastrointestinal symptoms in patients receiving radical pelvic radiotherapy. 
This benefit will be achieved at least partly by the anti-inflammatory action of short 
chain fatty acids (SCFA) resulting from the fermentation of soluble fibre by 
microbiota and partly through the beneficial effect of fibre on stool frequency and 
form ’ 
 
3.2.3 Design: summary 
The Fibre study was designed as a 3-arm, open label, nutritional intervention, 
randomised controlled trial. The author as principal study investigator was not blinded 
to the intervention. Further, it was not possible to blind patients to the intervention as 
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they would inevitably know whether they were receiving high fibre or low fibre dietary 
advice.  
 
The time-table for the collection of study measurements was designed to ensure 
similar amounts of time in terms of contact minutes with the author (a registered 
dietitian) were given to all patients to standardise any effect of dietetic input alone as 
distinct from the effect of the intervention. 
 
Patients randomised to the low fibre group and the high fibre group were given a 
target for daily dietary fibre intake and asked to follow a low or high fibre diet for the 
duration of radiotherapy. The control group were patients following their normal 
(habitual) dietary fibre intake. The low and high fibre groups received additional advice 
on how to achieve their required target fibre intake and also completed records 
detailing daily fibre intake to chart their compliance. All patients received standard 
medical care.  
 
The initial trial design allowed for an exploration of the relationship between 
proportion of irradiated bowel and GI toxicity in a sub-group of 56 patients. The data 
from this aspect of the study are currently undergoing analysis and will not be 
reported within this thesis. 
 
The study design is depicted in Figure 3.1. 
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3.2.4 Patients  
Patients eligible for the trial were adults due to receive a course of radical (long-
course) radiotherapy for the control of pelvic malignancies. This included patients with 
a diagnosis of gynaecological cancer (endometrial, cervical, vaginal, vulvar, ovarian); 
urological cancer (locally advanced prostate and bladder) and cancers of the lower 
gastrointestinal tract (colon, rectum, anus) and given the proximity of healthy small 
and large bowel tissues to these target organs, all patients were at risk of GI toxicity.  
 
Urology patients (locally advanced prostate and bladder cancers) were subsequently 
excluded from the study prior to recruitment commencing. This decision was made in 
view of the number of studies competing for this patient group and the emergence of 
new urology treatment protocols which would have resulted in increased 
heterogeneity in terms of volume of small and large bowel within the treatment field 
in the recruited sample.  
 
LOW fibre diet 
≤10g NSP/d 




3-arm randomised controlled trial (n=156)  
Key: NSP = Non starch polysaccharide 










YES Dose, volume and 
toxicity 
Analysis conducted 
All patients continue with intervention during RT treatment. Weekly compliance with fibre 
prescription monitored. Toxicity measurements and costs associated with toxicity undertaken 





Patients were excluded from the trial if: 
 
1. They were unable or unwilling to give informed consent. 
2. They were recruited to other studies where toxicity was a primary endpoint.  
3. They had a condition precluding oral nutritional intake. 
4. They had established wheat intolerance or have coeliac disease.  
5. They had been prescribed low residue diet for a clear medical reason. 
6. They had a gastrointestinal stent.  
7. They had a jejunostomy, ileostomy or colostomy.    
 
3.2.5 Radiotherapy treatment protocols  
Radiotherapy treatments were delivered in compliance with local Trust protocols and 
employed External Beam (EBRT) and Intensity Modulated (IMRT) techniques. All 
patients received at least 45 gray (Gy) to the pelvis in 1.8 Gy fractions in daily 
exposures (Monday to Friday) of 10 to 20 minutes total (appointment) duration over 
periods of 5 to 7 weeks. Concomitant chemotherapy agents were used for selected 
tumour sites with the aim of sensitising tumour cells to irradiation.  
 
Patients with gynaecological malignancies (cervix and endometrial cancers) received 
high or low dose brachytherapy treatment as an adjunct to external beam irradiation 
where indicated. Doses delivered using these (localised) techniques were not 
considered to contribute to GI toxicity and thus (in this trial) did not contribute to the 
computation of final radiotherapy dose.  
 
Treatment planning comprised one computed tomography (CT) radiotherapy planning 
scan simulating treatment delivery. Tumour extent and organs at risk were outlined by 
clinicians on each CT slice. Dosimetry calculations, performed by medical physicists, 
defined the dose to be received by the tumour and adjacent healthy organs. 
Treatment margins of 1-2 mm were added to the clinical target volume to allow for 




Radiotherapy treatment protocols used at the author’s institution are outlined in Table 
3.1 
 
Table 3.1 Radiotherapy treatment details for eligible patients 
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Key: * Plus brachytherapy using HDR delivery, typically 8Gy in 2 insertions (see section 1.3.1 
for explanation)  
 
3.2.6 Intervention 
Examples of all interventional tools described in this section are given in Appendix 1. A 
dietary-based intervention, in preference to supplement, was selected for 
physiological and palatability reasons. In a previous prospective cohort study in 
prostate cancer patients, dietary-based adjustments of daily fibre intake had proven 
feasible and popular with patients in this setting75.  
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In view of the differing therapeutic effects of soluble (highly fermentable) versus 
insoluble (poorly fermentable) fibre225, the fibre study was originally designed as a 4-
arm trial with the high fibre group split into soluble- and insoluble-rich groups. 
However, detailed consideration ruled this non-feasible. Firstly, it was felt that 
randomisation to the high fibre soluble-rich group would result in an unduly restrictive 
dietary regimen, unlikely to result in compliance. Secondly, there is poor discrimination 
in dietary software packages regarding estimation of poorly fermentable versus readily 
fermentable dietary fibre in food. This would have considerably complicated analysis. 
 
There is no recommended daily fibre intake for adults in receipt of pelvic radiotherapy 
and as reported earlier in this thesis, the evidence from RCT of high fibre or fibre-
restricted diets during pelvic radiotherapy is weak and inconclusive. Therefore, both 
high and low target fibre intakes, based on intakes for healthy adults in the UK, were 
selected for intervention139. Fibre targets were defined in grams per day of non-starch 
polysaccharide (NSP) calculated using the Englyst method of analysis226.  
 
A mean difference of 8g / day between the high and low fibre groups was postulated 
to demonstrate an effect of differing fibre intake if one existed. Thus the high fibre 
group were advised to consume between 18 and 22g of NSP per day (18g / day being 
the DRV for fibre intake for healthy adults in the UK139) and the low fibre group, no 
more than 10g per day. Both fibre targets (high fibre 18-22 g/d, low fibre ≤10 g/d) 
were deemed achievable for two reasons. First, with reference to fibre intake in 
healthy adults, mean average consumption of NSP for healthy adults (19 – 64 years) in 
London and the South East is 15.6 g/d per day (sd 6.06) for men and 13.0 g/d (sd 5.17) 
for women227. Second, with reference to a recent sample of men and women being 
treated with pelvic radiotherapy (n=44), mean daily fibre intake was assessed as being 
14.0 g/day (sd 5.1) at the start of radiotherapy and 12.7 g/d (sd 4.8) following 4-5 
weeks of treatment228.  
 
A guidance booklet entitled ‘Fibre in Foods’ was developed specifically for the trial by 
the author. This booklet listed the fibre (NSP) content of typical portions of commonly 
consumed food items.  The design and ease of use of this booklet was considered to be 
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a key feature in assisting and motivating patients to comply with the intervention. The 
16-page booklet, available in A4 or A5 sized versions according to patients’ preference, 
contained 405 food items arranged into 10 major food groups.  
 
Fibre (NSP) content of typical portions of all foods was detailed in the booklet as 
‘points’ equating to grams of fibre per portion. Patients were encouraged to count 
their daily fibre intake using this booklet, in points or grams per day and to record this 
in an accompanying exchange diary. Advice on reading food labels and converting 
between imperial and metric units was included on the inside back cover of the 
booklet.  
 
The fibre intake exchange diary, which accompanied the guidance booklet was 
intended to aid patient compliance with the high or low fibre interventions and did not 
constitute an outcome measure of fibre intake as the method is not validated for 
estimation of fibre intake. However, similar interventional strategies have been used 
successfully by our group and others in previous nutritional interventional research in 
oncology patients76 229-231. The guidance booklet and exchange diary were not made 
available to patients randomised to the control or normal diet group.  
 
The exchange diary, which was of similar design for both the high and low fibre groups, 
comprised a series of tick boxes printed for each day of treatment. The high fibre 
version of the diary displayed a series of 22 clear boxes printed per line arranged in a 
week per page style, with availability for recording fibre intake for up to 6 weeks of 
radiotherapy treatment, including weekend (non-treatment) days. The low fibre 
version of the diary was similar except that boxes 11 to 22 were shaded rather than 
clear. Patients in the high fibre group were advised to consume at least 18 grams or 
points of fibre a day but not to exceed 22 grams. Patients in the low fibre group were 
advised to consume 10 grams or less per day and thus not to use the shaded boxes.  
 
In addition to assisting patients with estimating their fibre intake, the exchange diary 
provided a useful starting point for discussion with them during treatment and allowed 
an immediate and approximate calculation of fibre intake by the principal trial 
 140 
investigator (the author) in the clinical setting. Prior to use in the trial, the guidance 
booklet and accompanying exchange diary were trialled in 10 healthy volunteers. 
 
The volunteers comprised dietetic and non-dietetic colleagues of the author, and 
friends and neighbours (males: 5, females: 4; age range 26 – 78 years). Suggestions 
made by volunteers to improve the layout and / or contents of the booklet were 
reviewed by the author and included as appropriate. The calculation of fibre intake, as 
a primary nutritional outcome measure, was accomplished using 7-day food diaries 
which were completed by patients in all trial groups during the first and last week of 
radiotherapy. 
 
3.2.7 Selection of primary endpoint and trial powering 
Treatment-induced toxicity is an ill-defined concept although bowel-related toxicity 
ranks as the most troublesome of all symptoms232. Minimising damage to healthy 
gastrointestinal tissue is of critical importance to ensure treatment completion without 
disruption and thus maximised possibility of tumour control. As discussed previously, 
non-invasive measurement of symptoms continues to be used for assessing toxicity. 
However validated indices for use in this setting such as the Radiation Therapy 
Oncology Group (RTOG) scoring tool67 are surprisingly blunt. The Inflammatory Bowel 
Disease Questionnaire (IBDQ) is patient-completed and comprises 32 questions each 
with 7 grades of severity233. It takes a few minutes to complete and has been shown to 
be more sensitive in the acute and late radiotherapy setting than the RTOG6 73.  
 
The increased discriminatory power of the IBDQ coupled with its use in previous trials 
in the radiotherapy setting were key factors in selecting this tool for measuring GI 
toxicity in this trial46 74-76. Patients complete the entire 32 question IBDQ and are 
unaware of the IBDQ-B ‘bowel domain’ questions: 1, 5, 9, 13, 17, 20, 22, 24, 26 and 29.  
The modified McMaster IBDQ was used for the trial as the terminology in this version 
has been modified for use in the UK72. The difference between groups in the change in 
IBDQ-B score between baseline (day 1 of radiotherapy) and nadir (worst) score during 
treatment was selected as the primary endpoint for the trial. 
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A difference of 6 points between groups (representing a 10% difference in maximum 
possible change in IBDQ-B score) was selected as constituting a meaningful clinical 
difference. This compares with ‘meaningful clinical improvement’ in Crohn’s patients 
of 1 point in two thirds of IBDQ questions234 and ‘significant improvement’ in ulcerative 
colitis patients or a rise in score of 20 points235, both of which are equivalent to a 9% 
change in score. In four previous mixed pelvic cancer cohorts (n=390) comprising 52% 
of patients with urological, 18% gastrointestinal and with 30% gynaecological tumours, 
the mean change in IBDQ-B score between start and end of radiotherapy was 9.3 
points (standard deviation: 8) representing a 15% change in score24 46 75 76.  
 
In order for the trial to have to 90% power (beta or probability of type 2 error of 10%) 
to detect a difference of 6 points in the change in score between groups, with a 
significance level (alpha or probability of type 1 error) of 0.02 for a three-way 
comparison, a total of 156 patients (52 per group) were required. A potential 15% 
contingency in recruitment was allowed to cover unplanned withdrawals, requiring an 
additional 7 patients per arm for a total of n=177.  
 
3.2.8 Trial measurements and blinding 
An overview of all trial measurements and time-points is given in Table 3.2. Neither 
the author, as Principal Investigator or patients was blinded to the intervention group 
allocation. However, extraction of data from 7-day food diaries was performed by 
research personnel blinded to the patients’ trial group allocation.  
 
A Case Report Form (CRF) detailing the set of measurements to be collected at 
baseline, weekly during treatment, on completion of treatment and at one year post 
treatment was developed to ensure systematic capture of all trial outcome data. A 
Cost Questionnaire detailing health economic data to be captured at each time-point 
accompanied the CRF. Data from this questionnaire is currently being analysed and will 
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Health economic  measurements 
Symptom costs  √   
Medication costs  √   
Employment costs  √   
Travel costs  √   
AHP contact hours  √ √  
Interventional  measurements (intervention groups only) 
Daily fibre intake 
(Fibre Points Diary) 




  √ 
 
Costs of compliance 
with intervention 
  √ 
 
Ease of Use of 
interventional tools 
(Questionnaire) 
  √ 
 
 
3.2.9 Recruitment sites and resourcing 
The trial was initially planned as a single centre trial with recruitment to take place at 
the Fulham Road (London) and Sutton (Surrey) sites of Royal Marsden NHS Foundation 
Trust.  
 
In September 2011 the fibre study was extended to a second site, the Royal Surrey 
County Hospital (RSCH) Guildford to increase the pool of eligible patients. Recruitment 
at RSCH was done primarily by the author with assistance from local clinicians and 





3.3 Clinical trial: procedures  
3.3.1 Ethical approval and trial registration 
Examples of documentation associated with trial governance including the Patient 
Information Sheet, GP letter, Consent Form, Case Report Form (CRF) and Cost 
Questionnaire are given in Appendix 2. A research protocol was developed by the 
author and submitted for review and scientific scrutiny by the Committee for Clinical 
Research (CCR) at The Royal Marsden NHS Foundation Trust. Following CCR approval, 
the trial was registered on-line using the NHS Integrated Research Administration 




Procedures covering all aspects of the trial including patient screening, obtaining 
consent and reporting of adverse events complied with Good Clinical Practice (GCP)236 
and guidelines for non-Clinical Trial Investigative Medicinal Products (non-CTIMP) 
studies. The collection and reporting of trial data including patient follow-up, reasons 
for drop-out and withdrawal complied with CONSORT recommendations237. Overall 
trial conduct was in compliance with the relevant Royal Marsden NHS Foundation 
Trust Standard Operational Policies (SOPs).  
 
A Trial Steering Committee was convened and met at least quarterly to review trial 
progress, operational issues and adverse events. These meetings were attended by the 
author, the Chief and Co-investigators, statisticians and a patient representative. Any 
trial personnel with ‘patient contact’ (including taking consent) were required to have 
completed GCP training not longer than two years prior to the date of taking a patient 
consent.  
 
The author, as Principal Investigator was responsible for all operational activities 
including patient screening, invitation, taking consent, obtaining trial measurements, 
reporting trial withdrawal and adverse events, capture and secure transfer of data and 
attending to daily operational queries from patients, clinicians and radiographers 
regarding trial participation. 
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3.3.3 Patient identification and screening 
Potentially eligible patients were identified from lists of new patients for pelvic 
radiotherapy presented at audit and from relevant new patient clinic lists. Each patient 
was given a unique (tracking) identifier, comprising sequential number and responsible 
consultant initials, and entered in a recruitment log to which only the author and trial 
Data Administrator had access. Screening outcomes (i.e. ‘missed’; ‘accepted’; 
declined’; ‘excluded’) and reasons why, were captured to allow analysis of recruitment 
trends and reasons for declining trial entry.  
 
3.3.4 Initial invitation to the trial 
If possible, patients were invited to the trial at their radiotherapy planning scan and if 
agreeable, given a Patient Information Sheet. Patients not seen at radiotherapy 
planning were contacted by telephone and sent a Patient Information Sheet. All 
patients were invited to contact the Principal Investigator or Chief Investigators with 
any questions or queries. At least 24 hours was required to have elapsed between 
receipt of Information Sheet by the patient and acceptance or refusal of trial entry. 
 
3.3.5 Obtaining consent and randomisation 
Consenting patients completed and signed a consent form which was witnessed by the 
author as Principal Investigator. An original copy of the consent form was filed in the 
patient’s trial file and a copy given to the patient if requested. With the patient’s 
consent, their General Practitioner was informed in writing of trial participation, using a 
standard letter approved by the research and ethics committees.  
 
Patients were randomised to the trial by the Institute of Cancer Research (ICR) 
randomisation office using the minimisation method and allocated one of three trial 
groups, stratified for concomitant chemotherapy (yes or no) and for pelvic site 
(gynaecological or gastrointestinal) and given a 6-digit trial identifier (Figure 3.2).  
Patients’ radiotherapy treatment sheets were annotated with randomisation group 
and date of trial entry. 
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Figure 3.2 The patient identifier (trial number) 
 
 
3.3.6 Trial withdrawal and adverse events 
Patients were withdrawn from the trial if they expressed a wish to withdraw or if they 
experienced toxicity that necessitated permanent cessation of their radiotherapy, 
precluded oral intake or required surgical intervention. Reasons for withdrawal were 
captured in the trial database.  
 
Patients were assured that trial withdrawal would not affect their standard medical 
care. Adverse events were reported in accordance with local (RMH) Standard 
Operating Procedures.  
 
3.4 Clinical trial: measurements  
3.4.1 Nutritional outcomes  
Nutritional status was measured at start and end of radiotherapy using weight, height 
and BMI. Patients recorded their nutritional intake during the first and last week of 
radiotherapy using a 7-day un-weighed, food diary. Once per week during 
radiotherapy, nutritional intake was assessed using the 24 hour recall method and 
dietary advice provided to help patients comply with fibre target.  
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At these weekly meetings, for those in the high and low fibre groups, self-reported 
compliance with target fibre intake was assessed with reference to the patient’s 
exchange diary. Palatability of intervention was assessed using a simple visual 
analogue scale designed for the trial.   
 
3.4.1.1 Height 
Height was measured using a stadiometer attached to electronic Seca weighing scales 
(Marsden, Oxon, UK). Patients were measured without shoes, standing straight with 




Patients were asked to remove outdoor clothing, heavy pocket contents and shoes 
before stepping onto electronic Seca column scales (Marsden, Oxon, UK).  Weight was 
recorded in kilograms to the nearest 0.1 Kg. Hospital scales are calibrated annually by 




3.4.1.3 Body Mass Index (BMI) 
Body Mass Index, a measure of appropriateness of weight in relation to height, was 
calculated using the equation: BMI (Kg/m²) = Weight (Kg) / [Height (m)]². 
Interpretation of BMI was as follows: < 16: severely underweight; 16-18.5: 
underweight; 18.5-25: normal range; 25-30: overweight; 30-40: obese; > 40 morbidly 
obese.  
 
3.4.1.4 Estimated nutritional and fibre intake (7-Day food diaries) 
The 7-day food diary was completed by patients in all trial groups. This method was 
chose for estimation since intake values for individual nutrients using this method has 
been shown to correlate more closely than any other method with 16-day weighed 
records238. The 7-D diary, available in A5 or A4 size, comprised two-pages per intake 
day and included advice on how to estimate portion sizes using standard household 
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measures. It also included a brief questionnaire detailing preferred choices in terms of 
size and type (or brand) of commonly consumed items (e.g. milk, bread).  
 
Patients were advised that there was no need to weigh items unless they had difficulty 
estimating portion sizes. However, they were encouraged to note the weight of 
consumed pre-packaged items. Data from the 7-day food diaries was entered into 
DietPlan dietary analysis software, Forestfield, Horsham, UK, v.6.70 by two 
investigators trained by the author in the use of the software. Diary items were 
entered with reference to UK standard portion sizes239 and food databases: UK 
Composition of Foods IDS 3424; UK Nutrient Databank 5934, supplemented by 
specialist databases as required.  
 
An aggregated (day-by-day) method of analysis was chosen which allowed for the 
future analysis of nutritional intake on an averaged basis for any combination or 
number of days. It was anticipated that this method would enable future examination 
of recording fatigue of patients participating in nutritional research studies. Fibre (NSP 
Englyst method) and macronutrient intake was analysed at start and end of 
radiotherapy. 
 
3.4.1.5 Compliance with target fibre intake 
The measurement of compliance with target fibre intake was considered to be a key 
aspect of the trial and one which is often overlooked. Percentage cut-offs were 
developed (Table 3.3) so that, for example, a patient in the high fibre group achieving 
an average daily intake of 14.4g NSP / day would be considered at least  80% compliant 
with the target intervention for this group of 18 g NSP / day. 
 
Table 3.3 Cut-offs for assessment of compliance 
Trial Group 80% 85% 90% 100% 
High fibre, g/d NSP >14.39 >15.29 >16.19 >17.99 
Low fibre, g/d NSP <12.01 <11.51 <11.01 <10.01 
 
 148 
3.4.1.6 Recalled intake (24 hour recall)  
At weekly intervals during radiotherapy, patients were asked to recall all food and drink 
consumed on the previous day using the 24 hour recall method and were encouraged to 
think of items consumed in sequence from waking until bed-time. Prompting from the 
author was done to clarify items consumed which may have contributed to fibre intake. 
Discussion regarding intake also served to reinforce standard dietary advice for those in 
the control group and for those in the high or low fibre groups was a useful opportunity 
to informally assess compliance with fibre target in conjunction with the exchange diary.  
The 24-hour recall data was not used as a primary nutritional outcome measure.   
 
3.4.1.7 Ease of use of the Fibre in Foods guidance booklet   
A questionnaire assessing the ease of use of the “Fibre in Foods” booklet was developed 
and given to a sample of patients in the interventional groups. Results were collated and 
expressed using descriptive techniques.  
 
3.4.1.8 Quality of Life (IBDQ score)   
The entire 32 question IBDQ questionnaire was used to assess change in quality of life 
indices between start and end of radiotherapy. Change between baseline and nadir score 
was also calculated. Mean difference in IBDQ score change between groups was analysed 
for significance.  
 
3.4.2 Toxicity outcomes  
All toxicity outcome tools (including the RTOG scoring tool for reference) and a copy of 
the patient instructions for the collection of faecal sample for SCFA analysis are given 
in Appendix 3. The primary toxicity endpoint for the trial was the difference in the 
change (fall) in IBDQ-B score between groups from start of radiotherapy to nadir 
(worst) score during treatment.  
 
3.4.2.1 Inflammatory Bowel Disease Questionnaire – Bowel subset score (IBDQ-B) 
IBDQ-B scores were assessed weekly during radiotherapy. Cumulative acute toxicity 
scores using the Area Under the Curve (AUC) method were also computed as these 
may be important predictors of longer-term outcomes46 47.  
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Weekly scores were transformed by subtraction from the maximum score attainable: 
70. Transformed scores were then summed as follows: [0.5 * baseline + sum of interim 
acute scores + 0.5 * final score] and the relationship between acute_ IBDQ-B_AUC and 
occurrence of late toxicity was explored. 
    
3.4.2.2 Stool output parameters (Bristol Stool Form scale)  
 
The Bristol Stool Form scale (usually referred to as the Bristol Stool Chart) was used to 
assess change in stool characteristics during treatment and was completed by patients 
in all trial groups. The tool is an accepted method for measurement of stool form240 
and comprises 7 stool forms ranging from type 1: ‘separate hard lumps, like nuts, hard 
to pass’ to type 7: ‘watery, no solid pieces, entirely liquid’.  
 
At our institution, the scale is embedded within the Royal Marsden Stool Chart, which 
allows for the recording of daily stool output or frequency. Previous studies from our 
group had shown this to be a feasible patient-completed tool for toxicity measurement 
in this setting75 although surprisingly there is still no one single accepted definition of 
diarrhoea in this or any other clinical setting.   
 
Patients (all groups) were coached in the interpretation of stool forms and asked to 
make daily entries in their stool chart from day one to final day of radiotherapy. The 
complete set of patient-reported data captured in the chart included: details of every 
bowel opening event / day (frequency); time of bowel opening event; stool form for 
each event (consistency); presence of blood in stool (yes / no); presence of mucus in 
stool (yes / no) and use of anti-diarrhoeal medication.  
 
On return of the BSF scale to the author, data was extracted and summarised into 
excel spreadsheets to allow calculation of the following variables: mean weekly stool 
frequency; number of days per week on which anti-diarrhoeal medication was used; 
mean weekly stool form and number of days per week on which a stool form of type 6 
or 7 was experienced.   
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3.4.2.3 Faecal Short Chain Fatty Acids (SCFA)  
Faecal samples were obtained from patients at the start and end of radiotherapy. A 
stool collection kit was provided with instructions. On receipt of returned stool sample 
5–10 g were decanted in one of three 15 ml collection tubes. Time since evacuation 
was recorded. Two tubes for future lyophilisation (freeze drying for correction of water 
content) were weighed empty and then with stool sample (lids removed in both cases) 
and then immediately frozen at -80 C. A further 5 grams of stool sample was decanted 
into a third collection tube and stored at -20 C for future analysis of SCFA 
concentrations. Weights were recorded to three decimal places. Storage freezers were 
located in a secure, alarmed, controlled access, tissue bank facility at RMH, Sutton.  
 
On trial completion, freeze drying and analysis of SCFA was conducted in batches with 
assistance from Ms Rosie Colakatsia (lyophilisation) and Mr Robert Gray (SCFA 
analysis) both of King’s College, London. Samples were transferred on dry ice to the 
laboratory of Professor Kevin Whelan at King’s College London for analysis by the 
author. Stool samples were placed in batch in a freeze dryer with separation of 
duplicates into different batches. Samples were dried in vacuum conditions at -47oC 
and weighed every 4 days until a stable weight (to within 0.01 of the previously 
obtained weight) was achieved. Mean water percentage and sample dry weights were 
calculated. This allowed calculation of SCFA concentration per gram of (wet) stool and 
also per gram of dry stool to account for confounding from stool dilution in those 
patients with diarrhoea. 
 
Samples for analysis of SCFA were defrosted and 3 -5 g weighed into a stomacher bag 
for SCFA extraction. Weight of sample in stomacher bag was noted and SCFA 
extraction buffer comprising 1% H2PO4 (Merck, Germany) 0.1% HgCl2 (Sigma, UK) to 
prevent further fermentation and a synthetic SCFA not metabolised by human gut 
microbiota, 2,2-dimethylbutyric acid (Sigma, UK) as an internal standard, added in 1:4 
dilution. The sample was then homogenised in a stomacher (Seward Stomacher 80) for 
one minute per side to extract SCFA. Immediately following, 5 ml of faecal slurry was 
extracted into a Flacon tube for centrifugation. Samples were centrifuged (Beckman 
GS6R Centrifuge) at 5,000 g, 4oC for 20 minutes.  
 
 151 
Following centrifugation, 1 ml of supernatant was filtered through a sterile 0.2µm filter 
to remove bacteria and aliquoted into a Gas Liquid Chromatography (GLC) compatible 
300 µm polypropylene snap ring microvial. Prepared sample vials were analysed in 
pairs (i.e. baseline and end of radiotherapy) and loaded into a 7890A Aligent 
Technology GLC system.  
 
Extracted SCFA (0.2 μl aliquot from each sample) were automatically injected splitless 
into GLC machine equipped with a 220 μm internal diameter, 25 m fused silica capillary 
column with a film thickness of 0.25 μm (ID-BP21, SGE, Australia). The oven was 
programmed with an initial temperature of 80°C, which was increased by 10°C/ min up 
to 145°C, and then 100°C/ min up to 200°C to complete the elution. Each sample was 
followed by an injection of 1.2% formic acid cleaning solution (Merck, Germany) to 
minimise carry over from the previous sample.  
 
All chromatograms were integrated on Agilent Chromatogram database (Agilent 
Technologies, US) running on Windows NT (Microsoft, US). The GC was calibrated with 
a blend of pure SCFA solutions at 6 different concentrations to produce area: 
concentration using linear regression from the calibration curves. Concentrations of 
acetic (2C), propionic (3C), butyric (4C), valeric (5C), isobutyric (4C branched) and 
isovaleric (5C branched) SCFA were obtained as µmol / g of wet faeces and converted 
to µmol / g of dry faces using percentage dry weights obtained in lyophilisation. 
 
3.5 Statistical methods and data analysis 
A Statistical Analysis Plan (SAP) was written by the author and approved by the Trial 
Chief Investigator (Appendix 4). Statistical analysis was performed in conjunction with 
the Research Unit’s Statistician at the Royal Marsden NHS Foundation Trust. Data was 
imported to SPSS v.22 for the statistical analysis. Statistical significance was set at 
p<0.05, except for three-way comparisons not using ANOVA techniques or multiple 
comparisons where it was set at p<0.025 or p<0.0125, where ‘p’ represents the 
probability of that result being obtained under the null hypothesis.  
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All data was firstly checked for normality of distribution and parametric or non-
parametric tests conducted accordingly. Quality control of all trial measurement data 
was performed by the trial’s Data Manager at the Royal Marsden NHS Foundation 
Trust, London.  
 
Analysis of trial recruitment data including number of patients screened, excluded, 
missed, invited, declined and withdrawn at each time-point was undertaken and 
presented using descriptive techniques in accordance with CONSORT requirements237. 
The reasons for exclusion and declining trial entry were pre-defined at trial outset and 
captured for each patient. The trial recruitment rate was defined as: [number of 
patients recruited] / [number of patients invited].  
 
Inter-researcher variability in the extraction of data from the 7-day food diaries was 
conducted since two independent researchers, blinded to trial intervention, had 
extracted diary data. A total of 18 end-of-treatment 7-day food diaries were randomly 
selected comprising six diaries per trial group. The estimation of fibre and energy 
intake by these two researchers was then compared to a gold standard (the author, 
‘LW’), who, also blinded to trial group allocation and patient identity, analysed the 
same 18 diaries. A non-significant value (p>0.05) for a three-way ANOVA comparison 
of estimation of fibre or energy intake between investigators was deemed to be 
indicative of no significant difference between the researchers in their estimation of 
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4.1 Trial performance 
4.1.1 Recruitment  
The randomised controlled trial opened in October 2010 and closed to recruitment in 
December 2013 following the recruitment of 166 patients. Originally powered for 156 
patients in total, a potential contingency of 7 patients per trial group was planned to 
allow for withdrawals and attrition of data, making a total of 177 patients. However, as 
the required data to satisfy the primary endpoint had been successfully captured at 
the recruitment of 166 patients, the trial was closed at this point to further patients.  
 
Between October 2010 and December 2013 a total of 882 patients were screened for 
eligibility to the trial with 583 patients being suitable for invitation. Of the 166 patients 
randomized to the trial, 55 patients were allocated to the Control group, 55 to the Low 
Fibre group and 56 to the High Fibre group. A total of 136 patients were recruited at 
The Royal Marsden NHS Foundation (RMH), London and Sutton sites and 30 patients at 
the Royal Surrey County Hospital in Guildford (RSCH).  
 
The trial is currently in the one year follow-up phase with 109 patients of 144 patients 
available for follow-up having completed their one year measurements (return rate: 
79%) leaving a further 35 patients to be contacted. 
 
Of those suitable, 417 patients declined trial entry and 166 agreed to participate 
representing a recruitment rate of 28%. Of those who declined trial entry, reluctance 
to adopt a possible change in diet was given as the major reason for refusal (36%) 
followed by ‘cannot cope’ with the demands of the trial in addition to radiotherapy 
treatment (31%).   
 
By far the major reason for exclusion in those screened was presence of a stoma (38%) 
which was a stated exclusion criterion. Trial data in compliance with CONSORT 
requirements are shown in Figure 4.1.  
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Figure 4.1 Trial CONSORT diagram depicting current trial status 
 
Randomized (n=166) 
Assessed for eligibility (n=882) 
Allocated to  
Low Fibre Arm  
(n=55) 
 
RMH (n=45)  





-  No Dietary Change (n=151) 
-  Acopia (n=131) 
-  No reason given (n=72) 
-  Social Circumstances (n=38) 





-  Stoma (n=114) 
-  Investigator Logistics (n=58) 
-  Plan change (n=32) 
-  Co-morbid/ poor ps (n=28) 
-  Consultant decision (n=20) 
-  Eligibility change (n=6) 
-  Others (n=41) 
 
 
Allocated to  
Control Arm  
(n=55) 
 
RMH (n=45)  
RSCH (n= 10) 
 
 
Allocated to  
High Fibre Arm  
(n=56) 
 
RMH (n=46)  
RSCH (n= 10) 
 
One Year Follow-up 
Allocation 
Enrolment  
Due (n= 49) 
 
- Completed  (n=34) 
- Lost to FU (n=6) 
- Withdrawn (n=2) 
- RIP (n=5) 
 
Due (n= 47) 
 
- Completed (n=40) 
- Lost to FU (n=2) 
- Withdrawn (n=2) 
- RIP (n=1) 
- Left country (n=1) 
- Too poorly (n=1) 
 
 
Due (n= 48) 
 
- Completed  (n=35) 
- Lost to FU (n=4) 
- Withdrawn (n=3) 
- RIP (n=3) 
- Refused (n=1) 
- Too Poorly (n=1) 
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4.1.2 Baseline characteristics 
Of the 166 patients randomised to the trial, the median (range) age of the cohort was 
62.5 years (26 – 91) of whom 42% were male (Table 4.1). Sixty four percent had 
gastrointestinal and 36% gynaecological cancers. Seventy two percent of patients 
received concomitant chemotherapy. Median radiotherapy dose was 50.4 Gray over a 
modal treatment period of 28 treatment days (equating to 5.5 weeks).  
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Key: CT: chemotherapy, *significant: p<0.05, *Kruskal-Wallis’ test, **Chi-squared test 
 
Trial groups were comparable at baseline; p values are all >0.05 for each group-wise 
comparison indicating no significant differences between groups in major demographic 
and oncological variables (Table 4.1).  
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4.1.3 Withdrawn patients  
Seven patients were withdrawn from the trial immediately after randomisation (n=4) 
or during the trial (n=3) and their data excluded from further analysis. The 
characteristics of withdrawn patients were: median (range) age: 53 years (39 – 67); 
males: 3; females: 4; gastrointestinal cancers: 6; gynaecological cancers: 1.  
 
Reasons for withdrawal and allocated trial groups at randomisation were: declined to 
commence intervention following randomisation: 2 (Low fibre); stoma placed prior to 
treatment: 2 (control: 1, high fibre: 1); hospitalization and cessation of radiotherapy: 2 
(control: 1, low fibre: 1); plan change resulting in no radiotherapy treatment: 1 (high 
fibre).  
 
4.1.4 Evaluable data  
4.1.4.1 Summary of data obtained 
Following exclusion of data from the seven withdrawn patients, 159 patients 
completed the acute phase of the trial and provided evaluable data. A summary of the 
evaluable data items obtained for the trial’s primary and secondary end-points shown 








Table 4.3 Evaluable data from the randomised controlled trial (total n=159) 
 
 








IBDQ-B (Primary Outcome) 
Baseline (start of radiotherapy)  53 52 54 100 
End of radiotherapy 53 52 54 100 
IBDQ (Quality of Life) 
Baseline (start of radiotherapy) 53 52 54 100 
End of radiotherapy 53 52 54 100 
Bristol Stool Chart 
Completed charts returned 44 39 42 79 
Faecal samples obtained for SCFA analysis 
Number of paired samples returned 16 15 10 26 
Weight (kg) 
Baseline (start of radiotherapy)  53 52 54 100 




Baseline (start of radiotherapy)  53 52 54 100 
End of radiotherapy 53 52 54 100 
7 Day Food Diaries 
Baseline (start of radiotherapy)  51 47 48 92 
End of radiotherapy  44 41 43 81 
Number of paired diaries returned 44 41 42 127 
Fibre Exchange Diaries  
Completed diaries returned  NA 34 36 66 
Ease of Use of Fibre in Foods booklet questionnaire 
Number completed  NA 22 22 NA 
Weekly 24 Hour Recalls  
Number completed in total 102 107 103 312 
Average number completed per group 1.9 2.1 1.9 2.0 
Visual Analogue Scales (palatability of trial diet)  
Number completed NA 40 38 74 
 
  Key:  * Percentage return calculated on basis of n=159 (all groups) or n=106 (low and high  






4.1.4.2 Completeness of primary endpoint: IBDQ-B scores 
Primary endpoint data, IBDQ-B scores, were obtained from 159 patients at baseline. 
Baseline equated to start of radiotherapy. A baseline IBDQ-B score was defined as one 
obtained on day one of radiotherapy or within five days of start of radiotherapy. Four 
patients, who were unable to complete the IBDQ during their first radiotherapy 
treatment, returned completed questionnaires within five days of the start of 
radiotherapy and these were treated as baseline scores.  
 
A final ‘end of radiotherapy’ time-point was created for each patient to enable 
statistical comparison. Missing end of radiotherapy scores were carried forward from 
the last available score provided it was within one week of their last radiotherapy 
treatment fraction (occurred for n=8 patients).  
 
4.1.4.3 Quality of Life endpoint data: IBDQ scores 
Quality of life data, IBDQ scores were obtained from the same number of patients as 
those providing IBDQ-B scores. Baseline scores were obtained for 159 patients on day 
one of radiotherapy and a further four patients provided a score within five days of the 
start of treatment. Final, end of radiotherapy scores were not available for eight 
patients on the last day of treatment and their IBDQ score for the immediately 
preceding week was carried forward. 
 
4.1.4.4 Secondary toxicity endpoint data: stool charts and faecal samples   
Of the secondary toxicity endpoints 125/159 (79%) patients returned completed stool 
charts, representing a total of approximately 4340 recording days, estimated on the 
basis of an average five week course of treatment. However, not all patients 
completed stool details for all weeks of radiotherapy.  
 
The total number of completed weeks of stool data and the number per trial group for 
each week of treatment was as follows: week 1 of radiotherapy: n=125 (control: 44; 
low fibre: 39; high fibre: 42), treatment week 2: n=122 (control: 43; low fibre: 38; high 
fibre: 41), treatment week 3: n=123 (control: 43; low fibre: 39; high fibre: 41), 
treatment week 4: n=123 (control: 44; low fibre: 39; high fibre: 40), treatment week 5: 
n=104 (control: 37; low fibre: 30; high fibre: 37) and treatment week 6: n=39 (control: 
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14; low fibre: 11; high fibre: 14). The number of stool charts obtained fell in week 6 
due to fewer patients remaining on treatment. 
 
Patients receiving treatment at the Royal Marsden NHS Foundation Trust were invited 
to provide a stool sample at baseline and the end of radiotherapy. Patients recruited at 
The Royal Surry County Hospital were not invited to provide stool samples as the 
second site approval did not extend to the collection of human tissue. Sixty patients 
provided stool samples at baseline and 42 provided samples at end of radiotherapy. Of 
these a total of 41 paired (i.e. baseline and end of radiotherapy) samples were 
obtained.  
 
All patients were invited to provide a stool sample. However, only a small percentage 
of those who took home a stool collection kit actually returned samples. Further, only 
68% (41/60) of those who provided baseline samples also provided one at the end of 
radiotherapy. Reasons for non-return of stool samples were not captured. However, 
many patients expressed regret that they were unable to do this and cited fatigue or 
loose, frequent and small quantities of stool that were difficult or unpleasant to 
collect. 
 
4.1.5 Analysis of reasons for declining trial entry  
An analysis of 417 patients (missing data: 20) who declined trial entry reveals the most 
frequently cited reason by females (both hospital sites) for declining trial entry was ‘no 
dietary change’, whilst that for males was ‘cannot cope’.  
 
 161 
Table 4.4 Characteristics of patients who declined trial entry 
 
Site: RMH (n=333) 
Missing data for n=20 
















Age: mean (sd) 65.1 (12.6) 63.0 (12.9) 65.0 (13.1) 66.2 (12.3) 65.6 (13.6) 
Males : Females 27 : 69 25 : 85 20 :45 15 : 19 14 : 14 
Site: RSCH (n=60) 
















Age: mean (sd) 70.2 (11.2) 58.6 (12.2) 56.8 (5.5) 66.5 (3.5) 65.5 (14.5) 
Males : Females 4 : 20 4 : 16 1 : 7 1 : 1 2 : 4 
Total combined sites (n=393) 
















Age: mean (sd) 66.1 (12.5) 62.3 (12.8) 64.1 (12.7) 66.2 (12.0) 65.6 (13.5) 
Males : Females (n) 
Males : Females (%) 
31 : 89 
27 : 32 
29 : 101 
26 : 36 
21 : 52 
19 : 19 
16 : 20 
14 : 7 
16 : 18 
14 : 6 
Total no. males declining All reasons 113 / 393 
Total no. females declining All reasons 280 / 393 
 
Key: RMH: Royal Marsden NHS Foundation Trust (Sutton, Surrey and London), RSCH: Royal           
         Surrey County Hospital, Guildford.  
 
4.1.6 Adverse events  
Four adverse events were reported due to admission to hospital for symptom control. 
No adverse effects were reported that were related to the trial diet and no patients 
withdrew citing reasons related to the intervention.  
 
4.2 Trial results: presentation 
Trial findings are presented in two chapters. Chapter 4 contains the clinical findings, 
Chapter 5, presents the nutritional findings and aims to provide nutritional insight into 
the findings presented in the current chapter. Each has a concluding discussion 
highlighting the main findings and indicating their possible importance.  
 
The clinical findings begin with an analysis of the trial’s primary trial endpoint (IBDQ-B). 
The findings then continue with further analysis of gastrointestinal symptoms, stool 
characteristics, faecal short chain fatty acids and quality of life (IBDQ).  
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The following conventions are used in the presentation of trial results. Negative values 
for a change in IBDQ-B and IBDQ scores between time-points indicate a fall in score 
and thus worsening symptoms.  
 
For statistical analyses, where one way ANOVA has been performed, the data has been 
assessed for normality and found to be acceptable to consider as normally distributed. 
Non-normally distributed data are analysed using an appropriate non-parametric test.  
 
4.3  Gastrointestinal symptom scores (IBDQ-B) 
The IBDQ-B tool was used to assess gastrointestinal symptoms. The primary, powered 
endpoint of the trial was difference between groups in the change in IBDQ-B scores 
between the acute time-points baseline (start of radiotherapy) and nadir (worst on 
treatment score). 
 
4.3.1 Scores at acute time-points 
The mean (sd) IBDQ-B scores at acute time-points: baseline, end of radiotherapy and 
nadir (lowest on-treatment) are given in Table 4.5.   
 











IBDQ-B score: Mean (sd) 
IBDQ-B 
Baseline score 
Start of RT 64.4 (6.7) 63.9 (9.4) 61.70 (9.7) 0.240 
IBDQ-B 
Nadir score 
Lowest on-treatment 48.9 (12.8) 52.1 (10.6) 51.5 (11.6) 0.331 
IBDQ-B  
End RT score 
End of RT 53.6 (13.0) 56.5 (10.9) 58.6 (10.5) 0.081 
 
 
A one way ANOVA indicated that there was no significant difference between groups 





4.3.2 Change in scores between time-points 
The primary endpoint for the trial was the difference between groups in the change in 
IBDQ-B scores between baseline and nadir (worst) score during radiotherapy.  
 
A one way ANOVA (Table 4.6) revealed no significant differences between groups 
(p=0.093) in the change in score between baseline and nadir. Although not statistically 
significant, the control group exhibits the greatest fall in score between baseline and 
nadir (-15.5 points) in comparison to the high fibre group (-10.2 points).  
 













Change in IBDQ-B score: Mean (sd) 
IBDQ-B  
Nadir change 
Baseline to Nadir -15.5 (13.4) -11.8 (10.7) -10.2 (13.7) 0.093 
IBDQ-B  
End RT change 
Baseline to end-RT -10.8 (13.6) -7.4 (11.6) -3.1 (13.0) 0.009* 
 
Key: Negative values represent a fall in score (worsening symptoms) 
 
A secondary endpoint was the difference between groups in the change in IBDQ-B 
scores between baseline and end of radiotherapy. The results of this analysis are also 
given in Table 4.6. A significant difference between groups was identified (p=0.009).  
 
Post-hoc, pair-wise, comparison between groups (Bonferroni method) identified a 
significant difference (p=0.007) of 7.7 points between the control and high fibre groups 
(Table 4.7) in favour of the high fibre group resulting in a smaller fall in IBDQ-B score.  
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Table 4.7 Post-hoc analysis: difference in the change in IBDQ-B score  
 
Group (i) Group (ii) 
Mean 
Difference 
(Grp I v Grp 2)  
95% Confidence Interval 
p value 
Lower Bound Upper Bound 
 Control Low fibre -3.4 2.7 -9.4 0.535 
High fibre -7.7 -1.7 -13.7   0.007* 
Low fibre Control 3.4 9.4 -2.7 0.535 
High fibre -4.3 1.7 -10.3 0.249 
High fibre Control 7.7 13.7 1.7   0.007* 
Low fibre 4.3 10.3 -1.7 0.249 
 
Key:  Positive values for mean difference favour Group (i), negative values favour Group (ii). 
          *significant: p<0.05. 
 
In contrast, the difference between the low and high fibre groups, with a mean 
difference in score of 4.3 points was not significant (p=0.249). 
 
4.3.2.1 Descriptive analysis: change in IBDQ-B score 
A graphical representation of the mean group IBDQ-B scores at each acute time-point 
is given in Figure 4.2. For all groups, the scores show some recovery post nadir but do 
not rebound to reach baseline levels for any group by the radiotherapy end point.   
 
When expressed as a percentage of the maximum possible change in IBDQ-B score 
between time-points (60 points), the change in score experienced by each group 
between baseline and nadir was 26% (control), 20% (low fibre) and 17% (high fibre). 
 
The change in score between baseline and end of radiotherapy was 18% (control), 12% 
(low fibre) and 5% (high fibre). Changes in score of >10% in either direction (i.e. 
worsening or improving symptoms) are taken to be clinically significant. 
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Figure 4.2 Change in group mean IBDQ-B scores at acute time-points 
 
Key:  Error bars show 1.96*standard error in both directions 
 
4.3.2.2 Change in IBDQ-B AUC score 
A further secondary endpoint of the trial was a comparison of the area under the curve 
(AUC) equating to the total increased symptom burden during treatment. Computation 
of IBDQ-B AUC values for 153 patients (control: 53; low fibre: 50; high fibre: 50) with a 
minimum of four consecutive weekly IBDQ-B scores resulted in a median (range) IBDQ-
B AUC for the cohort of 41.0 (0 – 179).  
 
No significant difference between groups was found in the acute IBDQ-B AUC 
(p=0.576) using a Kruskal Wallis’ non-parametric test. 
 
4.3.2.3 Exploratory sub-group analysis of IBDQ-B scores by pelvic site    
An exploratory sub-group analysis, defined by pelvic site was conducted. However, the 
study was not powered for this analysis and any statistically significant results must be 
viewed with caution.  
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For the 100 patients with gastrointestinal cancers, one way ANOVA revealed no 
significant differences between groups in IBDQ-B scores at the nadir or at the end of 
radiotherapy or in the change in score between baseline and these time-points (p>0.05 
for all comparisons).   
 
 
However, in the exploratory sub-group analysis of the 59 patients with gynaecological 
cancers, a significant difference was identified between groups in IBDQ-B scores at the 
end of radiotherapy (p=0.010) and in the change in score between groups from 
baseline to end of radiotherapy (p=0.013) as shown in Table 4.8. 
 













IBDQ-B score: Mean (sd) 
IBDQ-B 
Baseline score 











End RT score 




IBDQ-B Change in score: Mean (sd) 
IBDQ-B  
Nadir change 
Baseline to Nadir -18.8 (12.9) -12.4 (7.1) -11.0 (10.6) 0.054 
IBDQ-B  
End RT change 
Baseline to end-RT -12.6 (10.9) -7.4 (8.6) -2.5 (11.4) 0.013* 
 
Key: Negative values represent a fall in score (worsening symptoms), RT: radiotherapy   
        *significant: p<0.05 
 
 
Post-hoc analysis (Bonferroni method) identified a mean difference in score of 9.2 
points at the end of radiotherapy between the control and high fibre groups in favour 
of the high fibre group (p=0.008), but did not find any differences between any other 
groups. Further post-hoc analysis identified a difference in the change in score of 10.0 
points (baseline to end of radiotherapy) between the control and high fibre groups in 
favour of the high fibre group (p=0.010), but did not find any differences between any 
other groups.  
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4.4 Analysis of change in stool characteristics 
Changes in stool characteristics including frequency (number of daily bowel-opening 
events) stool form / consistency (Bristol stool form scale), use of anti-diarrhoeal 
medication and incidence of loose or unformed stool (stool type 6 or 7) were analysed 
to identify differences between groups.  
 
These analyses comprised secondary analyses and thus the trial was not powered to 
detect a difference in any of these outcomes. Statistically significant findings should 
thus be interpreted with caution. Further, an overall 21% of stool charts were not 
returned; control group: 83% returned, low fibre: 75% and high fibre: 78%. 
 
4.4.1 Interpretation of stool chart data  
For each patient returning a self-completed, or partially self-completed stool chart, 
mean daily stool frequency per (radiotherapy) week, mean daily stool type per week, 
number of days use of anti-diarrhoeal medication per week and number of days on 
which stool type of 6 or 7 was experienced per week were calculated.  
 
Mean weekly stool frequency and mean stool type was calculated for each study group 
for each week by summing the weekly scores for all patients within the group and 
calculating the mean value for the group. The number of days on which anti-diarrhoeal 
medication was used and the incidence of loose stool (number of days on which a stool 
type of 6 or 7 was experienced) were summed for each patient by treatment week. 
The average number of days per patient, per week, on which anti-diarrhoeal 
medication was used, or loose stool experienced, was then calculated for each group 
by dividing the total number of days on which these events occurred in that week by 
the number of patients in that group returning data for that week.  
 
An exploratory comparison of the difference between groups in stool frequency and 
type at week one, week four and end of radiotherapy was conducted. A comparison of 
the change over time (by treatment week) between groups in use of anti-diarrhoeal 
medication and incidence of loose stool is presented using descriptive statistics.  
 
 168 
4.4.2 Between group differences: stool frequency and type 
Stool frequency and stool type data were not normally distributed. Median (range) 
values and the non-parametric Kruskal Wallis’ test was used to compare differences 
between groups at week one, four and end of radiotherapy. No significant differences 
were identified (Table 4.9). 
  
Table 4.9 Stool frequency and type: between group analysis 
Stool characteristic / time-point Control Low fibre High fibre Kruskal Wallis’ 
P value 
Median (range) at each time-point 
Stool frequency  
(bowel movements per week) 
    
week 1    n n=43 n=39 n=42  
  1.9 
(0.4 – 6.7) 
1.7 
(0.7 – 12.1) 
2.0 
(0.7 – 13.9) 
0.797 
week 4    n n=44 n=39 n=40  
 2.8 
(0.6 – 9.7) 
2.6 
(0.9 – 13.4) 
2.5 
(0.6 – 12.6) 
0.825 
End of RT   n n=41 n=37 n=39  
 3.0 
(0.3 – 13.5) 
2.7 
(0.6 – 11.0) 
2.3 
(0.9 – 13.8) 
0.636 
Stool type  
(average stool type per week) 
    
week 1    n n=44 n=39 n=42  
 4.7 
(2.0 – 6.4) 
5.0 
(2.4 – 6.6) 
4.9 
(1.8 – 6.6) 
0.630 
week 4    n n=43 n=38 n=40  
 5.1 
(1.3 – 6.8) 
5.3 
(2.7 – 7.0) 
5.2 
(1.3 – 6.8) 
0.906 
End of RT   n n=40 n=37 n=39  
 4.8 
(2.5 – 6.8) 
5.2 
(3.9 – 7.0) 
5.1 




4.4.3 Descriptive analysis: use of anti-diarrhoeal medication  
The average number of days on which patients used anti-diarrhoeal medication, for 
each week of treatment is depicted in Figure 4.3.  
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Figure 4.3 Use of anti-diarrhoeal medication 
 
 
Figure 4.3 illustrates the increasing use of anti-diarrhoeal medication (most commonly 
Loperamide) as treatment progresses. There is a marked increase in the use of 
medication in week 5 for the high fibre group in comparison to the control or low fibre 
groups. 
 
The number of patients remaining on treatment at week six is less than for weeks one 
to five and thus the data for week six is not necessarily comparable to that obtained in 
the preceding weeks as group composition will have changed.  
 
4.4.4 Descriptive analysis: incidence of loose stool  
The average number of days on which patients experienced loose or unformed stool 
(Bristol stool type 6 or 7) for each week of treatment is depicted in Figure 4.4. The 
incidence of loose stool is largely comparable across groups for all treatment weeks 
although the number of days on which loose stool is experienced appears less per 
patient for the high fibre group for treatment weeks two, three and six compared to 
the control or low fibre groups. 
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However, the number of patients remaining on radiotherapy treatment at week six is 
less than for weeks one to five and thus the data for week six is not necessarily 
comparable to that obtained in the preceding weeks due to changes in trial group 
composition. 
 




4.5 Analysis of short-chain fatty acids 
Change in the concentrations of individual SCFA (acetate, propionate, butyrate, 
valerate, iso-butyrate, iso-valerate) and total SCFA were analysed to identify 
differences between groups. No previous studies have explored the change in SCFA 
during pelvic radiotherapy and thus both straight (Carbon: ‘C’) chain (acetate, 
propionate, butyrate, valerate) and branched chain (isobutyrate, isovalerate) fatty acid 
concentrations were measured as well at total SCFA as change in specific fatty acid 
concentrations could not be anticipated. Previous research in IBD patients has 
reported significant increases in butyrate concentration following fibre 
supplementation194 216 241.    
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Results are expressed as both ‘wet’ and ‘dry’ values representing the concentration of 
SCFA in µmol/g of wet or dry faeces. Dry values are obtained following freeze drying 
(lyophilisation) of samples and making a correction (based on the change in sample 
weight) for stool water content. Both wet and dry values were used as it was unclear 
which would be preferable. One previous study in IBD patients has reported wet 
weights216 two further studies did not define concentrations as being in wet or dry 
units194 241.  
 
Statistically significant findings should be viewed with caution as only a very small 
sample of patients (41/136) provided samples. Further, patients providing samples 
may have represented a biased group in terms of symptom burden, gender, age or 
other factors.  
 
The fibre trial was not powered to detect a difference in this outcome measure and 
with such a small sample, the analysis is extremely exploratory. 
 
4.5.1 Patients providing samples for SCFA analysis  
 
Only 41 patients provided paired faecal samples for the analysis of SCFA at baseline 
(start of radiotherapy) and end of radiotherapy. Samples were not obtained from 
patients recruited at the Royal Surrey County Hospital, Guildford.  
 
A total of 16 patients in the control group, 15 in the low fibre group and 10 from the 
high fibre group provided samples at both time-points (Table 4.10).  
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Male : Female 
 
8 : 8 
 
11 : 4 
 


























        Key: CT: chemotherapy 
 
 
4.5.2 Between group differences: faecal SCFA concentration  
 
Faecal concentrations and change in concentrations (baseline to end of radiotherapy) 
for individual and total SCFA are given in Tables 4.11 (wet faeces values) and Table 
4.12 (dry faeces values).  
 
At baseline (start of radiotherapy) one way ANOVA identified significant differences 
between groups in the concentration of valerate in wet faeces (p=0.042), with post-
hoc analysis indicating differences between the control and high fibre groups 
(p=0.040).  
 
Differences were also identified in the concentration of isobutyrate in dry faeces 
(p=0.029), post hoc analysis indicating the differences were between the control and 
high fibre groups (p=0.024) and valerate in dry faeces (p=0.020) with post hoc analysis 
indicating the differences were between the control and high fibre groups (p=0.018).  
 
No significant differences were identified between groups in the change in SCFA 
between baseline and end of radiotherapy (Table 4.11 and Table 4.12).  
 
 173 
Table 4.11 SCFA concentrations and change in concentration (stool wet weight) at 












Mean (sd) concentration: µmol/g wet faeces 
Acetate  Baseline 8.65 (3.18) 9.64 (3.69) 11.93 (4.88) 0.116 
 End of RT 6.92 (2.48) 7.95 (3.51) 9.11 (3.62) 0.240 
Propionate  Baseline 2.33 (1.14) 2.47 (1.33) 3.13 (2.08) 0.395 
 End of RT 1.67 (0.86) 2.54 (1.36) 2.51 (1.20) 0.076 
Butyrate Baseline 1.54 (0.74) 1.49 (0.74) 2.20 (1.23) 0.113 
 End of RT 1.20 (0.66) 1.14 (0.73) 1.48 (1.14) 0.572 
Isobutyrate Baseline 0.30 (0.16) 0.38 (0.18) 0.48 (0.31) 0.114 
 End of RT 0.26 (0.12) 0.28 (0.10) 0.30 (0.14) 0.740 
Valerate Baseline 0.14 (0.06) 0.16 (0.08) 0.23 (0.13) 0.042* 
 End of RT 0.12 (0.50) 0.12 (0.07) 0.14 (0.08) 0.662 
Isovalerate Baseline 0.27 (0.12) 0.34 (0.16) 0.40 (0.25) 0.187 
 End of RT 0.25 (0.10) 0.35 (0.09) 0.30 (0.14) 0.975 
Total SCFA Baseline 13.2 (4.7) 14.5 (5.4) 18.4 (8.3) 0.110 
 End of RT 10.4 (3.9) 12.3 (5.2) 13.8 (5.7) 0.225 
Mean (sd) change in concentration: µmol/g wet faeces 
Acetate Baseline to end RT -1.73 (3.61) -1.68 (5.09) -2.82 (7.44) 0.846 
Propionate Baseline to end RT -0.67 (1.29) 0.07 (1.41) -0.62 (1.95) 0.349 
Butyrate Baseline to end RT -0.34 (0.57) -0.34 (0.74) -0.72 (1.89) 0.646 
Isobutyrate Baseline to end RT -0.03 (0.14) -0.10 (0.20) -0.18 (0.29) 0.225 
Valerate Baseline to end RT -0.02 (0.07) -0.05 (0.08) -0.09 (0.15) 0.222 
Isovalerate Baseline to end RT -0.02 (0.11) -0.09 (0.17) -0.15 (0.21) 0.119 
Total SCFA Baseline to end RT -2.8 (5.12) -2.19 (7.21) -4.58 (11.45) 0.750 
 










Table 4.12 SCFA concentrations and change in concentration (stool dry weight) at 












Mean (sd) concentration: µmol/g dry faeces 
Acetate  Baseline 36.0 (18.7) 41.9 (22.7) 50.7 (21.6) 0.229 
 End of RT 29.2 (15.0) 40.1 (25.0) 40.1 (16.6) 0.234 
Propionate  Baseline 9.9 (7.1) 11.3 (8.3) 13.2 (9.1) 0.609 
 End of RT 7.1 (4.7) 13.4 (9.9) 11.6 (7.9) 0.080 
Butyrate Baseline 6.19 (3.34) 6.48 (4.13) 9.79 (6.08) 0.110 
 End of RT 4.49 (3.27) 5.61 (3.80) 6.36 (5.57) 0.702 
Isobutyrate Baseline 1.11 (0.48) 1.46 (0.60) 2.04 (1.39) 0.029* 
 End of RT 1.04 (0.39) 1.38 (0.63) 1.21 90.41) 0.183 
Valerate Baseline 0.54 (0.16) 0.66 (0.38) 0.99 (0.58) 0.020* 
 End of RT 0.50 (0.22) 0.56 (0.38) 0.58 (0.34) 0.774 
Isovalerate Baseline 1.01 (0.36) 1.29 (0.46) 1.70 (1.18) 0.050 
 End of RT 0.99 (0.35) 1.21 (0.57) 1.00 (0.23) 0.294 
Total SCFA Baseline 54.8 (27.2) 63.1 (33.9) 78.5 (37.0) 0.202 
 End of RT 43.8 (22.4) 62.2 (37.2) 60.9 (27.7) 0.184 
Mean (sd) change in concentration: µmol/g dry faeces 
Acetate Baseline to end RT -6.79 (23.16) -1.79 (28.04) -10.63 (34.48) 0.733 
Propionate Baseline to end RT -2.86 (8.94) 2.10 (8.01) -1.57 (9.22) 0.278 
Isobutyrate Baseline to end RT -0.06 (0.56) -0.08 (0.85) -0.83 (1.44) 0.099 
Butyrate Baseline to end RT -1.23 (3.31) -0.87 (4.35) -3.44 (8.91) 0.489 
Isovalerate Baseline to end RT -0.02 (0.43) -0.08 (0.72) -0.72 (1.11) 0.060 
Valerate Baseline to end RT -0.04 (0.32) -0.10 (0.43) - 0.4 (0.68) 0.156 
Total SCFA Baseline to end RT -11.0 (34.6) -0.84 (40.5) -17.6 (52.7) 0.599 
 
Key: RT: radiotherapy, *significant: p<0.05 
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4.5.3 Within group differences: faecal SCFA concentration 
Paired t-tests were used to detect within group differences in SCFA concentrations 
between baseline and end of radiotherapy. The analysis, using the paired 
concentrations for dry faeces identified no significant within-group differences.  
 
Paired t-tests using the paired concentrations for wet faeces identified: a significant 
fall in total SCFA concentration in the control group between baseline and end of 
radiotherapy (p=0.044), and a significant fall in butyrate concentration in the same 
group (p=0.030).  
 
Using the wet paired values, a significant fall in valerate concentration was detected in 
the low fibre group (p=0.038) and a significant fall in iso-valerate concentration in the 
high fibre group (p=0.044) between baseline and end of radiotherapy. 
 
4.5.4 Exploratory analysis: sample water content  
 
Stool water content was measured by lyophilisation (freeze drying) of stool samples. 
An analysis of the change in percentage water content of the faecal samples was 
undertaken to examine whether significant within-group differences were apparent 
between baseline and the end of radiotherapy.  
 
This identified that the percentage water content increased between baseline and the 
end of radiotherapy in the low fibre group (p=0.043). Percentage water content of 
samples obtained from the control and high fibre groups showed no significant 
differences between these time-points (Table 4.13). 
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Mean (sd) % water content of sample after lyophilisation 
Baseline sample 73.8 (6.4) 74.2 (7.4) 75.9 (5.4) 
End of RT sample 74.2 (6.0) 77.6 (6.9) 76.2 (6.6) 
Paired t-test 
P value 0.864 0.043* 0.872 
 
         Key: RT: radiotherapy, *significant: p<0.05 
 
 
4.6  Quality of Life (IBDQ) scores 
Scores obtained from patients’ responses to the full 32-question IBDQ were used as 
the quality of life (QoL) measure for the trial. Scores at acute time-points and change in 
scores between time-points were examined for significant differences between 
groups.  
 
All analyses using the IBDQ scores were treated as secondary trial outcomes. A one 
way ANOVA identified no differences between groups in scores at acute time-points 
(Table 4.14).  
 
However, a significant difference in the change in IBDQ scores between baseline and 
end of radiotherapy was identified between groups (p=0.012).  
 
Post-hoc, pair-wise, comparison between groups (Bonferroni method) identified this 
significant difference (p=0.010) was between the control and high fibre groups. The 






Table 4.14 IBDQ scores and change in score  








IBDQ score: Mean (sd) 
IBDQ 
Baseline score 











End RT score 




IBDQ Change in score: Mean (sd) 
IBDQ  
Nadir change 
Baseline to Nadir -33.0 (31.7) -25.0 (27.5) -23.7 (33.2) 0.245 
IBDQ  
End RT change 
Baseline to end RT -23.9 (32.0) -17.2 (26.5) -6.7 (30.2) 0.012* 
 
Key: Negative values represent a fall in score (worsening symptoms), RT: radiotherapy,   
        *significant: p<0.05 
 
 
Computation of IBDQ AUC values (indicative of symptom burden on QoL) for 153 
patients (control: 53; low fibre: 50; high fibre: 50) resulted in a median (range) IBDQ-
AUC for the cohort of 143 (48 - 592). Analysis of the difference between groups in 
acute IBDQ AUC identified no significant differences between groups (p=0.600) Kruskal 
Wallis’ non-parametric test. 
 
4.7 Discussion of clinical findings  
The hypothesis for this trial was that a high fibre diet (18 – 22 g NSP / day) would 
reduce or prevent gastrointestinal symptoms in patients receiving radical pelvic 
radiotherapy. It was postulated that the mechanism of action of dietary fibre was via 
its fermentation product, SCFAs, which have anti-inflammatory properties and through 
its beneficial effect on stool frequency and form. 
  
The results of the trial indicate that manipulating fibre intake does have a beneficial 
effect on gastrointestinal symptoms and thus the first part of the trial hypothesis can 
be accepted. However, the postulated mechanism of action of fibre needs further 
exploration and has not been unequivocally demonstrated by the trial’s results. 
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The trial’s primary endpoint was the difference in the change in score from baseline 
(start of radiotherapy) to nadir (worst) between groups with a difference of 6 points or 
more representing a clinically significant difference. The difference in score between 
groups between these points was not significant. However a significant difference was 
identified using the time-points baseline to end of radiotherapy.  
 
Between baseline and end of radiotherapy, the high fibre group’s IBDQ-B score fell -3.1 
points compared to the control group, whose score fell -10.8 points, thus representing 
a clinically significant difference of -7.7 points and indicating a beneficial effect of high 
dietary fibre on gastrointestinal symptoms. However, no significant difference was 
identified between the change in IBDQ-B score between the low and high fibre groups. 
Further, the fall in score of the control group was -3.4 points more than that of the low 
fibre group indicating that low fibre advice is no better than no dietary advice. 
 
The lack of a significant difference between the high and low fibre groups is puzzling. 
Firstly, the primary endpoint of the trial was the difference in IBDQ-B score between 
baseline and nadir and the difference between baseline and end of radiotherapy was a 
secondary endpoint. Could the study have been underpowered to detect a difference 
in this secondary endpoint resulting in a lack of difference between the high and low 
fibre groups? It is felt that under-powering of the study is unlikely. The nadir point was 
chosen to correspond to worst symptoms and thus the point of maximum possible 
difference between groups.  
 
However, data used to power the study came from previous pelvic cohorts in which 
the mean (sd) change in IBDQ-B score between baseline and end of radiotherapy was 
equal to -9.3 (8) points, equating to a 15% change in score24 46 75 76. The Fibre study 
sought to find a clinically significant a 6 point (10%) difference in the change in score 
and had 90% power to detect a difference between any trial groups. It recruited the 
required 156 patients and actually included 159 patients with evaluable data in the 
analysis. Therefore, the difference that has been observed between the high fibre and 
control groups is not thought to be due to chance.  
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A further possibility that could have affected the results could have been that the trial 
groups were unbalanced at baseline and that the control group exhibited patient or 
treatment characteristics which negatively influenced the results. Treatment related 
factors which might have rendered the control group more susceptible than the low 
fibre group to new onset gastrointestinal symptoms include radiotherapy dose, 
fraction size, treatment time, tolerance to concomitant chemotherapy, previous 
surgery and history of inflammatory pathology in the bowel. Patient related factors 
which negatively influence outcomes include increasing age, low BMI46, current 
smoking and use of anti-hypertensive medication and / or HMG CoA reductase 
inhibitors (statins)50. 
 
However, patients were stratified at randomisation by pelvic site and concomitant 
chemotherapy and the analysis of baseline characteristics identified that in terms of 
the main treatment-related parameters, trial groups were balanced. It is 
acknowledged that capture of additional information regarding previous surgery would 
be valuable as this can affect the movement of bowel structures, organ mobility and 
thus actual dose received. Further, data on precise dose, agent and tolerance to 
concomitant chemotherapy would certainly be valuable. Capture of details regarding 
previous surgery and chemotherapy administration would necessitate closer scrutiny 
of medical and pharmacy records, some of which are lodged in Trusts external to the 
Royal Marsden NHS Foundation Trust, which acts as the radiotherapy ‘partner’ to 
other host trusts administering chemotherapy agents and obviously retaining medical 
records. It is also recognised that not only do chemotherapy agents themselves cause 
gastrointestinal disturbance but additional medications which have known effects on 
gastrointestinal function may have influenced outcomes.  
 
Patients were stratified for concomitant chemotherapy at randomisation and thus 
those in receipt of chemotherapy agents during radiotherapy were balanced between 
groups at the start of treatment. Chemotherapy agents received by patients in this 
study included the anti-metabolite, Capecitabine and alkylating or DNA cross-linking 
agents, Mitomycin C and Cisplatin (Table 3.1). Of these agents, oral Capecitabine, 
through its metabolite 5FU (fluorouracil) is the most likely to cause diarrhoea. 
However, capture of the incidence of diarrhoea due to chemotherapy versus that due 
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to radiation-induced damage would have been difficult. A detailed evaluation of 
patients in whom Capecitabine dose was reduced due to severity of new-onset 
diarrhoea would have been complicated by the current lack of standardisation in the 
capture of on-treatment toxicity (e.g. consistent use of CTCAE v.4) and the fact that 
such patients would probably have been advised to increase their use of the anti-
diarrhoeal drug Loperamide thus complicating the analysis of true cause and effect.  
 
In addition to anti-cancer agents, other GP-prescribed medications may have adverse 
effects on gastrointestinal function and similarly could have confounded toxicity 
outcomes. These drugs include: the anti-diabetic drug Metformin; anti-emetics such as 
Ondansetron, Metaclopromide and Domperidone; opiod analgesics (codeine 
phosphate) and antibiotics. Capture of precise details regarding duration of use and 
dose of these agents or indeed concomitant use of anti-hypertensive agents and 
statins (which conversely may have improved outcomes) is complicated by poor 
patient recall and lack of comprehensive, accessible details regarding non-hospital 
prescribed medications on NHS Trust-based electronic patient records or notes. 
Contact with patients’ GP is the only reliable method of gathering such information 
and this can be very labour-intensive50.   Capture of additional patient-related details 
such as smoking status could however have been usefully captured at randomisation. 
 
The lack of difference between the low and high fibre groups may be an artefact of the 
known difficulties in using symptom scoring tools as indicators of toxicity. We choose 
to use a tool (IBDQ-B) that we had previously validated in the acute radiotherapy 
setting and were confident that it was able to capture the subtle differences in 
symptoms that patients experience6. However, it is acknowledged that we did not use 
other tools which may have provided historical context (RTOG/EORTC) or use 
additional tools that would have provided more detailed information on incontinence 
for stool such as the Vaizey questionnaire242, or urinary toxicity since it is not 
uncommon for patients to report both urinary and stool incontinence together. Use of 
multiple scoring tools is potentially burdensome for patients and thus in the fibre 
study, the number of questionnaires was kept to a minimum in view of the fairly 
intense nature of the dietary intervention.  
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However, the question remains as to how well symptom scoring tools reflect toxicity? 
In the low fibre group, other issues may have contributed to toxicity (e.g. urinary 
incontinence) that were not picked-up by the IBDQ-B and thus the change in score 
used as the primary outcome measure did not accurately reflect the true symptom 
burden. Some authors in the systematic review of fibre and IBD showed clear 
relationships between disease activity indices208 216 241 and objective markers of 
gastrointestinal damage (e.g. endoscopy scores) however these endpoints are 
generally clinician completed items. When additional patient-reported items (e.g. 
symptom diaries) are requested, they fail to correlate with these more objective end-
points208. Investigators in the radiotherapy setting have reported that nadir histological 
damage occurs prior to peak of worst symptoms22. Others investigating the onset of 
symptoms versus gastrointestinal damage in ulcerative colitis have noted a clear 
separation of two weeks between the emergence of microscopic or molecular damage 
to the gastrointestinal mucosa and onset of worst symptoms199.      
 
Since research in the radiotherapy setting rarely includes evidence of toxicity obtained 
in human tissues, the use of symptom scoring tools will continue and the choice of 
symptom scoring tool(s) may be challenged. Even with a validated tool other 
unforeseen problems in the research setting can emerge.  One study in the systematic 
review of fibre manipulation during radiotherapy using a validated (prostate) scoring 
tool upon which the study was statistically powered was unable to identify significant 
differences between groups due to the choice of pelvic cohort (prostate cancer 
patients) who exhibited so few symptoms that significant differences between groups 
could not be identified222.     
 
It is curious that the high fibre group in the current study commenced treatment with 
the lowest mean IBDQ-B score (worst symptoms) and yet ended treatment with the 
highest score (least symptoms) whilst the control group, who started treatment with 
the least symptoms, ended treatment with the worst. A brief exploratory analysis of 
the distribution of nadir scores by study group (Figure 4.5) shows that more patients in 




Figure 4.5 Number of patients with IBDQ-B nadir scores by treatment week   
 
 
The reason for this is unclear but may have influenced the results by accentuating the 
difference between the high fibre and control groups at the end of radiotherapy. The 
possibility that patients in the control group had longer treatment times (i.e. more 
patients in this group remained on treatment in week 6) should not have influenced 
the distribution of nadir scores in this group. Groups were balanced for pelvic site at 
randomisation and treatment protocols are standard so each trial group will have 
contained a comparable number of patients on 6 week schedules.  
    
The overall symptom burden, as indicated using the measure IBDQ-B AUC was not 
significantly different between groups. The effect of using the IBDQ-B AUC score 
should be to smooth differences between severe peak and moderate sustained toxicity 
in the single score. However, it is acknowledged that a fall in score in the IBDQ-B of 6 
points may be due to a one-point change in score on six questions versus a six point 
change in score on one question. The relevance of this distinction in the acute and late 
setting requires further exploration. Our group and others have previously shown that 
moderate but sustained toxicity in the acute setting predicts more strongly for the 
emergence of late effects than a single severe spike of symptoms46 47. However, the 
importance of a small change in score in many questions versus a large change in score 
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in one or two questions would require a validation study with careful design to 
ascertain, in terms of toxicity, if these are equitable. 
 
In summary, it is not immediately clear why the trial produced a significant result 
between the control and high fibre groups, in favour of the high fibre group but not 
between the high and low fibre groups. If fibre truly has a protective effect, a 
significant difference would have been expected between the low and high fibre 
groups. Is it possible that the measurement of fibre intake was flawed or that the 
planned differential in fibre intake between groups was not achieved in practice or 
that some other factor can account for this outcome? A more detailed analysis and 
discussion of nutritional findings (Chapter 5) may shed light on these questions.  
 
The conducting of a randomised controlled trial was justified on the basis of a lack of 
robust evidence from previous studies regarding the efficacy of manipulating fibre 
intake in the radiotherapy setting. The hypothesis for the current study was that 
dietary fibre would prevent or reduce gastrointestinal symptoms arising during 
treatment. If a positive effect of fibre on the emergence or severity of symptoms 
(reflected in the IBDQ-B score) could be demonstrated, it was anticipated that this 
might be reflected in enhanced concentrations of faecal SCFA and if so a tentative 
conclusion could be reached that the reduction in symptoms was due (or partly due) to 
a reduction in inflammatory processes mediated by SCFA. It is acknowledged that 
these hypotheses are very tentative. However, no previous studies had explored the 
potential of fibre to influence toxicity via this mechanism and very little progress has 
been made on the identification of a suitable biomarker of toxicity in this setting.  
 
Measurement of SCFA was utilised in three studies identified in the systematic review 
of fibre and IBD. Each examined the change in total SCFA and individual SCFA: acetate, 
butyrate and propionate after: 20 g/d of oat bran supplementation for 3 months in 19 
patients with quiescent ulcerative colitis241, 20 g/d of psyllium supplementation for 3 
months in 7 patients with ulcerative colitis in remission194 and 24 g/d of inulin 
supplementation for three weeks in 20 patients with pouchitis in remission216. All 
reported a significant increase in butyrate concentrations following supplementation 
but no significant changes in acetate or propionate or total SCFA. All used gas 
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chromatography (GC) techniques for SCFA measurement although only one study 
specified their results as concentrations in wet or dry faeces216.  
 
Since, it is feasible to measure the concentration of all fatty acids in one GC run, all 
individual acids and total SCFA were measured in the current study and the results 
reported as both wet and dry values. Forty one paired samples were obtained. No 
significant differences were identified (using wet or dry weights) in the change in 
concentrations, between groups. However, significantly reduced concentrations of 
butyrate and total SCFA were identified in the control group between start and end of 
radiotherapy using wet faeces. Further, it was noticed that the water content of faecal 
samples from the low fibre group was significantly increased to 77.6% (±6.9) at the end 
of radiotherapy indicative of loose and unformed stool243.  
 
The change in Butyrate and total SCFA observed in the fibre study is intriguing. 
However, measuring SCFA in faeces is not straightforward and is the result of dynamic 
process of both production and absorption, and therefore faecal SCFA is not just a 
marker of SCFA production alone. SCFA absorption is impacted by colonic gut transit 
time, which itself may be altered in those with GI toxicity and those with different fibre 
intakes. Therefore faecal SCFA concentrations reflect production (affected by fibre 
intake) as well as absorption (affected by toxicity and fibre intake).  
 
A decrease in faecal SCFA might be expected if pelvic radiotherapy resulted in a 
reduction in the total number of bacteria. There is limited evidence that this occurs. 
One older pre-clinical study using outdated culture-dependent techniques reported 
reduced Lactobacilli and Bifidobacteria following irradiation117. A small pilot study 
using more modern techniques reported a modified bacterial profile following pelvic 
radiotherapy48 and a further small pilot reported a reduction in Lactobacilli and 
Bifidobacteria following pelvic radiotherapy in placebo and prebiotic supplemented 
groups223. Increased gut transit time (GTT) with reduced colonic fermentation time 
would also be expected to reduce concentrations of SCFA and there is evidence that 
this occurs244 245.  
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A high fibre intake might be expected to increase SCFA concentration. Although 
increasing SCFA concentration does not necessarily reflect increased production246. In 
the current study, reduced bacterial numbers combined with increased GTT may have 
had differing effects on SCFA concentrations. However, further investigation is 
warranted in adequately powered samples. Powering of future studies will need to 
take account of the widely varying levels of these acids with 10-fold differences in the 
concentrations of faecal SCFA having been reported between individuals156.     
 
A further physiological measure (stool output or frequency and form) was included in 
the fibre study to provide additional insight into gastrointestinal toxicity and evidence 
(if this existed) of the therapeutic efficacy of fibre during radiotherapy. It is 
acknowledged that there is no recognised method of capture or synthesis of daily stool 
chart data. The Bristol Stool form scale provides a useful and readily interpretable 
measure of stool consistency but it must be used in conjunction with other measures 
such as stool frequency to reflect changes in bowel function during treatment. Whilst 
many patients are willing to complete stool diaries or charts, synthesis of patient-
reported data is extremely time-consuming. The current study used daily patient-
completed data and four different measurements to help reflect the change in bowel 
habit during treatment. These methods are not validated. It is hoped that as an aside 
to this study, a correlational analysis be conducted of patient-reported stool data with 
change in scores in specific IBDQ-B questions. This might enable a more precise 
definition of a diarrhoea day and abridgement of the data collected at present. 
Machine-readable stool charts would represent a considerable improvement on the 
manual methods of data extraction currently employed.  
 
Stool data produced in the fibre study yielded some interesting results. Stool 
frequency and form was not significantly different between groups at the start, mid-
point or end of radiotherapy and incidence of loose or unformed stool was 
comparative between groups. These findings are positive in the sense that they 
challenge the current advice to restrict fibre in the clinical setting but fall short of 
identifying a specific physiological effect of increased dietary fibre. However, one very 
important finding emerging from the analysis of stool chart data in the current study 
was the marked increase in the use of anti-diarrhoeal medication by the high fibre 
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group towards the end of treatment. What effect this had on IBDQ-B scores is 
impossible to discern. However, it is possible that it masked symptoms and affected 
symptom scores in the high fibre group at the end of treatment. Patients are free to 
use over-the-counter preparations and encouraged to use loperamide as first line 
treatment if they are experiencing difficulty with loose or unformed stool. Part of the 
reason for this is to ensure continuity of radiotherapy treatment. However, anti-
diarrhoeal medication may be taken for prophylactic or therapeutic use and in the 
current study patients were not asked to define this, although it is perhaps one simple 
improvement that could be readily introduced in future research.  
 
Quality of Life is an increasingly important clinical outcome in all research and more 
especially in the current era of increased cancer survivorship. Quality of life outcomes 
in patients undergoing pelvic radiotherapy have been explored in three previous 
studies including one of those included in the systematic review of the efficacy of fibre 
in patients undergoing pelvic radiotherapy222 247 248. The most recent of these by 
Pettersson (n=112 prostate cancer patients with evaluable data at the end of 
radiotherapy) used the quality of life measure EORTC QLQ-C30 (v.3) to evaluate the 
effect of gastrointestinal symptoms on quality of life. The EORTC QLQ-C30 (v.3) is a 30-
item oncology specific questionnaire, containing six functional scales (physical, 
emotional, cognitive, social, role, global health), three symptom scales (fatigue, pain, 
nausea or vomiting) and six single items assessing symptoms and the financial impact 
of disease. No significant differences in health related quality of life outcomes were 
found between those randomised to standard care and those following a low insoluble 
fibre, low lactose diet.  
 
In the three-arm study by Ravasco248, colorectal patients (n=111) were randomised at 
the start of radiotherapy to receive: individualised dietary counselling, protein 
supplements or normal ad libitum diet. Quality of life was measured using the same 
30-item EORTC QLQ-C30. The results of this study have direct relevance to the findings 
of the fibre study. The study demonstrated that manipulating the whole diet based on 
regular foods, rather than supplementing isolated components of the diet (e.g. 
protein), was much more effective in maintaining significantly improved nutritional 
status and quality of life during radiotherapy compared to supplementation or ad 
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libitum intake. Further, efficacy of the benefit of individualised dietary advice persisted 
for 3 months after radiotherapy treatment and in a recent long-term follow-up analysis 
(median 6.5 years) was associated with reduced toxicity (p<0.001) and improved Qol 
(p<0.002)249.  
 
The study by Isenring in a mixed cohort of head and neck and gastrointestinal cancer 
patients using the medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of 
the Amercan Dietetic Association (now the Academy of Nutrition and Dietetics) using 
the same QoL measure also reported improved global QoL (p=0.009), weight 
maintenance and nutritional status compared to those receiving usual care247 250. 
Higher protein intake (p<0.001), total energy intake (p=0.029) and a trend towards 
increased dietary fibre intake was also reported in the group receiving nutritional 
counselling versus usual care250.  
 
In the light of these observations, it is considered a limitation of the Fibre study that it 
did not employ an oncology-specific Quality of Life tool. Whilst the IBDQ scores are 
easily captured in a study focussing on the IBDQ-B, use of the EORTC QLQ-C30 would 
have allowed comparison with these previous studies. However, in line with the 
findings of these studies, the fibre study has identified a significant difference between 
groups in the change in IBDQ score between the start and end of radiotherapy in 
favour of the high fibre group whose score fell just -6.7 points compared to the control 
group whose score fell -23.9 points, a difference of -17.2 points.   
 
In summary, in the group instructed to follow a high fibre intake during radiotherapy a 
beneficial effect was observed on gastrointestinal symptoms and quality of Life using a 
non-oncology scoring tool. Thus, the first part of the trial (research) hypothesis could 
be accepted. However, many questions remain. What was the daily intake of fibre 
intake in this group and how did this compare to other study groups? How was the 
intake of fibre assessed? What was the difference in fibre intake between study 
groups? Would this difference have been sufficient to cause a differing effect on 
gastrointestinal symptoms between groups?    
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These questions are addressed in the next chapter which also assesses whether the 
study intervention has had a negative impact on nutritional status including body 
weight and BMI. Increased intake of dietary fibre has been associated with early 
satiety and energy intake and thus the impact of the trial interventional diet on 













A randomised controlled trial to investigate 
the role of low or high fibre diets in patients 






This chapter presents the nutritional results of the randomised controlled trial. An 
assessment of the validity of these findings is crucial to ascertaining whether the 
results presented in Chapter 4 can be attributed to the intervention. This requires 
assessing whether patients were able to comply with their target fibre prescription, 
what intakes they actually achieved in practice and whether a sufficient differential in 
fibre intake occurred between groups. Non-compliance might explain why the trial 
failed to identify a difference in gastrointestinal symptom scores between the high and 
low fibre groups.  
 
Few of the studies in the systematic review of fibre manipulation in IBD patients 
measured background diet. Further, in the studies identified in the review which did 
use a dietary intervention, few measured compliance or stated the criteria for 
assessing compliance. Advice regarding achievement of compliance with intervention 
target in the fibre study was given by a registered dietitian and the interventional tools 
(the Guidance booklet and fibre exchange diaries) were designed specifically to help 
patients meet their fibre target. The guidance booklet contained information on 
portion sizes but did not include photographic material helping patients to estimate 
their portion sizes.  
 
Analysis of fibre intake is a complex process, not least because of the differing 
definitions of fibre in use. The gold standard for the capture of dietary fibre intake data 
is seven days which takes account of daily fluctuations. However, extraction of data 
from 7 day food diaries is labour intensive and if the data is entered into a dietary 
software package there are many steps in the data entry process where errors can be 
made. 
 
The average time for capture of data from seven days food diaries is three hours. Thus 
the fibre study employed two researchers blinded to trial interventional group to 
extract food intake data and enter this into dietplan software. Efforts were made to 
ensure standardisation between these two researchers including provision of 
appropriate training and standardisation in methods employed.  
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The objectives of this chapter are as follows: 
 
1. To investigate the degree of variation between investigators in the capture of 
dietary intake data from seven day food diaries. 
 
2. To measure fibre intake in the recruited patients at week one and final week of 
radiotherapy. 
 
3. To measure compliance with fibre intervention using pre-determined cut-offs 
of fibre intake for patients in the intervention groups. 
 
4. To measure the effect of the intervention on anthropometric variables: body 
weight and BMI. 
 
5. To measure the effect of the intervention on macronutrient intake given the 
finding that energy and protein intakes are associated with improved quality of 
life outcomes. 
 
6. To measure the effect of the intervention on micronutrient status given the 
perception that high fibre intake leads to early satiety and compromised energy 
intake. 
 
7. To measure the acceptability and palatability of the intervention so that in the 
event that the intervention is deemed appropriate to be more widely adopted, 
then the diet itself and the interventional tools are deemed to be acceptable by 
patients.  
 
5.2 Trial results: presentation 
The following conventions are used in the presentation of results. Negative values for a 
change in fibre, nutrient intake, body weight and BMI between time-points indicate a 
fall compared to baseline.  
 
For statistical analyses, where one way ANOVA has been performed, the data has been 
assessed for normality and found to be acceptable to consider as normally distributed. 
Non-normally distributed data are analysed using an appropriate non-parametric test.  
 192 
 
All nutritional endpoints are secondary and any statistically significant findings should 
be viewed with caution as the trial was not powered to detect differences in these 
endpoints. 
 
5.3 Evaluable data  
The completeness of nutritional end-points is shown in Table 5.1.  
 
Table 5.1 Evaluable nutritional data (total n=159) 
 
 









Baseline (start of radiotherapy)  53 52 54 100 




Baseline (start of radiotherapy)  53 52 54 100 
End of radiotherapy 53 52 54 100 
7 Day Food Diaries 
Baseline (start of radiotherapy)  51 47 48 92 
End of radiotherapy  44 41 43 81 
Number of paired diaries returned 44 41 42 127 
Fibre Exchange Diaries  
Completed diaries returned  NA 34 36 66 
Ease of Use of Fibre in Foods booklet questionnaire 
Number completed  NA 22 22 NA 
Weekly 24 Hour Recalls  
Number completed in total 102 107 103 312 
Average number completed per group 1.9 2.1 1.9 2.0 
Visual Analogue Scales (palatability of trial diet)  
Number completed NA 40 38 74 
 
  Key:  * Percentage calculated on basis of n=159 (all groups) or n=106 (low & fibre groups). 
 
It is important to note that the 7 day food diaries obtained for week one of 
radiotherapy were completed by patients after randomisation and thus recorded 
dietary intake data after dietetic advice.  
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Of the nutritional outcomes, eight patients had missing weight data on body weight at 
the end of radiotherapy and therefore weight scores were carried forward from the 
start of treatment.  
 
Patients in all trial groups were asked to complete 7 Day Food Diaries for the first and 
last week of radiotherapy. Of the expected 318 diaries given to patients, a total of 274 
were returned. Of these, 127 were paired diaries for week one (i.e. after receipt of 
dietary advice for interventional groups) and the last week of radiotherapy.   
 
An average of two 24-hour dietary recalls were conducted per patient (all groups) 
whilst on treatment. Patients in the low and high fibre groups (n=106) were 
additionally requested to keep a fibre exchange diary detailing daily self-estimated 
fibre intake. Of these, 66% returned fibre exchange diaries at the end of radiotherapy.  
 
Forty four patients (low fibre: 22; high fibre: 22) voluntarily completed an Ease of Use 
questionnaire with reference to the Fibre in Foods booklet at the end of radiotherapy. 
This activity was undertaken in response to a request from a patient representative on 
the Fibre Trial Steering Committee.  
 
5.4 Between researcher analyses: dietary intake data  
The input of dietary data is laborious, time intensive and therefore expensive. For large 
samples with many completed 7 day food diaries, it often necessitates more than one 
researcher to undertake data entry.  
 
In the current study, two researchers (R1, R2) extracted details of dietary intake from 
the patient-completed 7 day food diaries. R1 (a research nurse trained in the use of 
Dietplan software) analysed 100 diaries and R2 (a registered dietitian with extensive 
experience of the Dietplan software) analysed 147 diaries. However, dual dietary data 
entry is notoriously problematic, with potential for wide variation in interpretation of 
food diaries and therefore poor reliability. 
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In order to measure the accuracy of data entry, the effect of different researchers on 
estimates of energy and fibre intake were compared to that of the current author (LW) 
as the gold standard.  
 
Briefly, a sample of end of radiotherapy food diaries selected at random using a 
random number generator by the data manager were used for this analysis (control: 6, 
low fibre: 6, high fibre: 6). All researchers were blinded to the patient’s group 
allocation. 
 
ANOVA identified no significant differences between researchers in the estimated 
energy (kcal/day) or fibre intake (g NSP/day) for the six diaries from each study group 
(Table 5.2).  
 
Table 5.2 Estimation of fibre and energy intake: between researcher analysis 
 
Trial Group, n=6 
diaries / group 
Mean (sd) fibre intake g NSP/day ANOVA 
p value R1 R2 LW 
Control  11.3 (5.3) 10.7 (4.3) 10.6 (4.2) 0.965 
Low fibre  10.2 (3.7) 8.9 (1.7) 9.5 (1.9) 0.695 




Diaries / group 
Mean (sd) estimated energy intake kcal /day ANOVA 
p value R1 R2 LW 
Control 1873 (573) 1689 (391) 1819 (391) 0.778 
Low fibre 1569 (453) 1395 (377) 1402 (342) 0.694 
High fibre 2294 (296) 2105 (407) 2148 (213) 0.567 
 
 
Bland Altman plots were used to examine the level of agreement between each 
researcher versus LW in the estimation of fibre intake (Figures 5.1 and 5.2).  
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Figure 5.1 Bland-Altman plot of dietary fibre intake for 18 food diaries analysed by  
      Researcher 1 (R1) versus gold standard (LW) 
 
 




Figure 5.2 Bland-Altman plot of dietary fibre intake for 18 food diaries analysed by 
Researcher 2 (R2) versus gold standard (LW) 
 
 




The mean difference between R1 and LW in the estimation of daily fibre intake was 0.5 
g NSP/day (n=18 diaries). The mean difference between R2 and LW in the estimation 
of daily fibre intake was -0.1 g NSP/day (n=18 diaries).  
 
As this analysis shows, better agreement was achieved between the two dietitians (R2 
and LW) than between the research nurse and dietitian (R1 versus LW).  However, 
importantly, mean differences between R1 and LW and between R2 and LW were low 
and there was no systematic trend for the level of agreement or disagreement 
depending upon actual fibre intake (i.e. differences were evenly distributed across low, 
medium and high intakes of fibre).  
 
Level of agreement between investigators was judged to be sufficiently good to have 
confidence in the estimation of further dietary intake data from the 7-day food diaries 
and that further nutritional analysis using this data was not subject to investigator bias. 
 
5.5 Analysis of dietary fibre intake 
Dietary fibre intake was assessed for each patient from 7 day food diaries completed 
during week one and the final week of radiotherapy. Fibre intake for week one of 
radiotherapy thus reflects intake following randomisation.   
 
Food diaries detailing dietary intake for week one of radiotherapy were returned from 
146 patients and for the final week from 125 patients. Mean (sd) intakes of dietary 
fibre for week one and final week of treatment (three methods for comparison) by trial 
group are shown in Table 5.3 
 
One way ANOVA was used to compare the difference in the group mean daily fibre 
intake across trial groups for both weeks. A significant difference in intake (all 
methods) was identified between groups at both the week one and final week time-
points (Table 5.3).  
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Table 5.3 Intake of dietary fibre: week one and final week of radiotherapy 
Fibre intake  
reporting method 
Control Low fibre High fibre ANOVA 
p value 
Mean (SD) Mean (SD) Mean (SD)  
 n=51 n=47 n=48  
Mean (sd) daily fibre intake during week one  
Fibre: NSP g /day 13.6 (5.3) 10.2 (3.4) 17.1 (4.8) <0.001 
Fibre: NSP g / 1000 kcal day 7.5 (2.0) 6.4 (2.3) 9.2 (2.2) <0.001 
Fibre: AOAC g/day 17.6 (6.9) 13.4 (6.7) 21.7 (5.6) <0.001 
Fibre: AOAC/1000 kcal day  9.6 (2.5) 8.3 (3.2) 11.7 (2.7) <0.001 
Mean (sd) daily fibre intake during final week  
 n=44 n=41 n=43  
Fibre: NSP g /day 12.2 (5.2) 8.9 (2.9) 15.7 (5.1) <0.001 
Fibre: NSP g / 1000 kcal day 7.2 (2.6) 5.8 (2.1) 8.7 (2.3) <0.001 
Fibre: AOAC g/day 15.7 (6.8) 11.6 (5.1) 19.8 (6.3) <0.001 
Fibre: AOAC/1000 kcal day  9.2 (3.5) 7.6 (2.5) 10.9 (3.0) <0.001 
 
Key: NSP: non-starch polysaccharide, AOAC: Association of Official Analytical Chemists,  
        *statistically significant (P<0.05), 
 
Post-hoc analysis (Bonferroni method) identified that during week one (i.e. after 
randomisation and following advice from the study dietitian regarding achievement of 
fibre target for interventional groups) the low fibre group consumed a mean -3.3 g NSP 
/ day (95% CI: -1.1 – -5.6) less than the control group (p=0.001) and the high fibre 
group consumed a mean 3.6 g NSP / day (95% CI: 1.3 – 5.8) more than the control 
group (p=0.001). The difference in the mean fibre intake between the high and low 
fibre groups during week one was 6.9 g NSP / day (95% CI: 4.6 – 9.2).  
 
During the final week of treatment, the low fibre group consumed a mean -3.3 g NSP / 
day (95% CI: -0.9 – -5.7) less than the control group (p=0.003) and the high fibre group 
consumed a mean 3.5 g NSP / day (95% CI: 1.1 - 5.9) more than the control group. The 
difference in the mean fibre intake between the high and low fibre groups during the 
final week of radiotherapy was 6.8 g NSP / day (95% CI: 4.4 – 9.2). 
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Within group analysis (paired t-test) using 127 paired diaries (control: 44, low: 41, high: 
42) identified a significant fall in fibre intake in all groups between week one and the 
final week of radiotherapy (p<0.05 all comparisons). 
   
5.6 Analysis of compliance 
Analysis of compliance with fibre target identified that during week one, 77% of 
patients in the low fibre group were at least 80% compliant with fibre target (≤ 10g 
NSP / day). In the high fibre group, 79% of patients were at least 80% compliant with 
fibre target (≥ 18g NSP / day). However, in the final week of radiotherapy, 80% 
compliance was achieved by 83% of patients in the low fibre group but only 63% in the 
high fibre group. 
 




Low fibre High fibre 
n (%) n (%) 
Week one  
Compliance n=47 n=48 
 80% 36 (77) 38 (79) 
 85% 34 (72) 34 (71) 
 90% 33 (70) 32 (67) 
 100% 27 (57) 20 (42) 
Final week 
Compliance n=41 n=43 
 80% 34 (83) 27 (63) 
 85% 34 (83) 25 (58) 
 90% 30 (73) 23 (54) 
 100% 25 (61) 16 (37) 
 
Few patients achieved 100% compliance with fibre target. Although it appears that 
patients in the low fibre group, 27/47 (57%) of whom were 100% compliant at week 
one and 25/41 (61%) of whom were compliant in the final week of treatment may 
have found it easier to meet the target. In contrast, in the high fibre group, only 20/48 
(42%) were 100% compliant at week one and 16/43 (37%) 100% compliant in the final 
week of treatment. 
 
This may partly be explained by impaired overall food intake. Reduced total energy 
intake at the end of radiotherapy may have favoured compliance with target in the low 
fibre group (as they may have been reducing overall food intake, as opposed to fibre 
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intake specifically). However, this would have had the opposite effect in the high fibre 
group. The quantity of fibre intake per 1000 kcal decreased by less than 1.0 g NSP / 
1000 kcal in all trial groups between week one and final week (Table 5.3) suggesting 
little change in fibre intake over time and suggesting that it was not influenced by total 
energy intake.  
 
A comparison of the proportion of the diet provided by carbohydrates for the low fibre 
group showed little change at week one (44% of total energy provided by 
carbohydrates) versus final week (45% from carbohydrates). These figures were 
comparable to the control (45% and 46%) and high fibre groups (46% and 45%) for the 
proportion of total energy from carbohydrates for both weeks respectively. 
 
5.7 Total energy and macronutrient intake 
Total daily energy intake (kcal/day) and intake of macronutrients (g/day) at week one 
and during the final week of radiotherapy was examined for differences between 
groups.  
 
A reduction in total energy intake was seen in all groups between week one and the 
final week of radiotherapy amounting to mean reduction of 118 kcal in the control 
group, 122 kcal in the low fibre and 62 kcal in the high fibre group (Table 5.5).  
 
One way ANOVA identified a significant difference in protein intake between groups in 
the final week of radiotherapy (p=0.012). Post hoc analysis identified this difference to 
be between the low and high fibre groups with a significantly reduced intake of protein 
in the low fibre group compared to the high fibre group of 14.6 g/day (95% CI for the 
difference: 2.7 – 26.5).  
 200 
Table 5.5 Intake of macronutrients: week one and final week of radiotherapy 
Nutrient 
Control Low fibre High fibre ANOVA 
p value 
Mean (SD) Mean (SD) Mean (SD)  
 n=51 n=47 n=48  
Mean (sd) intake at week one  
Total energy kcal / day 1833 (561) 1693 (415) 1898 (524) 0.134 
Protein g / day 73.4 (21.6) 70.9 (16.7) 78.3 (20.6) 0.187 
Fat g / day  71.1 (27.0) 69.7 (25.0) 75.6 (26.7) 0.511 
Carbohydrate g / day 207.3 (71.6) 186.3 (47.4) 216.9 (62.9) 0.051 
Mean (sd) intake at final week  
 n=44 n=41 n=43  
Total energy kcal / day 1715 (569) 1571 (496) 1836 (453) 0.062 
Protein g / day 68.6 (24.5) 63.8 (19.8) 78.4 (22.7) 0.012* 
Fat g / day  65.9 (24.5) 63.2 (22.8) 73.0 (23.2) 0.144 
Carbohydrate g / day 197.2 (72.8) 178.5 (66.1) 207.2 (57.7) 0.134 
 
Key: *statistically significant (P<0.0125) 
 
 
Total energy intake was reduced in all groups during the final week of radiotherapy 
although the difference between groups at this time-point was not significant 
(p=0.062).  
 
Within group differences in total daily energy and macronutrient intakes between 
weeks one and the final week of radiotherapy were explored using paired t-tests for 
patients with diaries at both time-points (Table 5.6).  
 
This analysis showed that, in the control group, total energy and protein intake fell 
significantly (p=0.010 and p=0.006 respectively) between week one and the final week 
of radiotherapy. Total protein intake also fell significantly (p=0.002) in the low fibre 
group. 
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Control Low fibre High fibre 
Mean (sd) Paired  
t-test 
Mean (sd) Paired  
t-test 
Mean (sd) Paired  
t-test 
 n=44  n=41  n=42  








Energy kcal / day 
Final week 
1715 (569) 1571 (496) 1834 (458) 
 








Protein g / day 
Final week 
68.6 (24.5) 63.8 (19.8) 78.3 (23.0) 
 








Fat g / day 
Final week 
65.9 (24.5) 63.2 (22.8) 73.3 (23.4) 
 








CHO g / day 
Final week 
197.2 (72.8) 178.5 (3.80) 206.0 (57.9) 
 
Key: CHO: carbohydrate, *statistically significant (P<0.0125 pairwise comparison)   
 
Whilst the difference in total energy intake was not significantly different between 
groups at the end of radiotherapy, the fall in total energy intake using paired values 
(Table 5.6) in the high fibre group during the final week of radiotherapy (-110 kcal) was 
less than that in the control group (-146 kcal) and less than that in the low fibre group 
(-122 kcal).  
 
It is possible that an effort to achieve the high fibre target may have positively 
influenced total energy intake although this cannot be verified. This finding is in 
contrast to the commonly held view that increasing fibre intake reduces appetite and 
energy intake. As this study and others have shown, in other healthcare settings251, 
recommending a high fibre diet to patients receiving pelvic radiotherapy did not result 
in a lowering of total energy or macronutrient intake. A recent systematic review 
showed that of 44 studies investigating the effect of acute fibre treatments on 
appetite and energy intake, 61% of treatments did not enhance satiety and 78% did 
not reduce food intake252.  
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5.8 Micronutrient intake 
The effect of the intervention during radiotherapy on micronutrient intake was 
explored. One way ANOVA was used to compare differences between groups in 
vitamin and mineral intake during week one (Table 5.7) and the final week of 
radiotherapy (Table 5.8).  
 
During week one, significant differences between groups are identified for the intake 
of minerals magnesium, iron and manganese. During the final week of radiotherapy, 
significant differences were identified between groups in the intake of vitamin K, 
magnesium, phosphorous, potassium, zinc and manganese (p<0.0125 for multiple 
comparisons at both time-points).  
 
These results are exploratory as the study was not powered to examine these 
endpoints. Post-hoc analysis was not conducted. However, although not statistically 
significant, in all cases where significant between group differences have been 
identified, intake of micro-nutrients in the high fibre group is higher compared to the 
control and low fibre groups indicating a possible benefit of increased overall total 
energy intake.  
 
Intakes less than the Reference Nutrient Intake (RNI) for adults over 50 years, using the 
minimum of the values given for males and females are also highlighted at both time-
points (Tables 5.7 and 5.8). The RNI represents the value two sd above the Estimated 
Average Requirement (EAR) and the value at which the requirements for 97.5% of the 
population are being met.   
 
During week one, the mean intakes of the various groups for vitamin D, potassium and 
selenium are below the RNI for all groups and in the final week of radiotherapy, intake 
of vitamin A, vitamin D, potassium, selenium and iodine was below the RNI.   
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Table 5.7 Micronutrient intake: week one of radiotherapy 
Nutrient 
Control Low fibre High fibre ANOVA 
p value 
Mean (SD) Mean (SD) Mean (SD)  
 n=51 n=47 n=48  
Mean (sd) intake at week one  
Vitamin A µg retinol/d 605 (1156) 426 (311)** 789 (1927) 0.405 
Vitamin B1 Thiamin mg/d 1.6 (0.7) 1.4 (0.4) 1.7 (0.6) 0.048 
Vitamin B2 Riboflavin mg/d 1.7 (0.7) 1.6 (0.6) 1.7 (0.7) 0.624 
Vitamin B3 Niacin mg/d 21 (7) 18 (6) 21 (7) 0.054 
Vitamin B6 mg/day 2.1 (0.7) 1.8 (0.5) 2.0 (0.7) 0.027 
Vitamin B12 µg/day 5.5 (4.9) 4.3 (1.6) 5.9 (6.7) 0.277 
Folate µg/day 270 (96) 236 (70) 279 (99) 0.045 
Vitamin C mg/d 102 (56) 88 (51) 108 (62) 0.202 
Vitamin D µg/d 3.2 (2.2)** 3.6 (3.4)** 4.0 (5.1)** 0.515 
Vitamin E md/d 8.1 (3.8) 7.1 (3.0) 8.7 (4.6) 0.132 
PUFA: n-3 g/d 0.5 (0.2) 0.5 (0.4) 0.6 (0.6) 0.161 
PUFA: n-6 g/d 3.5 (1.7) 3.2 (2.2) 4.2 (3.0) 0.096 
Vitamin K µg/d 67 (83) 52 (73) 74 (119) 0.518 
Calcium mg/d 872 (295) 892 (380) 827 (312) 0.613 
Magnesium mg/d 289 (108) 239 (55)** 305 (89) 0.001* 
Phosphorus mg/d 1252 (403) 1172 (282) 1319 (349) 0.125 
Sodium mg/d 2709 (1291) 2367 (738) 2801 (1094) 0.119 
Potassium mg/d 3210 (1242)** 2719 (685)** 3221 (827)** 0.015 
Chloride mg/d 3895 (1594) 3474 (1008) 4075 (1601) 0.115 
Iron mg/day  12.3 (5.5) 10.2 (3.0) 13.6 (5.9) 0.004* 
Zinc mg/d 8.8 (2.9) 8.7 (3.1) 10.0 (3.6) 0.100 
Copper mg/day 1.4 (1.2) 1.0 (0.4)** 1.6 (1.2) 0.015 
Selenium µg/d 39 (15)** 39 (12)** 43 (19)** 0.360 
Manganese mg/day 3.5 (1.4) 2.9 (0.8) 3.8 (1.4) 0.003* 
Iodine µg/d 144 (81) 137 (74)** 121 (47)** 0.251 
 




Table 5.8 Micronutrient intake: final week of radiotherapy 
Nutrient 
Control Low fibre High fibre ANOVA 
p value 
Mean (SD) Mean (SD) Mean (SD)  
 n=44 n=41 n=43  
Mean (sd) intake at week one  
Vitamin A µg retinol/d 418 (292)** 381 (253)** 551 (915)** 0.365 
Vitamin B1 Thiamin mg/d 1.4 (0.5) 1.3 (0.5) 1.6 (0.6) 0.117 
Vitamin B2 Riboflavin mg/d 1.6 (0.7) 1.5 (0.6) 1.6 (0.7) 0.645 
Vitamin B3 Niacin mg/d 18 (7) 17 (7) 20 (8) 0.184 
Vitamin B6 mg/day 1.8 (0.7) 1.7 (0.7) 2.0 (0.8) 0.156 
Vitamin B12 µg/day 4.6 (3.1) 3.9 (1.9) 6.1 (6.0) 0.057 
Folate µg/day 255 (95) 227 (108) 255 (85) 0.308 
Vitamin C mg/d 106 (66) 84 (60) 98 (57) 0.261 
Vitamin D µg/d 2.8 (2.0)** 3.3 (3.3)** 3.4 (3.1)** 0.562 
Vitamin E md/d 7.3 (3.8) 6.2 (2.6) 7.9 (3.9) 0.102 
PUFA: n-3 g/d 0.4 (0.3) 0.5 (0.4) 0.5 (0.3) 0.690 
PUFA: n-6 g/d 2.9 (1.5) 2.7 (1.8) 3.5 (2.8) 0.166 
Vitamin K µg/d 57 (58) 35 (37) 81 (95) 0.011* 
Calcium mg/d 817 (321) 718 (304) 791 (256) 0.283 
Magnesium mg/d 268 (114)** 203 (66)** 280 (83) 0.000* 
Phosphorus mg/d 1174 (431) 1011 (308) 1275 (343) 0.005* 
Sodium mg/d 2417 (1146) 2223 (837) 2796 (930) 0.027 
Potassium mg/d 2928 (1251)** 2321 (819)** 3029 (903)** 0.003* 
Chloride mg/d 3556 (1637) 3191 (1090) 4054 (1337) 0.018 
Iron mg/day  11.5 (5.4) 9.6 (3.9) 12.6 (4.5) 0.017 
Zinc mg/d 8.5 (3.0) 7.3 (2.5) 9.4 (3.1) 0.005* 
Copper mg/day 1.2 (0.8) 1.0 (0.3)** 1.3 (0.7) 0.016 
Selenium µg/d 37 (16)** 35 (12)** 40 (19)** 0.410 
Manganese mg/day 3.2 (1.4) 2.5 (1.0) 3.6 (1.7) 0.002* 
Iodine µg/d 139 (84)** 122 (55)** 121 (52)** 0.365 
 




5.9 Weight and BMI 
No significant differences were identified in body weight between groups at the start 
or end of radiotherapy or in the change in body weight between these time-points 
(Table 5.9).  
 
Weight fell in all groups during treatment. The wide standard deviation of weight 
change in the low fibre group shows that there was considerable individual variation in 
weight change in this group.   
 
However, a comparison of the change in body weight within groups (paired t-test) 
revealed no significant within group differences in the pair-wise comparisons.  
  
Table 5.9 Body weight and change in weight 
 
Time-point Control Low fibre High fibre 
ANOVA 
p value 
Weight (kg): Mean (sd) 
n 53 52 54  
Start of 
Radiotherapy 
81.0 (18.5) 78.3 (18.1) 77.5 (15.6) 0.559 
End of 
Radiotherapy 
80.4 (18.3) 77.5 (17.6) 77.0 (16.3) 0.543 
Weight change (kg): Mean (sd) 
n 53 52 54  
Weight change 
Start to end RT 
-0.6 (2.1) -0.8 (4.9) -0.5 (2.1) 0.814 
 
Key: sd: standard deviation, RT: radiotherapy *significant: p<0.05 
 
 
Further, no significant differences in mean BMI between trial groups at the start or end 
of radiotherapy or the change in BMI between these time-points were identified 
(Table 5.10).  
 
A comparison of the within group change in BMI (paired t-test) revealed no significant 




Table 5.10 BMI and change in BMI  
 





): Mean (sd) 
n 53 52 54  
Start of 
Radiotherapy  
28.4 (6.3) 27.8 (5.8) 28.0 (5.4) 0.866 
End of  
Radiotherapy 
28.2 (6.3) 27.4 (5.8) 27.8 (5.6) 0.782 
BMI (kg/m
2
): Mean (sd)  
n 53 52 54  
BMI change  
Start to end RT 
-0.2 (1.1) -0.4 (1.0) -0.2 (0.8) 0.207 
 
Key: sd: standard deviation, RT: radiotherapy *significant: p<0.05 
 
5.10 Study intervention: palatability analysis 
 
The Visual Analogue Scale (VAS) used to measure the palatability of the fibre 
intervention is given in Appendix 2, item 4. Responses on the 150 mm scale in 
response to the question ‘how palatable did you find the change in diet’ ranged from 0 
mm (‘much worse than my normal diet’) to 150 mm (‘much better than my normal 
diet’), with a mid-point answer at 75 mm (‘no different to my normal diet’).  
 
The median (range) VAS score for the 40 patients in the low fibre group who 
completed the scale was 78.5 mm (7 – 146) and for the 38 patients in the high fibre 
group who completed the scale it was 78.0 mm (5 – 150) indicating little difference, 
but wide variations in individual responses between the two groups.  
 
5.11 Study intervention: researcher contact time  
 
Analysis of the median (range) interview time in minutes with the study dietitian 
revealed that the contact time was similar for all groups. In the control group (53 with 
evaluable data) the average (range) time for each study interview was 16.5 (11.2 – 
36.3) minutes, in the low fibre group (n=49) it was 18.6 (8.8 – 31.4) minutes and in the 
high fibre group (n=38) it was 18.1 (10 – 34.2) minutes.  
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The average number of interviews conducted per patient was four, comprising one 
enrolment interview, one exit interview (end of study) and a minimum of two on-
treatment interviews for the collection of study measurements.  
 
5.12 Ease of use of interventional tools  
Forty four patients (low fibre: 22; high fibre: 22) completed the Ease of Use 
questionnaire of the Fibre in Foods booklet. These respondents had a mean (sd) age 
61.8 (12.7) years, females: 61; males: 39. Responses to the questionnaire are detailed 
in Table 5.11. 
 
All patients found the design and layout of the booklet ‘very easy’ or ‘quite easy’ to 
follow, with 48% of patients reporting that it was ‘very easy’ to follow. Responses were 
similar in the low and high fibre groups. A large proportion of patients (>85% for both 
low and high fibre groups) also reported that they would recommend the booklet to 
others wanting to estimate their fibre intake.  
 
Seventy percent of patients reported that they were ‘mostly’ able to find the fibre 
content of all the foods they consumed. Several reported difficulties with finding the 
fibre content of festive foods (around the Christmas period) and also ethnic items 
especially those from the Indian sub-continent. Where patients reported comments 
regarding which foods they experienced most difficulties with estimating fibre content, 
cereals and breads were most commonly cited. 
 
Fifty percent of patients reported that they didn’t feel the need to weigh food items 
and the remaining 50% who reported that they often or occasionally needed to weigh 
items to estimate fibre content were equally divided amongst both high and low fibre 
groups. About one third of patients reported using food labels to supplement booklet 
information although the majority needed to use them for less than 50% of the time.  
 
Sixty six percent of patients returned fibre exchange diaries (Table 5.1) and many 
reported finding these a useful aid to estimating their daily fibre intake.     
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Table 5.11 Responses to questionnaire in 44 patients: Ease of use of Fibre in Foods 
booklet 
 
Questionnaire section / responses 
ALL Low fibre High fibre 
n (%) of group agreeing with each 
response 1. Design / organisation: How easy was the Fibre in Foods booklet to use? 
Very easy 21 (48) 10 (45) 11 (50) 
Quite easy 23 (52) 12 (55) 11 (50) 
Undecided - - - 
Quite difficult - - - 
Very difficult - - - 
2. Would you recommend the booklet to others to estimate fibre intake?  
Definitely yes 39 (89) 20 (91) 19 (86) 
Maybe yes 5 (11) 2 (9) 3 (14) 
Undecided - - - 
Maybe no - - - 
Definite no - - - 
3. Were you able to find the fibre content of all the foods you ate?  
Yes, always 11 (25) 5 (23) 6 (27) 
Yes, mostly 31 (70) 15 (68) 16 (73) 
Undecided 2 (5) 2 (9) - 
No, partly - - - 
No, never - - - 
4. Did you weigh food items?  
Yes, often 8 (18) 4 (18) 4 (18) 
Occasionally 15 (34) 7 (32) 8 (36) 
Never 21 (50) 11 (50) 10 (46) 
5. Did you have to use food labels in addition to booklet information?  
Yes, more than 50% of the time 5 (11) - 5 (23) 
Yes, but less than 50% of the time 20 (45) 12 (55) 8 (36) 
No, never as I did not have time 4 (9) 2 (9) 2 (9) 
No, never as I did not need to 15 (35) 8 (36) 7 (32) 
 
5.13 Discussion of nutritional findings 
In this open label, nutritional interventional trial, confidence that a robust intervention 
was achieved was critical to the validity of the clinical and nutritional results. There are 
a number of factors which might have confounded outcomes. Neither the setting of 
fibre targets nor the measurement of daily fibre intake is straightforward. With respect 
to the setting of daily fibre targets, a bespoke guideline booklet was developed for use 
in the study. The design of the booklet was a balance between on the one hand, 
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including the maximum possible number of commonly-consumed fibre-containing 
items so that fibre intake could be assessed as accurately as possible, whilst on the 
other hand, not including so many items that recording of daily fibre intake became so 
time-consuming that poor compliance would result. All forty-four patients questioned 
regarding their use of the booklet reported that they found it either ‘very easy’ or 
‘quite easy’ to use and said that they would recommend it to others wishing to 
estimate their daily fibre intake (Table 5.11). So, in this respect, the booklet succeeded 
in its aim.   
 
However, the estimation of fibre intake is quite complex for patients and further 
complicated by the different definitions of fibre in use today. A decision was taken in 
the current study to base the daily fibre targets on the NSP content of foods and to use 
these values for defining the fibre content of foods in the guideline booklet. This was 
because daily reference values in the UK for fibre intake (albeit for healthy individuals) 
have been defined using the Englyst (NSP) method of analysis. Further, the dietary 
analysis software chosen for use in the study (Dietplan) has as its main reference 
source the UK Nutrient Databank. This database lists the fibre content of all foods it 
contains as g NSP but does not comprehensively (i.e. for all foods) include fibre 
content derived using other methods of analysis (e.g. Southgate estimates based on 
the AOAC methods).  
 
Patients in the interventional groups were provided with low or high fibre exchange 
diaries so that they could keep a record of daily self-estimated fibre consumption. 
However, UK food labelling is a source of potential confusion for patients. The 
nutritional breakdown of foods appearing on food packets is based on the fibre 
content of foods measured using the AOAC method of analysis which tends to result in 
higher values of fibre (1.6 x NSP) per 100 g food than the Englyst NSP method. When 
questioned as to their use of food labels (Table 5.11) 45% of the sample of 44 patients 
questioned did use food labels to help estimate their fibre content. Thus, in estimating 
their daily fibre intake, heavy reliance of food labels may have tended to over-estimate 
intake, whilst exclusive use of the guideline booklet to estimate the fibre content of 
the same foods would have resulted in lower values. Pre-trial validation of the use of 
the guideline booklet in comparison to use of food labels may have helped to shed 
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some light on possible differences. However, such a study was not possible within the 
time-frame and resources available.  
 
The assessment of fibre intake in all trial groups was achieved using 7 day food diaries. 
Patients were asked to record intake of food and drink and describe this in terms of 
household measures rather than weighing items. While 7 days is sufficient to take 
account of daily fluctuations in nutrient intake, the method is subject to error as 
information on portion sizes (e.g. photographic material) was not provided. The 
percentage return of food diaries was 92% for week one of treatment and 81% for the 
final week of treatment with the analysis of nutrient intake based on a final 127 paired 
diaries. It could be argued that a robust intervention was achieved and that statistically 
different intakes of fibre were obtained between groups at both time-points.  
 
However, clinically, the differences in fibre intake were relatively small. During week 
one, the low fibre group consumed -3.3g NSP / day less than the control group, the 
high fibre group consumed 3.6 g NSP / day  more than the control group, and the 
difference in intake between the high and low fibre groups was 6.9 g NSP / day. During 
the final week of radiotherapy, the low fibre group consumed -3.3g NSP / day less than 
the control group, the high fibre group consumed 3.5 g NSP / day  more than the 
control group, and the difference in intake between the high and low fibre groups was 
6.8 g NSP / day.  
 
Whilst a differential of 6.9 and 6.8 g NSP / day was maintained between the high and 
low fibre groups at week one and the final week of radiotherapy respectively, it is not 
clear whether this was enough to effect a difference. It is unclear why a significant 
difference in the change in IBDQ-B was observed between the high fibre and control 
groups and not between the high and low fibre groups. Figures 5.3 and 5.4 (horizontal 
floating bars representing the mean intake and mean ±1sd) illustrate the substantial 
overlap of intake at both time-points between groups (Table 5.12). The 80% cut-off for 
compliance in both high and low fibre groups is depicted on these figures. 
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Table 5.12 Mean ± 1sd fibre intake: week one and final week of radiotherapy  
 Control Low fibre High fibre 
Fibre intake (g NSP / day) : week one of radiotherapy 
Mean -1sd 8.3 6.8 12.4 
Mean 13.6 10.2 17.1 
Mean + 1sd 18.9 13.7 21.9 
Fibre intake (g NSP / day) : final week of radiotherapy 
Mean -1sd 7.0 5.9 10.6 
Mean 12.2 8.9 15.7 
Mean + 1sd 17.4 11.9 20.8 
 
 
The analysis of compliance showed that during week one, 77% and 79% of patients 
complied to within 80% of their fibre target. During the final week of radiotherapy, 
compliance (to within 80%) was higher in the low fibre group (83%) compared to that 
in the high fibre group (63%). A per protocol ANOVA in those patients who achieved 
80% compliance with fibre target revealed no significant difference in the change in 
IBDQ-B score between the low and high fibre groups between baseline and end of RT 
as in the main analysis (p=0.395). A comparison of scores at both time-points for the 
main analysis and per protocol (80% compliance cut-off) is given in Table 5.13.  
 
Table 5.13 Change in IBDQ-B and IBDQ scores: main versus per protocol analysis 
Measurement 
Analysis method 
Low fibre High fibre 
IBDQ-B - change in score Baseline to end RT: Mean (sd) 
n 52 54 
IBDQ-B main analysis -7.4 (11.6) -3.1(13.0) 
n 34 27 
IBDQ-B per protocol analysis -7.5 (10.9) -5.0 (11.8) 
IBDQ - change in score Baseline to end RT: Mean (sd) 
n 52 54 
IBDQ main analysis -17.2 (26.5) -6.7 (30.2) 
n 34 27 
IBDQ per protocol analysis -16.9 (26.7) -9.7 (22.6) 
 
 
Given the wide range of fibre intake amongst the trial groups, an analysis of change in 
IBDQ-B versus quartiles of fibre intake may be useful. An exploratory analysis of the 
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change in IBDQ-B (baseline – end RT) versus fibre intake (g NSP / 1000 kcal) reveals no 
obvious patterns (Figure 5.5).  
 




Two researchers extracted 7 day diary data and this could have been a source of error. 
However, analysis of inter-researcher variation revealed the lack of a systematic 
variation between researchers in the estimation of energy or fibre intake and 
reasonable agreement. One advantage of using two researchers, additional to the 
author (LW) to extract food diary data (apart from halving the time required to 
undertake this activity) is that they can be blinded to interventional group. Provision of 
adequate training in the use of Dietplan software and standardisation of approach are 
essential, both of which occurred. However, despite these checks and balances in 
approach, the quality of the data obtained regarding fibre intake in this study is reliant 
on the quality of the recording of fibre intake by patients themselves and it is probable 
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that there is considerable inter-patient variation in the quality of self-estimation of 
fibre intake. In the last decade, a plamsa biomarker of dietary fibre intake, 
alkylresourcinols ‘ARs’ (and its plasma and urinary metabolites) has been proposed and 
used successfully for the assessment of wholegrain and rye intake253. ARs (3,5-
dihydroxy-phenolic lipids) are found in appreciable quantities in wholegrain wheat, rye 
and barley cereal products with only a trace in corresponding refined alternatives. 
However, wide inter-individual variation exists in the levels of this biomarker in 
response to intake and its use in specific clinical cohorts remains untested253. Further, 
how well ARs correlate with total fibre intake from all dietary sources is unknown and 
at present their use may be more valuable in studies using supplemental fibre 
interventions based on known quantities of wheat, rye and barley substrates than in 
dietary based interventions such as that used in the present study. 
  
The intervention had no adverse effect on body weight or BMI with no significant 
differences between groups identified in the change in body weight or BMI at the end 
of treatment. In fact, the finding in this study that the high fibre intervention had a 
positive effect on total energy intake in the final week of radiotherapy in comparison 
to the control group is in keeping with recent research. Two recent reviews have 
challenged the long-held view that fibre leads to increased satiety and causes reduced 
energy intake251 252. In the review by Wanders251, effects of fibre on energy intake and 
body weight were small and distinct dose-response relationships were not observed. In 
the review by Clark252, neither type of dietary fibre or dose was related to satiety or 
food intake.  
 
Further, a significant difference in protein intake was also identified during the final 
week of radiotherapy between the high and low fibre groups with the high fire group 
consuming a mean 14.6 g protein/day more than the low fibre group. Other authors 
have found that dietary advice based on manipulation of the normal diet is more 
effective than supplementation alone or standard care in improving total energy and 
protein intake in patients receiving pelvic radiotherapy both in the acute setting and 
over longer-term follow-up. A positive relationship between individualized nutritional 
intervention and quality of life has been demonstrated with ‘early intervention and 
sensible partnerships with patients being key to success’248.   
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An exploratory analysis of micronutrient intake identified several specific 
micronutrients where daily intake was less than the UK RNI. The significance of this 
finding on micronutrient status was not examined and the study was not powered to 
detect differences in these nutritional endpoints. For the future, deficiencies in intake 
identified in week one of treatment could be usefully corrected with judicious 
supplementation if longer-term risk of ongoing depletion and reduced intake existed. 
 
In summary, it is concluded that the fibre intervention was a robust intervention and 
that differences in the clinical outcomes in favour of the high fibre group (Chapter 4) 
reflect, in part, differing fibre intake. In the trial, patients demonstrated that they were 
willing and able to follow detailed dietary advice for the duration of radical 
radiotherapy treatment. The time taken to develop appropriate and acceptable 
interventional tools was rewarded with a high rate of return for study documentation.  
 
The reason for the lack of a significant difference between the high and low fibre 
groups for the change in IBDQ-B and IBDQ scores remains unclear and may be 
influenced by treatment or patient-related factors discussed in the preceding chapter. 
As far as possible the interventional design used in the present study attempted to 
control for a wide range of issues which may confound outcomes and in comparison to 
many of the studies identified in the two systematic reviews, achieved this aim. 
 
One final point of discussion is the possible influence of the nature and purpose of 
professional dietetic input during treatment. Whilst the trial achieved standardised 
contact time between patients in all groups with the principal researcher (LW) the lack 
of detailed discussion regarding fibre intake in the control group patients may have left 
them feeling less well supported in making ‘appropriate’ dietary choices.  
 
Dietary manipulation, as illustrated by the number of patients citing this as a reason 
for declining study entry (36%), is clearly an important issue. It is speculative to suggest 
that dietetic input alone may have an effect although other researchers have hinted at 
such. In a recent Cochrane review, dietetic input, using mixed interventions, were seen 
to be better than no intervention to prevent or reduce onset of treatment-induced 
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diarrhea129. In the planned update of this review it is hoped that the results of the fibre 
study can be added to the sum of evidence although an agreed definition of 














6.1 Summary of findings 
The work undertaken in this thesis was carried out to test the hypothesis outlined 
below: 
 
‘Dietary fibre can prevent or reduce gastrointestinal inflammation in diseases such as 
inflammatory bowel disease and may be a simple cost-effective nutritional 
intervention to reduce or prevent acute symptoms during pelvic radiotherapy. Its 
mechanism of action is via production of anti-inflammatory fermentation products 
short chain fatty acids and through beneficial effects of dietary fibre on stool 
frequency and form’. 
 
I am able to only partially accept the first part of this hypothesis. Whilst increased 
(supplemental) fibre showed a modest benefit (4/23 studies) for disease outcomes in 
IBD, the results of the Fibre Study RCT showed that both a high and low fibre diet 
intervention had a positive effect in reducing bowel symptoms compared to the 
control group, with the difference between the high fibre and control groups reaching 
statistical significance (p=0.007). The mechanism(s) through which fibre intake is 
exerting these effects is not clear but may indicate that there are possibly differing, 
independent benefits of both high and low fibre intake. Evidence that beneficial effects 
are mediated through SCFA is lacking and thus I cannot accept the second part of the 
hypothesis. However, the results of the RCT suggest that, contrary to previously held 
views, increased dietary fibre does not necessarily have an adverse impact on stool 
frequency or form although the possible confounding effects on outcomes of increased 
use of anti-diarrhoeal medication in the high fibre group cannot be ignored.  
 
The systematic review of the efficacy of fibre in IBD identified a benefit of increased 
dietary fibre intake on disease outcomes for patients in remission and with active 
disease in ulcerative colitis (3/10 studies), and in patients in remission with pouchitis 
(1/1 study). Although no studies reported increased fibre intake to be of benefit on 
disease outcomes in Crohn’s disease (0/12 studies) and only one study reported a 
negative effect of increased fibre intake, three reported equivalence of low and high 
fibre intake, a finding that has some resonance with the outcome of the RCT. Meta-
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analysis was not possible due to the widely varying study designs and endpoints 
employed. 
 
IBD presents a model of gastrointestinal inflammation the pathophysiology of which 
shows many similar features to acute radiation-induced toxicity. Thus, finding a benefit 
of fibre in IBD was an important first step to justify an intervention in patients 
receiving pelvic radiotherapy, provided no previous studies had been undertaken. 
Unfortunately few studies identified in the systematic review of fibre and IBD 
combined clinical and physiological endpoints and thus possible mechanisms regarding 
the efficacy of dietary fibre could not be critically examined. However, many studies 
reported within-group benefits of increased fibre intake including positive effects on 
short chain fatty acids (SCFA), beneficial effects on microbiota species and reduction in 
pro-inflammatory cytokines. The studies also provided useful data with respect to 
differing interventional methodologies. 
 
In view of the modest but promising effects of fibre in patients with IBD a second 
systematic review was conducted to establish if any evidence for the efficacy of 
manipulating dietary fibre intake existed in patients undergoing pelvic radiotherapy. 
Very few studies were identified (only four RCTs) and these varied widely in design and 
endpoints. Whilst the possible efficacy of increased or manipulated fibre intake was 
hinted at in these studies it was concluded that the sum of evidence was weak and 
that there was adequate justification for conducting a properly powered RCT. The aim 
of this RCT would be to investigate the benefit of manipulating dietary fibre in patients 
receiving pelvic radiotherapy.  
 
Important lessons were learned from conducting the second systematic review. Of the 
four studies identified for inclusion in the review, all manipulated fibre in addition to 
imposing other dietary restrictions making it difficult to discern whether the effects 
observed were due to fibre or some other dietary component. Few measured 
compliance with intervention or attempted to measure background dietary intake. No 
studies combined clinical and physiological outcomes. Two studies addressing the 
efficacy of fibre for the prevention of treatment-induced diarrhoea were combined in 
meta-analysis. However, both used different tools for assessing the incidence of 
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treatment-induced diarrhoea and although one attempted to define diarrhoea using 
parameters of both stool frequency and form, this definition was not validated. 
Although not statistically significant, a slight benefit was identified for fibre 
intervention: Risk Ratio 0.75 (95% CI: 0.56 – 1.01).  
 
An interesting distinction between the two systematic reviews was that many of the 
studies conducted in IBD patients used supplement interventions, certainly the ones 
that showed a benefit in ulcerative colitis used this interventional strategy whilst those 
conducted in pelvic radiotherapy patients used dietary restrictions as secondary 
interventions in addition to the primary (supplement) intervention. The one study that 
did use a dietary intervention as the primary strategy in patients receiving pelvic 
radiotherapy was unable to quantify dietary fibre intake as the food frequency 
questionnaire devised for the study contained no information on portion sizes.  
      
The lack of robust evidence of the efficacy of fibre in the pelvic radiotherapy setting, 
justified and led to the conducting of a new RCT, the ‘Fibre study’. The design of this 
study was informed from the findings of the two systematic reviews and was powered 
to a specific clinical endpoint (symptom scores) but included a physiological outcome 
measure, SCFA and patient-reported data on daily stool frequency and form. A dietary 
intervention for the manipulation of fibre intake was chosen for palatability and 
physiological reasons. In the design of the interventional tools for the RCT, 
considerable attention was paid to the design and interventional strategy to enable 
patients to comply with interventional dietary advice. Our unit had previously 
demonstrated that patients in this setting are willing and able to follow dietary advice 
for the duration of radiotherapy. However, we had also seen that patients’ own 
perceptions can quickly over-rule research-based interventional targets resulting in a 
lack of differential between groups in the nutrient under test. 
 
The Fibre study identified a statistically significant benefit for a high fibre intervention 
and a non-significant benefit for a low fibre intervention, both in comparison to the 
control group for the change (worsening) in symptom scores, measured using the 
change in IBDQ-B scores between start and end of radiotherapy. This finding leads to 
the conclusion that both high and low fibre interventions may confer befit with respect 
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to the onset or severity of treatment-induced gastrointestinal symptoms compared to 
no intervention. It is possible that different, independent mechanisms are operating to 
confer benefit for the high and low fibre interventions compared to the no 
intervention group. It is also possible that dietitian-led advice, or perhaps increased 
awareness of fibre intake, results in a beneficial placebo-type effect in this therapy 
setting. In this context, it is interesting that the high fibre intervention also resulted in 
statistically significantly improved quality of life scores, measured using the IBDQ 
between start and end of radiotherapy compared to the control group. Once again the 
low fibre intervention also showed benefit in this respect in comparison to the control 
group but failed to achieve statistical significance.      
 
With respect to nutritional intake and status, randomisation to the high fibre group did 
not adversely affect total energy intake, whilst a within-group analysis revealed that 
the control group had a significantly reduced total energy and protein intake between 
week one and the final week of treatment and the low fibre group had a significantly 
reduced protein intake and borderline significantly reduced total energy intake. In  
contrast, the high fibre group experienced no significant change in total energy or 
protein intakes between these time-points.  
 
In summary, the fibre study recruited to target, was subject to a very low drop-out rate 
and enjoyed a high rate of return of study data. Whilst it has not unequivocally 
demonstrated that previously-given advice to reduce dietary fibre during radiotherapy 
is inappropriate, neither has it proven that increased dietary fibre intake during pelvic 
radiotherapy is significantly better than a low fibre regimen. However, it has 
demonstrated that dietitian-led advice regarding fibre intake during radiotherapy 
treatment appears to be helpful.  
 
Further investigation of the possibly differing mechanisms of protection conferred by 
low versus high dietary fibre intakes would be interesting to examine. A thorough 
examination of this question would benefit from the use of biological markers (if 
available) to monitor toxicity, markers (if available) to confirm or validate self-reported 
dietary fibre intake and the capture of data regarding the proportion of the fibre 
intervention provided by soluble (readily fermentable) versus insoluble (less well 
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fermented) fibre fractions. Finally, in future work, it is recommended that habitual 
fibre intake be recorded prior to fibre manipulation. Unfortunately this was not 
feasible in the Fibre study. However, change in fibre intake resulting from 
randomisation (e.g. to a higher or lower amount) may effect gastrointestinal function 
and thus outcomes. Therefore, adequate time for gastrointestinal acclimatisation 
should be built-in to future study time-lines.  
 
6.2 Answers to research questions  
In answer to the research questions posed earlier in this thesis it has been 
demonstrated that: 
 
 Manipulation of dietary fibre intake can be a useful intervention in the 
treatment and management of gastrointestinal inflammation in diseases such 
as IBD and may have a role in the prevention of radiation-induced 
gastrointestinal toxicity, although the assessment of toxicity using symptom 
indices is acknowledged as imperfect. 
 
 Advice to consume a high fibre diet may reduce the severity (or incidence) of 
new onset acute radiation-induced gastrointestinal toxicity during pelvic 
radiotherapy when compared to no dietary advice. However, advice to 
consume a low fibre diet may also be helpful indicating that dietary advice 
regarding fibre intake may in itself be a useful intervention. 
 
 Dietary fibre manipulation may affect the concentration or proportions of 
faecal SCFA during pelvic radiotherapy treatment although evidence from the 
Fibre study is inconclusive and too limited to be extrapolated to the 
randomised cohort. 
 
 Dietary fibre manipulation does not adversely affect stool frequency, stool form 
or incidence of loose stool during pelvic radiotherapy although use of anti-
diarrhoeal medication may mask these effects.   
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 Patients can comply with high or low fibre dietary interventional advice for the 
duration of pelvic radiotherapy. It is probable that compliance is enhanced by 
the production of accessible interventional tools. Compliance to 100% of target 
is not easily attainable.  
 
 Adherence to a high fibre target intake does not compromise body weight, 
body mass index (BMI), total energy intake or micronutrient intake. 
 
6.3 Future research activities 
The fibre study has raised some interesting issues with respect to the provision of 
dietary advice to increase or decrease fibre intake during pelvic radiotherapy. 
However, the scope of research outlined in the original trial protocol includes the 
capture of additional data which it is planned will answer further questions.  
 
In view of the important relationship between acute and late gastrointestinal toxicity 
one very important late primary endpoint that is yet to be analysed is: 
 
   An analysis of the difference between trial groups in the mean change in 
IBDQ-B score between the start and end of radiotherapy and score at one 
year. This will be done using paired scores from patients with scores at acute 
and late (one year) time-points. 
 
Data in respect of this question are currently maturing and it is anticipated that the 
analysis will be complete early in 2015. 
 
Although the Fibre study was not powered to answer the following research questions, 
an exploratory analysis of the following issues is also being carried out and will be also 
be reported in the near future: 
 
 What effect has the fibre intervention had on the level of bowel toxicity 
experienced?  Specifically has the intervention offered any benefits that can be 
detected between groups in terms of the anticipated levels of gastrointestinal 
toxicity versus volume of bowel treated and radiotherapy dose received? 
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 What is the economic burden to patients of managing gastrointestinal 
symptoms arising during pelvic radiotherapy? 
 
 Is there an economic burden to patients associated with attempting to follow 
the interventional fibre targets in the Fibre study?  
 
Aside from the Fibre study, it is hoped that a more thorough investigation of the role 
of SCFA in this setting can be conducted. This investigation should include the use of 
symptom scoring measures so that with adequate statistical powering it may be 
possible to determine whether these physiological markers can be associated with 
more commonly used subjective outcomes.  
 
6.4 Implications of findings for healthcare professionals 
It is clear that many patients actively seek dietary advice during treatment and 
welcome prescriptive advice as being empowering in an otherwise highly technical 
treatment environment into which they have very limited input. However, given the 
outcomes of the Fibre study, it is difficult to recommend what definitive advice should 
be given to patients in this setting.  
 
Given that statistically significant benefits were shown for patients asked to consume a 
high fibre intake, it is tempting to suggest that all patients increase their fibre intake 
during treatment. However, no clear benefit was seen for a high fibre intake in 
comparison to a low fibre intake and thus advice for all patients to increase fibre may 
not be appropriate as low fibre may also offer some benefit or may benefit certain 
individuals.  
 
One strategy could be to recommend that all patients follow their habitual fibre intake 
but are provided with access to a named, registered dietitian who can provide advice 
on specific aspects of fibre intake or diet when required and monitor nutritional status 
and intake. The no intervention (i.e. habitual fibre intake) group experienced the worst 
treatment-induced symptoms, most reduction in quality of life scores and had a 
significantly reduced total energy and protein at the end of treatment compared to the 
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start. It is possible that enhanced, individualised dietary care alone could be helpful in 
guarding against these outcomes. Such a strategy has resource implications and will 
require further discussion prior to implementation if deemed appropriate. 
   
The results of the one-year follow-up are awaited and may yet yield further evidence 
of the efficacy of high fibre intake in the acute setting on late outcomes. However, 
results will need to be interpreted with caution since loss to follow-up will alter the 
composition of groups between treatment and the one year follow-up time points.  
 
6.5 Personal reflection  
The Fibre study has been a resource-intensive study. The fact that it has largely been 
conducted by a single individual (LW) masks the fact that without the input of many 
other allied health professionals and clinicians, and the support of data management 
and statistical personnel, the study could not have been accomplished. 
 
All research work requires a champion or possibly champions, firstly to have the vision 
to generate credible and necessary hypotheses and secondly to ensure that the work is 
carried out to meet the exacting design and governance requirements. Research 
cannot be conducted in isolation and true multi-disciplinary working must be the key 
to success. 
 
Funding for research is competitively sought and completion is fierce. Once obtained, 
there is a clear responsibility of all involved not only to each other as healthcare 
professionals but to patients.  The work conducted in this thesis is to benefit patients 
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   Cakes and Pastries 
 
 
Description Portion size Points 
 
 Almond slice One (35g) 0.5  
 Apple turnover / Strudle One (100g) 0.5  
 Banana Bread One average slice (85g) 0.5  
 Bakewell tart One (43g) 1.0  
 Chelsea bun One (78g) 1.5  
 Cherry slice / cake One (40g) 0.5  
 Carrot cake One large slice (85g) 1.0  
 Currant bun / Hot Cross Bun One (60g) 3.0  
 Custard tart One individual (94g) 1.0  
 Custard Slice One large slice (140g) 1.5  
 Danish-style pastry  One average sized pastry 
(55g) 
1.0  
 Doughnut - jam One (75g) 0.5  
 Doughnut - ring One (60g) 0.5  
 Drop scones / Scotch pancakes One (31g) 0.5  
 Eccles cake One (45g) 0.5  
 Éclairs (and other fresh cream 
cakes) 
One  None  
 Flapjacks  See ‘biscuits’ -  
 Fruit cake / Christmas cake One slice (70g) 1.0  
 Greek style pastries (baklava) One small 0.5  
 Iced Bun One (65g) 0.5  
 Jam tart One (34g) 0.5  
 Macaroon / coconut pyramid One (28g) 1.0  
 Malt Loaf with fruit One small slice (35g) 1.0  
 Mince Pie One (55g) 1.0  
 Muffins – American style / 
Seeded 
One (85g) 1.5  
 Pancakes One medium pancake (110g) 1.0  
 Rock cakes One medium (60g) 1.0  
 Scones – fruit, plain, cheese One (48g) 1.0  
 Sponge cakes: 
Chocolate, gateau, mini (Swiss) 
rolls, ginger, lemon drizzle, 
Madeira, Battenberg, Cup cakes      
 
One individual cake or one 




 Teacake One (55g)  1.7  









USING FOOD LABELS 
 
Most foods have their nutritional content (including their fibre content) detailed in a 
label on the wrapper or packaging. The following label shows the nutritional breakdown 




1. One point of Fibre equals one gram of fibre. We would like you to estimate your 
fibre intake to the nearest gram or half gram, so if you ate the whole packet of crisps 
(above) this would amount to 1.5 grams.  
 
2. For all other foods, look at the label which will tell you how many grams (or points) of 
fibre the item of food contains. Then, tot-up or estimate the amount of food you have 
eaten. 
 
a)  If you eat MORE than the typical serving: e.g. If you ate TWICE as much as   
      the typical serving, double the number of grams (or points) of fibre you  
     actually consumed. 
 
b)  If you eat LESS (e.g. half) of a typical serving: divide by 2 to give you the  
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of which sugars 
 
Fat 
of which saturates 
of which mono-unsaturates 










  2.0 g 
 
17.7 g 
  0.7 g 
 
11.3 g 
  0.9 g 
  9.2 g 
  0.7 g 
   
 1.4 g 
 
  0.19 g 
 
  0.48 g 
2181 kJ 
523 kcal 
  5.8 g 
 
51.3 g 
  1.9 g 
 
32.7 g 
  2.5 g 
26.6 g 
  2.1 g 
  
  4.1 g 
  
 0.55 g 
 
  1.40 g 


























Questionnaire: Ease of use of the Fibre in Foods booklet 
 
Section 1 – General layout and design (please tick one box) 
 
Which size of booklet did you use? 
 
              □ Large size only        □ Small size only         □ Both sizes                
 
 
Was the design and organisation of the booklet easy to follow? 
 
              □ Very        □ Quite       □ Undecided       □ Quite       □ Very 
                        easy                   easy                                                        difficult                difficult 
 
 























Would you recommend this booklet to others if they wanted to estimate their fibre 
intake? 
 
         □ Definitely □ Maybe  □ Undecided   □ Maybe   □ Definitely 
                   ‘yes’                    ‘yes’                                              ‘No’                  ‘No’  
 





Section 2 – Completeness (Please tick one box) 
 
In general, were you able to find the fibre content of the foods that you ate? 
 
 □ yes, always    □  yes, mostly    □ Undecided   □ No, partly   □ No,  
















































Section 3 – Accuracy and use of Food Labels (Please tick one box) 
 
Did you weigh any items before recording your fibre intake? 
 

















Did you ever use food labels (rather than the booklet) to estimate your fibre points?   
 
   □ A lot               □ A little                        □ Never               □ Never                                                                        
(over 50% of the time)     (less than 50% of the time)    (I did not have time)     (I didn’t need                      
                                                                                                                              to)                                                                                                                 




Many thanks for completing this form.  Please return it to by 
hand or by post to: 
 
Linda Wedlake (Research Dietitian) 
 
Department of Nutrition and Dietetics, The Royal Marsden NHS 
Foundation Trust, Downs Road, Sutton. SM2 5PT 
 
 
Date (enter date)  
 























7 DAY FOOD DIARY 
 
 
The Royal Marsden NHS Foundation Trust – Department of Nutrition & Dietetics 
Page 259 
 
This diary is designed to obtain accurate 
information about the type and quantity of food 





Please return to:  Linda Wedlake 
                                    Research Dietitian 
                                    Nutrition & Dietetics 
                                    The Royal Marsden Hospital 
                                    Sutton  
                                    Surrey 






For research personnel use only: 
 
DIETPLAN Registration no.: ______________________ 
 
Date of entry: __________________________________ 
 
Assessment type: _______________________________ 
 
Activity level (recreational): ________________________ 
 
Activity level (occupational): _______________________ 
 
 
















Date of birth: …………………... 
 
                                     
 







Which type of bread do you usually eat? 
 
                     
                    White 
                    Brown/Hovis 
                    Granary 
                    Wholemeal 
                    None 
 
 
Do you usually buy large or small loaves, sliced or unsliced? 
 
                    Large 
                    Small 
                    Sliced 
                    Unsliced 
 
 






Which type of milk do you usually use? 
 
 
                      Full cream milk  
                      Semi-skimmed milk  
                      Skimmed milk  
                      Soya milk 
                      Lactose-free 






















How much milk do you usually use? 
 
                       1-2 pints daily 
                       ½ -1 pint 
                       ¼ - ½ pint 
                       None 
 
 
How many tablespoons of milk do you take in tea and coffee? 
 
                        ……… tablespoons in a cup of tea 
                   
                        ……… tablespoons in coffee 
      
                        None: Tea/Coffee* taken black 
                                    *please circle if applicable 
 
 
Which kind of fat do you usually use on bread, toast etc? 
            
                         Butter 
                         Margarine 
                         Low fat spread 
 
                          
                         Which brand do you usually use? 
                         …………………………………….. 
 
 
Which kind of fat do you usually use when cooking? 
 
                           Butter 
                           Olive Oil 
                           Vegetable oil 
                           Lard 



























What do you do with the visible fat on meat? 
 
                            Eat most of the fat 
                            Eat as little as possible 
                            Eat some of the fat 




How often do you eat food that is fried? 
 
                             Daily 
                             4-6 times/week 
                             1-3 times/week 






Do you drink alcoholic drinks? 
                              YES  □     NO □ 
 
 
If the answer is YES, please indicate how many units you 
drink/week. 
(i.e. 1 unit = ½ pint beer/lager or 1 small glass wine or 1 tot 
spirit) 
 
                              

















Read these instructions and the example carefully once or twice 
before you start. 
 
We would like you to record, as accurately as possible, what you eat 
and drink for 7 days. 
 
 Please record ALL food and drink consumed.  Record at the 
time of eating and NOT from memory at the end of the day.  
Keep this record sheet with you throughout the day. 
 
 You should include all meals and snacks, plus sweets, drinks 
etc.  When recording food eaten at meals, please include any 
sauces, dressings or extras, e.g. gravy, salad dressing, pickles 
as well as the main food. 
 
If you do not eat a particular meal or snack simply draw a line across 
the page at this point. 
 
 
Guidelines for describing food & drink: 
 




2. Give as many details as possible about the food: 
 
 
a) State brand name if applicable 
 i.e.  ‘Heinz’ baked beans OR 
           ‘John West’ tuna chunks in brine 
 
 
b) Name the type of biscuit, cake or cereal 
 i.e.  Chocolate Hob-Nob, Madeira, Branflakes 
 
               c)  Name the type of cheese, fish or meat 
                    i.e.  Red Leicester cheese, smoked haddock fillet,  
                               lamb chop 







3. Suggestions for recording quantity of food and drink: 
 
a) For many foods (vegetables, cereals and some fruit) a 
household measure is adequate, i.e. state the number of 
teaspoons (tsp), tablespoons (tbsp) or cups.  Also 






b) All convenience foods have their weight on the 
packaging and this can be quoted i.e. 150g carton Ski 
raspberry yoghurt OR ½ 440g tin of Heinz Tomato soup. 
 
 
c) Bread, fruit loaves etc. please indicate the size of loaf 




d) Cheese, fish, meat : if possible please weigh your 
portions.   
 
 Otherwise describe as well as you can i.e.   
- 2 large thin slices ham 
- 2 small pork chops (no fat) 











Remember to include everything you eat and drink including snacks, 
nibbles and food grabbed whilst out of the house.   
 
Please do not change what you normally eat just because you are 
filling out this record.  We want to see what is normal in your daily 
life. 
 
When recording home-made foods, please list all ingredients used in 
recipe and estimate how much of each ingredient was consumed in 
the portion of food you ate. 
 
The example on the following pages may be useful as a guide but 
please remember that although we have included space to record all 
possible meals and snacks, this does not mean that you have to eat 
at these specific times.  
 
If you do not have very regular meals, please try to record the food 
you eat throughout the day, starting with the first items you eat and 





THANK YOU VERY MUCH FOR YOUR HELP. 







DIETARY RECORD SHEET – EXAMPLE 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY:  ………………........               DATE:  ……………….. 
 
 
MEAL/ SNACK QUANTITY 
EATEN 




















3 heaped tbsp 
¼ pint 
1 thick slice 
1 rounded tsp 




Full cream milk (for cereal & drink) 
Poppy seed bread (small loaf, self cut) 
‘Olivio’ margarine 























2 thin strips 
1 large 
1 large mug 
 
Onion bagel, toasted 
Full fat cream cheese (Philadelphia) 
Smoked salmon 
Banana 
Hot chocolate (Cadbury’s) 
 
 





MEAL/ SNACK QUANTITY 
EATEN 












Orange squash (Robinson’s) 


























Chicken casserole (homemade with 
tomato/wine based sauce) containing: 
 
 
Chicken, baked (no skin) 
Olive oil  
Red wine 












































DIETARY RECORD SHEET 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY 1:  ……...................               DATE:  …………………….. 
 
MEAL/ SNACK QUANTITY 
EATEN 





















































MEAL/ SNACK QUANTITY 
EATEN 






































































DIETARY RECORD SHEET 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY 2:  ……...................               DATE:  …………………….. 
 
MEAL/ SNACK QUANTITY 
EATEN 























































MEAL/ SNACK QUANTITY 
EATEN 






































































DIETARY RECORD SHEET 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY 3:  ……...................               DATE:  …………………….. 
 
MEAL/ SNACK QUANTITY 
EATEN 























































MEAL/ SNACK QUANTITY 
EATEN 






































































DIETARY RECORD SHEET 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY 4:  ……...................               DATE:  …………………….. 
 
MEAL/ SNACK QUANTITY 
EATEN 























































MEAL/ SNACK QUANTITY 
EATEN 






































































DIETARY RECORD SHEET 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY 5:  ……...................               DATE:  …………………….. 
 
MEAL/ SNACK QUANTITY 
EATEN 























































MEAL/ SNACK QUANTITY 
EATEN 






































































DIETARY RECORD SHEET 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY 6:  ……...................               DATE:  …………………….. 
 
MEAL/ SNACK QUANTITY 
EATEN 























































MEAL/ SNACK QUANTITY 
EATEN 






































































DIETARY RECORD SHEET 
 
 Record ALL food and drink consumed during the day including 
snacks, nibbles, sauces and dressings. 
 
 Record method of cooking, type and quantity of food. 
 
 For home-made meals, please record all ingredients and the 
quantity of these consumed.         
 
DAY 7:  ……...................               DATE:  …………………….. 
 
MEAL/ SNACK QUANTITY 
EATEN 



















































MEAL/ SNACK QUANTITY 
EATEN 








































































 Use this page to make any notes or comments that may be helpful 













































 Use this page to make any notes or comments that may be helpful 




























































 Use this page to make any notes or comments that may be helpful 












































Fibre Exchange Diary – Example pages  
 
High (un-shaded) and Low (shaded) Fibre versions 
 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1. CCR 3142 ‘Fibre Study’ Consent Form 
2. Patient Information Sheet 
3. GP Letter 
4.  Case Report Form (CRF) 
5. Cost questionnaire 
 
  







Study Protocol Number: 
Ethics Protocol Number:  
Patient Identification No. for this trial: 
 
     CONSENT FORM 
      
Title of Project: 
A randomised controlled trial to investigate the role of low or high fibre diets in 
patients undergoing pelvic radiotherapy.  
 
Name of Principal Investigator: Dr. Jervoise Andreyev 
 
Please Tick Box 
 
1. I confirm that I have read and understand the information sheet dated 
……………….(version………) for the above study and that I have had an opportunity 
to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving a reason, and my medical care and legal rights will not be 
affected. 
 
3. I am willing to allow access to my medical records to check that the study is being 
carried out correctly. I have been assured that strict confidentiality will be maintained. 
 
4. I agree for my GP to be notified of my participation in this study.   
  
 
5. I agree to participate in the above study.        
  
 
6.  I would/would not like to be informed of the results of this study.  
 (please delete as appropriate). 
 
 
_______________________  ____________ ____________________ 
Name of Patient   Date   Signature 
 
_______________________  ____________ ____________________ 
Name of Person obtaining consent Date   Signature 
(if different from Principal 
Investigator) 
 
_______________________  ____________ ____________________ 




1 copy for Patient, 1 for Principal Investigator, 1 for Hospital Note 
 








The Fibre study. 
A randomised controlled trial to investigate the role of low or high 
fibre diets in patients undergoing pelvic radiotherapy. 
 
Introduction 
We would like to invite you to take part in a research study.  Before you decide, it is important 
for you to understand why the research is being done, and what it will involve.  Please take 
time to read the following information carefully and discuss it with friends, relatives and your 
GP if you wish.  Ask us if there is anything that is not clear to you or if you would like more 
information.  Take time to decide whether you or not you wish to take part.  Thank you for 
reading this. 
 
Why am I being invited to take part? 
You have been diagnosed with cancer of a pelvic origin and after discussion with you, 
radiotherapy has been chosen as an appropriate treatment.  This study will recruit men and 
women who will receive radiotherapy for cancers in the urinary tract or of a gynaecological 
origin or arising from the bowel, colon, rectum or anus.  
  
What is the purpose of the study? 
The study has two major objectives. The first is to see whether altering the amount of fibre in 
the diet during your treatment makes a difference to any bowel side effects you develop. The 
second is to see whether the amount of bowel that receives a particular dose of radiotherapy 
alters the symptoms that patients may experience.   
  
1) Effect of dietary fibre on gastrointestinal side effects: 
Over the last few years, considerable progress has been made in the way in which 
radiotherapy treatment is given. However, despite new ways of giving treatment more 
accurately to the tumour, we cannot completely protect healthy areas of the body, which lie 
close to the tumour, from the radiotherapy beams. During treatment for tumours in the pelvis, 
the gastrointestinal tract can become inflamed resulting in side effects such as loose stool, 
diarrhoea, having to rush to the lavatory and sometimes problems with being able to control 
the bowel. Our research indicates that up to 90% of patients develop changes in the way the 
bowel behaves during radiotherapy and 50% of patients state that these bowel changes are 
‘moderate’ or ‘severe’.  
 
For several years our research team has been seeing how we can use changes in diet 
during radiotherapy to protect the healthy gastrointestinal tract from the side effects of 
treatment. In this study, we want to see whether diets high in fibre or diets low in fibre are 
better for patients who are having radiotherapy. In the past, radiotherapy departments 
usually advised a low fibre diet during treatment but the potential benefits of this advice have 
never been properly tested. A high fibre diet might also be helpful but again, this has yet to 
be properly tested. If we were able to show that either a high or low fibre diet offered 
protection against unwanted changes in bowel habit during radiotherapy then we could 
advise future patients as to how best to change their fibre intake to reduce the risk of side-
effects. Preventing symptoms that occur during treatment may make treatment easier to 
carry out and may also reduce the risk of long term problems.   
 
2) Amount of bowel within the treatment field: 
In addition to assessing the effect of fibre on bowel symptoms, in a sub-set of patients with 
gynaecological or gastrointestinal tumours, we want to see whether there is a link between 
Patient Information Sheet 
 





the amount of bowel exposed to the radiotherapy and the risk of getting gastrointestinal side-
effects.  
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part, you will be 
given this information sheet to keep, and be asked to sign a consent form.  If you decide to 
take part, you are still free to change your mind or withdraw at any time without giving a 
reason. Your usual treatment plan will not be affected in any way. 
What will happen to me if I take part? 
If you decide to take part in this study, you will be assigned to one of three groups at random.  
This means you will be encouraged to stay on your normal diet, or to go onto a low fibre diet 
or to go onto a high fibre diet. Neither you nor the staff looking after you can choose which 
group you are put into. The type of diet you will be asked to follow will be chosen by 
computer. This helps avoid any bias that you or the staff may have from preconceived ideas 
about which treatment is best. Patients in each group will have a different treatment and then 
the results are compared. This is called a randomised trial.  
  
A trained dietitian will discuss with you the amount of fibre that we would like you to eat once 
we know which group you will be joining. If the computer has chosen a group for you which 
requires you to eat more or less fibre than normal, you will be given a Food Fibre Content 
booklet to enable you to estimate how much fibre is contained within the foods you normally 
eat and we will ask you to stick to your new fibre intake for the duration of your radiotherapy. 
We will not change any other aspect of your diet. If possible, we would like you to trial your 
new fibre intake and get familiar with the Food Fibre Content booklet in advance of your 
radiotherapy. This will ensure that we are able to discuss any problems that you may have 
on your first day of radiotherapy when we will meet with you and ask you to start eating your 
‘prescribed’ amount of fibre. You may be allocated to a group where you are asked to 
continue with your normal diet and not make changes to your intake of fibre. 
 
During the first and last week of your radiotherapy we will ask you to record everything you 
eat and drink for 7 days. We will also meet with you once a week during treatment to give 
you advice about your diet and see how you are managing. At these meetings we will ask 
you to remember what you have eaten on the previous day and also ask you to complete a 
simple questionnaire about any symptoms you are experiencing.  
 
In addition to following the diet which has been chosen for you, we will also ask you to 
complete a daily ‘Stool Chart’ throughout your radiotherapy treatment. Finally, we will also 
ask you to tell us about any costs you may have incurred in dealing with symptoms that you 
might have experienced. If you are in one of the groups in which you have changed your 
fibre intake, we will also ask you about the costs (if any) that you might have noticed in 
following the new diet and also ask you how palatable you found the change in diet. 
  
If you are a patient with a gynaecological or gastrointestinal tumour you may be asked to 
allow us to perform three additional CT scans during your treatment. This will allow us to see 
how much bowel is receiving radiotherapy. The scan is similar to previous CT scans you will 
have had to assess the tumour. The only possible difference is that beforehand you will be 
asked to drink a pint of a special drink with a orangey / lemony flavour that helps us to outline 
your bowel and allows us to take accurate measurements.  
 
Finally, we will ask you to give us a blood sample at the start, midway through, at the end of 
radiotherapy and one year later. These (small) samples will be taken if possible at the same 
time as the routine blood tests which you will have during your treatment. We will also ask 
you to provide us with a (small) stool sample. Both of these items will enable us to 
investigate more closely the changes that occur during radiotherapy.   
 





Are there any possible side-effects of participating in this study?  
  
1) The effects of a change in dietary fibre: 
You may experience a change in bowel habit as a result of changing your fibre intake. 
However your radiotherapy treatment will not be affected. Our fibre intervention is based on 
normal dietary foods rather than supplements and so your bowels should acclimatise 
gradually to the change without any side effects. 
 
 
2) The effects of the additional CT scans for the Bowel Volume Group: 
The additional dose of radiation that will be delivered as a result of the three extra scans that 
you will receive is very small compared to the overall dose of radiation that you will receive 
for your treatment. We are all exposed to a certain amount of background radiation and the 
additional dose that will be received resulting from the additional scans is equivalent to not 
more than 6 years’ worth of normal background radiation. 
 
3) Blood samples: 
There is a very small risk of bruising when a blood sample is taken. 
What are the possible disadvantages of taking part? 
The main disadvantage is that if you are assigned to study groups in which you need to 
change the amount of fibre in your diet, you might need to spend some time planning and 
obtaining foods to eat to make this change. The Stool Chart takes a couple of minutes to 
complete each day. Once a week during your treatment (and at the very end of treatment) 
we will ask you to spend an additional 10 – 15 minutes with us discussing your dietary and 
fibre intake and ask you to complete some simple symptom and cost questionnaires. If you 
are in the group asked to have the additional scans, you will have to spend an additional 
hour in the hospital on those days after your normal radiotherapy treatment.   
 
What are the possible benefits of taking part? 
There are no direct benefits to you in taking part in the study. However your participation will 
enable us to collect important data that in the longer term will allow us to givedeliver 
improved advice to future patients. It will also enable us to better understand the relationship 
between the amount of bowel that receives radiotherapy and the risk of side effects.  
 
Will my taking part in this study be kept confidential? 
Yes 
 
Who is organising and funding the research? 
This study is organised by the Royal Marsden NHS Trust jointly by the Departments of 
Rehabilitation and Radiotherapy. The Royal Marsden Charitable Trustees have kindly agreed 
to meet the costs of the study.  
  
Who has reviewed the study? 
The scientific quality of the study has been reviewed by the Royal Marsden/Institute of 
Cancer Research Committee for Clinical Research, and ethical approval has been granted 
by the Royal Marsden Research Ethics Committee. 
 
Further information 
Before you make a decision about your participation in this study, the study doctor is 
available to answer any questions you may have and to explain the study. Allow yourself as 
much time as you need to think through your decision.  If you then decide that you still wish 
to take part, your doctor will ask you to confirm in writing that you have read and understand 





this patient information, that all your questions have been answered completely and that you 
wish to continue with the study.   
If you have any questions please call Dr Peter Blake, Consultant Clinical Oncologist 
(Gynaecology) Tel: 0207 808 2581 or Dr HJN Andreyev, Consultant Gastroenterologist in 
Pelvic Radiation Disease, Tel: 020 7811 8216 or Ms Linda Wedlake, Research Dietitian, Tel: 
020 8642 6011 (ext. 1455) who will be happy to discuss the study with you. 
 
Thank you for considering taking part in this study. 
 
 


























Title: A randomized controlled trial to investigate the role of low or high fibre diets in 
patients undergoing pelvic radiotherapy 
 
 




Your patient, ________________________________________, has kindly agreed to 





If you have any questions, or would like further information, please contact Dr. HJN Andreyev 










Dr HJN Andreyev 











CCR 3142 ‘Fibre Study’ - CASE REPORT FORM 
 
Section 1: Patient’s Details 
 
Age:  ________            Gender: ___________________ 
 
Diagnosis:     □ Gynaecological       □ Colorectal/anal       □ Urological (bladder) 
    □ Ovarian                         □ Colorectal                  
   □ Endometrial                   □ Anal                           
           Other:       ___________                  ____________             
 
RMH Consultant: _______________________ 
   
 
 
Section 2: Screening / Eligibility 
Patient meets eligibility/exclusion criteria (refer to protocol)               □ yes 




Section 3.1: Consent / Randomisation 
 
Date patient consented:   _______________________ 
Consent form completed:                □ yes 
 
Date randomised:    _______________________ 
GP letter sent:                  □ yes 
HIS (CCRPAT) entry:                 □ yes 
Study Group:     □ Grp.1 (Low)      □ Grp.2 (High)    □ Grp.3 (Normal) 
Stratification:     □ Gynaecological  □ Colorectal/anal      □ Urological 
(bladder) 
Concomittant chemo: □ Yes □ No     
Food Fibre Content Booklet given (Groups 1 and 2 only):   □ yes 
















Section 3.2: Withdrawal 
Patient withdrawn from study:       □ yes 
 Expressed wish to withdraw       □ yes
  
         Radiotherapy cancelled       □ yes 
   




 Date withdrawn:     _______________________ 
 
 CCR PAT completed (date):   _______________________ 
 
(Please note that patients should only be withdrawn from the study if their radiotherapy has been cancelled for 
clinical reasons, or they wish to withdraw from all further data collection. Patients who are not following the 






































Section 4.1: Treatment Data - Radiotherapy Prescription 
 
Phase 1:  Dose (Gy): ______  Fraction size: _______  No. treatments: _______ 
 
Phase 2:  Dose (Gy): ______  Fraction size: _______  No. treatments: _______ 
 
Phase 3:  Dose (Gy): ______  Fraction size: _______  No. treatments: _______ 
 
TOTAL (EBRT) Dose: ______________     Brachytherapy:   □ yes □ No 
 
Radiotherapy start date: _______________    Completion date: _____________ 
 





Section 4.2: Treatment Data - Chemotherapy / Other medications 
 
Chemotherapy regimen: 
 Pre- or post-RT only     □ yes 
 Concomitant       □ yes 
 Concomitant + pre- and/or post-RT   □ yes 
 
 Name:_______________________     Dose: _____________________ 
 Pre-RT:    □ yes  During-RT:   □ yes 
 
 
 Name:_______________________     Dose: _____________________ 
 Pre-RT:    □ yes  During-RT:   □ yes 
 
Other relevant medications (e.g. statins, bowel agents) 
 
 Name:_______________________     Dose: _____________________ 
 Pre-RT:    □ yes  During-RT:   □ yes 
 
 
 Name:_______________________     Dose: _____________________ 
 Pre-RT:    □ yes  During-RT:   □ yes 
 
 
 Name:_______________________     Dose: _____________________ 
 Pre-RT:    □ yes  During-RT:   □ yes 
 
 





Section 5.1: Measurements: RT Day 1, Week 1 (Baseline) 
 
Day / date: ________________________________________   RT # Number: _________ 
 
Weight (kg):_______________  Height (m): __________ BMI (kg/m2):_________ 
 
7d Food Diary given:       □ yes  
IBDQ (Baseline) completed:   □ yes 
 
 IBDQ score: _____________  IBDQ-B score: _______________ 
Bristol Stool Chart given: □ yes  □ no 
 
Groups 1 (Low) and 2 (High) only:  
 Reinforce fibre advice:   □ yes  □ no 
Blood sample taken:  □ yes  □ no 
Stool sample received: □ yes  □ no 
 
Time taken for interview (mins): _________  Interviewer’s initials: ______________ 
 
 
Section 5.2: Measurements: RT Day 6, Week 2 
 
Day / date: ________________________________________   RT # Number: _________ 
7d Food Diary collected:    □ yes  □ no 
 
 Average daily fibre intake (g): ___________   Range (g): __________________ 
 Averaged daily intake (kcals): ______________    Kcals/BMR: ______________ 
 %CHO: _____________   %protein: ___________ % fat:__________________ 
IBDQ (week 1) completed:   □ yes 
 
 IBDQ score: _____________  IBDQ-B score: _______________ 
 
Bristol Stool Chart (results week 1): 
 
 Number of days toxicity: ____________________ 
(stool frequency >3 events of type 6 or 7 / day for >2 days, or  use of medication):  
 
Groups 1 (Low) and 2 (High) only:  
 Reinforce fibre advice:   □ yes  □ no 
Cost questionnaire completed:   □ yes  □ no 
 
Time taken for interview (mins): _________  Interviewer’s initials: ______________ 
 






Section 5.3: Measurements: RT Day 11, Week 3 
 
Day / date: ________________________________________   RT # Number: _________ 
24 hour recall completed:  □ yes  □ no   
 
 Date / day of recalled intake: _______________________   Fibre intake (g): 
________ 
IBDQ (week 2) completed:   □ yes 
 
 IBDQ score: _____________  IBDQ-B score: _______________ 
 
Bristol Stool Chart (results week 2): 
 
 Number of days toxicity: ____________________ 
(stool frequency >3 events of type 6 or 7 / day for >2 days, or  use of medication):  
 
Groups 1 (Low) and 2 (High) only:  
 Reinforce fibre advice:   □ yes  □ no 
Cost questionnaire completed:  □ yes  □ no 
Blood sample taken:    □ yes  □ no 
Stool sample received:   □ yes  □ no 
 
Time taken for interview (mins): _________  Interviewer’s initials: ______________ 
 
 
Section 5.4: Measurements: RT Day 16, Week 4 
 
Day / date: ________________________________________   RT # Number: _________ 
24 hour recall completed:  □ yes  □ no   
 
 Date / day of recalled intake: _________________  Fibre intake (g): ________ 
IBDQ (week 3) completed:   □ yes 
 
 IBDQ score: _____________  IBDQ-B score: _______________ 
 
Bristol Stool Chart (results week 3): 
 
 Number of days toxicity: ____________________ 
(stool frequency >3 events of type 6 or 7 / day for >2 days, or  use of medication)  
 
Groups 1 (Low) and 2 (High) only:  
 Reinforce fibre advice:   □ yes  □ no 
Cost questionnaire completed:   □ yes  □ no 
 





Time taken for interview (mins): _________  Interviewer’s initials: ______________ 
 
 
Section 5.5: Measurements: RT Day 21, Week 5 
 
Day / date: ________________________________________   RT # Number: _________ 
24 hour recall completed:  □ yes  □ no   
 
 Date / day of recalled intake: _______________________   Fibre intake (g): 
________ 
7d Food Diary given:     □ yes  
IBDQ (week 4) completed:   □ yes 
 
 IBDQ score: _____________  IBDQ-B score: _______________ 
 
Bristol Stool Chart (results week 4): 
 
 Number of days toxicity: ____________________ 
(stool frequency >3 events of type 6 or 7 / day for >2 days, or  use of medication)  
 
 
Groups 1 (Low) and 2 (High) only:  
 Reinforce fibre advice:   □ yes  □ no 
Cost questionnaire completed:   □ yes  □ no 
 




Section 5.6: Measurements: RT Day 26, Week 6 (Do NOT complete for 25 treatments) 
 
Day / date: ________________________________________   RT # Number: _________ 
7d Food Diary collected:    □ yes  □ no 
 Average daily fibre intake (g): ___________   Range (g): _____________________ 
 
 Averaged daily intake (kcals): ______________    Kcals/BMR: _________________ 
 %CHO: _____________   %protein: ___________ % fat:__________________ 
IBDQ (week 5) completed:   □ yes 
 
 IBDQ score: _____________  IBDQ-B score: _______________ 
 
Bristol Stool Chart (results week 6): 
 
 Number of days toxicity: ____________________ 
(stool frequency >3 events of type 6 or 7 / day for >2 days, or  use of medication)  
 
Cost questionnaire completed:  □ yes  □ no 
 






Section 5.6: Measurements: RT Day 26, Week 6 (continued) 
 
Groups 1 (Low) and 2 (High) only:  
 Reinforce fibre advice:   □ yes  □ no 
 




Section 5.7: Measurements: Exit Interview (RT Treatments: 25) 
 
Day / date: ________________________________________   RT # Number: _________ 
 
Weight (kg):_______________  Height (m): __________ BMI (kg/m2):_________ 
 
Bristol Stool Chart (results week 5): 
 
 Number of days toxicity: ____________________ 
(stool frequency >3 events of type 6 or 7 / day for >2 days, or  use of medication)  
 
Patient reminded to post 7d Food Diary:   □ yes  □ no 
 
 Average daily fibre intake (g): ___________   Range (g): _____________________ 
 Averaged daily intake (kcals): ______________    Kcals/BMR: __________________ 
 %CHO: _____________   %protein: ___________ % fat:__________________ 
Cost Questionnaire (part 1) completed:    □ yes  □ no 
Blood sample taken:      □ yes  □ no 
Stool sample received:      □ yes  □ 
no 
 
Groups 1 (Low) and 2 (High) only:  
 Cost questionnaire (part 2) completed:  □ yes  □ no 
 Palatability VAS completed:    □ yes  □ no 
 
  VAS score: ________________________ 
 














Section 5.8: Measurements: Exit Interview (RT Treatments: 28,30,31,32,34) 
 
Day / date: ________________________________________   RT # Number: _________ 
 
Weight (kg):_______________  Height (m): __________ BMI (kg/m2):_________ 
24 hour recall completed:  □ yes  □ no   
 
 Date / day of recalled intake: _______________________   Fibre intake (g): 
________ 
 
Bristol Stool Chart (results combined for weeks 6/7): 
 
 Number of days toxicity: ____________________ 
(stool frequency >3 events of type 6 or 7 / day for >2 days, or  use of medication)  
 
 
Cost Questionnaire (part 1) completed:    □ yes  □ no 
Blood sample taken:      □ yes  □ no 
Stool sample received:      □ yes  □ 
no 
  
Groups 1 (Low) and 2 (High) only:    
 Cost questionnaire (part 2) completed:  □ yes  □ no 
 Palatability VAS completed:    □ yes  □ no 
 
  VAS score: ________________________ 
 
 





Section 5.9 Measurements: One year follow-up 
 
Day / date: ________________________________________  
 
IBDQ score: __________________________   IBDQ-B score: _____________________ 
 
Blood sample taken:    □ yes  □ no 
 





Section 6: Bowel Volume Group 
 
Planned radiation doses per volume of bowel (Gy) from patient’s DVH 
 
Dose (Gy)  Volume of bowel (cc) receiving this dose (% of total) 
 Small bowel Large bowel 
5   
10   
15   
20   
25   
30   
35   
40   
 
 
Section 6.1: Bowel Volume Group: CT 1 
 
CT Scan 1 (Whole abdomin and pelvis @ 7.5mm slices) 
 
Day / date: ________________________________________   RT # Number: _________ 
 
Total large bowel volume (cc): __________ Total small bowel volume (cc): ____________ 
 




Section 6.2: Bowel Volume Group CT 2  
 
CT Scan 2 (pelvis @ 7.5mm slices) 
 
Day / date: ________________________________________   RT # Number: _________ 
 




Section 6.3: Bowel Volume Group CT 3 
 
CT Scan 1 (pelvis @ 7.5mm slices) 
 
Day / date: ________________________________________   RT # Number: _________ 
 














CCR 3142 ‘Fibre Study’ - COST QUESTIONNAIRE 
 
Part 0: Patient’s Details 
 
RMH Hospital Number: __________________          Study number: _____________ 
 
 
PART 1: ALL PATIENTS – WEEKLY COSTS OF SYMPTOM MANAGEMENT 
 
Week 2, RT Day 6 
 
In the last week have you: 
Used pads for faecal incontinence:   □ always   □ sometimes □ 
never 
Had extra laundry items due to accidents:  □ >5 items □ 1-5 items □ none 
 
Sought help from an NHS person for bowel problems:                □ yes   □ no 
   
          If ‘yes’ from whom?  _______________________________ 
Had extra travel costs because of bowel symptoms:            □ yes  □ no 
 
          If ‘yes’ can you estimate these costs?  £_________________ 
Purchased medication for bowel symptoms:            □ yes  □ no 
 
          If ‘yes’ can you estimate the costs?   £_________________ 
 
Incurred other symptom related costs (e.g. purchased new underwear or extra toilet paper)?:
                                                                                              □ yes         □ no        
    
         If ‘yes’:   1) What were these for? ____________________________ 
 
                        2) About how much did they cost?  £__________________ 
Are you in paid employment?                                       □ yes     □ no 
 
If ‘yes’ have you taken time off-work this week due to bowel symptoms?  
          □ yes, most of the time        □ yes, some of the time               □ no 
 
Have bowel symptoms prevented you from carrying out your normal activities this week?     











Week 3 and 4 RT Days 11 and 16 
In the last week have you: 
Used pads for faecal incontinence:   □ always   □ sometimes □ 
never 
Had extra laundry items due to accidents:  □ >5 items □ 1-5 items □ none 
 
Sought help from an NHS person for bowel problems:                □ yes   □ no 
   
          If ‘yes’ from whom?  _______________________________ 
Had extra travel costs because of bowel symptoms:            □ yes  □ no 
 
          If ‘yes’ can you estimate these costs?  £_________________ 
Purchased medication for bowel symptoms:            □ yes  □ no 
 
          If ‘yes’ can you estimate the costs?   £_________________ 
 
Incurred other symptom related costs (e.g. purchased new underwear or extra toilet paper)?:
                                                                                              □ yes         □ no        
    
         If ‘yes’:   1) What were these for? ____________________________ 
 
                        2) About how much did they cost?  £__________________ 
Are you in paid employment?                                       □ yes     □ no 
 
If ‘yes’ have you taken time off-work this week due to bowel symptoms?  
          □ yes, most of the time        □ yes, some of the time               □ no 
 
Have bowel symptoms prevented you from carrying out your normal activities this week?     
     □ yes, most of the time        □ yes, some of the time               □ no 
  





EXIT INTERVIEWS (Delete as applicable): 
 
Week 5, day 25,   Week 6, day 28 OR day 30,   Week 7, day 31 OR day 32 OR day 34 
 
In the last week have you: 
Used pads for faecal incontinence:   □ always   □ sometimes □ 
never 
Had extra laundry items due to accidents:  □ >5 items □ 1-5 items □ none 
 
Sought help from an NHS person for bowel problems:                □ yes   □ no 
   
          If ‘yes’ from whom?  _______________________________ 
Had extra travel costs because of bowel symptoms:            □ yes  □ no 
 
          If ‘yes’ can you estimate these costs?  £_________________ 
Purchased medication for bowel symptoms:            □ yes  □ no 
 
          If ‘yes’ can you estimate the costs?   £_________________ 
 
Incurred other symptom related costs (e.g. purchased new underwear or extra toilet paper)?:
                                                                                              □ yes         □ no        
    
         If ‘yes’:   1) What were these for? ____________________________ 
 
                        2) About how much did they cost?  £__________________ 
Are you in paid employment?                                       □ yes        □ no 
 
If ‘yes’ have you taken time off-work this week due to bowel symptoms?  
          □ yes, most of the time        □ yes, some of the time               □ no 
 
Have bowel symptoms prevented you from carrying out your normal activities this week?     
     □ yes, most of the time        □ yes, some of the time               □ no 
  






PART 2: INTERVENTIONAL GROUPS 1 AND 2 ONLY 
 
 
Part 2: Groups 1 and 2 only 
As a result of following the study diet, have you noticed a change in: 
  Weekly food bill costs:            □ increased □ reduced □ no effect 
  Time spent shopping:  □ increased □ reduced □ no effect 
  Food preparation time: □ increased □ reduced □ no effect 
 
Now that you have finished the study, do you intend to carry on with the diet? 
 
□ yes, all of the time   □ yes, some of the time □ no  □ don’t know    □ not sure 
 
 
Would you recommend this diet to others? 
 











Put a mark on the line below at a point which best describes how palatable you found the 




Much worse than                     No different to    Much better than 















Gastrointestinal toxicity scoring tools 
 
 
1. Radiotherapy Oncology Group scoring tool (RTOG) 
2. The Inflammatory Bowel Disease Questionnaire (IBDQ) 
3.  The Bristol Stool Form Scale in: The RMH Stool Chart 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Date: Enter date 
 
Dear: Enter patient’s name 
 
 
Subject: Instructions for collecting your stool sample 
 
 
Thanks so much for agreeing to do this! Instructions as follows: 
 
1) Please wear a pair of disposable gloves. 
2) Use the card tray to collect the stool before it drops into the pan. 
3) Decant enough stool to fill the yellow-top container using the wooden spatula. 
4) Place the yellow top container in the ‘biochemistry’ bag and seal the bag using 
the self-adhesive strip.  
5) Dispose of any surplus stool and collection items. 
6) Bring the sample with you when you come to your radiotherapy appointment 
and please ask the reception desk to call me when you arrive (ext. 1455).  
 
Please fill the yellow topped container as otherwise we will not have enough stool 
sample to perform a complete analysis. 
 
I look forward to collecting your sample and many thanks again. 
 





Tel: 020 8642 6011 (ext. 1455) 










Stool Collection Kit: Contents 
 
1. Copy of the above letter (‘Instructions for collecting your stool sample’) 
2. One pair of sterile gloves 
3. One wooden spatula 
4. One 25cm by 12cm cardboard tray 
5. One yellow screw-top sample collection pot 
6. One sterile ‘Biochemistry’ specimen bag with sealable strip 
7. One white envelope (self-addressed to the Research Dietitian) 
8. One pharmacy bag  
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1.0 Study Details 
1.1 Study objectives 
         Primary Objective (Acute setting)  
 To examine the effect of low, high or habitual (control group) fibre 
intake on gastrointestinal symptoms, measured using the IBDQ-B in 
patients receiving radical radiotherapy treatment for pelvic 
malignancies. 
 
         Primary Objective (Late setting)  
 
 To examine the effect of low, high or habitual fibre intake on 
gastrointestinal symptoms at one year after radical radiotherapy 




 To measure the effect of low, high or habitual fibre intake on Quality-
of-Life measured using the IBDQ in patients receiving radical 
radiotherapy treatment for pelvic malignancies. 
 
 To measure the effect of low, high or habitual fibre intake on stool 
form and frequency using the Bristol Stool Chart.  
 
 To measure the effect of low, high or habitual fibre intake on the 
change in faecal short chain fatty acids between week 1 of 
radiotherapy and end of radiotherapy.  
 
 To assess compliance with fibre prescription (study arms i and ii only) 
and daily habitual fibre intake measured as non-starch 
polysaccharides (NSP in grams/day) assessed using Dietplan software.   
 
 To assess changes in nutritional intake and nutritional status between 
week 1 and end of radiotherapy. 
 
 To measure compliance with fibre prescription using 7-Day Food 
Diaries at week 1 and end of radiotherapy.  
 
 To assess in the low and high fibre groups the ease of use of the 
study interventional guidance booklet for enabling patients to 
estimate their daily intake of NSP using of a study-specific 
questionnaire   
 
 To assess the variability between investigators in analysis of dietary 
data using Dietplan by taking a sample of 18 randomly selected end 





of radiotherapy 7 Day Food Diaries (i.e. six diaries from each study 
arm) and examining the difference in the analysis of these diaries 
between three investigators blinded to arm allocation.  
 
 To examine the relationship between volume of irradiated bowel and 
onset and severity of gastrointestinal symptoms as measured by the 
IBDQ-B and the Bristol Stool Chart. This analysis will be done using the 
ICR/RMH VODKA software platform by Dr Helen McNair (RMH) and Dr 
Sarah Gulliford (ICR) and will not be described further in this SAP.  
 
 To assess the economic burden of managing symptoms in all patients 
using the study specific Cost Questionnaire This analysis will be 
performed by Dr Heather Gage at Surrey University and will not be 
described further in this SAP.  
 
1.2 Study design 
The Fibre Study is a two centre randomised controlled trial in patients 
undergoing radical or adjuvant radiotherapy to the pelvis. Patients were 
recruited from The Royal Marsden NHS Foundation Trust (Sutton and 
London) and from The Royal Surrey County Hospital, Guildford. Patients 
were randomised into three groups: i) Low fibre; ii) high fibre; and iii) 
habitual fibre intake ‘control’ group. All groups received the same standard 
dietetic intervention (weekly interviews) but in addition the intervention 
groups (i and ii) received advice and written guidance on how to achieve 
their prescribed fibre (NSP) intake.  At randomisation the groups were 
stratified by disease site (i.e. gynaecological and gastrointestinal) and by 
receipt, or not, of concomitant chemotherapy. 
 
All patients were asked to keep a daily record of stool characteristics (stool 
type and frequency) using the Bristol Stool Chart.  Weekly IBDQ and IBDQ-B 
scores for measurement of QoL and bowel symptom severity respectively 
were collected weekly. All patients completed a short one page cost 
questionnaire (weekly) to assess the economic impact of symptom 
management.  Patients in the intervention arms (groups i and ii) completed 
several additional questions regarding the costs (if any) of adhering to their 
fibre prescription and the palatability of the intervention diet. Patients in the 
intervention arms were also asked to keep a fibre exchange diary detailing 
the number of fibre exchanges (which equate to grams of NSP) consumed 
each day. A study specific guidance booklet was designed to help patients 
estimate their daily fibre exchange intake.  Ease of use of the booklet was 
assessed using a study specific questionnaire.  
 
1.3 Number of subjects 
This 3-arm study with 90% power and alpha = 0.02 (3-way comparison for 
multiple testing) was designed to detect a difference of 6 points in the IBDQ-





B score (between baseline and on-treatment nadir) between any of the three 
arms (standard deviation of 8.35 in IBDQ-B scores using previous data) and 
required 52 patients per arm (n=156 in total). An additional 21 patients were 
to be recruited to allow for those who do not complete their radiotherapy or 
withdrew prematurely from the study making a total of 177 to be 
randomised. The study was closed to recruitment in December 2013 with 
166 patients randomised to the study. Seven patients were withdrawn 
making a total of 159 patients with data for analysis. 
2.0 Analysis Sets 
2.1 Definition of analysis sets 
All randomised patients with baseline and at least 1 further on-treatment 
IBDQ-B score will be included in the primary analysis. Patients missing a 
baseline score will be included if they have a week 2 score and two 
subsequent on-treatment scores. 
 
2.2 Scope of data to be analysed  
 
The majority of data to be analysed as described in this SAP are contained 
within the Case Report Form (CRF) for the study (version 6 May 2009). In 
addition a sub-set of supplementary data has been extracted from patient-
reported documents. This data has not been captured on the CRF and thus 
not entered into the Fibre study database. The reason for this is that the 
summary data required to be extracted from these patient completed 
documents has only recently been agreed. Appendix 1 lists these 
supplementary data items.  
 
It has been agreed with the Head of Statistics that the supplementary data 
items will be captured within Excel. These items will be added to the 
downloaded data set extracted from the Trust study database by the Study 
Statistician and all data will be used for the analyses described in this SAP. 
All secondary data items will be subjected to a sample 10% accuracy check 
by the Unit Data Manager prior to analysis. Randomised lists for checking of 
data will be generated by the Study Statistician. An error rate of >1% for 
any set of data items will trigger an escalated check which will be 
determined by the Statistician.   
 
The Head of Statistics has also agreed that the analysis of acute primary and 
secondary endpoints for the Fibre study can proceed in advance of the one 
year follow-up data being captured for all recruited patients. The last follow-
up measurement will be completed in December 2014.     
 





2.3 Violations and deviations 
There are no violations of the study protocol that will exclude patients from 
the planned analysis. Where there are missing scores for the primary 
endpoint (IBDQ-B) in the acute setting, missing values will be imputed by 
averaging the immediately preceding and immediately following scores and 
imputing the average of these two values.  
 
Since the study is a nutritional interventional study, compliance with 
prescribed fibre intake will be assessed although non-compliance will not be 
regarded as a violation. Patients will not be excluded from the analysis 
described in this SAP for non-compliance (i.e. not meeting their prescribed 
fibre intake).  
 
An Intention to Treat (ITT) analysis will be performed initially. However, a 
per-protocol analysis will also be performed. Patients in the interventional 
groups complying to within 80% of prescribed target fibre intake on the 
basis of their 7-Day Food Diary for the first week of treatment will be eligible 
for inclusion in the per protocol analysis.  
 
For Per protocol analysis, compliance will be defined as follows:  
 
a) Low Fibre Group: Achievement to within 80% (defined as a mean daily 
intake of ≤12.1 grams NSP per day) using 7-Day Food Diary at week one of 
radiotherapy. 
 
b) High Fibre Group: Achievement to within 80% (defined as a mean daily 
intake of ≥14.4 grams NSP per day) using 7-Day Food Diary at week one of 
radiotherapy.   
3.0 Primary and Secondary ENDPOINTS 
Primary endpoints (Acute setting):   
 
Difference between groups in the mean change in IBDQ-B score between 
baseline and worst (nadir) score obtained during radiotherapy treatment. 
 
Primary endpoints (Late setting):   
 
Difference between groups in the mean change in IBDQ-B scores between 
baseline and end-of-radiotherapy and one year using data only from 
patients with paired scores to ensure comparability of groups in the acute 











Secondary endpoints (Acute and Late setting): 
 
Difference between groups in the mean change in IBDQ-B scores between 
baseline and end of radiotherapy. 
 
Difference between groups in the mean change in IBDQ scores between 
baseline and worst (nadir) score obtained during radiotherapy treatment.   
 
Difference between groups in the mean change in IBDQ scores between 
baseline and end of radiotherapy and one year using data only from patients 
with paired scores to ensure comparability of groups in the acute and late 
setting. 
 
Association between the acute IBDQ-B_AUC score and the point score at one 
year using data from patients in all study groups but only in patients with 
paired scores in the acute and late setting. 
 
Association between the acute IBDQ_AUC score and the score at one year 
using data from patients in all study groups but only in patients with paired 
scores in the acute and late setting. 
 
Comparison of the acute mean IBDQ_AUC and IBDQ-B_AUC by study group.  
 
Difference between study arms between week 1 and end of radiotherapy in 
the following Bristol Stool Chart measurements: mean stool frequency, mean 
stool type, number of days on which anti-diarrhoeal medications were used, 
number of days on which stool form of 6 or 7 was recorded.   
 
Difference between study arms between week 1 and end of radiotherapy in 
the change in short chain fatty acids including: change in concentration of all 
fatty acids and change in individual fatty acids.   
 
Difference between study arms in the mean change in daily fibre intake 
between week 1 and end of radiotherapy.  
 
Difference between study arms in mean change in weight (kgs) from week 1 
to end of radiotherapy.  
 
Descriptive analysis of any change in macronutrient or micronutrient nutrient 
status intake for all groups between week 1 and end of radiotherapy, 
including differences between groups.  
 
Mean total time delivered per patient by dietitian to manage the intervention 
with a descriptive comparison of time spent between study arms.  
 





Analysis of between investigator variability in the interpretation of dietary 
intake data, specifically fibre and total energy intake, as recorded by patients 
in 7 Day Food Diaries and entered into Dietplan software.  
 
 
Exploratory endpoints (Acute setting): 
 
The following exploratory endpoints will be described for each arm. Formal 
statistical comparisons between arms will not be made for these endpoints; 
instead they will be used to generate hypotheses which may be confirmed by 
testing in further studies if necessary.  
 
Descriptive comparison of visual analogue scores for the palatability of the 
study diet (interventional groups I and ii only). 
  
Ease of use of the ‘Fibre in Foods’ booklet using questionnaire responses 
obtained from patients in the interventional study arms i and ii only. 
 
 
4.0 Analysis Methods 
 
4.1 General principles 
Data will first be summarised in the groups using descriptive analysis 
methods for continuous data and will be checked for normality both visually 
using histograms and formally with Kolmogorov-Smirnov tests. Binary 
variables will be summarised using counts and percentages. 
 
For comparison of means, provided normality of distribution is demonstrated 
and homogeneity of variance (Leven’s Test) is met, ANOVA techniques will 
be used in preference to multiple testing methods. This will be followed by 
an appropriate post-hoc analysis if applicable. A value of p<0.05 will be 
regarded as statistically significant.  
  
If multiple comparisons are used, they will be adjusted using the Bonforroni 
method. Two sided tests will be used to assess statistically significant 
differences between the groups. The p value will adjusted in line with the 
number of comparisons conducted. 
 
All data will be input into the Statistical Package for Social Sciences (SPSS) 
for statistical analysis. Statistical analysis of the primary endpoints will be 









4.2. Analysis methods 
4.2.1 Primary endpoint analysis (Acute setting):  
 
Difference in change in IBDQ-B scores between arms (acute): baseline to 
nadir 
 
The primary outcome measure is the difference in the change in mean 
IBDQ-B scores between study arms from baseline to nadir. This will be 
analysed using ANOVA techniques, provided normality of distribution and 
homogeneity of variance can be demonstrated.  Missing IBDQ-B scores will 
be replaced by taking the average value of the scores immediately preceding 
and following the missing score as described in section 2.3.  
 
ANOVA techniques will be used in preference to multiple testing if applicable. 
An appropriate post-hoc analysis will conducted if a significant difference is 
observed to establish where these differences occur. 
 
For the acute setting a statistically significant mean difference of 6 or more 
points between any of the groups will be considered to be a clinically 
significant difference. 
 
4.2.2 Primary endpoint analysis (Late setting): 
 
Difference in change in IBDQ-B scores between arms (late) 
 
The difference in the change in mean IBDQ-B scores between study arms 
from baseline to one year will be analysed using ANOVA techniques, 
provided normality of distribution and homogeneity of variance can be 
demonstrated. This analysis will only be conducted in patients with paired 
scores (i.e. scores at baseline and one year) to ensure comparability of 
groups. 
 
ANOVA techniques will be used in preference to multiple testing if applicable. 
An appropriate post-hoc analysis will conducted if a significant difference is 
observed to establish where these differences occur. 
 
For the late setting a statistically significant mean difference of 6 or more 










4.2.3 Secondary endpoints analysis (Acute and Late setting): 
 
 
Difference in the mean change in IBDQ-B scores between study arms 
(acute): baseline to end of radiotherapy 
 
Difference between groups in the mean change in IBDQ scores between 
baseline and worst (nadir) score obtained during radiotherapy treatment.   
 
 
Difference in the mean change in IBDQ scores between study arms 
(acute)  
 
The difference in the mean change in IBDQ scores between study arms from 
baseline to nadir will be analysed using ANOVA techniques provided 
normality of distribution and homogeneity of variance can be demonstrated. 
An appropriate post-hoc analysis will conducted if a significant difference is 
observed to establish where these differences occur. 
 
Difference in the mean change in IBDQ scores between study arms (late) 
 
The difference in the mean change in IBDQ scores by study arm using the 
acute change in IBDQ between study arms from baseline to end of 
radiotherapy and one year using data only from patients with paired scores 
will be analysed using ANOVA techniques provided normality of distribution 
and homogeneity of variance can be demonstrated. An appropriate post-hoc 
analysis will conducted if a significant difference is observed to establish 
where these differences occur.  
 
Comparison of IBDQ_AUC and IBDQ_B_AUC values between study arms 
(acute) 
 
The mean IBDQ_AUC and IBDQ-B_AUC values obtained by each study group 
will be compared using descriptive techniques. Missing values to compute 
AUC scores will be imputed from the average of the immediately preceding 
and following scores – see section 2.3. 
 
Association between IBDQ_AUC and IBDQ point score at one year AND 
IBDQ_B_AUC and IBDQ-B point scores at one year   
 
The IBDQ_AUC and IBDQ-B_AUC values obtained by each patient will be 
compared with their point IBDQ and IBDQ-B scores at one year using data 
only from patients with paired values. The intention of this analysis will be to 
see if there is a correlation between IBDQ _AUC or IBDQ-B_AUC scores and 
the respective point scores at one year. 
 
 
Difference in the incidence and severity of toxicity using the BSC data 
between arms 





For each patient, the following continuous variables have been collected: 
mean weekly stool frequency, mean weekly stool form. Multiple t-tests 
(independent samples) or ANOVA techniques will be used to compare the 
difference in means between arms at week 1, week 4 and end-of-
radiotherapy weeks.  
 
In addition, for each patient the following categorical variables have been 
collected: number of days with stool form ≥type 6 and number of days on 
which anti-diarrhoeal medication was used for week 1, week 4 and end-of-
radiotherapy weeks. The Kruskal-Wallis test will be used to compare days 
with toxicity between arms and number of days use of anti-diarrhoeal 
medication 
 
Difference in the change in concentration of short chain fatty acids 
between arms 
 
Difference in the change in concentration of short chain fatty acids (SCFA) between 
study arms between week 1 and end of radiotherapy will be assessed using the 
following descriptive techniques:   
 
a) Box whisker plots showing the individual change in SCFA values for each patient 
presented by study group  
 
b) Line graphs showing the mean change in SCFA values between baseline 
and end-of-radiotherapy by study group   
    
Difference in NSP (fibre) intake at week 1 and end of radiotherapy 
between arms 
 
The mean weekly fibre intake (grams / day) in intervention groups i and ii 
will be compared using ANOVA techniques at week 1 and end of RT weeks. 
The purpose of these comparisons will be to examine whether significant 
differences in fibre intake between arms are apparent at week 1 and that 
these differences are maintained at end of RT. 
 
Difference in the change in body weight between arms 
 
Difference in the mean change in body weight between study arms will be 
compared using ANOVA techniques from week 1 to end-of-radiotherapy weeks. 
The purpose of these comparisons will be to ensure that implementation of 
the study diet has no adverse effect on weight maintenance.  
 
Analysis of compliance 
 
The incidence of compliance versus non-compliance with fibre prescription in 
study arms i and ii will be reported using descriptive techniques. Compliance 
is defined as in section 2.3.   
 
 





Analysis of change in macro-nutrient and micro-nutrient intake  
 
The analysis of the percentage of the diet made up from carbohydrates, 
protein and fat will be assessed at week 1 and end of RT week using data 
from 7 Day Food diaries which has been entered into Dietplan for analysis. 
The results of this analysis will be reported using descriptive techniques. In 
addition, a similar analysis of micro-nutrients will be conducted. 
 
Time required for intervention  
 
At baseline and weekly during radiotherapy the total time taken for 
interviewing patients in the study by a dietician will be recorded. These times 
will be summed to give a total time per patient. These totals will be 
summarised by arm using descriptive statistics. 
 
Analysis of inter-investigator error in the analysis of 7 Day Food diaries 
 
Inter-observer error between investigators regarding input and interpretation 
of 7-Day Food Diary records to Dietplan will be assessed using 18 randomly 
selected end of RT week 7-Day Food Diaries.  
 
ANOVA techniques will be used to assess whether there are significant 
differences between investigators in each set of diaries analysed by study 
arm. Investigators will be blinded to the study arms to which the sample of 
18 patients have been allocated. 
 
4.2.4 Exploratory endpoints 
 
Palatability of study diet (intervention arms only): 
 
At the end of radiotherapy patients in the interventional arms only were 
asked to mark on a visual analogue scale (VAS, measured from 0 to 15cm) 
the palatability of the study diet. VAS scores by arm will be summarised 
using descriptive statistics. 
 
Analysis of Ease of Use of Fibre in Foods booklet using Questionnaire 
scores 
 
The returned questionnaires regarding ease of use of the ‘Fibre in Foods’ 
booklet will be analysed and reported using descriptive techniques. 
5.0 Interim Analyses 
The Head of Statistics has agreed that the analysis of acute data can be 
conducted in advance of the completion of one year follow-up 
measurements. The last one year post radiotherapy follow-up measurement 
will be completed in December 2014. 
 





The study Steering Committee has requested that the results of the acute 
analysis be disseminated amongst the Steering Committee members as soon 
as they become available. This has been agreed by the study Chief 
Investigator and the Head of Statistics.  
6.0 Changes of Analysis from Protocol 
Not applicable 
7.0 TIMING OF STATISTICAL ANALYSIS 
See above for information regarding the interim analysis. It is anticipated 
that the full acute analysis of data generated by this study will be completed 
by June 2014. 
8.0 References 
Authoring Instructions 
Appropriate references are included in the study protocol.  
9.0 Appendix 1 – Supplementary data items 
List of Data items to be included in the study analysis not captured within the CRF 
(see text for explanation) 
 
Source (capture) document Description of data items 
Bristol Stool Chart Mean stool frequency - week 1 of RT 
 Mean stool frequency - End of RT 
 Mean stool frequency by treatment week 
 Number of days stool type ≥ 6 - week 1 of RT  
 Number of days stool type ≥ 6 - End of RT 
 Number of days stool type ≥ 6 by treatment week 
 Mean stool type - week 1 of RT 
 Mean stool type - End of RT 
 Mean stool type by treatment week 
 Number of days medication used - week 1 of RT 
 Number of days medication used - End of RT 
 Number of days medication used by treatment 
week 
Faecal Short Chain Fatty 
Acids 
Total faecal SCFA concentration - week 1 of RT  
 Butyrate concentration - week 1 of RT 
 Propionate concentration - week 1 of RT 
 Acetate concentration - week 1 of RT 
 Total faecal SCFA concentration - End of RT  
 Butyrate concentration - End of RT 





 Propionate concentration - End of RT 
 Acetate concentration - End of RT 
Fibre Exchange Diary Mean NSP intake (fibre exchanges) - week 1 of RT 
(Study arms  i and ii only) Mean NSP intake (fibre exchanges) - End of RT 
 Mean NSP intake (fibre exchanges) by treatment 
week 
Nutritional Data (Dietplan) Mean NSP intake - week 1 of RT 
To include but not limited to: Mean NSP intake - End of RT 
 Total Energy intake (kcals) - week 1 of RT 
 Total Energy intake (kcals) - End of RT 
 Proportion of diet as carbohydrate - week 1 of RT  
 Proportion of diet as carbohydrate - End of RT  
 Proportion of diet as protein - week 1 of RT  
 Proportion of diet as protein - End of RT  
 Proportion of diet as fat - week 1 of RT  
 Proportion of diet as fat - End of RT  
 TEI (total energy intake) / BMR - week 1 of RT  
 TEI (total energy intake) / BMR - End of RT 
Study arms i and ii only: Compliance within 80% of NSP prescription - 
week 1 of RT 
 Compliance within 85% of NSP prescription - 
week 1 of RT 
 Compliance within 90% of NSP prescription - 
week 1 of RT 
 Compliance within 80% of NSP prescription - End 
of RT 
 Compliance within 85% of NSP prescription -  End 
of RT 
 Compliance within 90% of NSP prescription - End 
of RT 
Ease of Use of Guidance 
Tools 
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Fiber in the Treatment and Maintenance of Inﬂammatory Bowel
Disease: A Systematic Review of Randomized Controlled Trials
Linda Wedlake, MSc, RD,*,† Natalie Slack, MSc, RD,† H. Jervoise N. Andreyev, PhD,‡
and Kevin Whelan, PhD, RD†
Background: Dietary ﬁber may favorably inﬂuence fermentation, gastrointestinal inﬂammation, and disease progression in Crohn’s disease, ulcerative
colitis (UC), and pouchitis and offer an attractive therapeutic addition to pharmacological treatment. This systematic review appraised data from
randomized controlled trials of ﬁber in the management of inﬂammatory bowel disease.
Methods: The review followed Cochrane and PRISMA recommendations. Seven electronic databases were searched along with hand searching and
contacting experts. Inclusion criteria were randomized controlled trials of the effects of ﬁber on clinical endpoints (primarily disease activity for treatment
or maintenance) or physiological outcomes in patients with inﬂammatory bowel disease.
Results: In total, 23 randomized controlled trials fulﬁlled the inclusion criteria (UC, 10; Crohn’s disease, 12; and pouchitis, 1) recruiting 1296 patients.
In UC, 3/10 studies reported ﬁber supplementation to beneﬁt disease outcomes. In Crohn’s disease, 0/12 studies and in pouchitis 1/1 study reported
a beneﬁt on disease activity. Despite this, a number of studies reported favorable intragroup effects on physiological outcomes including fecal butyrate,
fecal calprotectin, inﬂammatory cytokines, microbiota, and gastrointestinal symptom indices. Meta-analysis was not possible.
Conclusions: There is limited weak evidence for the efﬁcacy of ﬁber in improving disease outcomes in UC and pouchitis. The potential
antiinﬂammatory role of ﬁber is intriguing and merits further investigation in adequately powered clinical trials. Excluding overt gastrointestinal
obstruction, there was no evidence that ﬁber intake should be restricted in patients with inﬂammatory bowel disease.
(Inﬂamm Bowel Dis 2014;20:576–586)
Key Words: Crohn’s disease, ulcerative colitis, pouchitis, ﬁber, prebiotic, gastrointestinal, inﬂammatory bowel disease
A pproximately 2 million people worldwide are affected byinﬂammatory bowel disease (IBD), which comprises Crohn’s
disease (CD), ulcerative colitis (UC), and pouchitis.1 During
active phases of disease, symptoms can have a profound impact
on patients’ quality of life2 and include diarrhea and abdominal
pain and in CD, in particular, anorexia, and undernutrition.3
The pathogenesis of IBD is not entirely understood. It is
postulated that it results in part from a mucosal immune response
to the commensal gastrointestinal microbiota in genetically suscep-
tible individuals.4 Although no single pathogen has yet been
implicated, the compromised mucosal barrier function in both
CD and UC may allow immunogenic luminal bacteria access to
the underlying lamina propria, thus perpetuating an on-going
inﬂammatory response.
The aim of clinical management is to induce and maintain
remission and prevent disease progression. Pharmacological
agents are the mainstay of management,5 although none are
entirely free of side-effects, and patients who become refractory
to them may require surgical intervention. Many patients with
IBD are interested in dietary approaches to managing symptoms.
CD in particular has been shown to be amenable to dietary inter-
vention with enteral formula inducing remission in 60% to 85% of
patients.6
The efﬁcacy of dietary ﬁber in managing IBD was ﬁrst
investigated over 30 years ago.7 The scientiﬁc rationale relates to
the beneﬁcial effects of ﬁber on gastrointestinal function8 and also
the production of the ﬁber metabolites short-chain fatty acids
particularly butyrate.8,9 Because intestinal inﬂammation is initi-
ated as a consequence of an aberrant response to the commensal
microbiota, it follows that dietary substrates that modify these
communities or their metabolites or enhance epithelial barrier
function9 may be helpful. Despite the potentially beneﬁcial impact
of ﬁber in reducing inﬂammation through such mechanisms,
many patients with IBD have been advised to reduce ﬁber con-
sumption.10,11 A number of trials have investigated the efﬁcacy
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and mechanisms of action of ﬁber in IBD. However, they vary
widely in the nature of the intervention and, to our knowledge,
have not been systematically reviewed to assist clinicians in mak-
ing informed decisions to guide practice. This aim of this system-
atic review is to identify, appraise, and assimilate the randomized
controlled trials (RCT) of dietary ﬁber in the management of IBD.
METHODS
The review was undertaken in line with the guidelines
within the Cochrane Handbook for Systematic Reviews of
Interventions12 and adheres to the relevant criteria of the PRISMA
statement (preferred reporting items for systematic reviews and
meta-analyses)13 and with particular reference to guidelines for
the reporting of nutritional reviews.14 The methods used were
agreed between the authors in advance and documented in
a review protocol.
Studies were identiﬁed through electronic database search-
ing, hand searching of conference abstracts, screening of references
of key articles, and contacting relevant experts. Online database
search strategies were developed in conjunction with a senior
information specialist. Electronic searching of the following 7
electronic databases was undertaken: MEDLINE (U.S. National
Library of Medicine); EMBASE (Elsevier B.V., The Netherlands);
CINAHL (CINAHL Information Systems, United States);
CENTRAL (The Cochrane Library, Chichester, United Kingdom);
Nutrition and Food Sciences (CAB International, United King-
dom); Web of Science (ISI Thomson Scientiﬁc, United Kingdom);
and Scopus (Elsevier). The ﬁnal electronic database search date was
done in December 2012. Search limits were applied only to exclude
animal studies. Database search terms, timeframes, and host
interfaces are detailed in Data, Supplemental Digital Content 1,
http://links.lww.com/IBD/A354.
Hand searching for relevant conference abstracts was
conducted for 2001–2012. The conference/societies and the name
of the publications searched were: Digestive Diseases Week (Gas-
troenterology) and annual conferences of the British Society of
Gastroenterology (Gut); the American Society for Parenteral and
Enteral Nutrition (J Parent Enteral Nutr); the European Society
for Clinical Nutrition and Metabolism (Clin Nutr; Clin Nutr Supp,
e-SPEN); the British Dietetic Association (J Hum Nutr Diet); and
the British Association for Parenteral and Enteral Nutrition (Proc
Nutr Soc). Reference lists of relevant reviews and studies were
also screened. Experts in “ﬁber in IBD” (n ¼ 10) and “ﬁber
broadly” (n ¼ 7) were contacted to request published or unpub-
lished studies not otherwise identiﬁed.
The research question and inclusion and exclusion criteria
were developed using a PICOS structure (patient, intervention,
comparators, outcome, and study design). RCT with appropriate
comparator arms, reporting the effect of an oral ﬁber intervention
(either increasing or decreasing intake) on clinical outcomes
(treatment or maintenance) or physiological outcomes in patients
with IBD in either remission or relapse were eligible for inclusion.
Primary endpoints were clinical indices that enabled reporting of
remission rates, remission duration, response rates, or disease
activity (Table 1). Studies using pharmacological ﬁber supple-
ments, food supplements (e.g., added cereal), or dietary advice
(e.g., high-ﬁber dietary advice) were eligible provided that the
stated focus of the intervention was dietary ﬁber modiﬁcation.
The deﬁnition of ﬁber encompassed either plant cell-wall non-
starch polysaccharide “NSP”15 or the recent CODEX deﬁnition.16,17
Studies employing solely enteral formulas were not eligible because
their efﬁcacy could relate to reasons other than presence or absence
of ﬁber alone.
All retrieved citations (titles and abstracts) were imported
into bibliographic software (EndNote v15; Adept Scientiﬁc,
Letchworth Garden City, United Kingdom), to facilitate review
and exclusion of duplicates. Two researchers independently
reviewed each reference to assess eligibility. Full articles were
obtained for all potentially eligible articles and the inclusion
criteria were applied to each. Where full articles contained
insufﬁcient information, the corresponding author was contacted
(1 article). Non-English titles/abstracts were screened by a native
speaker where possible.
Two researchers independently extracted and summarized
the data from eligible articles. Disagreements regarding eligibility
and data extraction were mediated by a third researcher. Suitability
of the data for meta-analysis was evaluated by the research team.
Quality scoring was undertaken using the Jadad scale.18
RESULTS
Articles
A total of 4232 nonduplicated articles were identiﬁed of
which 123 articles were potentially eligible. After full review, 23
articles (detailing 23 eligible studies) fulﬁlled the inclusion
criteria (Fig. 1). Ten studies were in patients with UC19–28 of
which 1 was published as an abstract only21; 12 were in CD,29–40
of which 2 were non-English language,35,40 2 were abstracts,30,37
and 1 a letter38; and 1 was in pouchitis.41 Of the 17 experts con-
tacted, 71% responded and 1 additional study was identiﬁed.
Patients, Comparators, and Interventions
The 23 studies comprised 1296 patients of which 35% were
male (where reported). This included 447 patients with UC (46%
remission; 26% active disease; 28% “mixed” disease activity),
829 with CD (56% remission; 23% active; 21% mixed), and 20
with pouchitis, all in remission. The methods used to classify
disease activity varied between and within diseases. Where em-
ployed (16/23 studies), 10 different indices were used. Use of
concomitant medications was reported in 20/23 studies.
Fiber supplements were used in 17 studies19–30,33–35,38,41 and
dietary interventions were used in 6 studies.31,32,36,37,39,40 All
except 1 study36 investigated the efﬁcacy of increased ﬁber intake.
Double blinding occurred in 10 studies,20,23–25,29,30,33,34,38,41 and
blinding of some or all researchers in an additional 7
studies.26,28,31,32,36,39,40 Most studies compared ﬁber with no inter-
vention or placebo. The majority (10/17) of ﬁber supplement
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studies were compared with placebo,20,23–25,29,30,33,34,38,41 whereas
most high-ﬁber dietary interventions were compared with other
dietary interventions (e.g., low ﬁber), but none were compared
with a “sham diet.”
In the ﬁber supplement studies, the intervention periods
ranged from 14 days to 24 months. All supplements were soluble
ﬁbers (e.g., germinated barley, inulin, oligosaccharide/inulin, and
psyllium) in doses ranging from 5 to 30 g/d. Seven studies also
used probiotics alongside the ﬁber supplement.23,24,27–30,33 In the
supplement studies, some reported compliance commonly based
on counts of unused sachets, however, none quantiﬁed ﬁber intake
from background diet. Of the dietary interventions, the duration
ranged from 28 days to 24 months resulting in intakes of between
13 and 46 g/d of ﬁber (where reported), although none reported
the relative contributions of insoluble and soluble ﬁbers. Methods
of monitoring dietary compliance and estimating ﬁber intake varied.
Adverse Events and Study Quality
Serious adverse events were inconsistently reported and
where reported were unrelated to intervention. No studies were
terminated on safety grounds. Most studies clearly reported
patient withdrawals (19/23). Few studies were of high quality
with only 17% (4/23) scoring the maximum 5 points, 26% (6/23)
4 points, 22% (5/23) 3 points, 17% (4/23) 2 points, and 17%
(4/23) 1 point on the Jadad score.
Efﬁcacy of Fiber: Summary
Fiber supplementation had a positive effect on disease
outcomes in 3/10 studies in UC19,21,26 and in the sole pouchitis
study.41 In contrast, none of the 12 studies in CD showed a beneﬁt
with 5/12 studies reporting no effect on disease outcomes29,30,33,34,38
and 3/12 equivalence32,36,40 (Table 2). In view of the variation in
patient groups, stage of disease (remission and active), interven-
tions, comparators, and the deﬁnition and methods of measuring
outcomes, meta-analysis of the studies were deemed not possible.
UC (Remission)
Four studies in patients with UC in remission recruited
213 patients (Table 3). Two reported positive results on disease
activity. In the large 3-arm RCT, comparing psyllium ﬁber versus
mesalamine versus mesalamine and psyllium ﬁber19 continued
remission at 12 months was similar across all groups implying
TABLE 1. Detailed Inclusion and Exclusion Criteria and Data Extracted
PICOS Inclusion and Exclusion Criteria Data Extracted
Patient Adult (inpatients or outpatients) older than 18 years of age with
CD, UC, or pouchitis in remission or relapse.
Location, clinical setting, age, gender, number of patients recruited,
number of patients evaluated (i.e., those with evaluable data at
study end), disease type, disease stage, and/or disease severity.
Original cohorts only (i.e., excluding previous or abbreviated
reports and abstracts of the same patient group) to avoid
duplication of patient numbers.
Intervention Oral pharmacological ﬁber supplement, food supplement, or dietary
advice to increase or decrease ﬁber intake were eligible. Fiber
interventions were required to meet the acknowledged deﬁnitions
of ﬁber,15–17 and therefore included prebiotic ﬁbers. Synbiotic
preparations containing a named prebiotic ﬁber complying with
the cited ﬁber deﬁnitions were also eligible irrespective of
probiotic species and strain(s) used.
Fiber source, dose, presentation, and period of administration.
Presence of coadministered “standard” medication(s) or
supplemental nutritional substances. Compliance with
interventional dose (if reported) and method of computing
compliance. Genus/species/strain of probiotic if administered in
conjunction with synbiotic preparation.
Comparators Reports including a comparator group of either a placebo, no
dietary intervention, an alternative dietary intervention, or
a pharmacological intervention were included. Reports
comparing different doses of ﬁber without any other
comparator group were excluded.
Patient numbers in the intervention and comparator groups and
nature of intervention. Group names standardized to avoid
confusion.
Outcomes Clinical outcomes or endpoints including remission, relapse,
mortality, morbidity, medication use, symptoms, and quality
of life. Physiological outcomes or endpoints related to
gastrointestinal inﬂammation including histology, inﬂammatory
and immunological markers, microbiota, and metabolic
substrates. Presence or absence of adverse events related to
interventional substrate.
Values, scores, or counts for remission rates, remission duration,
response rates, or disease activity (measured using standardized
indices), otherwise all other relevant clinical or physiological
outcomes or endpoints at relevant time-points including
statistical signiﬁcance if reported. Comparisons of endpoint data
between groups were extracted where possible, but within-group
comparisons between baseline and follow-up were extracted
where of interest.
Study design RCT. Open label, wholly or partially blinded or placebo-controlled
nutritional interventional studies were eligible. Single or
multicenter. English or foreign language. Non-RCTs and
uncontrolled trials were excluded.
Type of study design, nature of blinding, active interventional
period, and duration of follow-up. Authors and publication
details. Abstract or full report. Language of publication.
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equivalence between ﬁber and medication, in addition, lower
relapse rates were reported in the mesalamine plus psyllium ﬁber
group.19 Another small RCT reported lower relapse rates at
12 months for psyllium ﬁber plus mesalamine versus mesalamine
alone.21 Two further studies did not report disease outcomes.20,22
However, in one study, psyllium ﬁber resulted in lower gastroin-
testinal symptom scores at 2 months compared with placebo.20 In
the other study, beneﬁcial effects on proinﬂammatory blood
markers were reported at 2 months.22
UC (Active Disease or Mixed Active/Remission)
Five studies in patients with UC with active disease
recruited 114 patients (Table 3). One using 20 to 30 g/d of ger-
minated barley ﬁber reported positive results on disease activity
compared with no intervention at 1 month.26 In 3 other studies, no
effect of ﬁber supplementation on disease outcomes was reported,
although positive effects on inﬂammatory makers were noted. In
one study, there was no difference in the numbers achieving
remission after 2 weeks between patients receiving prebiotic ﬁbers
(oligofructose/inulin) or placebo.25 However, those receiving
prebiotic ﬁbers had signiﬁcantly lower fecal calprotectin on day
7 but not on day 14 compared with placebo. The same prebiotic
ﬁber was used in another study in combination with a probiotic
(synbiotic).24 The synbiotic did not result in signiﬁcantly lower
disease activity or sigmoidoscopy scores compared with placebo,
although it did increase luminal biﬁdobacteria-speciﬁc total rRNA
and caused a reduction in epithelial immunological markers com-
pared with baseline values.24 The largest study reported no beneﬁt
on disease activity of a synbiotic supplement at 1 year but noted
signiﬁcantly reduced expression of inﬂammatory marker myeloper-
oxidase between groups.27 One further study (disease outcomes not
reported) found that a prebiotic ﬁber (plus glutamine) caused
reduced expression of IL-6 and IL-8 compared with baseline but
not to placebo.23
One large RCT (n ¼ 120) in a mixed cohort (Table 3) com-
pared psyllium ﬁber versus probiotic versus psyllium ﬁber/probiotic.
Disease activity was not reported but improved gastrointestinal
symptom scores and reduced C-reactive protein occurred at 1 month
in the psyllium ﬁber/probiotic group.28
CD (Remission)
Four studies in patients with CD in remission recruited 465
patients. All reported on disease outcomes. Full details of
interventions, quality scores, and outcomes are reported in Data,
Supplemental Digital Content 2, http://links.lww.com/IBD/A355.
One large study (n ¼ 352) reported equivalence with no difference
in the number of patients with deteriorating disease at 24 months
between those consuming a high (mean intake, 27 g/d) versus low
(mean intake, 15 g/d) ﬁber diet.32 Two studies investigating
a ﬁber/prebiotic supplement in combination with probiotics
FIGURE 1. Summary of review process and results.
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reported no differences in clinical, endoscopic, or physiological
outcomes at 24 months29 or median time to next infusion at
6 months30 between intervention and placebo groups. One study
reported negative outcomes for patients consuming a high-ﬁber
diet with signiﬁcantly higher treatment failure and shorter time to
relapse (1.4 versus 2.8 months) compared with patients on a low-
ﬁber exclusion diet.31
CD (Active Disease or Mixed Active/
Remission)
Five studies in patients with CD with active disease recruited
193 patients. Disease outcomes were reported in 3 studies. One
small study (n ¼ 14) reported equivalence of a high-ﬁber diet
(mean intake 46 g/d) and a low-ﬁber diet (16 g/d) with a similar
proportion of patients achieving remission.36 Although improved
endoscopic appearance was reported in the high-ﬁber group at
6 weeks, no other differences in physiological or clinical outcomes
were observed.
Two further studies using 12 to 15 g/d of prebiotic ﬁber
(oligofructose/inulin) reported no effect on disease outcomes.33,34
In one study (n ¼ 24 evaluated), no differences in remission rates
were reported between groups, although reduced histological and
disease activity scores and increased biﬁdobacteria were noted at
6 months in the prebiotic group compared with baseline.33 In the
other larger RCT (n ¼ 103), no differences between groups were
found in clinical or inﬂammatory markers or selected microbiota
at 1 month.34 However, there were indications of a shift to greater
mucosal immunoregulation in the prebiotic group, including sig-
niﬁcantly higher IL-10 and lower IL-6 positive dendritic cells.34
Two further studies did not report on disease activity but
noted beneﬁts in other outcomes. In one study, signiﬁcantly
improved gastrointestinal symptom scores after a 28-day high-ﬁber
low reﬁned carbohydrate diet were reported versus those in the
nonintervention group, although numbers were small (n ¼ 7).37 In
the other study, signiﬁcantly improved stool consistency and slower
gut transit times were noted in the isphagula-supplemented group
compared with no intervention.35
Three studies in mixed cohorts (i.e., active disease/remission)
recruited 171 patients with all reporting disease outcomes. One
reported equivalence in clinical and physiological outcomes at
TABLE 2. Summary of Effects of Fiber on Disease Activity (Score, Remission Rates, and Relapse Rates) Compared
with Control Group
Study Disease Stage Study Aim
Effect on Disease Activity Between Groups
(Score, Remission, Relapse Rates) Summary Effect on Disease Activity
UC
19 Remission Maintenance Equivalent relapse rates to drug treatment Positive
21 Remission Maintenance Reduced relapse rate compared with no ﬁber Positive
26 Active Treatment Reduced disease activity compared with no intervention Positive
24 Active Treatment No effect on disease activity compared with placebo No effect
25 Active Treatment No effect on disease activity compared with placebo No effect
27 Active Treatment No effect on disease activity compared with no intervention No effect
20 Remission Physiological Disease activity not reported Not reported
22 Remission Physiological Disease activity not reported Not reported
23 Active Physiological Disease activity not reported Not reported
28 Mixed Physiological Disease activity not reported Not reported
CD
32 Remission Maintenance Equivalent relapse rates compared with low ﬁber Equivalence
36 Active Treatment Equivalent remission rates compared with low ﬁber Equivalence
40 Mixed Treatment Equivalent disease activity compared with exclusion diet Equivalence
29 Remission Maintenance No effect on relapse rates compared with placebo No effect
30 Remission Maintenance No effect on relapse times compared with placebo No effect
33 Active Treatment No effect on remission rates compared with placebo No effect
34 Active Treatment No effect on remission rates compared with placebo No effect
38 Mixed Treatment No effect on disease activity compared with placebo No effect
39 Mixed Maintenance No effect on disease activity of low ﬁber compared with normal diet No effect
31 Remission Maintenance Reduced relapse times in high ﬁber compared with low ﬁber Negative
35 Active Physiological Disease activity not reported Not reported
37 Active Physiological Disease activity not reported Not reported
Pouchitis
41 Remission Treatment Reduced disease activity compared with placebo Positive
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1 year between patients consuming a high-ﬁber diet compared with
those on an exclusion diet.40 Two further studies reported no effect
of increased supplemental38 or dietary ﬁber.39 In the dietary ﬁber
study, a ﬁber-restricted diet (mean intake 3 g/d) resulted in no
difference in clinical outcomes at 29 months compared with habit-
ual diet (mean intake 13 g/d).39 More recently supplementation with
the prebiotic ﬁber (oligofructose/inulin) resulted in no difference in
disease activity compared with placebo at 4 weeks, although sig-
niﬁcant increases in Biﬁdobacteria longum were reported in the
prebiotic ﬁber group compared with baseline values.38
Pouchitis
A single cross-over, double-blind, placebo-controlled RCT41
of 20 patients with pouchitis in remission has reported a positive
result and is reported in Data, Supplemental Digital Content 3,
http://links.lww.com/IBD/A356. Signiﬁcantly lower disease activity
and higher butyrate concentrations were reported during ﬁber sup-
plementation (inulin-enriched oral supplement for 3 weeks). No
differences were reported in biﬁdobacteria and lactobacilli, how-
ever, there was a reduction in Bacteroides fragilis, some strains of
which are enterotoxigenic and induce colitis.42
DISCUSSION
Dietary ﬁber has physiological properties that may impact
on gastrointestinal inﬂammation, and it may therefore be efﬁca-
cious in the management of IBD. This systematic review has
identiﬁed appraised and assimilated the data from 23 RCTs of
dietary ﬁber in the treatment or maintenance of UC, CD, and
pouchitis to assist clinicians in making informed decisions to
guide practice. The studies recruited patients in varying disease
stages (remission, active, and mixed) used a variety of supple-
ments (germinated barley, inulin, oligosaccharide/inulin mix, and
psyllium) or dietary advice (high ﬁber and low ﬁber) over a range
of differing time periods (2 weeks to 29 months) and recorded
a variety of clinical outcomes (remission rates, remission duration,
response rates, and disease activity) using varying indices in view
of which a meta-analysis was not possible.
Of the 17 ﬁber supplement studies, few reported positive
effects on the primary clinical endpoints (disease activity,
remission, and response). Three supplement studies reported
some positive effects in UC,19,21,26 although interestingly these
scored low on the Jadad quality score (scores ranged, 1–3). One
further high quality study (Jadad score 4) reported that inulin
lowered disease activity during remission of pouchitis.41 Of the
remaining 13 supplement studies, 8 found no difference in hard
endpoints of disease activity between groups,24,25,27,29,30,33,34,38
although many showed reductions in disease activity within the
ﬁber groups. In contrast, the 6 dietary intervention studies were all
conducted in patients with CD.31,32,36,37,39,40 Of those that reported
on disease activity, none reported signiﬁcant beneﬁt of high ver-
sus low-ﬁber diets32,36,37,39,40 with one showing negative results
for high-ﬁber diet compared with low.31
Despite limited evidence of efﬁcacy, the beneﬁts of ﬁber
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interventions and for the management of UC. All 4 of the studies
demonstrating clinical effectiveness, used ﬁber supplement
interventions,19,21,26,41 and this may be the case for a number of
reasons. First, there were many more ﬁber supplement studies
than dietary intervention studies (17 versus 6, respectively). Sec-
ond, in general, ﬁber supplement studies were more robustly
designed, receiving higher Jadad scores than dietary intervention
studies. For example, they were generally larger, thus reducing
the risk of a type 2 error and more frequently used placebos,
perhaps because of the complexity of using placebo “sham diets”
in dietary intervention studies. Third, supplements and dietary
advice are very different interventions, the former usually consist
of a single ﬁber with known fermentative properties and the latter
would vary between individuals, resulting in varying intakes of
different ﬁber components depending on the patients’ food
choice. Fourth, it is likely that for many patients, ﬁber supple-
ments are an easier approach to achieve a high-ﬁber intake than
modifying dietary intake. Compliance with dietary advice is
a complex process that requires patients to understand the infor-
mation (inﬂuenced by the skills of the health professional or
researcher), to value it (inﬂuenced by their health psychology),
and then have the ability to adopt it (inﬂuenced by their food
access, food knowledge, etc). Unfortunately compliance was not
robustly measured in many of the dietary intervention trials.
Therefore, the extent to which the lack of success of the dietary
intervention studies was because of poorer study design, the fail-
ure to achieve the dietary ﬁber target or a true lack of impact of
ﬁber from dietary sources to manage IBD is unclear.
Three studies in UC showed positive between group effects
of ﬁber on disease activity. No studies showed a positive effect in
CD, although 3 studies showed equivalent effects of a high-ﬁber
diet compared with another dietary intervention in active,36 inac-
tive,32 or mixed disease stage cohorts40 CD. Importantly, many of
the other studies showed signiﬁcant improvements in other clinical
outcomes (e.g., gastrointestinal symptoms) or physiological out-
comes (e.g., microbiota and short-chain fatty acid) between groups.
Many also showed improvements in disease activity between
baseline and endpoint values within the ﬁber group alone
However, as these effects were from RCT, they were not con-
sidered indicative of evidence of efﬁcacy in this systematic
review. However, details of the most relevant between group
and within-group effects have been described in the data tables
in order that clinicians and researchers can examine the evidence
for speciﬁc interventions.
This systematic review has shown that, in general, UC was
more amenable to therapeutic ﬁber interventions than CD. The
superior efﬁcacy of ﬁber in patients with UC may be linked to the
formation of its fermentation products, short-chain fatty acids,
and, in particular, butyrate in the colon at the site of the disease.
Approximately 26% of patients with CD have inﬂammation
regionalized only to the small intestine with another 43% having
both small and large intestinal inﬂammation.43 Therefore, in the
majority of patients with CD, inﬂammation occurs, at least in part,
proximal to the site of ﬁber fermentation. Two studies have
reported increased fecal or colonic butyrate19,41 in the high-ﬁber
group, 1 in UC19 and 1 in pouchitis.41
Although prebiotic ﬁbers might be expected to offer an
additional advantage, the evidence of this review does not support
this. Oligofructose and inulin are prebiotic ﬁbers that promote the
growth of key components of the gastrointestinal microbiota.
Although no studies provided statistically signiﬁcant evidence for
the efﬁcacy of prebiotic ﬁbers, 3 studies reported beneﬁcial trends
in immunological markers and selected species.33,34,38
Six trials (UC ¼ 4; CD ¼ 2) were identiﬁed but excluded
on the basis of their nonrandomized, albeit controlled, study
designs.7,10,11,44–46 One in UC reported signiﬁcantly raised fecal
butyrate in the high-ﬁber diet-treated group versus baseline
values.44 Another reported signiﬁcantly reduced number of hos-
pital admissions and length of stay in patients with active disease
placed on a high-ﬁber diet for 1 year versus the nondiet group.11
In contrast, one reported reduced likelihood of continued remis-
sion with a high-ﬁber diet versus sulphasalazine.7
In summary, this review has demonstrated the potential for
the efﬁcacy of ﬁber in IBD. There is limited, weak evidence of the
effectiveness of isphagula in maintenance of remission of UC,
germinated barley in active UC, and inulin in the maintenance of
remission in pouchitis. Many within-group effects were observed
and given the paucity of high-quality studies, these within
group observations merit further exploration in adequately
powered and controlled clinical trials. Future studies should
consider measurement of physiological outcomes to further
elucidate ﬁber’s mechanism of action, taking into account the
possible confounding effect of medication. It is recommended
that in patients with IBD without overt risk of obstruction, the
restriction of dietary ﬁber is unnecessary, but all patients
should be appropriately monitored regarding their tolerance
to ﬁber intake.
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SUMMARY
Background
Radiotherapy-induced damage to noncancerous gastrointestinal mucosa has effects
on secretory and absorptive functions and can interfere with normal gastrointestinal
physiology. Nutrient absorption and digestion may be compromised. Dietary manip-
ulation is an attractive option for the prevention and management of symptoms.
Aim
To synthesise the evidence for the use of elemental formula low- or modiﬁed-fat
diets, ﬁbre, lactose restriction and probiotics, prebiotics and synbiotics to protect the
gastrointestinal tract during pelvic radiotherapy.
Methods
Four electronic databases were searched. Randomised controlled trials (RCT), con-
trolled trials (CT) and case series in adult patients receiving radiotherapy for pelvic
cancers employing nutritional interventions to reduce gastrointestinal toxicity were
included. Methodological quality was assessed using a bespoke tool.
Results
Twenty-two original studies (2446 patients) were identiﬁed. Study quality was highly
variable with only 37% scoring ! 10 points (maximum 17: bespoke scale). Few stud-
ies assessed compliance with the intervention. End-points varied and included symp-
tom scales (IBDQ, CTC, Bristol Stool and RTOG). Evidence from RCTs was weak
for elemental, low- or modiﬁed-fat, ﬁbre and low-lactose interventions with 1/4, 3/4,
1/2, 0/1 trials respectively reporting favourable outcomes. Evidence for probiotics as
prophylactic interventions was more promising (4/5 favourable), but dose, strains
and methodologies varied.
Conclusions
There is insufﬁcient high-grade evidence to recommend nutritional intervention dur-
ing pelvic radiotherapy. Total replacement of diet with elemental formula may be
appropriate in severe toxicity. Probiotics offer promise, but cannot be introduced
into clinical practice without rigorous safety analysis, not least in immunocompro-
mised patients. The methodological quality of nutritional intervention studies needs
to be improved.
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INTRODUCTION
Radiotherapy-induced gastrointestinal toxicity:
the scale of the problem
Therapeutic irradiation (‘radiotherapy’) is now ﬁrmly
established as a cornerstone of modern cancer treatment
with an estimated half of all newly diagnosed cancer
patients receiving radiotherapy at some point in the
course of their disease.1 Pelvic radiotherapy for gynaeco-
logical, urological and lower gastrointestinal malignan-
cies, as sole therapy or in combination with surgery and
chemotherapy, is used to treat an estimated 300 000
patients annually in the United States and Western Eur-
ope. However, despite recent advances in the planning
and delivery of radiotherapy, treatment-induced toxicity
of noncancerous tissues remains dose-limiting.
During fractionated pelvic radiotherapy, delivered
daily over treatment periods of 5–7 weeks, up to 90% of
patients experience symptoms of varying severity due to
the close proximity of the gastrointestinal tract to the
pelvic organs.2 Symptoms experienced during treatment
include change in bowel habit (94%), loose stool (80%),
bowel frequency (74%), urgency (39%) and faecal incon-
tinence (37%).2 Once radiotherapy ceases, gastrointesti-
nal symptoms continue to emerge and 50% of patients
describe them as having a detrimental effect on their
quality of life.3–9
Mechanisms of normal tissue damage
Current opinion regarding the pathophysiology of tissue
damage is that the radio-therapeutic injury is similar to
a complex wound in organised tissues, which impor-
tantly includes many interacting and mutually dependent
cellular lineages together with biologically active extra-
cellular molecules.10 Radiotherapy-induced (free radical)
damage to cellular DNA affects any number of cells
within these organised structures and delivers a series of
fractionated repeated insults, contributing to accumulat-
ing direct tissue injury and inﬂammatory cell recruit-
ment. The process of wound healing is therefore
constantly interrupted, resulting in the composition of
affected noncancerous ‘normal tissue’ at the end of a
prolonged course of treatment being quite different from
that which existed before treatment commenced.10
Studies investigating changes in the morphology of
the rectal wall in patients during the acute phase of
treatment11, 12 have revealed an inﬂammatory process in
the mucosa that is maximal at 2 weeks after radiother-
apy commences, but in which reparative processes are
evident at 6 weeks despite worsening symptoms. Some
of these early lesions may resolve, but changes consistent
with chronic ischaemia and ﬁbrosis can emerge months
or years later, resulting in functional impairment to nor-
mal gastrointestinal physiology and a spectrum of clini-
cal outcomes recently deﬁned as ‘pelvic radiation
disease’.13
Radiotherapy-induced gastrointestinal tract toxicity
Mucosal biopsies from superﬁcial layers of irradiated rec-
tal wall11, 12 have revealed changes, which, if common to
both the small and large intestines, could affect absorp-
tive and secretory functions. These include atrophy of
surface epithelium, acute inﬂammation of the crypts,
inﬂammatory cell inﬁltration of surface epithelium, accu-
mulation of eosinophilic granulocytes,11 ﬂattening of
columnar cells, loss of goblet cells, oedema11 and exces-
sive collagen deposition.12 The damaging effects of pan-
creatic enzymes and bile acids given this scenario has
been well characterised in preclinical models.14–20 Atten-
dant nutrition-related problems include disaccharidase
malabsorption (notably lactose, fructose21–23 and possibly
sucrose), bile acid malabsorption,24, 25 fat malabsorption,
dysmotility26, 27 and small intestinal bacterial over-
growth.23 Whilst all of these disorders result from
speciﬁc aberrations in gastrointestinal functionality, they
often have the same clinical end-point, gastrointestinal
disturbance, malabsorption and abnormal stool output.
Potential role of dietary modulation
It is becoming increasingly clear that late radiotherapy-
induced toxicity has a ‘consequential’ component,28, 29
independent of dose and fractionation. The evidence to
support this includes the ﬁnding that cumulative acute,
sustained mild or moderate toxicity appears to be a better
predictor of chronic morbidity than a single acute severe
peak.30 Therefore, strategies including dietary manipula-
tion to limit the acute inﬂammatory processes should
protect against the subsequent self-perpetuating ﬁbrotic
processes. This article aims to provide a comprehensive
review of the potential beneﬁt of nutritional manipulation
during radical pelvic radiotherapy.
METHODS
For this review, on-line databases PUBMED, MEDLINE,
EMBASE and the Cochrane library were searched from
1966 to March 2012 using the following terms: ‘pelvic
radiotherapy’, ‘nutrition’, ‘radiation enteritis’, ‘radiation-
induced bowel damage’, ‘diarrhoea’, ‘bowel symptoms’,
‘nutrition’, ‘dietary intervention’, ‘elemental’, ‘reduced
fat’, ‘lactose’, ‘probiotic, ‘synbiotic’, ‘ﬁbre’, ‘non-starch
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polysaccharide’, ‘psyllium’, ‘ispaghula’, ‘plantago ovata’ to
retrieve potentially relevant articles. Animal and non-
adult studies were excluded. Retrieved articles were
reviewed for relevance, duplicates discarded and the full
text of all potentially relevant articles retrieved and
assessed for inclusion using predetermined criteria. Ref-
erence lists of all included articles were reviewed for
additional possibly relevant citations.
Randomised controlled trials (RCT), controlled trials
(CT) and case series recruiting adult patients, receiving
radical daily radiotherapy for pelvic malignancies,
employing nutritional interventions and reporting out-
comes related to gastrointestinal symptoms or treatment-
induced toxicity have been included. Studies investigating
more than one nutritional intervention are described
with respect to the primary intervention.
The methodological quality of trials was assessed
with reference to quality criteria from published
sources.31, 32 A tabulation detailing the extent to which
each study met each criteria and a quality score based
on the number of unequivocal ‘yes’ responses is pro-
vided as an online supplementary ﬁle. A summary of
inter-group effects (RCT only) is included detailing
‘improved’, ‘no difference’ or ‘worse’ outcomes vs. com-
parator group(s).
Two previous reviews have been published.33, 34 One
covers the period 1966–2003 and in contrast to the cur-
rent review, includes studies addressing malnutrition, but
does not cover prebiotic or synbiotic interventions.33 A
more recent meta-analysis has examined the efﬁcacy of
probiotic interventions (only) up to January 2009.34 The
current review extends the scope of both of these previ-
ous reviews to 2012, but does not include studies
addressing malnutrition.
RESULTS
Twenty-four papers21, 22, 25, 35–55 describing 22 original
studies, recruiting 2446 patients, satisﬁed the inclusion
criteria. The studies include 16 RCT,21, 25, 35–38,
41–43, 45, 48–53 two nonrandomised CT39, 40 and four case
series.22, 44, 46, 47 All studies were published in English
language and two were published as abstracts only
(Table S1).36, 41 In total, these studies comprised six ele-
mental formula interventions (836 patients),35–40 four
low- or modiﬁed-fat dietary interventions (316
patients),21, 25, 41, 42 four high- or low-ﬁbre interventions
(275 patients),43–46 three lactose interventions (275
patients)22, 47, 48 and ﬁve probiotic interventions (901
patients).49–53 A quality analysis is given in Table S2.
This indicates that only six studies scored ! 10 points of
a maximum 17 points. A summary of inter-group effects
(RCT only) is given in Table 1. Using only inter-group
outcomes, 9/16 studies reported favourable outcomes for
the intervention whilst 7/16 showed no difference or
worse outcomes. Evidence for the efﬁcacy of each inter-
vention is presented below together with the rationale
for the intervention and a brief concluding statement.
Elemental formula
Rational. Elemental nutritional formulas provides essen-
tial macronutrients in readily digestible form with pro-
tein supplied as amino-acids or peptides, fats primarily
as medium chain triglycerides (MCT) and carbohydrates
largely as maltodextrins. In appropriate volume, these
formulae contain all essential macronutrients and mi-
cronutrients and can be used as a sole source of nutri-
tion for prolonged periods. The rationale for their use
during radiotherapy is twofold: ﬁrst, the provision of
nutrients that can be readily absorbed by the gastrointes-
tinal mucosa and secondly, their potential to reduce
pancreatic and biliary secretions that may aggravate pre-
existing mucosal inﬂammation. Delivery of elemental
formula to the mid-distal and distal jejunum can
suppress pancreatic secretions,56, 57 whilst delivery of ele-
mental formula to the proximal duodenum suppresses
maximal mean postprandial pancreatic secretions by up
to 50%, compared to polymeric formula, in healthy
human volunteers.58
Evidence. Six studies, four RCT35–38 and two CT39, 40,
have recruited 836 patients. One study38 is an analysis of
a sub-group of patients recruited to a larger RCT.35 All
studies were preventative in aim with elemental formulas
providing between 33% and 100% of daily caloric needs.
Two studies used elemental formula as the sole nutri-
tional intervention;37, 40 the remaining studies advised
patients to additionally follow a low-ﬁbre diet35, 38 a
low-ﬁbre, lactose-restricted, low-fat diet39 or a natural
diet (not deﬁned).36 All studies (except one40) used an
interventional period of between 3 and 6 weeks coinci-
dent with radiotherapy treatment. The largest study
(n = 677) reported a signiﬁcant reduction in the propor-
tion of patients experiencing Radiotherapy Oncology
Group (RTOG) toxicity grades 1 and 2 in those patients
in the elemental group vs. those consuming a standard
diet group, but did not report a signiﬁcance value.36
However, a signiﬁcant decrease in the number of
patients whose treatment was interrupted due to toxicity
in the elemental group vs. the standard diet group was
reported. In three further studies,35, 37, 38 no signiﬁcant
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differences between elemental and non-intervention
groups were reported in mean stool frequency,35 time to
onset of diarrhoea,35 change in Inﬂammatory Bowel Dis-
ease Questionnaire-bowel score (IBDQ-B),37 change in
faecal calprotectin37 or change in markers of nutritional
status.38 Compliance with elemental prescription was a
concern. In one study,35 41% of patients were unable to
tolerate the elemental formula for the prescribed period
and in another study, mean dose of formula taken was
just 21% of daily energy requirement compared to the
prescribed 33%.37
Two further nonrandomised studies have been
reported. A phase II investigation of 17 patients with
gynaecological cancer receiving a 4/5 week course of
treatment,39 which additionally asked patients to reduce
ﬁbre, lactose and fat, reported a signiﬁcant reduction in
the proportion of compliant patients experiencing RTOG
grade 2/3 diarrhoea (P < 0.001) together with reduced






Effect of intervention on
GI toxicity end-points
Elemental formulae
35 RCT Open-label: Preventative 7 Low-ﬁbre diet vs. low-ﬁbre diet plus
elemental formula (900kcals/d)
No difference compared to
low-ﬁbre diet
36 RCT Open-label: Preventative 4 Standard diet vs. natural diet plus
elemental formula (33% TE)
Improved outcomes compared
to standard diet
37 RCT Open-label: Preventative 10 Normal diet vs. normal diet with
elemental formula (33% TE)
No difference compared to
normal diet
38 RCT Open-label: Preventative 7 Low-ﬁbre diet vs. low-ﬁbre diet plus
elemental formula (900 kcals/d)
No difference compared to
low-ﬁbre diet
Low- or modiﬁed-fat diets




25 RCT Double-blind placebo:
Therapeutic
12 Low-fat diet (40 g/d) plus placebo




41 RCT Open-label: Preventative 3 Low-fat diet (20 g/d) vs. low-fat diet




42 RCT Open-label: Preventative 13 Normal diet (LCT 40% TE) vs.
Low-fat (LCT 20%) vs. Low-fat
(LCT 20%) plus MCT (20%)
No difference compared to normal
or MCT-supplemented diet
Low- or high-ﬁbre diets
43 RCT Open-label: Crossover:
Therapeutic
9 Standard medication (codeine
phosphate) vs. ﬁbre supplement
(psyllium)
Worse outcome for ﬁbre
supplement compared to
medication
45 RCT Open-label: Preventative 8 Low-ﬁbre and fat (LFF) diet vs. LFF
diet plus ﬁbre supplement
(psyllium)
Improved outcomes compared to
low-(dietary) ﬁbre low-fat diet
Low-lactose diets
48 RCT Open-label: Preventative 6 Normal lactose vs. low-lactose
vs. normal lactose plus enzyme
No difference between groups
Probiotics and Synbiotics
49 RCT Open-label: Preventative 5 Low-ﬁbre, fat and lactose(LFFL)
diet vs. LFFL diet plus synbiotic
Improved outcomes compared
to LFFL diet alone
50 RCT Double-blind placebo:
Therapeutic
14 Placebo vs. probiotic No difference compared
to placebo
51 RCT Double-blind placebo:
Preventative
5 Placebo vs. probiotic Improved outcomes compared
to placebo
52 RCT Double-blind placebo:
Preventative
12 Placebo vs. probiotic Improved outcomes compared
to placebo
53 RCT Double-blind placebo:
Preventative
12 Placebo vs. probiotic Improved outcomes compared
to placebo
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need for antidiarrhoeal medication.39 Compliance was
reportedly high in the elemental group with 76.5% of
patients taking the prescribed formula for >80% of the
time. The second nonrandomised trial commenced as an
RCT in patients receiving presurgical, short course radio-
therapy for invasive bladder cancer.40 The duration of
the intervention period was just 5 days with elemental
formula providing 100% of energy intake.40 Randomisa-
tion to the conventional feeding group (normal hospital
diet or parenteral nutrition) was halted after a beneﬁt
was identiﬁed in just four patients receiving elemental
feeding.40 The authors reported a signiﬁcant reduction in
the incidence of severe post-operative diarrhoea in ele-
mentally fed patients when compared with a retrospec-
tive group receiving conventional feeding (P < 0.001).
Summary. Evidence for the efﬁcacy of elemental formula
from RCTs is weak. Whilst the sole study36 that did
report improved outcomes was by far the largest, it is
published in abstract only and was judged to have a low
quality score (Table 1). Three higher quality studies failed
to provide evidence of efﬁcacy, although these suffered
from poor compliance, and thus it is unclear whether the
intervention itself was ineffective or the lack of end-points
in noncompliant patients resulted in underpower-
ing.35, 37, 38 One non-RCT in which diet was completely
replaced with elemental formula provided evidence of
efﬁcacy in presurgical patients in a short-term setting
albeit using retrospective controls.40 Whether 100%
replacement of normal diet with elemental formula could
be achieved in patients during long course radiotherapy is
debatable.
Low- or modiﬁed-fat diets
Rationale. In the UK, dietary reference values (DRVs) for
fat intake are that fat should comprise approximately
one-third of total caloric requirements, approximately
95 g fat/day (males) and 70 g fat/day (women).59 Dietary
fats comprise long-chain triacylglycerols (LCTs) with
three fatty acids, mostly 12–18 carbon units in length. In
contrast, medium-chain triacylglycerols (MCTs) comprise
8–14 carbon fatty acids that are absorbed directly into
portal blood. They occur in only a few foods (e.g. coco-
nut), but may be prescribed in supplement form under
medical or dietetic supervision. The rationale for the use
of low- or modiﬁed-fat (MCT-predominant) diets during
radiotherapy is four-fold. Damage to the gastrointestinal
brush border60 may reduce its ability to absorb LCTs,
high-fat (LCT-based) diets may be pro-inﬂammatory,61
reduced production of bile acids may occur25, 62 and
MCTs do not stimulate exocrine pancreatic secretions
(speciﬁcally amylase and lipase)63 sparing gastrointestinal
mucosa from the proteolytic effects of these enzymes.
Evidence. Four RCTs recruiting 316 patients21, 25, 41, 42
have examined the efﬁcacy of low- or modiﬁed-fat diets
in preventing radiation toxicity. Dietary interventions
were used in all four studies with the low LCT fat groups
consuming 20 g/day41 or 40 g/day.21, 25, 42 Intervention
strategies differed, two studies41, 42 used MCT-based
supplements to compensate for reduced total energy
intake, lactose was additionally restricted in one study21
and in another,25 all patients were instructed to follow a
low-fat diet, but were randomised at 2 weeks to receive
the bile acid binder cholestyramine (4 g twice daily) or
placebo. Two studies21, 25 reported beneﬁts associated
with a low-fat diet. In one, signiﬁcant differences
between patients consuming a low-fat, low-lactose diet
vs. patients on a regular hospital diet were reported
including a halving of the incidence of new onset diar-
rhoea, a 50% reduction in the mean number of antidiar-
rhoeal tablets used (P < 0.01) and a signiﬁcant reduction
in the number of loose, watery stools per week
(P < 0.01).21 In the other study, diarrhoea control was
signiﬁcantly better (P < 0.05) in the cholestyramine arm,
although >50% patients in this group reported side
effects including nausea and abdominal cramps.25
In the remaining two studies, one reported reduced
bowel frequency in the low-fat MCT-supplemented group
vs. the low-fat group; however, these results were not sig-
niﬁcant and the difference in frequency, modest (mean
1.6 " 0.9 vs. 2.0 " 1.0 stools per day).41 The other study
used a 3-arm design to compare a normal fat diet vs. low-
fat vs. low-fat and MCT supplement (50:50 ratio of LCT:
MCT) and reported no signiﬁcant difference in the
change in IBDQ-B scores or change in secondary nutri-
tional end-points between groups. Poor compliance in the
normal fat group42 resulted in the majority of patients
consuming a diet with low LCT content. The authors
commented that the fall in IBDQ-B score for the cohort
(n = 107) compared favourably with a mean pooled fall
of 9 points from previous studies in similar cohorts
(n = 409), suggesting a positive impact of dietary inter-
vention (irrespective of study arm) and/or a beneﬁt of
reduced fat intake across all groups.2, 23, 30, 37
Summary. Evidence for the efﬁcacy of low LCT fat inter-
ventions is limited. Whilst two high-quality RCT pro-
vided evidence of efﬁcacy, neither manipulated fat as the
sole intervention making it difﬁcult to determine which
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intervention was responsible for efﬁcacy.21, 25 Although a
third RCT41 reported a modest beneﬁt of low fat, it is
published in abstract only and achieved a low quality
score (Table 1). The ﬁnal adequately powered high-qual-
ity study found no signiﬁcant difference in outcomes
between groups, although inadequate differential in fat
intake between groups precluded robust conclusions.42
Dietary Fibre
Rationale. The deﬁnition of ﬁbre has been debated for
years and measurement techniques vary. In 2008, a
Codex (Codex Alimentarius Commission) Committee
on Nutrition and Foods for Special Dietary Uses
agreed on a deﬁnition of dietary ﬁbre as ‘carbohydrate
polymers with ten or more monomeric units which are
not hydrolysed by endogenous enzymes in the small
intestine of human beings’.64 This deﬁnition encom-
passes naturally occurring, edible, plant-based polymers
found in fruits, vegetables, seeds, nuts and cereals (i.e.
items promoted as components of a healthy diet) and
also extracted or synthetic carbohydrate polymers with
proven physiological effects. Naturally occurring dietary
ﬁbre comprises both soluble and insoluble fractions
with distinct properties. Both fractions occur naturally
in most foods, but one or the other normally predomi-
nates in extracted or synthetic supplements. Insoluble
ﬁbre is less completely fermentable than soluble ﬁbre
and provides stool bulk and promotes motility. Soluble
ﬁbre (e.g. psyllium) provides a fermentable substrate
for the gastrointestinal microbiota, producing short-
chain fatty acids (SCFA), of which butyrate has
received much attention due to its trophic, immune-
modulatory and anti-inﬂammatory actions.65, 66 A
recent meta-analysis suggested that ﬁbre has a unique
moderating effect with the ability to both reduce bowel
frequency when undesirably high and yet increase it
when too low.67
Evidence. Four studies43–46 recruiting 275 patients and
comprising two RCT43, 45 and two case series44, 46 have
explored the beneﬁt of manipulating dietary and/or sup-
plemental ﬁbre during pelvic irradiation. Three studies44–46
explored the preventative role of ﬁbre in reducing
gastrointestinal toxicity, whilst a fourth study43 explored
the therapeutic efﬁcacy of the psyllium vs. codeine phos-
phate for the control of radiation-induced diarrhoea.43
One RCT reported reduced incidence (P = 0.049)
and severity (P = 0.030) of diarrhoea (using a nonvali-
dated scale) in patients following a low-ﬁbre, low-stimu-
lant (caffeine and alcohol), low-fat diet plus psyllium
supplement vs. those following the diet alone.45 This
study also reported reduced need for antidiarrhoeal med-
ication in the diet plus psyllium group, although the dif-
ference between groups was not signiﬁcant. The other
RCT instructed all patients to follow a low-ﬁbre diet and
used a crossover design to compare the efﬁcacy of psyl-
lium with codeine phosphate on presentation of treat-
ment-induced diarrhoea.43 This study was terminated
early after recruitment of ten patients due to lack of efﬁ-
cacy of psyllium, with all patients crossed-over to
codeine phosphate.
Two further case series44, 46 have reported favourable
effects of reduced44 or increased ﬁbre consumption.46 A
large retrospective study imposed dietary restrictions
(low residue, restricted caffeine, alcohol and spicy foods)
in 156 prostate cancer patients and reported improved
genitourinary and gastrointestinal symptoms in compli-
ant vs. noncompliant patients. Noncompliant patients all
experienced side effects and grade 1 toxicity (41% of
patients) was easily managed by reinforcement of dietary
advice. In the smaller prospective study46 (n = 22), pros-
tate cancer patients were given individual advice to
increase dietary ﬁbre and ﬂuid with the aim of stabilising
rectal dimensions to prevent prostate deformation during
treatment. Improved IBDQ-B scores were reported in
those who met their ﬁbre prescription vs. those who did
not.
Summary. Evidence for the efﬁcacy of ﬁbre is weak. No
high-quality RCTs have been conducted (Table 1). One
RCT that reported a beneﬁt used nonvalidated outcomes
and manipulated both dietary fat and ﬁbre, whilst addi-
tionally giving a ﬁbre supplement.45 In the other RCT,
worse outcomes with a ﬁbre supplement vs. a pharmaco-
logical preparation were reported.43 Evidence from case
series is inconclusive. Whilst the prospective series
reported positive outcomes with higher ﬁbre intake, the
study was small and not powered for toxicity end-
points.46
Lactose restriction
Rationale. Lactose is a disaccharide of glucose and galac-
tose found in milk and milk products. Typical quantities
are 13.5 g/half pint (284 mL) of full cream or skimmed
milk with similar amounts in other dairy products such
as yoghurt and ice cream. Lactose must be cleaved to its
monomeric units by the enzyme lactase present in the
brush border, prior to absorption. Unabsorbed lactose
contributes to an osmotic load in the colon causing
watery diarrhoea. In many races, a genetically
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programmed fall in lactase occurs after weaning resulting
in intolerance to lactose. In white Caucasian populations,
endogenous lactase does not diminish with adulthood,
although genetic lactase deﬁciency can occur in 5–19%
of adults. Interestingly, it is not unusual for adults to
mistakenly attribute abdominal symptoms to lactose
intolerance; however, an important study found that
most adults can actually consume small amounts of
lactose without any problem and that only large doses
actually elicit symptoms.68 Lactase deﬁciency may arise
secondary to radiation-induced damage of the intestinal
mucosa and depletion of brush border enzymes.
Although the incidence of new-onset lactose intolerance
during radiotherapy has not been deﬁnitively quantiﬁed,
one small study23 in a cohort of 26 patients has
suggested that it may be about 15%.
Evidence. Three studies recruiting 118 patients have
examined the incidence of lactose malabsorption22, 47
and the efﬁcacy of a lactose restricted or modiﬁed diet
during treatment.48 Two prospective case series22, 47 in
white Caucasian cohorts have demonstrated new-onset
lactose intolerance during pelvic radiotherapy. In the ﬁrst
of these studies, 12/24 (50%) patients exhibited signiﬁ-
cantly reduced lactose absorption as assessed by14C
lactose breath test22 and a signiﬁcant correlation was
reported between the breath test results at 5 weeks and
increased stool frequency, suggesting that patients with
the most marked lactose malabsorption also had the
most severe diarrhoea. A later study by the same group
investigated the impact of volume of small bowel irradi-
ated on lactose malabsorption47 and found a clear sepa-
ration in absorption rates in patients with large bowel
volumes within the radiotherapy ﬁeld compared with
those with smaller volumes, but there was no correlation
between the change in breath test and stool frequency in
either group.
Only one RCT has examined the efﬁcacy of lactose-
restricted diets during pelvic radiotherapy.48 In a 3-arm
study in which 64 mixed pelvic site patients were rando-
mised to follow diets [supplemented with 480 mL milk]
vs. [lactose restriction, amounts not reported] vs. [sup-
plemented with 480 cc milk + lactase enzyme], no bene-
ﬁt was found in any arm on multivariate analysis in
reduced stool frequency or number of diarrhoea tablets
used. The authors suggested that delayed gastric empty-
ing following 5 weeks of radiotherapy may have con-
founded breath test results in the earlier studies22, 47
and/or that sites of maximal lactose absorption (mid-
jejunum and upper ileum) escaped irradiation and/or
that other factors (e.g. bile acid malabsorption) over-
whelmed any beneﬁt of the lactose restriction.
Summary. Whilst it is acknowledged that true lactose
malabsorption is less prevalent than commonly sup-
posed,68 limited evidence suggests that patients can
become lactose-intolerant during pelvic radiotherapy,
but there is no evidence that restricting its consump-
tion (or providing it in prehydrolysed form) is helpful.
The sole RCT found no difference between groups in
relevant gastrointestinal end-points.48 Whilst this study
used an elegant design, the published paper lacked
data on study powering (Table S2), and given the 17%
drop out, the possibility of a type II error cannot be
ruled out.
Probiotics, Prebiotics, Synbiotics
Rationale. Probiotics are live microorganisms (bacteria)
that, when administered in adequate amounts, confer a
health beneﬁt on the host.69 They include (but are not
limited to) lactobacilli and biﬁdobacteria species and
remain viable after passage through the human stomach
and small intestine. ‘A prebiotic is a selectively fermented
ingredient that allows speciﬁc changes, in the composi-
tion and/or activity in the gastrointestinal microbiota
that confers beneﬁts on host wellbeing and health’.70
Prebiotics include inulin, lactulose and the short-chain
carbohydrates fructo-oligosaccharides (‘oligofructose’)
and galacto-oligosaccharides. Synbiotics are combinations
of probiotics and prebiotics.
There are a variety of mechanisms through which
probiotics exert their effects. These include modiﬁcation
in the incumbent microbiota population to favour non-
pathogenic species, by reducing luminal pH, competitive
inhibition of pathogenic strains and secretion of anti-
pathogenic compounds including bacteriocidins and de-
fensins. Probiotics also exert additional beneﬁcial
immunomodulatory effects on local mucosal and sys-
temic immune systems.71 Prebiotics provide a substrate
for the preferential growth of nonpathogenic species
resulting in the enhanced production of SCFA, which
promote optimal colonic ﬂuid balance, stimulate water
and sodium absorption and preserve mucosal barrier
function.65 Synbiotics offer a potentially synergistic
option, but differ in efﬁcacy depending on the speciﬁc
combination.
Evidence. Five RCT recruiting 901 patients49–53 have
examined the efﬁcacy of probiotic or synbiotic prepara-
tions. Outcomes for the largest study51 are reported in
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three separate publications,51, 54, 55 but here, quality is
assessed with reference to one publication.51 Four of the
studies are preventative in aim49, 51–53 and one, thera-
peutic.50 In the earliest open-label study,49 twenty-four
patients were randomised to receive either a synbiotic
comprising 2 9 109 radiation-resistant Lactobacillus aci-
dophilus plus 8 g/day lactulose in addition to a low-ﬁbre,
low-lactose, low-fat diet or diet alone. The incidence of
diarrhoea was signiﬁcantly reduced in the synbiotic plus
diet group (P < 0.01) vs. the diet alone group. The
authors postulated that the synbiotic decreased faecal pH
and favourably altered faecal microbiota, features that
had been demonstrated in earlier work but remain
unpublished. In a later double-blind, therapeutic study,50
206 patients were randomised to receive either a probiot-
ic containing 1.5 g of L. rhamnosus (1.5 9 109 CFU) or
placebo to manage treatment-induced mild-to-moderate
diarrhoea. No signiﬁcant difference was found between
groups in the time to use of, or frequency of use of ‘res-
cue’ diarrhoea medication.
The largest study to date used a double-blind, pla-
cebo-controlled design to test the efﬁcacy of the probiot-
ic VSL#3, comprising 8 different bacterial strains
(450 9 109 CFU) to reduce treatment-induced gastroin-
testinal toxicity assessed using the World Health Organi-
sation (WHO) 5-point grading scale.51 Earlier reports of
the same cohort were published (n = 190 patients)54, 55
in which it was stated that patients were additionally
instructed to follow a hypercaloric diet (due to ‘radio-
therapy-induced metabolic stress’), which entailed
restricting fat and fructose, but maintaining a normal
ﬁbre intake.54 However, it is not clear whether these
additional dietary instructions applied to all those
recruited to this study. A signiﬁcantly reduced number
of patients in the probiotic group vs. placebo experienced
‘radiation-induced enteritis and colitis’ (31.6% vs. 51.8%
respectively, P < 0.001) although this condition remained
undeﬁned by the authors and a signiﬁcantly higher pro-
portion of patients in the placebo group experienced
grade 3 or 4 toxicity (P < 0.001). The daily number of
bowel movements for patients with radiation-induced
diarrhoea was reduced (P < 0.005) in the probiotic
group vs. placebo (5.1 " 3 vs. 14.7 " 6) together with
signiﬁcantly increased (P < 0.001) mean time to use of
rescue diarrhoea medication.
In a later double-blind study, n = 118 patients were
randomly assigned to receive a probiotic drink
(108 CFU/g of L. casei) or placebo.52 Whilst patients in
the probiotic group had a signiﬁcantly improved stool
consistency (P = 0.04) including greater median time
before experiencing Bristol stool type ! 6 (14 days vs.
10), there was no signiﬁcant difference between groups
in the need for antidiarrhoeal medication or incidence of
Common Toxicity Criteria (CTC) grade-2 toxicity. The
most recent study also used a double-blind design and
randomised 63 patients to receive a probiotic preparation
(109 L. acidophilus and 109 Biﬁdobacterium biﬁdum) or
placebo starting 7 days prior to radiotherapy and contin-
uing during treatment.53 Signiﬁcantly fewer patients in
the probiotic group experienced CTC grade ! 2 diar-
rhoea vs. the placebo group (P = 0.002). Use of antidiar-
rhoeal medication was also signiﬁcantly reduced
(P = 0.03) together with improved stool consistency
(P < 0.001) in the probiotic group vs. placebo group.
Summary. There is limited evidence for the efﬁcacy of
probiotics in reducing diarrhoea acutely. However, the
methodological quality of studies varied widely with the
largest study51 scoring a low quality score (Table 1). Of
the two high-quality studies52, 53 reporting a beneﬁt, one
achieved only 55% of planned recruitment and failed to
ﬁnd a signiﬁcant difference between groups in the pri-
mary outcome, although reported improvements in sec-
ondary outcomes, and the other only partly addressed
the issue of study powering (Table S2) and did not state
a speciﬁc end-point.53
DISCUSSION
With the burden of cancer doubling globally between
1975 and 2000 and survival in the UK continuing to rise
by 3% per annum,72 it is appropriate to explore strategies
to prevent or reduce gastrointestinal toxicity resulting
from therapeutic radiotherapy for pelvic cancers. Nutri-
tional intervention is often a low-cost option with sound
scientiﬁc rationale. This review has identiﬁed twenty-two
original studies, recruiting 2446 patients to ﬁve major die-
tary interventions: elemental, low-/modiﬁed-fat, ﬁbre, lac-
tose restriction and probiotic or synbiotic interventions.
The studies vary widely in design with 16 being RCT, of
which 13 were preventative studies and three therapeutic.
Only ﬁve studies (four probiotic interventions and one
therapeutic study) used a double-blind design.25, 50–53 The
difﬁculty of providing sham diets is acknowledged and
thus all dietary interventions were open-label. However,
only 50% of studies used a sole dietary intervention, whilst
the remaining studies either failed to deﬁne this accurately
or used multiple interventions making it impossible to
determine the active component.
Similarly, study quality was highly variable. We used a
bespoke quality assessment tool for this review and
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acknowledge that quality scoring has its limitations;
however, of the 16 RCT, only six studies scored ! 10
points of the maximum 17 points available. Excluding
‘adequate concealment’, which was the most frequent
quality criteria not met (mostly because it was not sta-
ted), many studies failed to provide details of study pow-
ering or nominate a primary end-point nor provided an
analysis of compliance, the latter being essential to
nutritional intervention RCTs. Given the diverse range
of outcomes and comparators, we have not attempted
meta-analysis nor undertaken any formal statistical ana-
lysis of bias (e.g. publication bias).
Of all nutritional interventions in this review, probiot-
ic supplementation appears to offer the most promise as
a prophylactic for positively inﬂuencing toxicity out-
comes. From a practical perspective, probiotic supple-
mentation may also represent a more easily achievable
approach than dietary manipulation. However, our
knowledge about the precise mix of dynamic and diverse
microbiota that inhabits the human gastrointestinal tract
is still limited and is highly individual. Attempting to
manipulate such an ill-deﬁned ecosystem should be
approached with caution especially as our methods of
analysing the effects of such supplementation on the
incumbent microbiota are still relatively crude outside
the research setting. The probiotic interventions dis-
cussed above used differing doses and combinations of
strains each of which should be appropriately tested
prior to introduction to clinical practice. Furthermore,
only three of the ﬁve probiotic studies provided details
of concomitant chemotherapy agents, which are used
increasingly in combination with radiotherapy. Immuno-
suppressed patients may respond differently and repre-
sent a higher risk group so probiotic intervention in
these patients must be preceded by preliminary safety
trials with appropriate data monitoring, clinical gover-
nance and accurate and visible adverse event reporting.73
In summary, there is insufﬁcient high-grade evidence
to recommend any of the nutritional interventions in
this review be implemented in clinical practice. Restric-
tive low-lactose, low-fat and low-ﬁbre diets should not
be recommended during radical pelvic radiotherapy
unless a clear clinical rationale is provided or unless their
efﬁcacy is explored within the context of an appropriate
RCT. If so, they should only be implemented with
appropriate dietetic monitoring. Total replacement of
diet with elemental formula can probably only be
achieved after placement of a nasogastric or gastrostomy
tube and the evidence does not support its use except in
exceptional clinical settings or within the context of
clinical trials. High-dose probiotic preparations should
not be implemented until full safety testing of each indi-
vidual preparation is completed.
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